در این صفحه اطلاعات بانک دارویی ایران را بر اساس آخرین آپدیت وزرات بهداشت و درمان مشاهده می کنید.
برای پیدا کردن داروی مورد نظر کافیست نام یا اطلاعات مربوط به آن را جستجو کنید
بانک اطلاعات دارویی ایران
نام دارو | ملح | شکل دارويي | مقدار دارو | راه مصرف | دسته دارو | ترکیبات | کاربرد بالینی تایید شده | سطح دسترسی | توضیحات | تاریخ | |
---|---|---|---|---|---|---|---|---|---|---|---|
Drug Name | Salt | Dosage Form | Strengh | Route of Admin | ATC Code | Ingredient | Approved clinical indications | Access level | Remarks | Date | |
A.C.A | TABLET | ORAL | N02BE51 | Acetaminophen 162.5mg+caffeine 32.5mg+ASA 325mg | OTC medicines | ||||||
A.C.A | TABLET | ORAL | N02BE51 | Acetaminophen 250mg+caffeine 65mg+ASA 250mg | OTC medicines | 1387/05/06 | |||||
Abacavir | AS Sulfate | TABLET | 300 mg | ORAL | J05AF06 | Treatment of AIDS related complex. | For Health Dept. of MOH only | 1393/10/14 | |||
Abacavir+Lamivudine | TABLET | ORAL | J05AR02 | Abacavir as Sulfate 600 mg+Lamivudine 300 mg | Treatment of AIDS related complex. | For Health Dept. of MOH only | 1397/02/11 | ||||
Abacavir+Lamivudine | TABLET | ORAL | J05AR02 | Abacavir as Hydrochloride 600 mg+Lamivudine 300 mg | Treatment of AIDS related complex. | For Health Dept. of MOH only | 1397/02/30 | ||||
Abacavir | As Sulfate | SOLUTION | 20mg/ml | ORAL | J05AF06 | Treatment of AIDS related complex. | For Health Dept. of MOH only | 1394/03/31 | |||
Abciximab | INJECTION | 2 mg/ml | PARENTERAL | B01AC13 | Hospital use only | 1385/03/30 | |||||
Abiraterone | Acetate | TABLET | 250 mg | ORAL | L02BX03 | Metastic castration resistant prostate cancer | 1396/11/29 | ||||
Abiraterone | Acetate | TABLET | 500 mg | ORAL | L02BX03 | Metastic castration resistant prostate cancer | 1396/11/29 | ||||
Absorption Base | BULK | V03 | Bulk medicines | ||||||||
Acamprosate | As Calcium | TABLET, DELAYED RELEASE | 300 mg | ORAL | N07BB03 | 1393/03/04 | |||||
Acarbose | TABLET | 100 mg | ORAL | A10BF01 | 1382/03/04 | ||||||
Acarbose | TABLET | 50 mg | ORAL | A10BF01 | 1382/03/04 | ||||||
Acetaminophen | INJECTION, SOLUTION | 10 mg/ml | INTRAVENOUS | N02BE01 | Hospital use only | 1386/03/23 | |||||
Acetaminophen | TABLET | 325 mg | ORAL | N02BE01 | OTC medicines | 1385/11/4 | |||||
Acetaminophen | SUSPENSION | 100 mg/ml | ORAL | N02BE01 | OTC medicines | 1385/11/18 | |||||
Acetaminophen | SOLUTION | 100 mg/ml | ORAL | N02BE01 | OTC medicines | 1372/06/20 | |||||
Acetaminophen | SUSPENSION | 120 mg/5ml | ORAL | N02BE01 | OTC medicines | 1369/08/02 | |||||
Acetaminophen | SOLUTION | 120 mg/5ml | ORAL | N02BE01 | OTC medicines | ||||||
Acetaminophen | TABLET, ORALLY DISINTEGRATING | 125 mg | ORAL | N02BE01 | OTC medicines | for local production only | 1389/07/17 | ||||
Acetaminophen | SUPPOSITORY | 125 mg | RECTAL | N02BE01 | OTC medicines | 1369/10/30 | |||||
Acetaminophen | SUPPOSITORY | 75 mg | RECTAL | N02BE01 | 1396/12/08 | ||||||
Acetaminophen | INJECTION, SOLUTION, CONCENTRATE | 150 mg/ml | INTRAVENOUS DRIP | N02BE01 | Hospital use only | ||||||
Acetaminophen | TABLET, DISPERSIBLE | 160 mg | ORAL | N02BE01 | OTC medicines | 1389/06/29 | |||||
Acetaminophen | TABLET, ORALLY DISINTEGRATING | 250 mg | ORAL | N02BE01 | OTC medicines | for local production only | 1389/07/17 | ||||
Acetaminophen | SUPPOSITORY | 325 mg | RECTAL | N02BE01 | OTC medicines | 1369/10/30 | |||||
Acetaminophen | TABLET | 325 mg | ORAL | N02BE01 | OTC medicines | 1369/10/30 | |||||
Acetaminophen | TABLET, ORALLY DISINTEGRATING | 500 mg | ORAL | N02BE01 | OTC medicines | for local production only | 1389/07/17 | ||||
Acetaminophen | TABLET, EFFERVESCENT | 500 mg | ORAL | N02BE01 | OTC medicines | 1387/05/16 | |||||
Acetaminophen | TABLET | 500 mg | ORAL | N02BE01 | OTC medicines | 1369/10/30 | |||||
Acetaminophen | CAPSULE, LIQUID FILLED | 500 mg | ORAL | N02BE01 | OTC medicines | 1385/08/17 | |||||
Acetaminophen | CAPSULE, LIQUID FILLED | 325 mg | ORAL | N02BE01 | OTC medicines | 1395/09/13 | |||||
Acetaminophen | TABLET, DISPERSIBLE | 80 mg | ORAL | N02BE01 | OTC medicines | 1386/12/06 | |||||
Acetaminophen+Caffeine | TABLET | ORAL | N02BE51 | Acetaminophen 500mg + Caffeine 65 mg | OTC medicines | 1387/07/07 | |||||
Acetaminophen+Caffeine | TABLET, EFFERVESCENT | ORAL | N02BE51 | Acetaminophen 500mg + Caffeine 65 mg | OTC medicines | 1396/04/31 | |||||
Acetaminophen+Caffeine+Codeine | TABLET | ORAL | N02BE51 | Acetaminophen300mg + Caffeine 15 mg+ Codeine phosphate 15 mg | 1395/02/02 | ||||||
Acetaminophen+Caffeine+Ibuprofen | CAPSULE, LIQUID FILLED | ORAL | N02BE71 | Acetaminophen 325mg + Caffeine 40 mg+ Ibuprofen 200mg | OTC medicines | 1390/07/04 | |||||
Acetaminophen+Caffeine+Ibuprofen | CAPSULE | ORAL | N02BE71 | Acetaminophen 325mg + Caffeine 40 mg+ Ibuprofen 200mg | OTC medicines | 1385/02/12 | |||||
Acetaminophen+Chlorpheniramine+Dextrometorphan+Phenylephrine | SYRUP | ORAL | R05X | (Acetaminophen160 mg/Chlorpheniramine Maleate 1 mg/DextrometorphanHBr 5 mg/Phenylephrine HCl 2.5mg)/5ml | OTC medicines | 1392/09/25 | |||||
Acetaminophen+Caffeine+Chlorpheniramine+Vitamin C | CAPSULE | ORAL | R05X | Acetaminophen 200 mg+ Caffeine 25 mg+Chlorpheniramine Maleate 2.5 mg+Vitamine C 150 mg | OTC medicines | 1396/12/08 | |||||
Acetaminophen+Codeine | CAPSULE, LIQUID FILLED | ORAL | N02BE71 | Acetaminophen 300mg + Codeine Phosphate 20mg | 1393/10/14 | ||||||
Acetaminophen+Codeine | TABLET | ORAL | N02BE71 | Acetaminophen 300mg + Codeine Phosphate 20mg | 1393/10/14 | ||||||
Acetaminophen+Diphenhydramine+Phenylephrine | SYRUP | ORAL | R05X | (Acetaminophen 160 mg/DiphenhydramineHCl 12.5mg/phenylephrine HCl 2.5 mg)/5ml | OTC medicines | 1391/06/13 | |||||
Acetaminophen+Guaifensine+Phenylephrine | SYRUP | ORAL | R05X | Acetaminophen 125/Guaifenesine 50mg/phenylephrine 2.5/5ml | OTC medicines | 1392/05/01 | |||||
Acetaminophen+Ibuprofen | TABLET | ORAL | N02BE51 | Acetaminophen 500 mg+Ibuprofen 200 mg | 1397/04/03 | ||||||
Acetaminophen+Oxycodone | TABLET | ORAL | N02AJ17 | Acetaminophen 325mg + Oxycodone Hydrochloride 5 mg | Accessible only in Hospital, Universities and Elected Pharmacies | 1397/02/02 | |||||
Acetaminophen+Oxycodone | TABLET | ORAL | N02AJ17 | Acetaminophen 325mg + Oxycodone Hydrochloride 10 mg | Accessible only in Hospital, Universities and Elected Pharmacies | 1397/02/02 | |||||
Acetazolamide | TABLET | 250 mg | ORAL | S01EC01 | |||||||
Acetazolamide | As Sodium | INJECTION, POWDER | 500 mg | PARENTERAL | S01EC01 | Hospital use only | |||||
Acetic Acid | BULK | V03 | Bulk medicines | ||||||||
Acetone | BULK | V03 | Bulk medicines | ||||||||
Acetylcholine | Chloride | INJECTION | 1% | OPHTHALMIC | S01EB09 | Hospital use only | 1360/09/15 | ||||
Acetylcysteine | SOLUTION | 100 mg/ml | RESPIRATORY | R05CB01 | Hospital use only | Nebulisation | 1393/10/14 | ||||
Acetylcysteine | SOLUTION, CONCENTRATE | 20% | ORAL | R05CB01 | 1397/02/11 | ||||||
Acetylcysteine | SOLUTION | 10% | ORAL | R05CB01 | 1397/02/11 | ||||||
Acetylcysteine | TABLET | 200 mg | ORAL | R05CB01 | 1378/05/10 | ||||||
Acetylcysteine | TABLET | 600 mg | ORAL | R05CB01 | Mucolytic | 1395/06/31 | |||||
Acetylcysteine | TABLET, EFFERVESCENT | 200 mg | ORAL | R05CB01 | 1386/08/09 | ||||||
Acetylcysteine | INJECTION | 200 mg/ml | PARENTERAL | V03AB23 | Hospital use only | ||||||
Acetylcysteine | INJECTION | 100 mg/ml | PARENTERAL | V03AB23 | Hospital use only | 1395/12/07 | |||||
Acetylcysteine | POWDER | 600 mg | ORAL | R05CB01 | Sachet | 1388/03/13 | |||||
Acetylcysteine | GRANULE | 100 mg | ORAL | R05CB01 | Sachet | 1397/02/11 | |||||
Acetylcysteine | GRANULE | 200 mg | ORAL | R05CB01 | Sachet | 1397/02/11 | |||||
Acetylcysteine | TABLET, EFFERVESCENT | 600 mg | ORAL | R05CB01 | 1380/06/25 | ||||||
Acetylcysteine+Ascorbic Acid | POWDER | ORAL | R05CB | (Acetylcysteine 600mg + Vitamin C 75mg)/sachet | 1387/03/08 | ||||||
Aciclovir | OINTMENT | 3% | OPHTHALMIC | S01AD03 | 1363/10/02 | ||||||
Aciclovir | CREAM | 5% | TOPICAL | D06BB03 | 1363/10/02 | ||||||
Aciclovir | TABLET | 200 mg | ORAL | J05AB01 | 1363/10/02 | ||||||
Aciclovir | INJECTION, POWDER, LYOPHILIZED | 250 mg | PARENTERAL | J05AB01 | 1363/10/02 | ||||||
Aciclovir | TABLET | 400 mg | ORAL | J05AB01 | 1371/08/24 | ||||||
Aciclovir | INJECTION, POWDER | 500 mg | PARENTERAL | J05AB01 | 1382/04/29 | ||||||
Aciclovir | TABLET | 800 mg | ORAL | J05AB01 | 1387/05/06 | ||||||
Acitretin | CAPSULE | 10 mg | ORAL | D05BB02 | 1376/03/11 | ||||||
Acitretin | CAPSULE | 25 mg | ORAL | D05BB02 | 1376/03/11 | ||||||
Aclidinium+Formoterol | INHALATION, POWDER | RESPIRATORY | R03AL05 | (Aclidinium Bromide 396 mcg+Formoterol Fumarate Dihydrate 11.8 mcg)/ dose | 1396/09/12 | ||||||
Activated Prothrombin Complex (concentrated) | INJECTION, POWDER, LYOPHILIZED | 1000 U | PARENTERAL | B02BD03 | |||||||
Activated Prothrombin Complex (concentrated) | INJECTION, POWDER, LYOPHILIZED | 500U | PARENTERAL | B02BD03 | |||||||
Adalimumab | INJECTION, SOLUTION | 40mg/0.8ml | PARENTERAL | L04AB04 | 1391/12/23 | ||||||
Adapalene | CREAM | 0.10% | TOPICAL | D10AD03 | 1384/12/09 | ||||||
Adapalene | GEL | 0.10% | TOPICAL | D10AD03 | 1383/09/02 | ||||||
Adapalene | LOTION | 0.10% | TOPICAL | D10AD03 | 1386/01/22 | ||||||
Adapalene | SOLUTION | 0.10% | TOPICAL | D10AD03 | 1383/02/13 | ||||||
Adapalene | GEL | 0.30% | TOPICAL | D10AD03 | 1397/02/02 | ||||||
Adapalene+Benzoyl Peroxide | GEL | TOPICAL | D10AD53 | Adapalene 0.1%+Benzoyl Peroxide 2.5% | 1396/11/29 | ||||||
Adefovir | Dipivoxil | TABLET | 10 mg | ORAL | J05AF08 | 1385/02/12 | |||||
Adenosine | INJECTION | 3 mg/ml | PARENTERAL | C01EB10 | Hospital use only | 1377/11/18 | |||||
Adult Cold Preparations_1: (Decongestant+ Analgesic) | CAPSULE, LIQUID FILLED | ORAL | R05X | As Decongestant: Phenylephrine HCl (5, 10 mg) or Pseudoephedrine HCl (30mg ,120mg) ,As Analgesic: Acetaminophen ( 250,325, 500, 650 mg) or Ibuprofen(200mg) or Naproxen sodium( 200mg) | OTC medicines | The combinations to be exist in international Pharmacopoeia , if 120 mg Pseudoephedrine is in formulation it would be extended release | 1388/10/30 | ||||
Adult Cold Preparations_1: (Decongestant+ Analgesic) | POWDER FOR SOLUTION | ORAL | R05X | As Decongestant: Phenylephrine HCl (5, 10 mg) or Pseudoephedrine HCl (30mg ,120mg) ,As Analgesic: Acetaminophen ( 250,325, 500, 650 mg) or Ibuprofen(200mg) or Naproxen sodium( 200mg) | OTC medicines | The combinations to be exist in international Pharmacopoeia , if 120 mg Pseudoephedrine is in formulation it would be extended release | 1397/04/30 | ||||
Adult Cold Preparations_1: (Decongestant+ Analgesic) | TABLET | ORAL | R05X | As Decongestant: Phenylephrine HCl (5, 10 mg) or Pseudoephedrine HCl (30mg ,120mg) ,As Analgesic: Acetaminophen ( 250,325, 500, 650 mg) or Ibuprofen(200mg) or Naproxen sodium( 200mg) | OTC medicines | The combinations to be exist in international Pharmacopoeia, if 120 mg Pseudoephedrine is in formulation it would be extended release | 1388/10/30 | ||||
Adult Cold Preparations_2: (Decongestant + Expectorant+ Analgesic) | CAPSULE, LIQUID FILLED | ORAL | R05X | As Decongestant: Pseudoephedrine HCl (30 mg),As Expectorant : Guaifenesin ( 200 mg), As Analgesic: Acetaminophen ( 325 mg) | OTC medicines | The combinations to be exist in international Pharmacopoeia | 1388/05/07 | ||||
Adult Cold Preparations_2: (Decongestant + Expectorant+ Analgesic) | TABLET | ORAL | R05X | As Decongestant: Pseudoephedrine HCl (30 mg),As Expectorant : Guaifenesin ( 200 mg), As Analgesic: Acetaminophen ( 325 mg) | OTC medicines | The combinations to be exist in international Pharmacopoeia | 1388/05/07 | ||||
Adult Cold Preparations_3: (Antihistamine + Analgesic ) | TABLET | ORAL | R05X | As Antihistamine: Chlorpheniramine maleate(2mg) or Diphenhydramine HCl (12.5 ,25mg), As Analgesic : Acetaminophen ( 325, 500 mg) or Ibuprofen (200 mg) | OTC medicines | The combinations to be exist in international Pharmacopoeia | 1388/05/07 | ||||
Adult Cold Preparations_3: (Antihistamine + Analgesic ) | CAPSULE, LIQUID FILLED | ORAL | R05X | As Antihistamine: Chlorpheniramine maleate(2mg) or Diphenhydramine HCl (12.5 ,25mg), As Analgesic : Acetaminophen ( 325, 500 mg) or Ibuprofen (200 mg) | OTC medicines | The combinations to be exist in international Pharmacopoeia | 1388/05/07 | ||||
Adult Cold Preparations_4: (Decongestant +Antihistamine+ Analgesic) | TABLET | ORAL | R05X | As Analgesic: Acetaminophen ( 162.5 , 300,325, 500, 650 mg) ,As Decongestant: Phenylephrine HCl (5,10 mg) or Pseudoephedrine (30,60mg) , As Antihistamine: Diphenhydramine HCl (12.5, 25 mg) or Chlorpheniramine maleate (2 , 4 mg) or Clemastine fumarate (0.335mg) | OTC medicines | The combinations to be exist in international Pharmacopoeia | 1388/05/07 | ||||
Adult Cold Preparations_4: (Decongestant +Antihistamine+ Analgesic) | POWDER FOR SOLUTION | ORAL | R05X | As Analgesic: Acetaminophen ( 162.5 , 300,325, 500, 650 mg) ,As Decongestant: Phenylephrine HCl (5,10 mg) or Pseudoephedrine (30,60mg) , As Antihistamine: Diphenhydramine HCl (12.5, 25 mg) or Chlorpheniramine maleate (2 , 4 mg) or Clemastine fumarate (0.335mg) | OTC medicines | The combinations to be exist in international Pharmacopoeia | 1397/05/10 | ||||
Adult Cold Preparations_4: (Decongestant +Antihistamine+ Analgesic) | CAPSULE, LIQUID FILLED | ORAL | R05X | As Analgesic: Acetaminophen ( 162.5 ,250, 300,325, 500, 650 mg) ,As Decongestant: Phenylephrine HCl (5,10 mg) or Pseudoephedrine (30,60mg) , As Antihistamine: Diphenhydramine HCl (12.5, 25 mg) or Chlorpheniramine maleate (2 , 4 mg) or Clemastine fumarate (0.335mg) | OTC medicines | The combinations to be exist in international Pharmacopoeia | 1388/09/04 | ||||
Adult Cold Preparations_5: (Antitussive + Decongestant + Analgesic ) | TABLET | ORAL | R05X | As Antitussive: Dextromethorphan HBr (10,15, 20mg) , As Decongestant : Pseudoephedrine HCl (30 mg) or Phenylephrine HCl (5, 10 mg), As Analgesic: Acetaminophen (325-650 ) | OTC medicines | The combinations to be exist in international Pharmacopoeia | 1388/05/07 | ||||
Adult Cold Preparations_5: (Antitussive + Decongestant + Analgesic ) | CAPSULE, LIQUID FILLED | ORAL | R05X | As Antitussive: Dextromethorphan HBr (10,15, 20mg) , As Decongestant : Pseudoephedrine HCl (30 mg) or Phenylephrine HCl (5, 10 mg), As Analgesic: Acetaminophen (325-650 ) | OTC medicines | The combinations to be exist in international Pharmacopoeia | 1388/05/07 | ||||
Adult Cold Preparations_5: (Antitussive + Decongestant + Analgesic ) | POWDER FOR SOLUTION | ORAL | R05X | As Antitussive: Dextromethorphan HBr (10,15, 20mg) , As Decongestant : Pseudoephedrine HCl (30 mg) or Phenylephrine HCl (5, 10 mg), As Analgesic: Acetaminophen (325-650 ) | OTC medicines | The combinations to be exist in international Pharmacopoeia | 1397/05/10 | ||||
Adult Cold Preparations_6: (Antitussive+ Antihistamine+ Analgesic ) | CAPSULE, LIQUID FILLED | ORAL | R05X | As Analgesic : Acetaminophen(300, 500 mg), As antihistamine: Chlorpheniramine maleate (2 mg ) , As Antitussive: Dextromethorphan(15 mg ) | OTC medicines | The combinations to be exist in international Pharmacopoeia | 1388/05/07 | ||||
Adult Cold Preparations_6: (Antitussive+ Antihistamine+ Analgesic ) | TABLET | ORAL | R05X | As Analgesic : Acetaminophen(300, 500 mg), As antihistamine: Chlorpheniramine maleate (2 mg ) , As Antitussive: Dextromethorphan(15 mg ) | OTC medicines | The combinations to be exist in international Pharmacopoeia | 1388/05/07 | ||||
Adult Cold Preparations_7 :(Antitussive+ Antihistamine+ Decongestant+ Analgesic) | TABLET | ORAL | R05X | As Antitussive : Dextromethorphan(10,15, 20 mg), As Antihistamine: Chlorpheniramine maleate (2 mg) , As Decongestant : Pseudoephedrine (30 mg) or Phenylephrine HCl (5, 10 mg), As Analgesic: Acetaminophen (250, 325,500, 650 mg) | OTC medicines | The combinations to be exist in international Pharmacopoeia | 1388/05/07 | ||||
Adult Cold Preparations_7 :(Antitussive+ Antihistamine+ Decongestant+ Analgesic) | CAPSULE, LIQUID FILLED | ORAL | R05X | As Antitussive : Dextromethorphan(10,15, 20 mg), As Antihistamine: Chlorpheniramine maleate (2 mg) , As Decongestant : Pseudoephedrine (30 mg) or Phenylephrine HCl (5, 10 mg), As Analgesic: Acetaminophen (250, 325,500, 650 mg) | OTC medicines | The combinations to be exist in international Pharmacopoeia | 1388/05/07 | ||||
Adult Cold Preparations_8: (Antitussive+ Expectorant+ Decongestant+ Analgesic) | CAPSULE, LIQUID FILLED | ORAL | R05X | As Antitussive : Dextromethorphan (10, 15 mg), As Expectorant : Guaifenesin (100, 200 mg), As Decongestant : Pseudoephedrine HCl (30mg) or Phenylephrine HCl (5mg), As Analgesic: Acetaminophen(250, 325 mg) | OTC medicines | The combinations to be exist in international Pharmacopoeia | 1388/05/07 | ||||
Adult Cold Preparations_8: (Antitussive+ Expectorant+ Decongestant+ Analgesic) | TABLET | ORAL | R05X | As Antitussive : Dextromethorphan (10, 15 mg), As Expectorant : Guaifenesin (100, 200 mg), As Decongestant : Pseudoephedrine HCl (30mg) or Phenylephrine HCl (5mg), As Analgesic: Acetaminophen(250, 325 mg) | OTC medicines | The combinations to be exist in international Pharmacopoeia | 1388/05/7 | ||||
Aflibercept | INJECTION, SOLUTION | 40mg/ml | PARENTERAL | S01LA05 | Macular Oedema | Hospital use only | 1395/08/02 | ||||
Agomelatine | TABLET | 25 mg | ORAL | N06AX22 | 1396/09/12 | ||||||
Albendazole | TABLET, CHEWABLE | 200 mg | ORAL | P02CA03 | Treatment of hydatid disease (cystic echinococcosis due to E. granulosus larvae or alveolar echinococcosis due to E. multilocularis larvae). | ||||||
Albendazole | SUSPENSION | 200 mg/5ml | ORAL | P02CA03 | Treatment of hydatid disease (cystic echinococcosis due to E. granulosus larvae or alveolar echinococcosis due to E. multilocularis larvae). | ||||||
Albendazole | TABLET, CHEWABLE | 400 mg | ORAL | P02CA03 | Treatment of hydatid disease (cystic echinococcosis due to E. granulosus larvae or alveolar echinococcosis due to E. multilocularis larvae). | 1370/10/01 | |||||
Albumin (Human) | INJECTION, SOLUTION | 25% | PARENTERAL | B05AA01 | Hospital use only | 1396/04/18 | |||||
Albumin (Human) | INJECTION, SOLUTION | 20%, 100ml | PARENTERAL | B05AA01 | Hospital use only | ||||||
Albumin (Human) | INJECTION, SOLUTION | 20%, 10ml | PARENTERAL | B05AA01 | Hospital use only | ||||||
Albumin (Human) | INJECTION, SOLUTION | 20%, 250ml | PARENTERAL | B05AA01 | Hospital use only | 1385/08/17 | |||||
Albumin (Human) | INJECTION, SOLUTION | 20%, 500ml | PARENTERAL | B05AA01 | Hospital use only | 1385/08/17 | |||||
Albumin (Human) | INJECTION, SOLUTION | 20%, 50ML | PARENTERAL | B05AA01 | Hospital use only | ||||||
Albumin (Human) | INJECTION, SOLUTION | 5%, 100ML | PARENTERAL | B05AA01 | Hospital use only | ||||||
Albumin (Human) | INJECTION, SOLUTION | 5%, 250ml | PARENTERAL | B05AA01 | Hospital use only | 1385/08/17 | |||||
Albumin (Human) | INJECTION, SOLUTION | 5%, 500ml | PARENTERAL | B05AA01 | Hospital use only | 1385/08/17 | |||||
Alemtuzumab | INJECTION, SOLUTION, CONCENTRATE | 30 mg/ ml | INTRAVENOUS DRIP | L04AA34 | 1388/04/21 | ||||||
Alemtuzumab | INJECTION, SOLUTION, CONCENTRATE | 10 mg/ ml | INTRAVENOUS DRIP | L04AA34 | Relapsing Remitting Multiple Sclerosis | Orphan medicines | 1395/09/01 | ||||
Alendronate | TABLET | 10 mg | ORAL | M05BA04 | |||||||
Alendronate | As Sodium | TABLET | 35 mg | ORAL | M05BA04 | 1381/12/27 | |||||
Alendronate | As Sodium | TABLET | 70 mg | ORAL | M05BA04 | 1381/12/27 | |||||
Alendronate | As Sodium | EFFERVESCEN TABLET | 70 mg | ORAL | M05BA04 | 1397/02/11 | |||||
Alendronic acid+Colecalciferol | TABLET | ORAL | M05BB03 | Alendronic acid 70mg+Colecalciferol 70mcg | for local production only | 1390/03/09 | |||||
Alendronic acid+Colecalciferol | TABLET | ORAL | M05BB03 | Alendronic acid 70mg+Colecalciferol 140mcg | 1390/01/29 | ||||||
Alfentanil | INJECTION | 0.5 mg/ml | PARENTERAL | N01AH02 | As HCl | Hospital use only | |||||
Alglucosidase Alfa | INJECTION, POWDER | 50 mg | PARENTERAL | A16AB07 | Orphan medicines | 1390/07/05 | |||||
Allopurinol | TABLET | 100 mg | ORAL | M04AA01 | |||||||
Allopurinol | TABLET | 300 mg | ORAL | M04AA01 | 1378/05/10 | ||||||
Alprazolam | TABLET | 0.5 mg | ORAL | N05BA12 | 1373/09/20 | ||||||
Alprazolam | TABLET | 1 mg | ORAL | N05BA12 | 1373/09/20 | ||||||
Alteplase | INJECTION, POWDER | 10 mg | PARENTERAL | B01AD02 | Acute Ischemic Strock Acute Myocardial Infarction Pulmonary Embolism | for local production only | 1387/09/09 | ||||
Alteplase | INJECTION, POWDER | 20 mg | PARENTERAL | B01AD02 | Acute Ischemic Strock Acute Myocardial Infarction Pulmonary Embolism | 1387/09/09 | |||||
Alteplase | INJECTION, POWDER | 50 mg | PARENTERAL | B01AD02 | Acute Ischemic Strock Acute Myocardial Infarction Pulmonary Embolism | 1387/09/09 | |||||
Aluminium Chloride | BULK | V03 | Bulk medicines | 1361/11/17 | |||||||
Aluminium Hydroxide | TABLET, CHEWABLE | 300 mg | ORAL | A02AB01 | OTC medicines; as Dried Gel | 1369/06/11 | |||||
Aluminium Hydroxide | SUSPENSION | 320 mg/5ml | ORAL | A02AB01 | OTC medicines; Gel | 1369/06/11 | |||||
Aluminium/Magnesium/Simethicone | SUSPENSION | ORAL | A02AF02 | (Aluminium hydroxide 225mg+magnesium hydroxide 200mg+simethicone 25mg)/5ml | OTC medicines | 1369/10/30 | |||||
Aluminium+Magnesium | SUSPENSION | ORAL | A02AX | (Aluminium hydroxide 225mg+magnesium hydroxide 200)/5ml | OTC medicines | 1369/10/30 | |||||
Aluminium+Magnesium | SUSPENSION | ORAL | A02AX | (Aluminium hydroxide 225mg+magnesium hydroxide 200mg)/5ml Sachet | OTC medicines | 1369/10/30 | |||||
Aluminium+Magnesium | POWDER, FOR SUSPENSION | ORAL | A02AX | (Aluminium hydroxide 564mg + Magnesium hydroxide 174mg)/sachet | OTC medicines | 1363/10/23 | |||||
Aluminium+Magnesium | TABLET, CHEWABLE | ORAL | A02AX | Aluminium hydroxide 200mg + magnesium hydroxide 200mg | OTC medicines | 1369/10/30 | |||||
Aluminium+Magnesium+Simethicone | SUSPENSION | ORAL | A02AF02 | (Aluminium hydroxide 225mg+magnesium hydroxide 200mg+simethicone 25mg)/5ml/sachet | OTC medicines | 1369/10/30 | |||||
Aluminium+Magnesium+Simethicone | TABLET, CHEWABLE | ORAL | A02AF02 | Aluminium hydroxide 200mg+magnesium hydroxide 200mg+simethicone 25mg | OTC medicines | 1369/10/30 | |||||
Amantadine | HCl | CAPSULE | 100 mg | ORAL | N04BB01 | ||||||
Ambenonium | Chloride | TABLET | 10 mg | ORAL | N07AA30 | ||||||
Amikacin | As Sulfate | INJECTION | 250 mg/ml | PARENTERAL | J01GB06 | Treatment of bronchopulmonary Pseudomonas aeruginosa infections in cystic fibrosis patients | Hospital use only | ||||
Amikacin | As Sulfate | INJECTION | 50 mg/ml | PARENTERAL | J01GB06 | Hospital use only | |||||
Amiloride+Hyrochlorothiazide | TABLET | ORAL | C03EA01 | Amiloride as dihydrate 5 mg+Hyrochlorothiazide 50 mg | 1369/10/16 | ||||||
Amino Caproic Acid | INJECTION | 250 mg/ml | PARENTERAL | B02AA01 | Hospital use only | 1382/03/04 | |||||
Amino Caproic Acid | INJECTION | 400 mg/ml | PARENTERAL | B02AA01 | Hospital use only | 1382/03/04 | |||||
Aminoacid | INJECTION, SOLUTION | 5% | INTRAVENOUS DRIP | B05BA01 | Hospital use only | Total weight of Amino Acids equal to 50g/l | 1390/02/21 | ||||
Aminoacid | INJECTION, SOLUTION, CONCENTRATE | 10% | INTRAVENOUS DRIP | B05BA01 | Hospital use only | Total weight of Amino Acids equal to 100g/l | 1389/08/24 | ||||
Aminoacid | INJECTION, SOLUTION | 10% | INTRAVENOUS DRIP | B05BA01 | Hospital use only | Total weight of Amino Acids equal to 100g/l | 1391/05/04 | ||||
Aminoacid | INJECTION, SOLUTION | 15% | INTRAVENOUS DRIP | B05BA01 | Hospital use only | Total weight of Amino Acids equal to 150g/l | 1396/12/08 | ||||
Aminoacid+ Electrolyte | INJECTION, SOLUTION | 5% | INTRAVENOUS DRIP | B05BA01 | Isoleucine 2.55g+Leucine 4.45g+lysine HCl 3.50g+Methionine 1.90g+Phenylalanine 2.55g+Threonine 2.05g+Tryptophane 0.90g+Valine 2.40g+Arginine 4.60g+Histidine 2.60g+Alanine 6.85g+Glycine 3.95g+Asparagine H2O 1.86g+Asparatic acid 0.65g+Acetylcysteine 0.34g+Glutamic acid 2.30g+Ornithine HCl 1.60g+Proline 4.45g+Serine 1.20g+Tyrosine 0.30g+Acetyltyrosine 0.43g+Sodium acetate 3H2O 3.95g+Potassium acetate 2.454g+Magnesium acetate 4H2O 0.558g+Sodium dihydrogen phosphate dihydrate 1.4g+Malic acid 1.01g+Sodium hydroxide 0.2g Water for inj. Q.S. to 1000 ml | Hospital use only | 1389/11/04 | ||||
Aminoacid+Electrolyte | INJECTION, SOLUTION | 5% | INTRAVENOUS DRIP | B05BA01 | Isoleucine 2.50g+Leucine 4.45g+lysine HCl 4.28g+Methionine 2.20g+Phenylalanine 2.35g+Threonine 2.10g+Tryptophane 0.80g+Valine 3.10g+Arginine 5.75g+Histidine 1.50g+Alanine 5.25g+Glycine 6.00g+ Asparatic acid 2.80g+ Glutamic acid 3.60g +Proline 2.75g+Serine 1.15g+Tyrosine 0.40g+ Sodium acetate 3H2O 1.361g+ Sodium chloride 0.964g + Sodium hydroxide 0.140g+potassium acetate 2.453g+ Magnesium chloride 6H2O 0.508g+Disodium phosphate dodecahydrate 3.581g+ Water for inj. Q.S. to 1000 ml | Hospital use only | 1390/1/29 | ||||
Aminoacid+Electrolyte | INJECTION, SOLUTION | 10% | INTRAVENOUS DRIP | B05BA01 | {Isoleucine (0.77-13.80)mg+leucine (1.10-15.76)mg+Lysine HCL(1.08-15.75)mg+Methionine (0.40-8.80)mg+Phenylalanine (0.75-8.80)mg+Threonine (0.50-9.00)mg+Tryptophane (0.23-3.00)mg+ Valine (0.75-12.40)mg+ Arginine (0.93-20.00)mg+ Histidine (0.65-9.80)mg+ Alanine (0.846-82.00)mg+ Glycine (0.31-19.20)mg + Asparatic acid (0.65-10.50)mg + Glutamic acid (1.14-11.07)mg+Proline (1.15-17.00)mg + Serine (0.60-14.10)mg+ Tyrosine (0.05-10.16)mg+Sodium Acetate 3H2O 2.858mg+Sodium Hydroxide 0.360mg+Pottassium Acetate 2.453mg + Magnesium Chloride 6H2O 0.508mg+Disodium Phosphate dodecahydrate 3.581mg}/ml | Hospital use only | 1390/1/29 | ||||
Aminoacid+Electrolyte | INJECTION, SOLUTION, CONCENTRATE | 10% | INTRAVENOUS DRIP | B05BA01 | {Isoleucine (0.77-13.80)mg+leucine (1.10-15.76)mg+Methionine (0.40-8.80)mg+Phenylalanine (0.75-8.80)mg+Threonine (0.50-9.00)mg+Tryptophane (0.23-3.00)mg+ Valine (0.75-12.40)mg+ Arginine (0.93-20.00)mg+ Histidine (0.65-9.80)mg+ Alanine (0.846-82.00)mg+ Taurine (0.12-2.00)mg+Proline (1.15-17.00)mg+ Serine (0.60-14.10)mg+ Tyrosine (0.05-10.16)mg+ Cysteine (0.074-2.00)mg+ Asparagine (0.32-4.09)mg+ Asparatic acid (0.65-10.50)mg+ Glycine (0.31-19.20)mg+ Glutamic acid (1.14-11.07)mg+ Lysine hydrochloride (1.08-15.75)mg+ Lysine acetate (3.34-9.31)mg+Ornithine (0.63-3.75)mg +Glutamine (1.20-22.08)mg +Acetylcysteine 0.68 mg+N-Acetyltyrosine 1.23 mg+Sodium Acetate 3H2O 3.95mg+Pottassium Acetate 2.454mg+Magnesium Acetate 4H2O 0.56mg+Sodium Dihydrogen Phosphate dihydrate 1.404mg+Malic Acid 1.01mg+Sodium Hydroxide 0.2mg}/ml | Hospital use only | 1389/11/04 | ||||
Aminoacid+Lipid+Glucose 1 | INJECTION,EMULSION | INTRAVENOUS DRIP | B05BA10 | nutriflex lipid plus: Isoleucine 2.26g +Leucine 3.01g+Lysine HCl 2.73g +Methionine 1.88g+Phenylalanine3.37g+Threonine 1.74g+Tryptophane 0.54g+Valine 2.50g+Arginine 2.59g+Histidine HCl monohydrate 1.62g+Alanine 4.66g+Glycine 1.58g+Aspartic acid 1.44g+Glutamic acid 3.37 g+Proline 3.26g+Serine 2.88+ Sodium Chloride 0.402g+Sodium acetate trihydrate 0.222g+ Potassium acetate 2.747g+ Magnesium Acetate tetrahydrate 0.686g + Calcium Chloride dihydrate 0.470g + Sodium hydroxide 0.781 g+Glucose monohydrate 132g+Sodium dihydrogen phosphate dihydrate 1.872g+Zinc acetate dihydrate 5.264g+Triglycerids,mediumchain 20g+Soya-bean oil,refined 20g+Water for inj. Q.S. to 1000 ml | Hospital use only | 1389/11/4 | |||||
Aminoacid+Lipid+Glucose 2 | INJECTION, EMULSION | INTRAVENOUS DRIP | B05BA10 | nutriflex lipid special: Isoleucine 3.28g + Leucine 4.38g + Lysine HCl 3.98g + Methionine 2.74g + Phenylalanine4.92g + Threonine 2.54g + Tryptophane 0.8g + Valine 3.6g + Arginine 3.780g + Histidine HCl monohydrate 2.37g + Alanine 6.79g + Glycine 2.31g + Aspartic acid 2.1g + Glutamic acid 4.91g +Proline 4.76g +Serine 4.2g + Sodium Chloride 0.378g+Sodium acetate trihydrate 0.25g+ Potassium acetate 3.689g+ Magnesium Acetate tetrahydrate 0.91g + Calcium Chloride dihydrate 0.623g + Sodium hydroxide 1.171 g+Glucose monohydrate 158.4g+Sodium dihydrogen phosphate dihydrate 2.496g+Zinc acetate dihydrate 7.02g+Triglyceride,mediumchain 20g+Soya-bean oil,refined 20g+Water for inj. Q.S. to 1000 ml | Hospital use only | 1389/11/4 | |||||
Aminoacid+Lipid+Glucose 3 | INJECTION,EMULSION | INTRAVENOUS DRIP | B05BA10 | nutriflex lipid peri: Isoleucine 1.872g +Leucine 2.504g+Lysine HCl 2.272g +Methionine 1.568g+Phenylalanine2.808g+Threonine 1.456g+Tryptophane 0.456g+Valine 2.08g+Arginine 2.160g+Histidine HCl monohydrate 1.352g+Alanine 3.88g+Glycine 1.32g+Aspartic acid 1.20g+Glutamic acid 2.80 g+Proline 2.72g+Serine 2.40g+ Sodium Hydroxide 0.64g + Sodium Chloride 0.865g+Sodium acetate trihydrate 0.435g+ Potassium acetate 2.354g+ Magnesium Acetate 4H2o 0.515g + Calcium Chloride dihydrate 0.353g + Glucose monohydrate 70.4g +Sodium dihydrogen phosphate dihydrate 0.936g+Zinc acetate dihydrate 5.28g+Triglycerids,mediumchain 20g+Soya-bean oil,refined 20g+Water for inj. Q.S. to 1000 ml | Hospital use only | 1389/11/04 | |||||
Aminobenzoic Acid+Padimate | LOTION | TOPICAL | D02BA | Para Aminobenzoic Acid 5% w/w + Padimate O 3.2% w/w( Paba-p) | |||||||
Aminobenzoic Acid | LOTION | 5% | TOPICAL | D02BA01 | Paba | 1362/8/15 | |||||
Aminoglutethimide | TABLET | 250 mg | ORAL | L02BG01 | |||||||
Aminophylline | INJECTION | 25 mg/ml | PARENTERAL | R03DA05 | Hospital use only | ||||||
Amiodarone | HCl | INJECTION, SOLUTION | 150 mg/100ml | PARENTERAL | C01BD01 | For the acute treatment and prophylaxis of life-threatening ventricular tachycardia or ventricular fibrillation. | Hospital use only | 1391/10/03 | |||
Amiodarone | HCl | TABLET | 200 mg | ORAL | C01BD01 | ||||||
Amiodarone | HCl | INJECTION | 50 mg/ml | PARENTERAL | C01BD01 | For the acute treatment and prophylaxis of life-threatening ventricular tachycardia or ventricular fibrillation. | Hospital use only | 1364/11/06 | |||
Amitriptyline | HCl | TABLET | 10 mg | ORAL | N06AA09 | 1377/05/25 | |||||
Amitriptyline | HCl | TABLET | 100 mg | ORAL | N06AA09 | 1371/06/08 | |||||
Amitriptyline | HCl | TABLET | 25 mg | ORAL | N06AA09 | 1377/5/25 | |||||
Amitriptyline | HCl | TABLET | 50 mg | ORAL | N06AA09 | 1372/5/24 | |||||
Amlodipine | As Besilate | TABLET | 10 mg | ORAL | C08CA01 | 1386/08/09 | |||||
Amlodipine | As Besilate | TABLET | 2.5 mg | ORAL | C08CA01 | 1386/08/09 | |||||
Amlodipine | As Besilate | TABLET | 5 mg | ORAL | C08CA01 | ||||||
Amlodipine+Atorvastatin | TABLET | ORAL | C10BX03 | Amlodipine (As Besilate0 10mg+ Atorvastatin As Calcium10mg | 1388/08/20 | ||||||
Amlodipine+Atorvastatin | TABLET | ORAL | C10BX03 | Amlodipine (As Besilate) 5mg+ Atorvastatin As Calcium 20mg | 1385/10/26 | ||||||
Amlodipine+Atorvastatin | TABLET | ORAL | C10BX03 | Amlodipine (As Besilate) 5mg+ Atorvastatin As Calcium10mg | 1387/03/08 | ||||||
Amlodipine+Bisoprolol | TABLET | ORAL | C07FB07 | Amlodipine (As Besilate) 5mg+ Bisoprolol Fumarate 5mg | 1397/04/30 | ||||||
Amlodipine+Bisoprolol | TABLET | ORAL | C07FB07 | Amlodipine (As Besilate) 5mg+ Bisoprolol Fumarate10mg | 1397/04/30 | ||||||
Amlodipine+Bisoprolol | TABLET | ORAL | C07FB07 | Amlodipine (As Besilate) 10 mg+ Bisoprolol Fumarate 5 mg | 1397/04/30 | ||||||
Amlodipine+Bisoprolol | TABLET | ORAL | C07FB07 | Amlodipine (As Besilate)10 mg+ Bisoprolol Fumarate10 mg | 1397/04/30 | ||||||
Amlodipine+Valsartan | TABLET | ORAL | C09DB01 | Amlodipine (As Besilate) 10 mg/ Valsartan 160 mg | for local production only | 1390/07/04 | |||||
Amlodipine+Valsartan | TABLET | ORAL | C09DB01 | Amlodipine (As Besilate) 10 mg/ Valsartan 320 mg | for local production only | 1390/07/04 | |||||
Amlodipine+Valsartan | TABLET | ORAL | C09DB01 | Amlodipine (As Besilate) 5 mg/ Valsartan 160 mg | for local production only | 1390/07/04 | |||||
Amlodipine+Valsartan | TABLET | ORAL | C09DB01 | Amlodipine (As Besilate) 5 mg/ Valsartan 320 mg | for local production only | 1390/07/04 | |||||
Amlodipine+Valsartan | TABLET | ORAL | C09DB01 | Amlodipine (As Besilate) 5 mg/ Valsartan 80 mg | for local production only | 1390/07/04 | |||||
Amlodipine+Valsartan+Hydrochlortiazid | TABLET | ORAL | C09DX01 | Amlodipine (As Besilate) 10 mg+ Valsartan 160 mg+Hydrochlortiazid 12.5mg | for local production only | 1392/03/11 | |||||
Amlodipine+Valsartan+Hydrochlortiazid | TABLET | ORAL | C09DX01 | Amlodipine (As Besilate) 10 mg+ Valsartan 160 mg+Hydrochlortiazid 25mg | for local production only | 1392/03/11 | |||||
Amlodipine+Valsartan+Hydrochlortiazid | TABLET | ORAL | C09DX01 | Amlodipine (As Besilate) 5 mg+ Valsartan 160 mg+Hydrochlortiazid 12.5mg | for local production only | 1392/03/11 | |||||
Amlodipine+Valsartan+Hydrochlortiazid | TABLET | ORAL | C09DX01 | Amlodipine (As Besilate) 5 mg+ Valsartan 160 mg+Hydrochlortiazid 25mg | for local production only | 1392/03/11 | |||||
Ammonium Alum | BULK | V03 | Bulk medicines | ||||||||
Ammonium Chloride | TABLET, DELAYED RELEASE | 500 mg | ORAL | G04BA01 | |||||||
Ammonium Chloride | BULK | V03 | Bulk medicines | 1362/01/21 | |||||||
Ammonium Hydroxide | BULK | V03 | Bulk medicines | 1376/12/10 | |||||||
Amoxicillin | POWDER, FOR SUSPENSION | 125 mg/5ml | ORAL | J01CA04 | |||||||
Amoxicillin | TABLET, DISPERSIBLE | 125mg | ORAL | J01CA04 | |||||||
Amoxicillin | POWDER, FOR SUSPENSION | 200 mg/5ml | ORAL | J01CA04 | |||||||
Amoxicillin | POWDER, FOR SUSPENSION | 250 mg | ORAL | J01CA04 | |||||||
Amoxicillin | TABLET, CHEWABLE | 250 mg | ORAL | J01CA04 | |||||||
Amoxicillin | TABLET, DISPERSIBLE | 250 mg | ORAL | J01CA04 | |||||||
Amoxicillin | CAPSULE | 250 mg | ORAL | J01CA04 | |||||||
Amoxicillin | POWDER, FOR SUSPENSION | 250 mg/5ml | ORAL | J01CA04 | |||||||
Amoxicillin | POWDER, FOR SUSPENSION | 400 mg/5ml | ORAL | J01CA04 | |||||||
Amoxicillin | TABLET | 500 mg | ORAL | J01CA04 | |||||||
Amoxicillin | TABLET | 875 mg | ORAL | J01CA04 | 1396/06/12 | ||||||
Amoxicillin | CAPSULE | 500 mg | ORAL | J01CA04 | |||||||
Amoxicillin | TABLET, EXTENDED RELEASE | 775 mg | ORAL | J01CA04 | 1397/05/10 | ||||||
Amphotericin-B | GEL | 0.4% | TOPICAL | A01AB04 | Nanoliposomal | 1392/04/04 | |||||
Amphotericin-B | INJECTION, POWDER, LYOPHILIZED | 50 mg | PARENTERAL | J02AA01 | Hospital use only | ||||||
Amphotericin-B | As Complex with Sodium Cholesteryl Sulphate | INJECTION, POWDER, LYOPHILIZED | 50 mg | PARENTERAL | J02AA01 | Hospital use only | |||||
Amphotericin-B Liposome | INJECTION, POWDER | 50 mg | PARENTERAL | J02AA01 | Treatment of invasive protothecosis. Treatment of invasive sporotrichosis. Treatment of invasive coccidioidomycosis. Treatment of invasive zygomycosis. Treatment of invasive candidiasis. Treatment of invasive fungal infections. | for Health Dept. of MOH only | 1385/09/07 | ||||
Ampicillin | As Sodium | INJECTION, POWDER | 1 g | PARENTERAL | J01CA01 | ||||||
Ampicillin | POWDER, FOR SUSPENSION | 125 mg/5ml | ORAL | J01CA01 | |||||||
Ampicillin | As Sodium | INJECTION, POWDER | 250 mg | PARENTERAL | J01CA01 | ||||||
Ampicillin | CAPSULE | 250 mg | ORAL | J01CA01 | |||||||
Ampicillin | POWDER, FOR SUSPENSION | 250 mg/5ml | ORAL | J01CA01 | |||||||
Ampicillin | As Sodium | INJECTION, POWDER | 500 mg | PARENTERAL | J01CA01 | 1360/08/24 | |||||
Ampicillin | CAPSULE | 500 mg | ORAL | J01CA01 | |||||||
Ampicillin+Sulbactam | INJECTION, POWDER | 1.5 g | PARENTERAL | J01CR01 | 1 g Ampicillin + 0.5 g Sulbactam | 1382/04/01 | |||||
Ampicillin+Sulbactam | INJECTION, POWDER | 3 g | PARENTERAL | J01CR01 | 2 g Ampicillin +1 g Sulbactam | 1382/04/01 | |||||
Amyl Nitrite | INHALER | RESPIRATORY | V03AB22 | Treatment of cyanide poisoning | Orphan medicines | 1377/05/25 | |||||
Anagrelide | HCl | CAPSULE | 500 mcg | ORAL | L01XX35 | Orphan medicines | 1388/02/27 | ||||
Anakinra | INJECTION, SOLUTION | 100mg/0.67 ml | PARENTERAL | L04AC03 | Arthritis rheumatoid in combination with Methotrexate not responded to Methotrexate alone, CAPS, SJIA | Orphan medicines | 1396/11/29 | ||||
Anthocyanoside A | TABLET | ORAL | C04A | Myrtillus Anthocyanosidic Extract of Vaccinium Myrtillus 100mg + Betacarotene 5mg | 1380/04/17 | ||||||
Anticoagulant | POWDER | B01 | (Sodium citrate dehydrate 2.63 g + Citric acid anhydrous 0.299 g + Sodium biphosphate monohydrate 0.222 g + Dextrose monohydrate 3.19 g + Adenine 0.0275 g ) /100 ml BLOOD PACK | ||||||||
Anticoagulant | SOLUTION | B01 | (Sodium citrate dehydrate 2.63 g + Citric acid anhydrous 0.299 g + Sodium biphosphate monohydrate 0.222 g + Dextrose monohydrate 3.19 g + Adenine 0.0275 g ) /100 ml BLOOD PACK | 1397/08/15 | |||||||
Anti-D Immunoglobulin | INJECTION | 250 mcg | INTRAMUSCULAR | J06BB01 | Hospital use only | 1373/11/23 | |||||
Anti-D Immunoglobulin | INJECTION, POWDER, LYOPHILIZED | 250 mcg | INTRAMUSCULAR | J06BB01 | Hospital use only | 1373/11/23 | |||||
Anti-D Immunoglobulin | INJECTION | 300 mcg | INTRAMUSCULAR | J06BB01 | Hospital use only | ||||||
Anti-D Immunoglobulin | INJECTION, POWDER, LYOPHILIZED | 300 mcg | INTRAMUSCULAR | J06BB01 | Hospital use only | ||||||
Anti-D Immunoglobulin | INJECTION | 50 mcg/ml | INTRAVENOUS | J06BB01 | Treatment of immune thrombocytopenic purpura. | Hospital use only | |||||
Antihemorrhoid | OINTMENT | RECTAL | N01BB52 | (Lidocaine 50mg+hydrocortisone acetate 2.75mg+aluminium subacetate 35mg+zinc oxide 180mg)/g | OTC medicines | ||||||
Antihemorrhoid | SUPPOSITORY | RECTAL | N01BB52 | Lidocaine 60mg+hydrocortisone acetate 5mg+aluminium subacetate 50mg+zinc oxide 400mg | OTC medicines | ||||||
Antihistamine Decongestant | TABLET | ORAL | R01BA53 | Chlorpheniramine Maleate4mg/phenylephrine HCL 10mg | OTC medicines | ||||||
Antihistamine Decongestant | CAPSULE, EXTENDED RELEASE | ORAL | R01BA51 | Brompheniramine Maleate 12mg+ Pseudoephedrine HCl 120 mg | OTC medicines | 1383/09/02 | |||||
Antihistamine Decongestant | TABLET, EXTENDED RELEASE | ORAL | R01BA51 | Brompheniramine Maleate 12mg+ Pseudoephedrine HCl 120 mg | OTC medicines | 1383/09/02 | |||||
Antihistamine Decongestant | CAPSULE, LIQUID FILLED | ORAL | R01BA51 | Chlorpheniramine maleate 2 mg + Pseudoephedrine HCl 30 mg | OTC medicines | 1385/11/04 | |||||
Antihistamine Decongestant | TABLET | ORAL | R01BA51 | Chlorpheniramine maleate 2 mg + Pseudoephedrine HCl 30 mg | OTC medicines | 1383/09/02 | |||||
Antilymphocyte Immunoglobulin | INJECTION | 20 mg/ml | PARENTERAL | L04AA03 | Hospital use only | ||||||
Antilymphocyte Immunoglobulin | INJECTION | 50 mg/ml | PARENTERAL | L04AA03 | Hospital use only | ||||||
Antiscorpion Venom Serum | INJECTION | PARENTERAL | J06AA | 1368/03/07 | |||||||
Antisnake Venom Serum | INJECTION | PARENTERAL | J06AA03 | ||||||||
Antithymocyte Immunoglobulin | INJECTION | 20 mg/ml | PARENTERAL | L04AA04 | (rabbit); myelodys plastic syndrom(mds); allograft rejection, including solid organ(kidney,liver,heart,lung,pancreas)and bone marrow transplantation. | Hospital use only | |||||
Antithymocyte Immunoglobulin | INJECTION, POWDER, LYOPHILIZED | 25 mg | PARENTERAL | L04AA04 | Treatment of myelodysplastic syndrome (MDS) | Hospital use only | |||||
Antithymocyte Immunoglobulin | INJECTION | 50 mg/ml | PARENTERAL | L04AA04 | Treatment of myelodysplastic syndrome (MDS) | Hospital use only | |||||
Apixaban | TABLET | 2.5 mg | ORAL | B01AF02 | Antithrombotic | 1397/07/28 | |||||
Apixaban | TABLET | 5 mg | ORAL | B01AF02 | Antithrombotic | 1397/07/28 | |||||
Apomorphine | HCl | INJECTION | 10 mg/ml | PARENTERAL | N04BC07 | Treatment of the on-off fluctuations associated with late-stage Parkinson's disease. For the treatment of patients in a vegetative state or minimally conscious state for up to 12 months following a severe traumatic brain injury (traumatic or spontaneous) | Hospital use only | ||||
Apomorphine | HCl | INJECTION | 5 mg/ml | PARENTERAL | N04BC07 | Treatment of the on-off fluctuations associated with late-stage Parkinson's disease. | Hospital use only | For Infusion, For Subcutaneous use | 1396/03/21 | ||
Aprepitant | CAPSULE | 125 mg | ORAL | A04AD12 | 1387/06/26 | ||||||
Aprepitant | CAPSULE | 80 mg | ORAL | A04AD12 | 1387/06/26 | ||||||
Aprotinin | INJECTION | 10,000 KIU/ml | PARENTERAL | B02AB01 | For prophylactic use to reduce perioperative blood loss and the homologous blood transfusion requirement in patients undergoing cardiopulmonary bypass surgery in the course of repeat coronary artery bypass graft surgery, and in selected cases of primary c | Hospital use only | |||||
Aprotinin | INJECTION | 20,000 KIU/ml | PARENTERAL | B02AB01 | For prophylactic use to reduce perioperative blood loss and the homologous blood transfusion requirement in patients undergoing cardiopulmonary bypass surgery in the course of repeat coronary artery bypass graft surgery, and in selected cases of primary c | Hospital use only | 1376/06/30 | ||||
Arginine | HCl | POWDER | 100 g | ORAL | B05XB01 | Treatment of hyperamonemia | Orphan medicines | 1387/10/15 | |||
Arginine | HCl | INJECTION | 100 mg/ml | PARENTERAL | B05XB01 | Treatment of hyperamonemia | Orphan medicines | 1387/10/15 | |||
Arginine | HCl | INJECTION | 950 mOsmol/L | PARENTERAL | B05XB01 | Hospital use only | 1361/09/14 | ||||
Arginine | HCl | INJECTION | PARENTERAL | B05XB01 | Treatment of sickle cell disease and beta thalassemia. | Orphan medicines | |||||
Aripiprazole | TABLET | 10 mg | ORAL | N05AX12 | 1387/12/21 | ||||||
Aripiprazole | TABLET | 15 mg | ORAL | N05AX12 | 1387/12/21 | ||||||
Aripiprazole | TABLET | 5 mg | ORAL | N05AX12 | 1388/02/30 | ||||||
Arsenic Trioxide | INJECTION | 0.10% | PARENTERAL | L01XX27 | Treatment of malignant glioma Treatment of chronic myeloid leukemia Treatment of acute promyelocytic leukemia Treatment of multiple myeloma. Treatment of liver cancer Treatment of chronic lymphocytic leukemia Treatment of myelodysplastic syndrome. | Hospital use only | 1382/03/04 | ||||
Artemether | CAPSULE | 40 mg | ORAL | P01BE02 | Acute treatment of malaria | for Health Dept. of MOH only | 1383/04/07 | ||||
Artemether | INJECTION | 80 mg | PARENTERAL | P01BE02 | Acute treatment of malaria | for Health Dept. of MOH only | 1383/04/07 | ||||
Artemether+ Lumefantrine | TABLET | ORAL | P01BF01 | Artemether 20 mg+ Lumefantrine 120mg | Acute treatment of malaria | for Health Dept. of MOH only | 1394/03/31 | ||||
Artesunate | TABLET | 50 mg | ORAL | P01BE03 | for Health Dept. of MOH only | 1397/03/01 | |||||
Artesunate | TABLET | 100 mg | ORAL | P01BE03 | for Health Dept. of MOH only | ||||||
Artesunate | TABLET | 200 mg | ORAL | P01BE03 | Immediate treatment of malaria | for Health Dept. of MOH only; Orphan medicine | 1385/09/07 | ||||
Artesunate | INJECTION | 200 mg | PARENTERAL | P01BE03 | Immediate treatment of malaria | for Health Dept. of MOH only; Orphan medicine | |||||
Artesunate | SUPPOSITORY | 50 mg | RECTAL | P01BE03 | Immediate treatment of malaria | for Health Dept. of MOH only | |||||
Artesunate | SUPPOSITORY | 200 mg | RECTAL | P01BE03 | Immediate treatment of malaria | for Health Dept. of MOH only | 1394/11/13 | ||||
Artesunate | INJECTION | 60 mg/ml | PARENTERAL | P01BE03 | Immediate treatment of malaria | for Health Dept. of MOH only | 1386/04/27 | ||||
Articaine+Epinephrine | INJECTION | PARENTERAL | N01BB58 | Articaine Hydrochloride 4% + Epinephrine 1/100000 | 1385/06/14 | ||||||
Articaine+Epinephrine | INJECTION | PARENTERAL | N01BB58 | Articaine Hydrochloride 4% + Epinephrine 1/200000 | 1385/06/14 | ||||||
Artificial Saliva | SPRAY | ORAL | A16AX | OTC medicines | 1381/12/04 | ||||||
Artificial Saliva | GEL | ORAL | A16AX | OTC medicines | 1381/12/04 | ||||||
ASA (Acetylsalicylic Acid) | TABLET, CHEWABLE | 100 mg | ORAL | N02BA01 | N02BA01 | ||||||
ASA (Acetylsalicylic Acid) | TABLET | 325 mg | ORAL | N02BA01 | OTC medicines | 1369/10/23 | |||||
ASA (Acetylsalicylic Acid) | TABLET, EFFERVESCENT | 325 mg | ORAL | N02BA01 | OTC medicines | 1374/07/30 | |||||
ASA (Acetylsalicylic Acid) | TABLET, DELAYED RELEASE | 325 mg | ORAL | N02BA01 | 1369/10/23 | ||||||
ASA (Acetylsalicylic Acid) | SUPPOSITORY | 325 mg | RECTAL | N02BA01 | 1369/10/23 | ||||||
ASA (Acetylsalicylic Acid) | TABLET | 500 mg | ORAL | N02BA01 | OTC medicines | Microcoated | 1369/10/23 | ||||
ASA (Acetylsalicylic Acid) | TABLET | 100 mg | ORAL | N02BA01 | OTC medicines | ||||||
ASA (Acetylsalicylic Acid) | TABLET, DELAYED RELEASE | 80 mg | ORAL | B01AC06 | OTC medicines | 1373/03/22 | |||||
ASA (Acetylsalicylic Acid) | TABLET , DELAYED RELEASE | 81 mg | ORAL | B01AC06 | OTC medicines | 1391/11/02 | |||||
ASA (Acetylsalicylic Acid) | TABLET , ORALLY DISINTEGRATING | 300 mg | ORAL | B01AC06 | OTC medicines | 1396/08/02 | |||||
ASA (Acetylsalicylic Acid)+ Atorvastatin+Enalapril+Hydrochlorthiazide | TABLET | ORAL | C09BA02 | ASA 81 mg+ Atorvastatin (As Calcium) 20 mg+ Enalapril Maleate 5 mg+ Hydrochlorthiazide 12.5 mg (Polypill E) | 1393/10/14 | ||||||
ASA (Acetylsalicylic Acid)+Atorvastatin+Hydrochlorthiazide+Valsartan | TABLET | ORAL | C09DA03 | ASA 81 mg+ Atorvastatin (As Calcium) 20 mg+ Hydrochlorthiazide 12.5 mg+ Valsartan 40 mg (Polypill V) | 1393/10/14 | ||||||
ASA+Ascorbic acid | TABLET, EFFERVESCENT | ORAL | N02BA51 | ASA 400mg+Ascorbic acid 240mg | OTC medicines | ||||||
ASA+Codeine | TABLET | ORAL | N02BA71 | ASA 500mg + -Codeine phosphate 10mg | |||||||
Asparaginase | INJECTION, POWDER | PARENTERAL | L01XX02 | ||||||||
Atazanavir | Sulphate | CAPSULE | 150 mg | ORAL | J05AE08 | For Health Dept. of MOH only | 1393/10/14 | ||||
Atazanavir | As Sulphate | CAPSULE | 200 mg | ORAL | J05AE08 | For Health Dept. of MOH only | 1397/02/11 | ||||
Atazanavir | Sulphate | CAPSULE | 300 mg | ORAL | J05AE08 | For Health Dept. of MOH only | 1393/10/14 | ||||
Atazanavir+Ritonavir | TABLET | ORAL | J05 | Atazanavir Sulfate 300mg+Ritonavir 100mg | For Health Dept. of MOH only | 1396/05/28 | |||||
Atenolol | TABLET | 100 mg | ORAL | C07AB03 | 1361/02/26 | ||||||
Atenolol | TABLET | 50 mg | ORAL | C07AB03 | 1366/02/06 | ||||||
Atomoxetine | HCl | CAPSULE | 10 mg | ORAL | N06BA09 | 1391/02/07 | |||||
Atomoxetine | HCl | CAPSULE | 18 mg | ORAL | N06BA09 | 1391/02/07 | |||||
Atomoxetine | HCl | CAPSULE | 25 mg | ORAL | N06BA09 | 1391/02/07 | |||||
Atomoxetine | HCl | CAPSULE | 40 mg | ORAL | N06BA09 | 1391/02/07 | |||||
Atomoxetine | HCl | CAPSULE | 60 mg | ORAL | N06BA09 | 1391/02/07 | |||||
Atorvastatin | As Calcium | TABLET | 10 mg | ORAL | C10AA05 | 1379/12/07 | |||||
Atorvastatin | As Calcium | TABLET | 20 mg | ORAL | C10AA05 | 1379/12/07 | |||||
Atorvastatin | As Calcium | TABLET | 40 mg | ORAL | C10AA05 | 1379/12/07 | |||||
Atorvastatin | As Calcium | TABLET | 80 mg | ORAL | C10AA05 | 1395/06/24 | |||||
Atorvastatin+Ezetimibe | TABLET | ORAL | C10BA05 | Atorvastatin (As Calcium) 10 mg+Ezetimibe 10 mg | 1396/11/29 | ||||||
Atorvastatin+Ezetimibe | TABLET | ORAL | C10BA05 | Atorvastatin (As Calcium) 20 mg+Ezetimibe 10 mg | 1396/11/29 | ||||||
Atorvastatin+Ezetimibe | TABLET | ORAL | C10BA05 | Atorvastatin (As Calcium) 40 mg+Ezetimibe 10 mg | 1396/11/29 | ||||||
Atorvastatin+Ezetimibe | TABLET | ORAL | C10BA05 | Atorvastatin (As Calcium) 80 mg+Ezetimibe 10 mg | 1396/11/29 | ||||||
Atovaquone+Chloroghanide | TABLET | ORAL | P01AX | Atovaquone 250mg+Chloroghanide Hydrochloride100 mg | Prevention of Pneumocystis carinii pneumonia (PCP) in high-risk, HIV-infected patients | ||||||
Atovaquone+Chloroghanide | TABLET | ORAL | P01AX | Atovaquone 62.5mg+Chloroghanide Hydrochloride25 mg | Prevention of Pneumocystis carinii pneumonia (PCP) in high-risk, HIV-infected patients | ||||||
Atovaquone+Proguanil | TABLET | ORAL | P01AX | Atovaquone 250 mg + Proguanil Hydrochloride 100 mg | For Health Dept. of MOH only | ||||||
Atovaquone+Proguanil | TABLET | ORAL | P01AX | Atovaquone 62.5 mg + Proguanil Hydrochloride 25 mg | For Health Dept. of MOH only | ||||||
Atracurium | Besylate | INJECTION | 10 mg/ml | PARENTERAL | M03AC04 | Hospital use only | |||||
Atropine | Sulfate | SOLUTION/ DROPS | 0.50% | OPHTHALMIC | S01FA01 | 1361/12/23 | |||||
Atropine | Sulfate | SOLUTION/ DROPS | 1% | OPHTHALMIC | S01FA01 | ||||||
Atropine | Sulfate | OINTMENT | 1% | OPHTHALMIC | S01FA01 | ||||||
Atropine | Sulfate | TABLET | 0.5 mg | ORAL | A03BA01 | ||||||
Atropine | Sulfate | INJECTION | 0.5 mg/ml | PARENTERAL | A03BA01 | Hospital use only | 1361/11/10 | ||||
Atropine | Sulfate | INJECTION | 1 mg/ml | PARENTERAL | A03BA01 | Hospital use only | 1381/04/23 | ||||
Atropine | Sulfate | INJECTION | 10 mg/ml | PARENTERAL | A03BA01 | Hospital use only | 1379/05/24 | ||||
Atropine | Sulfate | INJECTION | 2.5 mg/ml | PARENTERAL | A03BA01 | Hospital use only | |||||
Azathioprine | TABLET | 25 mg | ORAL | L04AX01 | 1388/08/20 | ||||||
Azathioprine | As Sodium | INJECTION, POWDER | 50 mg | PARENTERAL | L04AX01 | ||||||
Azathioprine | TABLET | 50 mg | ORAL | L04AX01 | |||||||
Azelaic Acid | CREAM | 20% | TOPICAL | D10AX03 | 1383/05/04 | ||||||
Azelaic Acid | BULK | V03 | Bulk medicines | ||||||||
Azelastine | As HCl | SPRAY | 125 mcg/Puff | NASAL | R01AC03 | 0.10% | 1391/02/07 | ||||
Azelastine+Fluticasone | SPRAY | NASAL | R01AD58 | (Azelastine HCl 137 mcg+Fluticasone Prppionate 50 mcg)/ Puff | 1397/09/27 | ||||||
Azithromycin | SOLUTION/ DROPS | 1% | OPHTHALMIC | S01AA26 | 1390/01/29 | ||||||
Azithromycin | SOLUTION/ DROPS | 1.5% | OPHTHALMIC | S01AA26 | 1395/09/01 | ||||||
Azithromycin | POWDER, FOR SUSPENSION | 1 g | ORAL | J01FA10 | 1392/03/21 | ||||||
Azithromycin | POWDER, FOR SUSPENSION | 100 mg/5ml | ORAL | J01FA10 | |||||||
Azithromycin | POWDER, FOR SOLUTION | 2 g | ORAL | J01FA10 | |||||||
Azithromycin | POWDER, FOR SUSPENSION | 200 mg/5ml | ORAL | J01FA10 | 1373/12/21 | ||||||
Azithromycin | CAPSULE | 250 mg | ORAL | J01FA10 | 1373/12/21 | ||||||
Azithromycin | TABLET | 250 mg | ORAL | J01FA10 | |||||||
Azithromycin | CAPSULE | 500 mg | ORAL | J01FA10 | |||||||
Azithromycin | INJECTION, POWDER | 500 mg | PARENTERAL | J01FA10 | 1385/10/26 | ||||||
Azithromycin | TABLET | 500 mg | ORAL | J01FA10 | |||||||
Bacitracin | OINTMENT | 500 U/g | OPHTHALMIC | D06AX05 | |||||||
Baclofen | TABLET | 10 mg | ORAL | M03BX01 | 1361/06/21 | ||||||
Baclofen | TABLET | 25 mg | ORAL | M03BX01 | 1362/02/18 | ||||||
Barium | Sulfate | POWDER, FOR SUSPENSION | 135 g | ORAL | V08BA02 | sachet | 1364/11/27 | ||||
Barium | Sulfate | SUSPENSION | 240 g/240 ml | ORAL | V08BA02 | 1390/06/14 | |||||
Bedaquiline | As Fumarate | TABLET | 100 mg | ORAL | J04AK05 | For Health Dept. of MOH only | 1396/05/28 | ||||
BCG | INJECTION, POWDER, LYOPHILIZED | INTRAVESICAL | L03AX03 | ||||||||
BCG | INJECTION, POWDER, LYOPHILIZED | INJECTION, POWDER | J07AN | ||||||||
Beclomethasone | Dipropionate | NEBULISATION | 0.8 mg/2ml | RESPIRATORY | R03BA01 | 1386/07/18 | |||||
Beclomethasone | Dipropionate | AEROSOL | 100 mcg/dose | RESPIRATORY | R03BA01 | HFA Only | 1389/08/24 | ||||
Beclomethasone | Dipropionate | AEROSOL | 250 mcg/dose | RESPIRATORY | R03BA01 | 1389/08/24 | |||||
Beclomethasone | Dipropionate | INHALER | 50 mcg/dose | RESPIRATORY | R03BA01 | 1389/08/24 | |||||
Beclomethasone | Dipropionate | INHALER | 50 mcg/dose | NASAL | R01AD01 | ||||||
Beclomethasone+ Formoterol | AEROSOL, METERED | RESPIRATORY | R03AK08 | (Beclomethasone Dipropionate 100 mcg+ Formoterol Fumarate 6 mcg)/metered dose | Extrafine Beclomethasone | 1396/09/12 | |||||
Beclomethasone+ Formoterol | AEROSOL, METERED | RESPIRATORY | R03AK08 | (Beclomethasone Dipropionate 200 mcg+ Formoterol Fumarate 6 mcg)/metered dose | Extrafine Beclomethasone | 1396/12/08 | |||||
Belladonna Pb | ELIXIR | ORAL | A03CB02 | (Atropine Sulfate 19.4mcg+Hyoscine HBr 6.5mcg+Hyoscyamine Sulfate 103.7mcg+Phenobarbital 16.2mg)/5ml | |||||||
Belladonna Pb | TABLET | ORAL | A03CB02 | Atropine Sulfate 19.4mcg+Hyoscine HBr 6.5mcg+Hyoscyamine Sulfate 103.7mcg+Phenobarbital 16.2mg | |||||||
Bendamustine | HCl | INJECTION, POWDER | 25 mg | PARENTERAL | L01AA09 | Non-Hodgkin's lymphoma | 1395/03/09 | ||||
Bendamustine | HCl | INJECTION, POWDER | 100 mg | PARENTERAL | L01AA09 | Non-Hodgkin's lymphoma | 1395/03/09 | ||||
Bendamustine | HCl | INJECTION | 25 mg/ml | PARENTERAL | L01AA09 | Non-Hodgkin's lymphoma | 1396/04/27 | ||||
Benzocaine | OINTMENT | 5% | TOPICAL | D04AB04 | OTC medicines | 1369/10/30 | |||||
Benzocaine | GEL | 7.50% | BUCCAL | D04AB04 | 1390/1/29 | ||||||
Benzoic Acid | BULK | V03 | Bulk medicines | 1376/12/10 | |||||||
Benzoin Tincture | BULK | V03 | Bulk medicines | 1376/12/10 | |||||||
Benzoyl Peroxide | SOAP | 5% | TOPICAL | D10AE01 | w/w | ||||||
Benzoyl Peroxide | LOTION | 5% | TOPICAL | D10AE01 | w/w or w/v | 1381/06/31 | |||||
Benzoyl Peroxide | GEL | 5% | TOPICAL | D10AE01 | 1369/10/30 | ||||||
Benzoyl Peroxide | SOAP | 10% | TOPICAL | D10AE01 | w/w | ||||||
Benzoyl Peroxide | LOTION | 10% | TOPICAL | D10AE01 | w/w or w/v | 1369/10/30 | |||||
Benzoyl Peroxide | GEL | 10% | TOPICAL | D10AE01 | 1369/10/30 | ||||||
Benzoyl Peroxide+Clindamycin | GEL | TOPICAL | D10AF51 | Benzoyl Peroxide 5%+Clindamycin (As Phosphate) 1% | 1396/08/02 | ||||||
Benztropine | Mesylate | TABLET | 2 mg | ORAL | N04AC01 | ||||||
Benzydamine | HCl | MOUTHWASH | 0.15% | IRRIGATION | A01AD02 | 1376/07/27 | |||||
Benzyl Benzoate | LOTION | 25% | TOPICAL | P03AX01 | 1365/04/15 | ||||||
Benzyl Benzoate | BULK | V03 | Bulk medicines | ||||||||
Bephenium | Hydroxynaphthoate | GRANULE | 5 g/sachet | ORAL | P02CX02 | ||||||
Beractant | CAPSULE | 15 mg | ORAL | A11CA02 | OTC medicines | ||||||
Beractant | INJECTION, SUSPENSION | 25 mg/ ml | INTRATRACHEAL | R07AA | Treatment of full-term newborn infants with respiratory failure caused by meconium aspiration syndrome, persistent pulmonary hypertension of the newborn, or pneumonia and sepsis. (Survanta) | Hospital use only | 1381/12/04 | ||||
Betacarotene | CAPSULE | 25 mg | ORAL | A11CA02 | |||||||
Betacarotene | CAPSULE | 30 mg | ORAL | A11CA02 | 1361/10/19 | ||||||
Betahistine | Dihydrochloride | TABLET | 16 mg | ORAL | N07CA01 | 1386/09/07 | |||||
Betahistine | Dihydrochloride | TABLET | 8 mg | ORAL | N07CA01 | 1362/05/02 | |||||
Betahistine | Dihydrochloride | TABLET | 24 mg | ORAL | N07CA01 | 1397/06/24 | |||||
Betaine | POWDER FOR SOLUTION | 1g | ORAL | A16AA06 | Treatment of hemocysteonuria | Orphan medicines | 1387/10/15 | ||||
Betamethasone | As Valerate | CREAM | 0.1% | TOPICAL | D07AC01 | ||||||
Betamethasone | As Valerate | LOTION | 0.1% | TOPICAL | D07AC01 | ||||||
Betamethasone | As Valerate | OINTMENT | 0.1% | TOPICAL | D07AC01 | ||||||
Betamethasone | As Disodium Phosphate | SOLUTION/ DROPS | 0.1% | OPHTHALMIC and OTIC and NASAL DROPS | S03 | ||||||
Betamethasone | As Disodium Phosphate | OINTMENT | 0.1% | OPHTHALMIC | S01BA06 | ||||||
Betamethasone | TABLET | 0.5 mg | ORAL | H02AB01 | 1359/11/08 | ||||||
Betamethasone | As Disodium Phosphate | INJECTION | 4 mg/ml | PARENTERAL | H02AB01 | ||||||
Betamethasone | BULK | V03 | Bulk medicines | ||||||||
Betamethasone | INJECTION, SUSPENSION, EXTENDED RELEASE | PARENTERAL | H02AB01 | (Betamethasone acetate 3mg+Betamethasone(as disodium phosphate) 3mg)/ml | 1359/06/08 | ||||||
Betaxolol | As HCl | SOLUTION/ DROPS | 0.50% | OPHTHALMIC | S01ED02 | 1374/09/12 | |||||
Bethanechol | Chloride | TABLET | 10 mg | ORAL | N07AB02 | ||||||
Bethanechol | Chloride | TABLET | 25 mg | ORAL | N07AB02 | 1388/08/20 | |||||
Bevacizumab | INJECTION, SOLUTION, CONCENTRATE | 25 mg/ml | PARENTERAL | L01XC07 | Orphan medicines. Hospital use only | 1385/06/14 | |||||
Bicalutamide | TABLET | 150 mg | ORAL | L02BB03 | 1392/5/29 | ||||||
Bicalutamide | TABLET | 50 mg | ORAL | L02BB03 | 1388/04/21 | ||||||
Bicarbonate Concentrate | POWDER | 500 mg | NOT APPLICABLE | B05ZA | For Haemodyalysis Machine | 1385/06/14 | |||||
Bicarbonate Concentrate | POWDER | 650 mg | NOT APPLICABLE | B05ZA | For Haemodyalysis Machine | 1385/06/14 | |||||
Bicarbonate Concentrate | POWDER | 750 mg | NOT APPLICABLE | B05ZA | For Haemodyalysis Machine | 1385/06/14 | |||||
Bimatoprost | SOLUTION/ DROPS | 0.01% | OPHTALMIC | S01EE03 | 1393/01/24 | ||||||
Bimatoprost | SOLUTION/ DROPS | 0.03% | OPHTALMIC | S01EE03 | Hypotrichosis | With applicator | 1396/05/28 | ||||
Biotin | TABLET | 5 mg | ORAL | L01XC07 | Orphan medicines | 1387/10/15 | |||||
Biotin | TABLET | 100 mg | ORAL | A11HA05 | PPMS | Orphan medicines | 1396/12/13 | ||||
Biotin | INJECTION, SOLUTION | 5 mg /ml | INTRAMUSCULAR | A11HA05 | 1392/04/04 | ||||||
Biperiden | HCl | TABLET | 2 mg | ORAL | N04AA02 | ||||||
Biperiden | HCl | TABLET, EXTENDED RELEASE | 4 mg | ORAL | N04AA02 | 1372/08/09 | |||||
Biperiden | Lactate | INJECTION | 5 mg/ml | PARENTERAL | N04AA02 | ||||||
Bisacodyl | SUPPOSITORY | 10 mg | RECTAL | A06AB02 | OTC medicines | 1369/10/30 | |||||
Bisacodyl | TABLET, DELAYED RELEASE | 5 mg | ORAL | A06AB02 | OTC medicines | 1369/10/30 | |||||
Bisacodyl | SUPPOSITORY | 5 mg | RECTAL | A06AB02 | 1369/10/30 | ||||||
Bismuth | Subcitrate | TABLET | 120 mg | ORAL | A02BX05 | OTC medicines | |||||
Bismuth | Subcitrate | TABLET | Equ. To Bismuth Oxide 120 mg | ORAL | A02BX05 | 1372/07/11 | |||||
Bismuth | BULK | V03 | Bulk medicines | ||||||||
Bisoprolol | Fumarate | TABLET | 2.5 mg | ORAL | C07AB07 | Hypertension, Angina | 1394/07/05 | ||||
Bisoprolol | Fumarate | TABLET | 5 mg | ORAL | C07AB07 | Hypertension, Angina | 1394/07/05 | ||||
Bisoprolol | Fumarate | TABLET | 10 mg | ORAL | C07AB07 | Hypertension, Angina | 1394/07/05 | ||||
Bisoprolol+Hydrochlorthiazide | TABLET | ORAL | C07BB07 | Bisoprolol Fumarate 2.5 mg+ Hydrochlorthiazide 6.25 mg | 1397/04/31 | ||||||
Bisoprolol+Hydrochlorthiazide | TABLET | ORAL | C07BB07 | Bisoprolol Fumarate 5 mg+ Hydrochlorthiazide 6.25 mg | 1397/04/31 | ||||||
Bisoprolol+Hydrochlorthiazide | TABLET | ORAL | C07BB07 | Bisoprolol Fumarate 10 mg+ Hydrochlorthiazide 6.25 mg | 1397/04/31 | ||||||
Bisoprolol+Hydrochlorthiazide | TABLET | ORAL | C07BB07 | Bisoprolol Fumarate 5 mg+ Hydrochlorthiazide 12.5 mg | 1397/04/31 | ||||||
Bisoprolol+Hydrochlorthiazide | TABLET | ORAL | C07BB07 | Bisoprolol Fumarate 10 mg+ Hydrochlorthiazide 25 mg | 1397/04/31 | ||||||
Bleomycin | INJECTION | 15 IU | PARENTERAL | L01DC01 | Equal with 15,000 U in UK (Pancreatic cancer) | ||||||
Bleomycin | INJECTION, POWDER | 15 U | PARENTERAL | L01DC01 | Treatment of malignant pleural effusion. Treatment of pancreatic cancer. | ||||||
Borax | BULK | V03 | Bulk medicines | 1376/12/10 | |||||||
Boric Acid | BULK | V03 | Bulk medicines | 1376/12/10 | |||||||
Bortezomib | INJECTION, POWDER, LYOPHILIZED | 3.5mg | PARENTERAL | L01XX32 | Orphan medicines; hospital use only | 1387/06/26 | |||||
Bortezomib | INJECTION, POWDER, LYOPHILIZED | 1mg | PARENTERAL | L01XX32 | Orphan medicines; hospital use only | 1395/10/08 | |||||
Bosentan | TABLET | 125 mg | ORAL | C02KX01 | 1387/12/18 | ||||||
Bosentan | TABLET | 62.5 mg | ORAL | C02KX01 | 1387/12/18 | ||||||
Botulinum A Toxin | INJECTION | PARENTERAL | M03AX01 | Treatment of dynamic muscle contractures in pediatric cerebral palsy patients. Treatment of essential blepharospasm. Treatment of spasmodic torticollis (cervical dystonia). | |||||||
Botulinum A Toxin | INJECTION, POWDER, LYOPHILIZED | PARENTERAL | M03AX01 | Treatment of dynamic muscle contractures in pediatric cerebral palsy patients. Treatment of essential blepharospasm. Treatment of spasmodic torticollis (cervical dystonia). | |||||||
Botulism Monovalent | INJECTION | PARENTERAL | J06AA04 | Antitoxin | For Health Dept. of MOH only | 1361/08/20 | |||||
Botulism Polyvalent (A+B+E) | INJECTION | PARENTERAL | J06AA04 | Antitoxin | For Health Dept. of MOH only | ||||||
Bovactant | INJECTION | 50 mg/1.2ml | INTRATRACHEAL | R07AA30 | Treatment of full-term newborn infants with respiratory failure caused by meconium aspiration syndrome, persistent pulmonary hypertension of the newborn, or pneumonia and sepsis. | Hospital use only | |||||
Bovine Lung Surfactant | INJECTION, POWDER, LYOPHILIZED | 120 mg | INTRATRACHEAL | R07AA | Newfactan | ||||||
Brentuximab | Vedotin | INJECTION, POWDER | 50 mg | PARENTERAL | L01XC12 | Refractory CD-30 positive Hodgkin's (autologous stem cell transplant following) and systematic anplastic large cell lymphoma | Orphan medicines | 1396/11/29 | |||
Brimonidine | Tartrate | SOLUTION/ DROPS | 0.2% | OPHTHALMIC | S01EA05 | Treatment of anterior ischemic optic neuropathy. | Orphan medicines | 1379/06/20 | |||
Brimonidine+Timolol | SOLUTION/ DROPS | OPHTHALMIC | S01ED51 | Brimonidine tartrate 0.2%+Timolol (As Maleate) 0.5% | 1397/05/10 | ||||||
Brimonidine | As Tartrate | GEL | 3 mg/g | TOPICAL | D11AX21 | Facial Erythema in Rosacea | 0.33% | 1396/11/29 | |||
Brinzolamide | SUSPENSION/ DROPS | 1% | OPHTHALMIC | S01EC04 | 1379/05/02 | ||||||
Brinzolamide+Timolol | SUSPENSION/ DROPS | OPHTHALMIC | S01ED51 | Brinzolamide 10mg/ml + Timolol (as maleate) 5mg/ml | 1391/07/25 | ||||||
Bromhexine | HCl | INJECTION | 2 mg/ml | PARENTERAL | R05CB02 | ||||||
Bromhexine | HCl | ELIXIR | 4 mg/5ml | ORAL | R05CB02 | OTC medicines | |||||
Bromhexine | HCl | TABLET | 8 mg | ORAL | R05CB02 | OTC medicines | |||||
Bromocriptine | As Mesylate | TABLET | 2.5 mg | ORAL | G02CB01 | ||||||
Budesonide | NEBULISATION | 0.5 mg/2ml | RESPIRATORY | R03BA02 | 1385/03/23 | ||||||
Budesonide | NEBULISATION | 1 mg/2ml | RESPIRATORY | R03BA02 | 1385/03/23 | ||||||
Budesonide | INHALER | 100 mcg/dose | RESPIRATORY | R03BA02 | 1385/03/23 | ||||||
Budesonide | INHALER | 200 mcg/dose | RESPIRATORY | R03BA03 | 1385/03/23 | ||||||
Budesonide | INHALER | 400 mcg/dose | RESPIRATORY | R03BA02 | 1385/03/23 | ||||||
Budesonide | INHALER | 64 mcg/dose | NASAL | R01AD05 | 1385/03/23 | ||||||
Budesonide | INHALER | 100 mcg/dose | NASAL | R01AD05 | 1396/03/21 | ||||||
Budesonide | CAPSULE, DELAYED RELEASE | 3 mg | ORAL | A07EA06 | Crohn's disease | 1397/07/28 | |||||
Budesonide | CAPSULE, DELAYED RELEASE | 9 mg | ORAL | A07EA06 | Crohn's disease | 1397/07/28 | |||||
Budesonide | TABLET, EXTENDED RELEASE | 9 mg | ORAL | A07EA06 | Crohn's disease | 1397/09/03 | |||||
Budesonide+Formoterol | INHALER | RESPIRATORY | R03AK07 | (Budesonide 160mcg + Formoterol Fumarate 4.5mcg)/dose | 1387/06/13 | ||||||
Budesonide+Formoterol | INHALER | RESPIRATORY | R03AK07 | (Budesonide 320mcg + Formoterol Fumarate 9mcg)/dose | 1387/06/13 | ||||||
Budesonide+Formoterol | INHALER | RESPIRATORY | R03AK07 | (Budesonide 80mcg + Formoterol Fumarate 4.5mcg)/dose | 1387/06/13 | ||||||
Bupivacaine | HCl | INJECTION | 0.25% | PARENTERAL | N01BB01 | Hospital use only | 1361/12/01 | ||||
Bupivacaine | HCl | INJECTION | 0.50% | PARENTERAL | N01BB01 | Hospital use only | 1381/05/20 | ||||
Bupivacaine | HCl | INJECTION | 0.5%, 4ml | INTRASPINAL | N01BB01 | Hospital use only | 1381/05/20 | ||||
Bupivacaine+Epinephrine | INJECTION | PARENTERAL | N01BB51 | Cartridge: Bupivacaine Hydrochloride 0.5%+ Epinephrine 1:200000 (5 mcg/ml) | 1393/10/14 | ||||||
Buprenorphine | As HCl | INJECTION | 0.3 m/ml | PARENTERAL | N02AE01 | Hospital use only | 1370/12/18 | ||||
Buprenorphine | As HCl | CAPSULE | 0.4 mg | SUBLINGUAL | N02AE01 | ||||||
Buprenorphine | As HCl | TABLET | 0.4 mg | SUBLINGUAL | N07BC01 | ||||||
Buprenorphine | As HCl | TABLET | 2 mg | SUBLINGUAL | N07BC01 | 1383/09/28 | |||||
Buprenorphine | As HCl | TABLET | 8 mg | SUBLINGUAL | N07BC01 | 1383/09/28 | |||||
Buprenorphine+Naloxone | TABLET | SUBLINGUAL | N07BC51 | Buprenorphine (As Hydrochloride) 2 mg + Naloxone (As Hydrochloride) 0.5 mg | 1385/06/14 | ||||||
Buprenorphine+Naloxone | TABLET | SUBLINGUAL | N07BC51 | Buprenorphine (As Hydrochloride) 8 mg + Naloxone (As Hydrochloride) 2 mg | 1385/06/14 | ||||||
Buprenorphine+Naloxone | FILM | SUBLINGUAL | N07BC51 | Buprenorphine (As Hydrochloride) 2 mg + Naloxone (As Hydrochloride) 0.5 mg | 1395/12/22 | ||||||
Buprenorphine+Naloxone | FILM | SUBLINGUAL | N07BC51 | Buprenorphine (As Hydrochloride) 8 mg + Naloxone (As Hydrochloride) 2 mg | 1395/12/22 | ||||||
Bupropion | HCl | TABLET | 100 mg | ORAL | N06AX12 | 1379/02/04 | |||||
Bupropion | HCl | TABLET, EXTENDED RELEASE | 150 mg | ORAL | N06AX12 | 1379/02/04 | |||||
Bupropion | HCl | TABLET | 75 mg | ORAL | N06AX12 | 1379/02/04 | |||||
Burn Ointment | OINTMENT | TOPICAL | D03AA | Cod liver oil 50%+Zinc oxide 30% | OTC medicines | 1360/02/09 | |||||
Buserelin | INJECTION | 1 mg/ml | PARENTERAL | L02AE01 | As Acetate | 1372/06/07 | |||||
Buserelin | SPRAY | 150 mcg/dose | NASAL | L02AE01 | As Acetate | ||||||
Buspirone | HCl | TABLET | 10 mg | ORAL | N05BE01 | 1382/09/03 | |||||
Buspirone | HCl | TABLET | 5 mg | ORAL | N05BE01 | ||||||
Busulfan | TABLET | 2 mg | ORAL | L01AB01 | |||||||
Busulfan | INJECTION | 6 mg/ml | PARENTERAL | L01AB01 | As preparative therapy in the treatment of malignancies with bone marrow transplantation. Treatment of primary brain malignancies. | 1385/04/13 | |||||
C1-Esterase inhibitor | INJECTION, POWDER | 500 U | PARENTERAL | B06AC01 | Hereditary angioedema | Hospital use only, Orphan medicines | Use based on guideline | 1395/03/09 | |||
C1-Esterase inhibitor | INJECTION, POWDER | 2100 U | PARENTERAL | B06AC01 | Hereditary angioedema | Hospital use only, Orphan medicines | Use based on guideline, Recambinant | 1396/12/08 | |||
C-14 Urea | CAPSULE | 1 mCi | ORAL | V09 | Radiopharmaceuticals | 1397/02/18 | |||||
C-14 Urea | SOLUTION | 1 mCi | ORAL | V09 | Radiopharmaceuticals | 1397/02/18 | |||||
Cabergoline | TABLET | 0.5 mg | ORAL | G02CB03 | 1382/03/04 | ||||||
Cabergoline | TABLET | 1 mg | ORAL | G02CB03 | 1382/03/04 | ||||||
Cabergoline | TABLET | 2 mg | ORAL | N04BC06 | |||||||
Cade Oil | BULK | V03 | Bulk medicines | ||||||||
Caffeine | As Citrate | INJECTION, SOLUTION | 10mg/ml | PARENTERAL | N06BC01 | hospital use only | 1386/11/03 | ||||
Caffeine | As Citrate | SOLUTION | 10mg/ml | ORAL | N06BC01 | hospital use only | |||||
Calamine | CREAM | 8% | TOPICAL | D02AB | OTC medicines | ||||||
Calamine | LOTION | 8% | TOPICAL | D02AB | OTC medicines | ||||||
Calcipotriol | OINTMENT | 50 mcg/g | TOPICAL | D05AX02 | 1379/11/09 | ||||||
Calcipotriol | SOLUTION | 50 mcg/ml | TOPICAL | D05AX02 | 1385/09/29 | ||||||
Calcipotriol+Betamethasone | GEL | TOPICAL | D05AX52 | Calcipotriol 0.005% + Betamethasone (as Dipropionate) 0.05% | 1390/03/09 | ||||||
Calcipotriol+Betamethasone | OINTMENT | TOPICAL | D05AX52 | Calcipotriol 0.005% + Betamethasone (as Dipropionate) 0.05% | 1389/07/17 | ||||||
Calcitonin | INJECTION | 100 IU/ml | PARENTERAL | H05BA03 | Treatment of symptomatic Paget's disease | ||||||
Calcitonin | INJECTION | 50 IU/ml | PARENTERAL | H05BA03 | Treatment of symptomatic Paget's disease | ||||||
Calcitonin, Salmon | SPRAY | 100 IU/dose | NASAL | H05BA01 | Treatment of symptomatic Paget's disease | 1373/05/30 | |||||
Calcitonin, Salmon | SPRAY | 200 IU/dose | NASAL | H05BA01 | Treatment of symptomatic Paget's disease | 1378/02/19 | |||||
Calcitriol | CAPSULE | 0.25 mcg | ORAL | A11CC04 | 1361/09/14 | ||||||
Calcitriol | INJECTION | 1 mcg/ml | PARENTERAL | A11CC04 | Hospital use only | 1387/06/13 | |||||
Calcitriol | INJECTION | 2 mcg/ml | PARENTERAL | A11CC04 | Hospital use only | 1387/06/13 | |||||
Calcium Acetate | TABLET | 667 mg | ORAL | A12AA12 | 1384/09/20 | ||||||
Calcium Chloride | INJECTION | 100 mg/m | PARENTERAL | A12AA07 | 1377/02/09 | ||||||
Calcium Dobesilate | TABLET | 250 mg | ORAL | C05BX01 | 1380/04/17 | ||||||
Calcium Dobesilate | CAPSULE | 500 mg | ORAL | C05BX01 | 1388/09/04 | ||||||
Calcium Dobesilate | TABLET | 500 mg | ORAL | C05BX01 | 1386/03/23 | ||||||
Calcium Folinate | INJECTION | 10 mg/ml | V03AF03 | Hospital use only | Folinic Acid 10 mg (as Calcium Folinate) | 1390/01/29 | |||||
Calcium Folinate | INJECTION, POWDER | 100 mg | PARENTERAL | V03AF03 | Hospital use only | Folinic Acid 100mg (as Calcium Folinate) | 1385/03/23 | ||||
Calcium Folinate | INJECTION | 25 mg/ml | PARENTERAL | V03AF03 | |||||||
Calcium Folinate | TABLET | 15 mg | ORAL | V03AF03 | |||||||
Calcium Folinate | CAPSULE | 15 mg | ORAL | V03AF03 | 1396/03/21 | ||||||
Calcium Folinate | TABLET | 25 mg | ORAL | V03AF03 | |||||||
Calcium Folinate | INJECTION | 3 mg/ml | PARENTERAL | V03AF03 | |||||||
Calcium Folinate | INJECTION, POWDER | 30 mg | PARENTERAL | V03AF03 | |||||||
Calcium Folinate | INJECTION, POWDER | 350 mg | PARENTERAL | V03AF03 | 1396/04/27 | ||||||
Calcium Folinate | INJECTION, POWDER | 50 mg | PARENTERAL | V03AF03 | 1396/04/27 | ||||||
Calcium Folinate | TABLET | 5 mg | ORAL | V03AF03 | |||||||
Calcium Gluconate | GEL | 2.50% | TOPICAL | D11AX03 | for local production only | 1390/07/05 | |||||
Calcium Gluconate | INJECTION | 10% | PARENTERAL | A12AA03 | |||||||
Calcium Pantothenate | TABLET | 100 mg | ORAL | A11HA31 | OTC medicines | 1369/10/30 | |||||
Calfactant | SUSPENSION | 35 mg/ml | INTRATRACHEAL | R07AA02 | 1395/12/22 | ||||||
Camphor | BULK | V03 | Bulk medicines | ||||||||
Capecitabine | TABLET | 150 mg | ORAL | L01BC06 | 1383/08/10 | ||||||
Capecitabine | TABLET | 500 mg | ORAL | L01BC06 | 1383/08/10 | ||||||
Capreomycin | As Sulfate | INJECTION, POWDER | 1g | INTRAMUSCULAR | J04AB30 | Hospital use only | 1369/01/26 | ||||
Captopril | TABLET | 25 mg | ORAL | C09AA01 | 1369/10/16 | ||||||
Captopril | TABLET | 50 mg | ORAL | C09AA01 | 1369/10/16 | ||||||
Carbamazepine | SUSPENSION | 100 mg/5ml | ORAL | N03AF01 | 1385/02/12 | ||||||
Carbamazepine | SYRUP | 100 mg/5ml | ORAL | N03AF01 | |||||||
Carbamazepine | TABLET | 200 mg | ORAL | N03AF01 | |||||||
Carbamazepine | TABLET, EXTENDED RELEASE | 200 mg | ORAL | N03AF01 | 1374/04/18 | ||||||
Carbamazepine | TABLET, EXTENDED RELEASE | 400 mg | ORAL | N03AF01 | 1374/06/26 | ||||||
Carbetocin | INJECTION, SOLUTION | 100 mcg | PARENTERAL | H01BB03 | 1393/06/02 | ||||||
Carboplatin | INJECTION | 10 mg/ml | PARENTERAL | L01XA02 | 1374/07/09 | ||||||
Carboplatin | INJECTION, SOLUTION, CONCENTRATE | 10 mg/ml | PARENTERAL | L01XA02 | 1385/03/23 | ||||||
Carboplatin | INJECTION, SOLUTION | 150 mg | INTRAVENOUS DRIP | L01XA02 | 1371/04/14 | ||||||
Carboplatin | INJECTION, SOLUTION | 50 mg | INTRAVENOUS DRIP | L01XA02 | 1371/04/14 | ||||||
Carboprost | As Tromethamine | INJECTION | 250 mcg/ml | PARENTERAL | G02AD04 | 1385/10/26 | |||||
Carglumic Acid | TABLET, DISPERSIBLE | 200 mg | ORAL | A16AA05 | Orphan medicines | 1393/01/24 | |||||
Carmustine | INJECTION, POWDER | 100 mg | PARENTERAL | L01AD01 | Treatment of intracranial malignancies | 1374/08/21 | |||||
Carvedilol | TABLET | 12.5 mg | ORAL | C07AG02 | 1382/10/07 | ||||||
Carvedilol | TABLET | 25 mg | ORAL | C07AG02 | 1382/10/07 | ||||||
Carvedilol | TABLET | 3.125 mg | ORAL | C07AG02 | 1388/08/20 | ||||||
Carvedilol | TABLET | 6.25 mg | ORAL | C07AG02 | 1382/10/07 | ||||||
Casoni Test | INJECTION | PARENTERAL | V04 | Hospital use only | 1361/08/20 | ||||||
Caspofungin | As Acetate | INJECTION, POWDER | 50 mg | PARENTERAL | J02AX04 | 1385/09/07 | |||||
Caspofungin | As Acetate | INJECTION, POWDER | 70 mg | PARENTERAL | J02AX04 | 1385/09/07 | |||||
Cefalexin | POWDER, FOR SUSPENSION | 125 mg | ORAL | J01DB01 | Sachet | 1365/01/24 | |||||
Cefalexin | POWDER, FOR SUSPENSION | 125 mg/5ml | ORAL | J01DB01 | |||||||
Cefalexin | POWDER, FOR SUSPENSION | 250 mg | ORAL | J01DB01 | Sachet | 1365/01/24 | |||||
Cefalexin | CAPSULE | 250 mg | ORAL | J01DB01 | |||||||
Cefalexin | TABLET | 250 mg | ORAL | J01DB01 | |||||||
Cefalexin | POWDER, FOR SUSPENSION | 250 mg/5ml | ORAL | J01DB01 | |||||||
Cefalexin | CAPSULE | 500 mg | ORAL | J01DB01 | |||||||
Cefalexin | TABLET | 500 mg | ORAL | J01DB01 | |||||||
Cefazolin | As Sodium | INJECTION, POWDER | 1 g | PARENTERAL | J01DB04 | ||||||
Cefazolin | As Sodium | INJECTION, POWDER | 250 mg | PARENTERAL | J01DB04 | ||||||
Cefazolin | As Sodium | INJECTION, POWDER | 500 mg | PARENTERAL | J01DB04 | ||||||
Cefepime | As HCl or DiHCl | INJECTION, POWDER | 1 g | PARENTERAL | J01DE01 | Hospital use only | 1381/12/04 | ||||
Cefepime | As HCl or DiHCl | INJECTION, POWDER | 2 g | PARENTERAL | J01DE01 | Hospital use only | 1381/12/04 | ||||
Cefepime | As HCl or DiHCl | INJECTION, POWDER | 500mg | PARENTERAL | J01DE01 | Hospital use only | 1381/12/04 | ||||
Cefixime | POWDER, FOR SUSPENSION | 100 mg | ORAL | J01DD08 | 1379/02/04 | ||||||
Cefixime | POWDER, FOR SUSPENSION | 200 mg | ORAL | J01DD08 | 1395/06/24 | ||||||
Cefixime | POWDER, FOR SUSPENSION | 100 mg | ORAL | J01DD08 | 1395/06/24 | ||||||
Cefixime | TABLET | 200 mg | ORAL | J01DD08 | 1379/02/04 | ||||||
Cefixime | CAPSULE | 400 mg | ORAL | J01DD08 | |||||||
Cefixime | TABLET | 400 mg | ORAL | J01DD08 | 1379/02/04 | ||||||
Cefixime | POWDER, FOR SUSPENSION | 50 mg | ORAL | J01DD08 | Sachet | 1373/03/22 | |||||
Cefotaxime | As Sodium | INJECTION, POWDER | 1 g | PARENTERAL | J01DD01 | Hospital use only | 1376/06/30 | ||||
Cefotaxime | As Sodium | INJECTION, POWDER | 500 mg | PARENTERAL | J01DD01 | Hospital use only | 1372/03/30 | ||||
Ceftazidime | As Pentahydrate | INJECTION, POWDER | 1 g | PARENTERAL | J01DD02 | Hospital use only | 1372/07/11 | ||||
Ceftazidime | As Pentahydrate | INJECTION, POWDER | 2 g | PARENTERAL | J01DD02 | Hospital use only | 1374/04/31 | ||||
Ceftazidime | As Pentahydrate | INJECTION, POWDER | 500 mg | PARENTERAL | J01DD02 | Hospital use only | 1372/07/11 | ||||
Ceftizoxime | As Sodium | INJECTION, POWDER | 1 g | PARENTERAL | J01DD07 | Hospital use only | 1368/06/19 | ||||
Ceftizoxime | As Sodium | INJECTION, POWDER | 500 mg | PARENTERAL | J01DD07 | Hospital use only | 1368/06/19 | ||||
Ceftriaxone | As Sodium | INJECTION, POWDER | 1 g | PARENTERAL | J01DD04 | 1370/11/20 | |||||
Ceftriaxone | As Sodium | INJECTION, POWDER | 2 g | PARENTERAL | J01DD04 | 1388/02/30 | |||||
Ceftriaxone | As Sodium | INJECTION, POWDER | 250 mg | PARENTERAL | J01DD04 | 1371/08/24 | |||||
Ceftriaxone | As Sodium | INJECTION, POWDER | 500 mg | PARENTERAL | J01DD04 | 1370/11/20 | |||||
Cefuroxime | As Sodium | INJECTION, POWDER | 1.5 g | PARENTERAL | J01DC02 | 1381/07/28 | |||||
Cefuroxime | As Axetil | TABLET | 125 mg | ORAL | J01DC02 | 1379/12/07 | |||||
Cefuroxime | As Axetil | POWDER, FOR SUSPENSION | 125 mg/5ml | ORAL | J01DC02 | 1379/12/07 | |||||
Cefuroxime | As Sodium | INJECTION, POWDER | 250 mg | PARENTERAL | J01DC02 | 1381/07/28 | |||||
Cefuroxime | As Axetil | TABLET | 250 mg | ORAL | J01DC02 | 1379/12/07 | |||||
Cefuroxime | As Axetil | POWDER, FOR SUSPENSION | 250 mg/5ml | ORAL | J01DC02 | ||||||
Cefuroxime | As Axetil | TABLET | 500 mg | ORAL | J01DC02 | 1379/12/07 | |||||
Cefuroxime | As Sodium | INJECTION, POWDER | 750 mg | PARENTERAL | J01DC02 | 1381/07/28 | |||||
Celecoxib | CAPSULE | 100 mg | ORAL | M01AH01 | 1379/10/11 | ||||||
Celecoxib | CAPSULE | 200 mg | ORAL | M01AH01 | 1380/06/03 | ||||||
Cephalothin | As Sodium | INJECTION, POWDER | 1 g | PARENTERAL | J01DA04 | Hospital use only | |||||
Cetirizine | HCl | TABLET | 10 mg | ORAL | R06AE07 | ||||||
Cetirizine | HCl | CAPSULE, LIQUID FILLED | 10 mg | ORAL | R06AE07 | 1386/07/18 | |||||
Cetirizine | HCl | TABLET | 5 mg | ORAL | R06AE07 | 1381/02/09 | |||||
Cetirizine | HCl | SYRUP | 5mg/5ml | ORAL | R06AE07 | 1381/02/09 | |||||
Cetirizine+Pseudoephedrine | TABLET, EXTENDED RELEASE | ORAL | R06AE | Cetirizine Dihydrochloride 5mg (Immediate Relaese )+Pseudoephedrine Hydrochloride 120mg | 1385/11/18 | ||||||
Cetrorelix | As Acetate | INJECTION, POWDER | 250 mcg | PARENTERAL | H01CC02 | ||||||
Cetrorelix | As Acetate | INJECTION, POWDER | 3 mg | PARENTERAL | H01CC02 | ||||||
Cetuximab | INJECTION | 2mg/ml | PARENTERAL | L01XC06 | Treatment of neck and head cancer for 65 Yrs old pateints with Karnofsky Performance status >90% | 1387/11/06 | |||||
Cetuximab | INJECTION | 5mg/ml | PARENTERAL | L01XC06 | Treatment of neck and head cancer for 65 Yrs old pateints with Karnofsky Performance status >90% | 1389/03/31 | |||||
Charcoal Activated | TABLET | 250 mg | ORAL | A07BA01 | OTC medicines | 1375/07/01 | |||||
Charcoal Activated | SUSPENSION | 30 g/240ml | ORAL | A07BA01 | OTC medicines | 1369/10/30 | |||||
Charcoal Activated | POWDER, FOR SUSPENSION | 50 g | ORAL | A07BA01 | OTC medicines | 1376/12/10 | |||||
Charcoal Activated | SUSPENSION | 0.2 g/ml | ORAL | A07BA01 | OTC medicines | 1395/10/07 | |||||
Chloral Hydrate | SOLUTION | 250 mg/5ml | ORAL | N05CC01 | 1386/04/26 | ||||||
Chlorambucil | TABLET | 2 mg | ORAL | L01AA02 | |||||||
Chlorambucil | CAPSULE | 2 mg | ORAL | L01AA02 | 1396/04/18 | ||||||
Chloramphenicol | SOLUTION/ DROPS | 0.50% | OPHTHALMIC | S01AA01 | |||||||
Chloramphenicol | As Sodium Succinate | INJECTION, POWDER | 1 g | PARENTERAL | J01BA01 | Hospital use only | |||||
Chloramphenicol | As Palmitate | SUSPENSION | 150 mg/5ml | ORAL | J01BA01 | ||||||
Chloramphenicol | CAPSULE | 250 mg | ORAL | J01BA01 | |||||||
Chlordiazepoxide | TABLET | 10 mg | ORAL | N05BA02 | |||||||
Chlordiazepoxide | TABLET | 5 mg | ORAL | N05BA02 | |||||||
Chlorhexidine Gluconate | SOLUTION | 4% | TOPICAL | D08AC02 | 1387/05/16 | ||||||
Chlormadinone+Ethinyl Estradiol | TABLET | ORAL | G03FB03 | Chlormadinone Acetate 2 mg + Ethinyl Estradiol 0.03 mg | 1385/08/09 | ||||||
Chlormethine (Nitrogen mustard) | HCl | INJECTION, POWDER | 10 mg | PARENTERAL | L01AA05 | 1362/09/27 | |||||
Chloroacetic Acid | BULK | V03 | Bulk medicines | ||||||||
Chloroquine | As Sulfate | SYRUP | 25 mg/5ml | ORAL | P01BA01 | ||||||
Chloroquine | Phosphate | TABLET | 250 mg | ORAL | P01BA01 | 1360/02/02 | |||||
Chloroquine | AS Phosphate | TABLET | 150 mg | ORAL | P01BA01 | 1397/03/27 | |||||
Chloroquine | As Phosphate | INJECTION | 30 mg/ml | PARENTERAL | P01BA01 | ||||||
Chloroquine | As Phosphate | INJECTION | 40 mg/ml | PARENTERAL | P01BA01 | ||||||
Chloroquine | As Sulfate | SYRUP | 50 mg/5ml | ORAL | P01BA01 | 1369/05/21 | |||||
Chloroquine | As Phosphate | SUSPENSION | 80 mg/5ml | ORAL | P01BA01 | For Health Dept. of MOH only | 1396/05/28 | ||||
Chloroquine | Sulfate | INJECTION | 50 mg/ml | PARENTERAL | P01BA01 | ||||||
Chlorpheniramine | Maleate | INJECTION | 10 mg/ml | PARENTERAL | R06AB04 | ||||||
Chlorpheniramine | Maleate | SYRUP | 2 mg/5ml | ORAL | R06AB04 | OTC medicines | 1378/01/22 | ||||
Chlorpheniramine | Maleate | TABLET | 4 mg | ORAL | R06AB04 | OTC medicines | 1369/10/30 | ||||
Chlorpheniramine | Maleate | TABLET, EXTENDED RELEASE | 8 mg | ORAL | R06AB04 | OTC medicines | 1360/09/29 | ||||
Chlorpheniramine +phenylephrine | SYRUP | ORAL | R01BA53 | (Chlorpheniramine Maleate1mg+phenylephrine HCL 2.5mg)/ 5ml | OTC medicines | 1395/07/28 | |||||
Chlorpheniramine+Dextromethorphan+Phenylephrin | SYRUP | ORAL | R05DA20 | (Chlorpheniramine Maleate 2mg+Dextromethorphan HBr 15mg+Phenylephrine 5mg)/ 5ml | OTC medicines | 1395/08/12 | |||||
Chlorpheniramine+Guaifenesin+Phenylephrin | SYRUP | ORAL | R05DA20 | (Chlorpheniramine Maleate 2mg+Guaifenesin 100mg+Phenylephrine 5mg)/ 5ml | OTC medicines | 1395/10/07 | |||||
Codeine+Guaifenesin+Phenylephrin | SYRUP | ORAL | R05DA20 | (Codeine 10 mg+Guaifenesin 100mg+Phenylephrine 5mg)/ 5ml | 1395/10/07 | ||||||
Chlorpromazine | HCl | TABLET | 100 mg | ORAL | N05AA01 | 1379/01/29 | |||||
Chlorpromazine | HCl | TABLET | 25 mg | ORAL | N05AA01 | 1379/01/29 | |||||
Chlorpromazine | HCl | INJECTION | 25 mg/ml | INTRAMUSCULAR | N05AA01 | ||||||
Chlorpropamide | TABLET | 250 mg | ORAL | A10BB02 | |||||||
Chlorthalidone | TABLET | 100 mg | ORAL | C03BA04 | |||||||
Cholera Vaccine | SUSPENSION | ORAL | J07AE01 | Inactivated | 1393/06/02 | ||||||
Cholestyramine | POWDER, FOR SUSPENSION | 4 g | ORAL | C10AC01 | sachet | ||||||
Choriogonadotropin Alfa | INJECTION | 500 mcg/ml | PARENTERAL | G03GA08 | Recombinant | 1385/11/24 | |||||
Chorionic Gonadotrophin (Human) | INJECTION, POWDER | 1500 U | PARENTERAL | G03GA01 | |||||||
Chorionic Gonadotrophin (Human) | INJECTION, POWDER | 500 U | PARENTERAL | G03GA01 | |||||||
Chorionic Gonadotrophin (Human) | INJECTION, POWDER | 5000 U | PARENTERAL | G03GA01 | |||||||
Ciclesonide | AEROSOL, METERED | 160mcg/puff | INHALATION | R03BA08 | Need to be assessed by clinical trial before registration. For local production only | 1389/05/30 | |||||
Ciclesonide | SPRAY, SUSPENSION | 50mcg/Actuation | INTRANASAL | R01AD13 | For local production only | 1390/07/04 | |||||
Ciclesonide | AEROSOL, METERED | 80mcg/puff | INHALATION | R03BA08 | Need to be assessed by clinical trial before registration. For local production only | 1389/05/30 | |||||
Ciclosporin | SOLUTION | 0.05% | OPHTHALMIC | S01XA18 | 1386/04/27 | ||||||
Ciclosporin | SOLUTION | 2% | OPHTHALMIC | S01XA18 | Treatment of patients at high risk of graft rejection following penetrating keratoplasty. For use in corneal melting syndromes of known or presumed immunologic etiopathogenesis, including Mooren's ulcer. | ||||||
Ciclosporin | CAPSULE | 100 mg | ORAL | L04AA01 | Kidney, liver and heart transplantation, rheumatoid arthritis, psoriasis | ||||||
Ciclosporin | SOLUTION | 100 mg/ml | ORAL | L04AA01 | 1363/04/31 | ||||||
Ciclosporin | CAPSULE | 25 mg | ORAL | L04AA01 | Kidney, liver and heart transplantation, rheumatoid arthritis, psoriasis | ||||||
Ciclosporin | CAPSULE | 50 mg | ORAL | L04AA01 | Kidney, liver and heart transplantation, rheumatoid arthritis, psoriasis | ||||||
Ciclosporin | INJECTION, SOLUTION | 50 mg/ml | INTRAVENOUS DRIP | L04AA01 | |||||||
Cimetidine | As HCl | INJECTION | 100 mg/ml | PARENTERAL | A02BA01 | ||||||
Cimetidine | As HCl | TABLET | 200 mg | ORAL | A02BA01 | ||||||
Cimetidine | As HCl | SYRUP | 200 mg/5ml | ORAL | A02BA01 | 1374/07/30 | |||||
Cinacalcet | As HCl | TABLET | 30 mg | ORAL | H05BX01 | 1391/02/07 | |||||
Cinacalcet | As HCl | TABLET | 60 mg | ORAL | H05BX01 | 1391/02/07 | |||||
Cinacalcet | As HCl | TABLET | 90 mg | ORAL | H05BX01 | 1391/02/07 | |||||
Cinnarizine | TABLET | 25 mg | ORAL | N07CA02 | |||||||
Cinnarizine | TABLET | 75 mg | ORAL | N07CA02 | |||||||
Ciprofloxacin | As HCl | SOLUTION/ DROPS | 0.30% | OPHTHALMIC | S01AE03 | 1373/11/09 | |||||
Ciprofloxacin | As HCl | OINTMENT | 0.30% | OPHTHALMIC | S01AE03 | ||||||
Ciprofloxacin | As Lacate | INJECTION, SOLUTION | 10 mg/ml | INTRAVENOUS | J01MA02 | ||||||
Ciprofloxacin | As Lacate | INJECTION, SOLUTION | 2 mg/ml | INTRAVENOUS DRIP | J01MA02 | Hospital use only | 1372/08/09 | ||||
Ciprofloxacin | As HCl | TABLET | 250 mg | ORAL | J01MA02 | 1372/08/09 | |||||
Ciprofloxacin | SUSPENSION | 250 mg/5ml | ORAL | J01MA02 | 1390/12/22 | ||||||
Ciprofloxacin | As HCl | TABLET | 500 mg | ORAL | J01MA02 | 1372/08/09 | |||||
Ciprofloxacin | As HCl | TABLET | 750 mg | ORAL | J01MA02 | 1396/07/22 | |||||
Ciprofloxacin | TABLET, EXTENDED RELEASE | 500 mg | ORAL | J01MA02 | Containing both Ciprofloxacin base and Ciprofloxacin Hydrochloride | Bilayer tablet | 1396/07/22 | ||||
Ciprofloxacin | TABLET, EXTENDED RELEASE | 1000 mg | ORAL | J01MA02 | Containing both Ciprofloxacin base and Ciprofloxacin Hydrochloride | Bilayer tablet | 1396/07/22 | ||||
Ciprofloxacin+Dexamethasone | SUSPENSION/ DROPS | OTIC | S02AA | Ciprofloxacin (As Hydrochloride) 0.3% + Dexamethasone 0.1% | 1386/12/26 | ||||||
Cisatracurium | As Besylate | INJECTION | 2 mg/ml | PARENTERAL | M03AC11 | Hospital use only | |||||
Cisatracurium | As Besylate | INJECTION | 5 mg/ml | PARENTERAL | M03AC11 | Hospital use only | |||||
Cisplatin | INJECTION, SOLUTION ,CONCENTRATE | 0.5 mg/ml | INTRAVENOUS DRIP | L01XA01 | |||||||
Cisplatin | INJECTION, SOLUTION,CONCENTRATE | 1 mg/ml | INTRAVENOUS DRIP | L01XA01 | 1391/11/02 | ||||||
Cisplatin | INJECTION, POWDER | 10 mg | INTRAVENOUS DRIP | L01XA01 | |||||||
Cisplatin | INJECTION, POWDER | 50 mg | INTRAVENOUS DRIP | L01XA01 | |||||||
Citalopram | As HBr | TABLET | 20 mg | ORAL | N06AB04 | 1379/12/07 | |||||
Citalopram | As HBr | TABLET | 40 mg | ORAL | N06AB04 | 1379/12/07 | |||||
Citalopram | As HCl | SOLUTION/ DROPS | 40 mg/ml | ORAL | N06AB04 | 1379/12/07 | |||||
Citicoline | As Sodium | INJECTION | 125 mg/ml | PARENTERAL | N06BX06 | Hospital use only | 1365/10/14 | ||||
Citric Acid | BULK | V03 | Bulk medicines | ||||||||
Cladribine | INJECTION, SOLUTION | 1mg/ml | INTRAVENOUS DRIP | L01BB04 | Treatment of acute myeloid leukemia. Treatment of the chronic progressive form of MS Treatment of non-Hodgkin's lymphoma. | Orphan medicines | 1374/03/28 | ||||
Cladribine | INJECTION, SOLUTION | 2 mg/ml | INTRAVENOUS DRIP | L01BB04 | Treatment of acute myeloid leukemia. Treatment of the chronic progressive form of MS Treatment of non-Hodgkin's lymphoma. | Orphan medicines | 1381/07/28 | ||||
Clarithromycin | POWDER, FOR SUSPENSION | 125 mg/5ml | ORAL | J01FA09 | 1379/10/11 | ||||||
Clarithromycin | GRANULE, FOR SUSPENSION | 250 mg | ORAL | J01FA09 | sachet | 1384/04/20 | |||||
Clarithromycin | TABLET | 250 mg | ORAL | J01FA09 | 1379/10/11 | ||||||
Clarithromycin | POWDER, FOR SUSPENSION | 250 mg/5ml | ORAL | J01FA09 | 1386/06/28 | ||||||
Clarithromycin | TABLET | 500 mg | ORAL | J01FA09 | 1380/06/25 | ||||||
Clarithromycin | TABLET, EXTENDED RELEASE | 500 mg | ORAL | J01FA09 | 1397/06/24 | ||||||
Clemastine | As Fumarate | INJECTION | 1 mg/ml | PARENTERAL | R06AA04 | Hospital use only | |||||
Clemastine | As Fumarate | TABLET | 1mg | ORAL | R06AA04 | OTC medicines | |||||
Clidinium+Chlordiazepoxide | TABLET | ORAL | A03CA02 | Clidinium bromide 2.5mg + Chlordiazepoxide 5mg | |||||||
Clindamycin | As Phosphate | CREAM | 2% | VAGINAL | G01AA10 | 1397/03/12 | |||||
Clindamycin | As HCl | CAPSULE | 150 mg | ORAL | J01FF01 | ||||||
Clindamycin | As Phosphate | INJECTION | 150 mg/ml | PARENTERAL | J01FF01 | Treatment of Pneumocystis carinii pneumonia associated with AIDS patients. | Hospital use only | ||||
Clindamycin | As HCl | CAPSULE | 300 mg | ORAL | J01FF01 | 1386/03/23 | |||||
Clindamycin | As Palmitate Hydrochloride | SUSPENSION | 75 mg/5ml | ORAL | J01FF01 | ||||||
Clindamycin | As Palmitate Hydrochloride | POWDER, FOR SOLUTION | 75 mg/5ml | ORAL | J01FF01 | 1395/09/01 | |||||
Clindamycin | As Phosphate | GEL | 1% | TOPICAL | D10AF01 | 1377/06/22 | |||||
Clindamycin | As Phosphate | SWAB | 1% | TOPICAL | D10AF01 | 1397/09/27 | |||||
Clindamycin | As Phosphate | SOLUTION | 10 mg/ml | TOPICAL | D10AF01 | 1374/09/12 | |||||
Clindamycin | As Phosphate | SUPPOSITORY | 100 mg | VAGINAL | G01AA10 | ||||||
Clindamycin | As Phosphate | BULK | V03 | Bulk medicines | 1376/12/10 | ||||||
Clindamycin+Clotrimazole | CREAM | VAGINAL | G01A | Clindamycin(as Phosphate ) 2% + Clotrimazole2% W/W | 1392/03/21 | ||||||
Clindamycin+Tretinoin | GEL | TOPICAL | D10AF51 | Clindamycin Phosphate 1.2% + Tretinoin 0.025% | 1386/12/26 | ||||||
Clobazam | TABLET | 10 mg | ORAL | N05BA09 | 1371/08/03 | ||||||
Clobetasol | Propionate | CREAM | 0.05% | TOPICAL | D07AD01 | 1359/07/13 | |||||
Clobetasol | Propionate | LOTION | 0.05% | TOPICAL | D07AD01 | ||||||
Clobetasol | Propionate | OINTMENT | 0.05% | TOPICAL | D07AD01 | ||||||
Clobutinol | HCl | INJECTION | 10 mg/ml | PARENTERAL | R05DB03 | Hospital use only | 1363/08/06 | ||||
Clobutinol | HCl | TABLET | 40 mg | ORAL | R05DB03 | ||||||
Clobutinol | HCl | SOLUTION/ DROPS | 60 mg/ml | ORAL | R05DB03 | ||||||
Clofazimine | CAPSULE | 100 mg | ORAL | J04BA01 | Treatment of lepromatous leprosy, including dapsone-resistant lepromatous leprosy and lepromatous leprosy complicated by erythema nodosum leprosum. | Orphan medicines | 1362/09/20 | ||||
Clofazimine | CAPSULE | 50 mg | ORAL | J04BA01 | Treatment of lepromatous leprosy, including dapsone-resistant lepromatous leprosy and lepromatous leprosy complicated by erythema nodosum leprosum. | Orphan medicines | 1368/06/19 | ||||
Clofibrate | CAPSULE | 500 mg | ORAL | C10AB01 | |||||||
Clomiphene | Citrate | TABLET | 50 mg | ORAL | G03GB02 | ||||||
Clomipramine | HCl | TABLET | 10 mg | ORAL | N06AA04 | ||||||
Clomipramine | HCl | TABLET | 25 mg | ORAL | N06AA04 | ||||||
Clomipramine | HCl | TABLET | 50 mg | ORAL | N06AA04 | ||||||
Clomipramine | HCl | TABLET | 75 mg | ORAL | N06AA04 | 1375/07/01 | |||||
Clonazepam | TABLET | 1 mg | ORAL | N03AE01 | |||||||
Clonazepam | TABLET | 2 mg | ORAL | N03AE01 | 1379/04/13 | ||||||
Clonidine | HCl | TABLET | 0.2 mg | ORAL | C02AC01 | ||||||
Clonidine | HCl | PATCH, EXTENDED RELEASE | 0.2 mg/24h | TRANSDERMAL | C02AC01 | ||||||
Clopidogrel | as Bisulfate | TABLET | 300 mg | ORAL | B01AC04 | Hospital use only | 1390/03/09 | ||||
Clopidogrel | as Bisulfate | TABLET | 75 mg | ORAL | B01AC04 | 1380/05/07 | |||||
Clotrimazole | CREAM | 1% | TOPICAL | D01AC01 | |||||||
Clotrimazole | SOLUTION | 1% | TOPICAL | D01AC01 | |||||||
Clotrimazole | CREAM | 1% | VAGINAL | G01AF02 | OTC medicines | ||||||
Clotrimazole | CREAM | 2% | VAGINAL | G01AF02 | OTC medicines | 1381/02/09 | |||||
Clotrimazole | SUPPOSITORY | 100 mg | VAGINAL | G01AF02 | OTC medicines | ||||||
Clotrimazole | TABLET | 100 mg | VAGINAL | G01AF02 | OTC medicines | ||||||
Clotrimazole | SUPPOSITORY | 200 mg | VAGINAL | G01AF02 | OTC medicines | ||||||
Clotrimazole | SUPPOSITORY | 500 mg | VAGINAL | G01AF02 | 1381/07/28 | ||||||
Clotrimazole | TABLET | 500 mg | VAGINAL | G01AF02 | |||||||
Clotrimazole | CAPSULE, LIQUID FILLED | 500 mg | VAGINAL | G01AF02 | 1393/06/02 | ||||||
Clotrimazole+Betamethasone | CREAM | TOPICAL | D07CC01 | Clotrimazole 1% + Betamethasone (As Dipropionate) 0.05% | 1387/02/04 | ||||||
Clotrimazole+Betamethasone | LOTION | TOPICAL | D07CC01 | Clotrimazole 1% + Betamethasone (As Dipropionate) 0.05% | 1385/03/23 | ||||||
Clotrimazole+Hydrocortisone | CREAM | TOPICAL | D01AC20 | Clotrimazole 1% + Hydrocortison 1% | 1396/06/25 | ||||||
Cloxacillin | As Sodium | INJECTION, POWDER | 1g | PARENTERAL | J01CF02 | 1377/10/20 | |||||
Cloxacillin | As Sodium | CAPSULE | 250 mg | ORAL | J01CF02 | 1371/09/15 | |||||
Cloxacillin | As Sodium | INJECTION, POWDER | 250 mg | PARENTERAL | J01CF02 | ||||||
Cloxacillin | As Sodium | TABLET | 250 mg | ORAL | J01CF02 | ||||||
Cloxacillin | As Sodium | CAPSULE | 500 mg | ORAL | J01CF02 | 1371/09/15 | |||||
Cloxacillin | As Sodium | INJECTION, POWDER | 500 mg | PARENTERAL | J01CF02 | ||||||
Cloxacillin | As Sodium | TABLET | 500 mg | ORAL | J01CF02 | ||||||
Clozapine | TABLET | 100 mg | ORAL | N05AH02 | |||||||
Clozapine | TABLET | 25 mg | ORAL | N05AH02 | |||||||
Coal Tar | LOTION | 5% | TOPICAL | D05AA | |||||||
Coal Tar | OINTMENT | 2% | TOPICAL | D05AA | 1396/03/21 | ||||||
Coal Tar | BULK | V03 | Bulk medicines | ||||||||
Co-amoxiclav | POWDER, FOR SUSPENSION | ORAL | J01CR02 | (Amoxicillin(as trihydrate) 600mg+Clavulanic acid(as potassium) 42.9mg)/ 5ml | for local production only | 1390/03/09 | |||||
Co-amoxiclav | POWDER, FOR SUSPENSION | ORAL | J01CR02 | (Amoxicillin(as trihydrate) 125mg+Clavulanic acid(as potassium) 31.25mg)/5ml | |||||||
Co-amoxiclav | POWDER, FOR SUSPENSION | ORAL | J01CR02 | (Amoxicillin(as trihydrate) 125mg+Clavulanic acid(as potassium) 31.25mg)/Sachet | |||||||
Co-amoxiclav | POWDER, FOR SUSPENSION | ORAL | J01CR02 | (Amoxicillin(as trihydrate) 200mg+Clavulanic acid(as potassium) 28.5 mg)/5ml | |||||||
Co-amoxiclav | POWDER, FOR SUSPENSION | ORAL | J01CR02 | (Amoxicillin(as trihydrate) 250mg+Clavulanic acid(as potassium) 62.5mg)/5ml | |||||||
Co-amoxiclav | POWDER, FOR SUSPENSION | ORAL | J01CR02 | (Amoxicillin(as trihydrate) 250mg+Clavulanic acid(as potassium) 62.5mg)/Sachet | |||||||
Co-amoxiclav | POWDER, FOR SUSPENSION | ORAL | J01CR02 | (Amoxicillin(as trihydrate) 400mg+Clavulanic acid(as potassium) 57 mg)/5ml | |||||||
Co-amoxiclav | INJECTION, POWDER, FOR SOLUTION | PARENTERAL | J01CR02 | Amoxicillin(as sodium)1000mg+Clavulanic acid(as potassium)200mg | 1392/03/21 | ||||||
Co-amoxiclav | INJECTION, POWDER, FOR SOLUTION | PARENTERAL | J01CR02 | Amoxicillin(as sodium)500mg+Clavulanic acid(as potassium)100mg | 1392/03/21 | ||||||
Co-amoxiclav | TABLET | ORAL | J01CR02 | Amoxicillin(as trihydrate) 250mg+Clavulanic acid(as potassium) 125mg | |||||||
Co-amoxiclav | TABLET | ORAL | J01CR02 | Amoxicillin(as trihydrate) 250mg+Clavulanic acid(as potassium) 125mg | |||||||
Co-amoxiclav | TABLET, DISPERSIBLE | ORAL | J01CR02 | Amoxicillin(as trihydrate) 500mg+Clavulanic acid(as potassium) 125mg | 1387/03/28 | ||||||
Co-amoxiclav | TABLET | ORAL | J01CR02 | Amoxicillin(as trihydrate) 875mg+Clavulanic acid(as potassium) 125mg | 1396/06/12 | ||||||
Co-amoxiclav | TABLET, EXTENDED RELEASE | ORAL | J01CR02 | Amoxicillin(as trihydrate) 1000 mg+Clavulanic acid(as potassium) 62.5 mg | 1397/07/28 | ||||||
Co-amoxiclav | TABLET | ORAL | J01CR02 | Amoxicillin(as trihydrate) 500mg+Clavulanic acid(as potassium) 125mg | |||||||
Co-amoxiclav | TABLET | ORAL | J01CR02 | Dispersible Amoxicillin(as trihydrate) 500mg+Clavulanic acid(as potassium) 125mg | |||||||
Cobicistat+Elvitegravir+Emtricitabine+Tenofovir | TABLET | ORAL | J05AR09 | Cobicistat 150 mg+Elvitegravir 150 mg+Emtricitabine 200 mg+Tenofovir disoproxil (as fumarate) 245 mg | HIV infection | For Health Dept. of MOH only | Tenofovir disoproxil fumarate 300 mg | 1394/03/31 | |||
Codeine | Phosphate | TABLET | 30 mg | ORAL | R05DA04 | ||||||
Codeine+Guaifenesine | SYRUP | ORAL | R05DA20 | (Codeine phosphate 10mg+Guaifenesine 100mg)/5ml | 1395/08/12 | ||||||
Codeine+Guaifenesine | SYRUP | ORAL | R05DA20 | (Codeine phosphate 8mg+Guaifenesine 200mg)/5ml | 1395/08/12 | ||||||
Codeine+Guaifenesine | SYRUP | ORAL | R05DA20 | (Codeine phosphate 7.5mg+Guaifenesine 225mg)/5ml | 1395/08/12 | ||||||
Codeine+Guaifenesin+Phenylephrin | SYRUP | ORAL | R05DA20 | (Codeine phosphate 10 mg+Guaifenesin 100mg+Phenylephrine 5mg)/ 5ml | 1395/10/07 | ||||||
Colchicine | TABLET | 1 mg | ORAL | M04AC01 | Treatment of familial Mediterranean fever For arresting the progression of neurologic disability caused by chronic progressive multiple sclerosis. For the treatment of Behcet's Syndrome. | ||||||
Colchicine | TABLET | 0.6 mg | ORAL | M04AC01 | Treatment of familial Mediterranean fever For arresting the progression of neurologic disability caused by chronic progressive multiple sclerosis. For the treatment of Behcet's Syndrome. | 1395/07/17 | |||||
Colistimethate | Sodium | INJECTION, POWDER | 1,000,000 U | PARENTERAL | J01XB01 | Antibiotic, misellaneous | Hospital use only | 1394/11/13 | |||
Colistimethate | Sodium | INJECTION, POWDER | 2,000,000 U | PARENTERAL | J01XB01 | Antibiotic, misellaneous | Hospital use only | 1394/11/13 | |||
Colistimethate | Sodium | INJECTION, POWDER | 4,500,000 U | PARENTERAL | J01XB01 | Antibiotic, misellaneous | Hospital use only | 1395/03/19 | |||
Collagen | BULK | V03 | Bulk medicines | ||||||||
Collodion | SOLUTION | TOPICAL | V03 | (Pyroxylin 40g+Ether 750 ml+Alcohol 250 ml )/1000 ml | OTC medicines | ||||||
Collodion | BULK | V03 | (Pyroxylin 40g+Ether 750 ml+Alcohol 250 ml)/1000 ml | Bulk medicines | |||||||
Conjugated Estrogens | TABLET | 0.625 mg | ORAL | G03CA57 | |||||||
Conjugated Estrogens | TABLET | 0.3 mg | ORAL | G03CA57 | 1395/09/01 | ||||||
Conjugated Estrogens | TABLET | 0.45 mg | ORAL | G03CA57 | 1395/09/01 | ||||||
Conjugated Estrogens | TABLET | 0.9 mg | ORAL | G03CA57 | 1395/09/01 | ||||||
Conjugated Estrogens | CREAM | 0.625 mg/g | VAGINAL | G03CA57 | |||||||
Conjugated Estrogens | TABLET | 1.25 mg | ORAL | G03CA57 | |||||||
Conjugated Estrogens | INJECTION | 5 mg/ml | PARENTERAL | G03CA57 | |||||||
Contraceptive DE | TABLET | ORAL | G03AA09 | Desogestrel 0.15mg+Ethinylestradiol 20mcg | With obstetricians and General Practitioners prescriptions only | 1391/05/02 | |||||
Contraceptive DE | TABLET | ORAL | G03AA09 | Desogestrel 0.15mg+Ethinylestradiol 30mcg | With obstetricians and General Practitioners prescriptions only | 1377/06/22 | |||||
Contraceptive Four-phasic | TABLET | ORAL | G03AB08 | 2 Tab: (Estradiol Valerate 3mg)+ 5 Tab: (Estradiol Valerate 2mg+ Dienogest 2mg)+ 17 Tab: (Estradiol Valerate 2mg+ Dienogest 3mg)+ 2 Tab: (Estradiol Valerate 1mg)+ 2 Tab: Inactive | With obstetricians and General Practitioners prescriptions only | 1393/06/02 | |||||
Contraceptive HD | TABLET | ORAL | G03FA04 | Norgestrel (or 1/2 amount of levonorgestrel) 0.5mg+Ethinylestradiol 50mcg | With obstetricians prescriptions only | ||||||
Contraceptive LD | TABLET | ORAL | G03FA04 | Norgestrel (or 1/2 amount of levonorgestrel) 0.3mg+Ethinylestradiol 30mcg | With obstetricians and General Practitioners prescriptions only | ||||||
Contraceptive LD | TABLET | ORAL | G03FA04 | Norgestrel (or 1/2 amount of levonorgestrel) 0.1mg+Ethinylestradiol 20mcg | With obstetricians and General Practitioners prescriptions only | 1397/02/11 | |||||
Contraceptive LD+Fe | TABLET | ORAL | G03AA06 | 21 Tab. [Norgestrel (or 1/2 amount of levonorgestrel) 0.3mg+Ethinylestradiol 30mcg] + [ 7 Tab. of 24.65 mg Iron as Ferrous Sulfate or Fumarate )] | With obstetricians and General Practitioners prescriptions only | 1379/11/25 | |||||
Contraceptive Triphasic | TABLET | ORAL | G03AA06 | 6 Tab: (Levonorgestrel 0.05mg + Ethinylestradiol 30mcg) + 5 Tab: (Levonorgestrel 0.075mg + Ethinylestradiol 40mcg) + 10 Tab: (Levonorgestrel 0.125mg + Ethinylestrdiol 30mcg) | With obstetricians and General Practitioners prescriptions only | 1368/04/18 | |||||
Copper Sulfate | BULK | V03 | Bulk medicines | ||||||||
Copper+Zinc | LOTION | TOPICAL | D11 | Copper Sulfate 1 g + Zinc Sulfate 1.5 g + Concentrated Comphor Water 2.5 ml + water qs to 100 ml | OTC medicines | ||||||
Corifollitropin Alfa | INJECTION, SOLUTION | 200 mcg/ml | PARENTERAL | G03GA09 | Overian Stimulation | 1396/12/08 | |||||
Corifollitropin Alfa | INJECTION, SOLUTION | 300 mcg/ml | PARENTERAL | G03GA09 | Overian Stimulation | 1396/12/08 | |||||
Corticotrophin | INJECTION | 40 U/ml | PARENTERAL | H01AA01 | Hospital use only | 1366/11/04 | |||||
Corticotrophin | INJECTION | 80 U/ml | PARENTERAL | H01AA01 | Hospital use only | 1375/07/29 | |||||
Co-trimoxazole | INJECTION, SOLUTION | INTRAVENOUS DRIP | J01EE01 | (Sulfamethoxazole 400mg+Trimethoprim 80mg)/5ml | Hospital use only | 1361/11/17 | |||||
Co-trimoxazole | SUSPENSION | ORAL | J01EE01 | (Sulfamethoxazole 200mg+Trimethoprim 40mg)/5ml | |||||||
Co-trimoxazole | TABLET | ORAL | J01EE01 | Sulfamethoxazole 100mg+Trimethoprim 20mg | |||||||
Co-trimoxazole | TABLET | ORAL | J01EE01 | Sulfamethoxazole 400mg+Trimethoprim 80mg | |||||||
Co-trimoxazole | TABLET | ORAL | J01EE01 | Sulfamethoxazole 800mg+Trimethoprim 160mg | 1384/02/12 | ||||||
Cream Base | BULK | V03 | Bulk medicines | ||||||||
Cresol | BULK | V03 | Bulk medicines | ||||||||
Cromolyn | Sodium | INHALER | 1 mg/dose | RESPIRATORY | R03BC01 | 1369/08/06 | |||||
Cromolyn | Sodium | NEBULISATION | 10 mg/ml | RESPIRATORY | R03BC01 | 1374/06/26 | |||||
Cromolyn | Sodium | INHALER | 20 mg/capsule | RESPIRATORY | R03BC01 | ||||||
Cromolyn | Sodium | SOLUTION | 20 mg/ml | OPHTHALMIC | S01GX01 | Treatment of vernal keratoconjunctivitis. | 1369/08/06 | ||||
Cromolyn | Sodium | SPRAY | 20 mg/ml | NASAL | R01AC01 | 1365/02/21 | |||||
Crotamiton | CREAM | TOPICAL | P03AX | OTC medicines | |||||||
Cyclopentolate | HCl | SOLUTION | 1% | OPHTHALMIC | S01FA04 | ||||||
Cyclophosphamide | INJECTION, POWDER | 200 mg | PARENTERAL | L01AA01 | Rheumatoid arthritis | ||||||
Cyclophosphamide | TABLET | 50 mg | ORAL | L01AA01 | Rheumatoid arthritis | ||||||
Cyclophosphamide | INJECTION, POWDER | 500 mg | PARENTERAL | L01AA01 | Rheumatoid arthritis | ||||||
Cyclophosphamide | INJECTION, POWDER | 1 g | PARENTERAL | L01AA01 | Rheumatoid arthritis | 1395/04/08 | |||||
Cycloserine | CAPSULE | 250 mg | ORAL | J04AB01 | 1361/03/23 | ||||||
Cycloserine | TABLET | 250 mg | ORAL | J04AB01 | |||||||
Cyproheptadine | HCl | SOLUTION | 2 mg/5 ml | ORAL | R06AX02 | For local prodcution only | 1390/09/21 | ||||
Cyproheptadine | HCl | TABLET | 4 mg | ORAL | R06AX02 | ||||||
Cyproterone | Acetate | TABLET | 100 mg | ORAL | G03HA01 | For local prodcution only | 1391/02/25 | ||||
Cyproterone | Acetate | TABLET | 50 mg | ORAL | G03HA01 | Treatment of severe hirsutism. | 1359/10/24 | ||||
Cyproterone Compound | TABLET | ORAL | G03HB01 | Cyproterone acetate 2mg+Ethinylestradiol 35mcg | With obstetricians and General Practitioners prescriptions only | ||||||
Cysteamine | As Bitartarte | CAPSULE | 150 mg | ORAL | A16AA04 | Treatment of corneal cystine crystal accumulation in cystinosis patients. Treatment of nephropathic cystinosis. | Orphan medicines | ||||
Cysteamine | As Bitartarte | CAPSULE | 50 mg | ORAL | A16AA04 | Orphan medicines | 1387/10/15 | ||||
Cytarabine | INJECTION, POWDER | 1 g | PARENTERAL | L01BC01 | 1381/06/31 | ||||||
Cytarabine | INJECTION, POWDER | 100 mg | PARENTERAL | L01BC01 | |||||||
Cytarabine | INJECTION, SOLUTION | 20 mg/ml | PARENTERAL | L01AX04 | |||||||
Cytarabine | INJECTION, SOLUTION | 50 mg/ml | PARENTERAL | L01AX04 | |||||||
Cytarabine | INJECTION, SOLUTION | 100 mg/ml | PARENTERAL | L01AX04 | 1395/06/24 | ||||||
Cytarabine | INJECTION, POWDER | 500 mg | PARENTERAL | L01BC01 | 1391/07/25 | ||||||
Dabigatran Etexilate | As Mesylate | CAPSULE | 110 mg | ORAL | B01AE07 | 1390/03/07 | |||||
Dabigatran Etexilate | As Mesylate | CAPSULE | 150 mg | ORAL | B01AE07 | 1390/09/21 | |||||
Dabigatran Etexilate | As Mesylate | CAPSULE | 75 mg | ORAL | B01AE07 | 1390/03/07 | |||||
Dacarbazine | INJECTION, POWDER | 100 mg | PARENTERAL | L01AX04 | |||||||
Dacarbazine | INJECTION, POWDER | 200 mg | PARENTERAL | L01AX04 | |||||||
Dacarbazine | INJECTION, POWDER | 500 mg | PARENTERAL | L01AX04 | |||||||
Daclatasvir | As Dihydrochloride | TABLET | 30 mg | ORAL | J05AX14 | Hepatitis C infection | 1394/07/05 | ||||
Daclatasvir | As Dihydrochloride | TABLET | 60 mg | ORAL | J05AX14 | Hepatitis C infection | 1394/07/05 | ||||
Daclatasvir+Sofosbuvir | TABLET | ORAL | J05AX | Daclatasvir (As Dihydrochloride) 60 mg+Sofosbuvir 400 mg | Hepatitis C infection | 1394/07/05 | |||||
Dactinomycin | INJECTION, POWDER | 0.5 mg | PARENTERAL | L01DA01 | |||||||
Dalteparin | Sodium | INJECTION | 10000 U/ml | PARENTERAL | B01AB04 | ||||||
Dalteparin | Sodium | INJECTION | 12500 U/ml | PARENTERAL | B01AB04 | ||||||
Dalteparin | Sodium | INJECTION | 25000 U/ml | PARENTERAL | B01AB04 | ||||||
Dalteparin | Sodium | INJECTION | 7500 U/0.3 ml | PARENTERAL | B01AB04 | ||||||
Danaparoid | Sodium | INJECTION | 1250 U/ml | PARENTERAL | B01AB09 | 1385/10/26 | |||||
Danazol | CAPSULE | 100 mg | ORAL | G03XA01 | 1361/12/15 | ||||||
Danazol | CAPSULE | 200 mg | ORAL | G03XA01 | 1361/12/15 | ||||||
Dantrolene | Sodium | INJECTION, POWDER | 20 mg | PARENTERAL | M03CA01 | Treatment of the neuroleptic malignant syndrome. | Hospital use only; Orphan medicines | ||||
Dantrolene | Sodium | CAPSULE | 25 mg | ORAL | M03CA01 | Orphan medicines | |||||
Dapagliflozin | As Propanediol | TABLET | 5 mg | ORAL | A10BK01 | Diabetes Mellitus type 2 | 1397/09/03 | ||||
Dapagliflozin | As Propanediol | TABLET | 10 mg | ORAL | A10BK01 | Diabetes Mellitus type 2 | 1396/11/29 | ||||
Dapagliflozin+Metformin | TABLET, EXTENDED RELEASE | ORAL | A10BD15 | Dapagliflozin as Propanediol 5 mg+Metformin HCl 1000 mg | Diabetes Mellitus type 2 | 1396/11/29 | |||||
Dapagliflozin+Metformin | TABLET, EXTENDED RELEASE | ORAL | A10BD15 | Dapagliflozin as Propanediol 10 mg+Metformin HCl 1000 mg | Diabetes Mellitus type 2 | 1396/11/29 | |||||
Dapoxetine | As HCl | TABLET | 30 mg | ORAL | G04BX14 | Premature ejaculation | 1395/03/09 | ||||
Dapoxetine | As HCl | TABLET | 60 mg | ORAL | G04BX14 | Premature ejaculation | 1396/03/13 | ||||
Dapsone | GEL | 5% | TOPICAL | D10AX05 | 1392/04/04 | ||||||
Dapsone | TABLET | 100 mg | ORAL | J04BA02 | For the combination treatment of Pneumocystis carinii pneumonia in conjunction with trimethoprim. | Orphan medicines | |||||
Dapsone | TABLET | 50 mg | ORAL | J04BA02 | For the combination treatment of Pneumocystis carinii pneumonia in conjunction with trimethoprim. | Orphan medicines | 1368/09/19 | ||||
Darunavir | As Ethanolate | TABLET | 600 mg | ORAL | J05AE10 | Treatment of AIDS related complex. | For Health Dept. of MOH only | 1393/10/14 | |||
Darunavir | As Ethanolate | TABLET | 300 mg | ORAL | J05AE10 | Treatment of AIDS related complex. | For Health Dept. of MOH only | 1394/03/31 | |||
Darunavir | As Ethanolate | TABLET | 150 mg | ORAL | J05AE10 | Treatment of AIDS related complex. | For Health Dept. of MOH only | 1395/05/03 | |||
Dasatinib | TABLET | 20 mg | ORAL | L01XE06 | CML | Local production only | 1397/10/04 | ||||
Dasatinib | TABLET | 50 mg | ORAL | L01XE06 | CML | Local production only | 1397/10/04 | ||||
Dasatinib | TABLET | 70 mg | ORAL | L01XE06 | CML | Local production only | 1397/10/04 | ||||
Dasatinib | TABLET | 80 mg | ORAL | L01XE06 | CML | Local production only | 1397/10/04 | ||||
Dasatinib | TABLET | 100 mg | ORAL | L01XE06 | CML | Local production only | 1397/10/04 | ||||
Dasatinib | TABLET | 140 mg | ORAL | L01XE06 | CML | Local production only | 1397/10/04 | ||||
Daunorubicin | As HCl | INJECTION, POWDER | 20 mg | PARENTERAL | L01DB02 | ||||||
Deferasirox | TABLET, DISPERSIBLE | 125 mg | ORAL | V03AC03 | 1385/08/09 | ||||||
Deferasirox | TABLET, DISPERSIBLE | 250 mg | ORAL | V03AC03 | 1385/08/09 | ||||||
Deferasirox | TABLET, DISPERSIBLE | 500 mg | ORAL | V03AC03 | 1385/08/09 | ||||||
Deferasirox | TABLET | 90 mg | ORAL | V03AC03 | 1395/11/12 | ||||||
Deferasirox | TABLET | 180 mg | ORAL | V03AC03 | 1395/11/12 | ||||||
Deferasirox | TABLET | 360 mg | ORAL | V03AC03 | 1395/11/12 | ||||||
Deferiprone | TABLET, EFFERVESCENT | 500 mg | ORAL | V03AC02 | 1393/05/12 | ||||||
Deferiprone | TABLET, DELAYED RELEASE | 500 mg | ORAL | V03AC02 | 1389/09/22 | ||||||
Deferiprone | SOLUTION | 100 mg/ ml | ORAL | V03AC02 | 1395/12/22 | ||||||
Deferoxamine | Mesylate | INJECTION, POWDER | 500 mg | PARENTERAL | V03AC01 | ||||||
Deferoxamine | Mesylate | INJECTION, POWDER LYOPHILIZED | 2 g | PARENTERAL | V03AC01 | ||||||
Denosumab | INJECTION. SOLUTION | 60 mg/ml | PARENTERAL | M05BX04 | Prevention of Osteoporotic Fractures | 1394/07/05 | |||||
Denosumab | INJECTION. SOLUTION | 120 mg/1.7ml | PARENTERAL | M05BX04 | Reduction of bone damage in patients with bone metastasis frome solid tumours | 1395/04/09 | |||||
Desipramine | HCl | TABLET | 25 mg | ORAL | N06AA01 | 1371/06/08 | |||||
Desloratadine | TABLET | 5 mg | ORAL | R06AX27 | 1396/09/12 | ||||||
Desloratadine | SYRUP | 2.5 mg/5ml | ORAL | R06AX27 | 1396/09/12 | ||||||
Desmopressin | As Acetate | TABLET | 0.1 mg | ORAL | H01BA02 | 1380/02/30 | |||||
Desmopressin | As Acetate | TABLET | 0.2 mg | ORAL | H01BA02 | 1380/02/30 | |||||
Desmopressin | As Acetate | SPRAY | 10 mcg/dose | NASAL | H01BA02 | ||||||
Desmopressin | As Acetate | TABLET | 120 mcg | SUBLINGUAL | H01BA02 | 1385/12/02 | |||||
Desmopressin | As Acetate | INJECTION | 15 mcg/ml | PARENTERAL | H01BA02 | Hospital use only | 1376/07/27 | ||||
Desmopressin | As Acetate | TABLET | 240 mcg | SUBLINGUAL | H01BA02 | ||||||
Desmopressin | As Acetate | INJECTION | 4 mcg/ml | PARENTERAL | H01BA02 | Hospital use only | 1376/07/27 | ||||
Desmopressin | As Acetate | TABLET | 60 mcg | SUBLINGUAL | H01BA02 | 1385/12/02 | |||||
Desmopressin | As Acetate | TABLET | 25 mcg | SUBLINGUAL | H01BA02 | 1396/08/29 | |||||
Desmopressin | As Acetate | TABLET | 50 mcg | SUBLINGUAL | H01BA02 | 1396/08/29 | |||||
Desogestrel | TABLET | 75mcg | ORAL | G03AC09 | OTC medicines | 1390/12/22 | |||||
Desonide | CREAM | 0.05% | TOPICAL | D07AB08 | 1389/10/25 | ||||||
Desonide | OINTMENT | 0.05% | TOPICAL | D07AB08 | 1397/06/24 | ||||||
Dexamethasone | As Disodium Phosphate | INJECTION | 4 mg/ml | PARENTERAL | H02AB02 | ||||||
Dexamethasone | TABLET | 0.5 mg | ORAL | H02AB02 | |||||||
Dexamethasone | TABLET | 4 mg | ORAL | H02AB02 | 1395/08/02 | ||||||
Dexamethasone | As Acetate | TABLET | 40 mg | ORAL | H02AB02 | 1396/06/07 | |||||
Dexamethasone | ELIXIR | 0.5 mg/5ml | ORAL | H02AB02 | |||||||
Dexamethasone | SOLUTION | 2 mg/5ml | ORAL | H02AB02 | 1395/09/01 | ||||||
Dexamethasone | BULK | V03 | Bulk medicines | ||||||||
Dexmedetomidine | As HCl | INJECTION, CONCENTRATE | 100mcg/ml | PARENTERAL | N05CM18 | Hospital use only | 1391/02/07 | ||||
Dexmedetomidine | As HCl | INJECTION, SOLUTION | 4 mcg/ml | PARENTERAL | N05CM18 | Hospital use only | 1395/08/02 | ||||
Dexpanthenol | CREAM | 5% | TOPICAL | D03AX03 | OTC medicines | 1369/10/30 | |||||
Dexpanthenol | INJECTION, SOLUTION | 250mg/ml | PARENTERAL | A11HA30 | 1392/09/25 | ||||||
Dextran+NaCl | INJECTION, SOLUTION | 500 ml | INTRAVENOUS DRIP | B05BB02 | Dextran70 6%+ NaCl 0.9% | Hospital use only | |||||
Dextroamphetamine | Sulfate | TABLET | 10 mg | ORAL | N06BA02 | 1379/12/21 | |||||
Dextroamphetamine | Sulfate | TABLET | 5 mg | ORAL | N06BA02 | 1379/12/21 | |||||
Dextromethorphan | HBr | TABLET | 15 mg | ORAL | R05DA09 | OTC medicines | 1359/06/08 | ||||
Dextromethorphan | HBr | CAPSULE, LIQUID FILLED | 15 mg | ORAL | R05DA09 | OTC medicines | 1385/09/15 | ||||
Dextromethorphan | HBr | SYRUP | 15 mg/5ml | ORAL | R05DA09 | OTC medicines | 1369/10/30 | ||||
Dextromethorphan | HBr | SOLUTION/ DROPS | 4 mg/ml | ORAL | R05DA09 | OTC medicines | |||||
Dextromethorphan+Pseudoephedrine | SYRUP | ORAL | R05DA20 | (Dextromethorphan HBr 15mg+Pseudoephedrine HCl 30mg)/5ml | OTC medicines | ||||||
Dextromethorphan+Guaifenisin+Phenylephrin | SYRUP | ORAL | R05CA | (Dextromethorphan HBr 10mg+Guaifenisin 100mg+Phenylephrin 5mg)/5ml | OTC medicines | 1395/08/12 | |||||
Dextromethorphan+Guaifenisin+Phenylephrin | SYRUP | ORAL | R05CA | (Dextromethorphan HBr 20mg+Guaifenisin 100mg+Phenylephrin HCl 10mg)/5ml | OTC medicines | 1395/08/12 | |||||
Dextromethorphan+Guaifenisin+Phenylephrin | SYRUP | ORAL | R05CA | (Dextromethorphan HBr 30mg+Guaifenisin HCl 200mg+Phenylephrin HCl 10mg)/5ml | OTC medicines | 1395/08/12 | |||||
Dextromethorphan+Guaifenisin+Phenylephrin | SYRUP | ORAL | R05CA | (Dextromethorphan HBr 15mg+Guaifenisin HCl 350mg+Phenylephrin HCl 10mg)/5ml | OTC medicines | 1395/08/12 | |||||
Dextromethorphan+Guaifenisin+Pseudoephedrine | SYRUP | ORAL | R05CA | (Dextromethorphan HBr 15mg+Guaifenisin HCl 200mg+Pseudoephedrine HCl 30 mg)/5ml | OTC medicines | For Adults | 1397/07/14 | ||||
Dextromethorphan+Guaifenisin | SYRUP | ORAL | R05CA | (Dextromethorphan HBr 5mg+Guaifenisin HCl 100mg)/5 ml | 1396/06/25 | ||||||
Dextrose | INJECTION, SOLUTION | 10%, 500ml | INTRAVENOUS DRIP | B05BA03 | Dextrose anhydrous or monohydrate Eq. to 10 g Dextrose/100 ml | ||||||
Dextrose | INJECTION, SOLUTION | 20% , 50ml | INTRAVENOUS DRIP | B05CX03 | Dextrose anhydrous or monohydrate Eq. to 20 g Dextrose/100 ml | ||||||
Dextrose | INJECTION, SOLUTION | 20%, 1lit | INTRAVENOUS DRIP | B05CX03 | Dextrose anhydrous or monohydrate Eq. to 20 g Dextrose/100 ml | 1373/10/18 | |||||
Dextrose | INJECTION, SOLUTION | 20%, 500ml | INTRAVENOUS DRIP | B05CX03 | Dextrose anhydrous or monohydrate Eq. to 20 g Dextrose/100 ml | ||||||
Dextrose | INJECTION, SOLUTION | 5% , 250ml | PARENTERAL | B05BA03 | Dextrose anhydrous or monohydrate Eq. to 5 g Dextrose/ 100 ml | 1384/02/12 | |||||
Dextrose | SOLUTION | 5%, 100ml | INTRAVENOUS DRIP | B05BA03 | Dextrose anhydrous or monohydrate Eq. to 5 g Dextrose/ 100 ml | ||||||
Dextrose | INJECTION, SOLUTION | 5%, 1lit | INTRAVENOUS DRIP | B05BA03 | Dextrose anhydrous or monohydrate Eq. to 5 g Dextrose/ 100 ml | ||||||
Dextrose | INJECTION, SOLUTION | 5%, 500ml | INTRAVENOUS DRIP | B05BA03 | Dextrose anhydrous or monohydrate Eq. to 5 g Dextrose/ 100 ml | ||||||
Dextrose | INJECTION, SOLUTION, CONCENTRATE | 50%, 1lit | INTRAVENOUS DRIP | B05BA03 | Dextrose anhydrous or monohydrate Eq. to 50 g Dextrose/100 ml_ In 2000 ml Container | ||||||
Dextrose | INJECTION, SOLUTION, CONCENTRATE | 50%, 200ml in 2 litr bag | INTRAVENOUS DRIP | B05BA03 | 1389/02/01 | ||||||
Dextrose | INJECTION, SOLUTION, CONCENTRATE | 50%, 400ml in 2 litr bag | INTRAVENOUS DRIP | B05BA03 | 1389/02/01 | ||||||
Dextrose | INJECTION, SOLUTION, CONCENTRATE | 50%, 500ml | INTRAVENOUS DRIP | B05CX01 | Dextrose anhydrous or monohydrate Eq. to 50 g Dextrose/100 ml_In 1000 ml Container | 1373/10/18 | |||||
Dextrose | INJECTION, SOLUTION, CONCENTRATE | 50%, 50ml | INTRAVENOUS DRIP | B05CX01 | Dextrose anhydrous or monohydrate Eq. to 50 g Dextrose/100 ml | ||||||
Dextrose | INJECTION, SOLUTION, CONCENTRATE | 70%, 1lit | PARENTERAL | B05CX01 | In 2000 ml Container | 1385/11/24 | |||||
Dextrose/ Ehthanol | INJECTION, SOLUTION | 5/5%, 1000ml | INTRAVENOUS DRIP | B05BA10 | Dextrose 5% + EHTHANOL 5% | Hospital use only | |||||
Dextrose/ NaCl | INJECTION, SOLUTION | 3.33/0.3%, 1000ml | INTRAVENOUS DRIP | B05BB02 | Dextrose 3.33% NaCl 0.3% Dextrose anhydrous or monohydrate Eq. to 3.33% Dextrose/100 ml | 1387/08/15 | |||||
Dextrose/ NaCl | INJECTION, SOLUTION | 3.33/0.3%, 500ml | INTRAVENOUS DRIP | B05BB02 | Dextrose 3.33% NaCl 0.3% Dextrose anhydrous or monohydrate Eq. to 3.33% Dextrose/100 ml | 1387/08/15 | |||||
Dextrose/ NaCl | INJECTION, SOLUTION | 5/0.45%, 1000ml | INTRAVENOUS DRIP | B05BB02 | Dextrose 5% NaCl 0.45% Dextrose anhydrous or monohydrate Eq. to 5 g Dextrose/100 ml | ||||||
Dextrose/ NaCl | INJECTION, SOLUTION | 5/0.45%, 500ml | INTRAVENOUS DRIP | B05BB02 | Dextrose 5% NaCl 0.45% Dextrose anhydrous or monohydrate Eq. to 5 g Dextrose/100 ml | ||||||
Dextrose/ NaCl | INJECTION, SOLUTION | 5/0.9%, 1000ml | INTRAVENOUS DRIP | B05BB02 | Dextrose 5% NaCl 0.9% Dextrose anhydrous or monohydrate Eq. to 5 g Dextrose/100 ml | ||||||
Dextrose/ NaCl l | INJECTION, SOLUTION | 5/0.9%, 250m | INTRAVENOUS DRIP | B05BB02 | Dextrose 5% NaCl 0.9% Dextrose anhydrous or monohydrate Eq. to 5 g Dextrose/100 ml | 1384/02/12 | |||||
Dextrose/ NaCl | INJECTION, SOLUTION | 5/0.9%, 500ml | INTRAVENOUS DRIP | B05BB02 | Dextrose 5% NaCl 0.9% Dextrose anhydrous or monohydrate Eq. to 5 g Dextrose/100 ml | ||||||
Dextrose/ NaCl | INJECTION, SOLUTION | 5/0.9%, 500ml | INTRAVENOUS DRIP | B05BB02 | Dextrose 5% NaCl 0.9% Dextrose anhydrous or monohydrate Eq. to 5 g Dextrose/100 ml | ||||||
Dextrose | BULK | V03 | Bulk medicines | ||||||||
Diacetyl-bis(N4-methylthiosemicarbazone) (ATSM) | INJECTION, SOLUTION | (5-10) mCi (64Cu) | PARENTERAL | V10 | 1389/10/25 | ||||||
Diazepam | ENEMA | 10 mg | RECTAL | N05BA01 | For the management of selected, refractory, patients with epilepsy, on stable regimens of antiepileptic drugs (AEDs), who require intermittent use of diazepam to control bouts of increased seizure activity. | 1372/08/23 | |||||
Diazepam | SUPPOSITORY | 10 mg | RECTAL | N05BA01 | |||||||
Diazepam | TABLET | 10 mg | ORAL | N05BA01 | 1382/03/04 | ||||||
Diazepam | TABLET | 2 mg | ORAL | N05BA01 | |||||||
Diazepam | SOLUTION | 2 mg/5ml | ORAL | N05BA01 | |||||||
Diazepam | ENEMA | 5 mg | RECTAL | N05BA01 | 1372/08/23 | ||||||
Diazepam | SUPPOSITORY | 5 mg | RECTAL | N05BA01 | |||||||
Diazepam | TABLET | 5 mg | ORAL | N05BA01 | |||||||
Diazepam | INJECTION | 5 mg/ml | PARENTERAL | N05BA01 | |||||||
Diazoxide | CAPSULE | 100 mg | ORAL | C02DA01 | |||||||
Diazoxide | INJECTION | 15 mg/ml | PARENTERAL | V03AH01 | Hospital use only | ||||||
Diazoxide | CAPSULE | 50 mg | ORAL | V03AH01 | 1361/09/14 | ||||||
Dichloroacetic Acid | BULK | V03 | Bulk medicines | ||||||||
Diclofenac | Sodium | SOLUTION/ DROPS | 0.10% | OPHTHALMIC | S01BC03 | 1378/03/30 | |||||
Diclofenac | Diethylammonium | GEL | 1% | TOPICAL | D11AX18 | OTC medicines | 1371/10/27 | ||||
Diclofenac | Sodium | SOLUTION | 1.50% | TOPICAL | M01AB05 | 1389/06/15 | |||||
Diclofenac | Sodium | CAPSULE, EXTENDED RELEASE, PELLETS | 100 mg | ORAL | M01AB05 | ||||||
Diclofenac | Sodium | TABLET, EXTENDED RELEASE | 100 mg | ORAL | M01AB05 | 1371/08/24 | |||||
Diclofenac | Sodium | SUPPOSITORY | 100 mg | RECTAL | M01AB05 | 1379/03/02 | |||||
Diclofenac | Diethylamine | PLASTER | 120 mg | TOPICAL | M02AA15 | 1392/05/29 | |||||
Diclofenac | Epolamine | PATCH | 1.30% | TOPICAL | M02AA15 | 1395/10/07 | |||||
Diclofenac | Sodium | SOLUTION | 2.00% | TOPICAL | M02AA15 | 1396/09/18 | |||||
Diclofenac | Potassium | CAPSULE, LIQUID FILLED | 25 mg | ORAL | M01AB05 | 1393/03/25 | |||||
Diclofenac | Sodium | TABLET, DELAYED RELEASE | 25 mg | ORAL | M01AB05 | 1361/06/28 | |||||
Diclofenac | Sodium | INJECTION | 25 mg/ml | PARENTERAL | M01AB05 | Hospital use only | 1367/12/14 | ||||
Diclofenac | Potassium | TABLET | 50 mg | ORAL | M01AB05 | 1388/08/20 | |||||
Diclofenac | Sodium | SUPPOSITORY | 50 mg | RECTAL | M01AB05 | 1372/09/07 | |||||
Diclofenac | Sodium | TABLET, DELAYED RELEASE | 50 mg | ORAL | M01AB05 | ||||||
Diclofenac | Sodium | TABLET, EXTENDED RELEASE | 75 mg | ORAL | M01AB05 | 1389/03/31 | |||||
Dicyclomine | HCl | ELIXIR | 10 mg/5ml | ORAL | A03AA07 | 1359/11/08 | |||||
Dicyclomine | HCl | TABLET | 10 mg | ORAL | A03AA07 | ||||||
Dicyclomine | HCl | INJECTION | 10 mg/ml | PARENTERAL | A03AA07 | 1361/02/05 | |||||
Didanosine | CAPSULE | 200 mg | ORAL | J05AF02 | For Health Dept. of MOH only | ||||||
Didanosine | CAPSULE, DELAYED RELEASE | 200 mg | ORAL | J05AF02 | For Health Dept. of MOH only | 1396/04/18 | |||||
Didanosine | TABLET | 200 mg | ORAL | J05AF02 | Hospital use only | ||||||
Dienestrol | CREAM | 0.01% | VAGINAL | G03CB01 | |||||||
Dienestrol | TABLET | 2mg | ORAL | G03DB08 | 1393/06/02 | ||||||
Dienogest | TABLET | 2mg | ORAL | G03DB08 | OTC medicines | 1391/02/07 | |||||
Dienogest+Ethinylestradiol | TABLET | ORAL | G03AA16 | Dienogest 2mg+ Ethinylestradiol 0.03 mg | With obstetricians and General Practitioners prescriptions only | 1391/02/07 | |||||
Digestive | TABLET, DELAYED RELEASE | ORAL | A09AA | Pancreatin+simethicone 40 mg | OTC medicines | ||||||
Digoxin | ELIXIR | 0.05 mg/ml | ORAL | C01AA05 | 1362/03/29 | ||||||
Digoxin | TABLET | 0.25 mg | ORAL | C01AA05 | |||||||
Digoxin | INJECTION | 0.25 mg/ml | PARENTERAL | C01AA05 | Hospital use only | ||||||
Digoxin | SOLUTION/ DROPS | 0.5 mg/ml | ORAL | C01AA05 | |||||||
Digoxin Specific Antibody | INJECTION | 40 mg | PARENTERAL | V03AB24 | Treatment of digitalis intoxication; refractory to management by conventional therapy. | Orphan medicines | 1385/11/24 | ||||
Dihydroergotamine | Mesylate | INJECTION | 1 mg/ml | PARENTERAL | N02CA01 | ||||||
Dihydroergotamine | Mesylate | TABLET | 1.5 mg | ORAL | N02CA01 | ||||||
Dihydroergotamine | Mesylate | TABLET | 2.5 mg | ORAL | N02CA01 | ||||||
Dihydrotachysterol | SOLUTION | 0.25 mg/ml | ORAL | A11CC02 | |||||||
Dihydrotachysterol | SOLUTION | 1 mg/ml | ORAL | A11CC02 | 1396/12/08 | ||||||
Diloxanide | Furoate | TABLET | 500 mg | ORAL | P01AC01 | 1369/10/30 | |||||
Diltiazem | HCl | GEL | 2% | TOPICAL | C05AE | 1390/09/21 | |||||
Diltiazem | HCl | INJECTION, POWDER | 100 mg | PARENTERAL | C08DB01 | Hospital use only | |||||
Diltiazem | HCl | INJECTION, SOLUTION | 5 mg/ml | PARENTERAL | C08DB01 | Hospital use only | 1371/07/19 | ||||
Diltiazem | HCl | CAPSULE, EXTENDED RELEASE | 120 mg | ORAL | C08DB01 | ||||||
Diltiazem | HCl | TABLET, EXTENDED RELEASE | 120 mg | ORAL | C08DB01 | 1377/09/01 | |||||
Diltiazem | HCl | TABLET | 60 mg | ORAL | C08DB01 | 1369/10/16 | |||||
Diltiazem | HCl | TABLET | 30 mg | ORAL | C08DB01 | 1397/04/31 | |||||
Diltiazem | HCl | TABLET | 90 mg | ORAL | C08DB01 | 1397/04/31 | |||||
Dimenhydrinate | TABLET | 50 mg | ORAL | OTC medicines | 1369/10/30 | ||||||
Dimercaprol | INJECTION | 100 mg/ml | INTRAMUSCULAR | V03AB09 | |||||||
Dimethyl Fumarate | CAPSULE, DELAYED RELEASE | 120 mg | ORAL | N07XX09 | 1393/02/07 | ||||||
Dimethyl Fumarate | CAPSULE, DELAYED RELEASE | 240 mg | ORAL | N07XX09 | 1393/02/07 | ||||||
Dimethyl Sulfoxide | SOLUTION | 50% | PARENTERAL | G04BX13 | Treatment of cutaneous manifestations of scleroderma. Treatment of palmar-plantar erythrodysethesia syndrome. | Orphan medicines | 1382/03/04 | ||||
Diphenhydramine | HCl | SOLUTION | 12.5 mg/5ml | ORAL | R06AA02 | OTC medicines | 1369/10/30 | ||||
Diphenhydramine | HCl | TABLET | 25 mg | ORAL | R06AA02 | OTC medicines | 1369/10/30 | ||||
Diphenhydramine | HCl | CAPSULE, LIQUID FILLED | 25 mg | ORAL | R06AA02 | OTC medicines | 1385/09/15 | ||||
Diphenhydramine | HCl | INJECTION | 50 mg/ml | PARENTERAL | R06AA02 | 1361/11/17 | |||||
Diphenhydramine+Ammonium chloride | SYRUP | ORAL | R06AA52 | (Diphenhydramine HCl 12.5mg + Ammonium chloride 125mg) / 5ml | 1369/10/30 | ||||||
Diphenoxylate | HCl | TABLET | 2.5 mg | ORAL | A07DA01 | Diphenoxylate HCl 2.5mg+Atropine sulfate 25mcg | |||||
Diphteria Antitoxin Equine | INJECTION | PARENTERAL/vaccine | J06AA01 | ||||||||
Diphteria Toxoid+Tetanus Toxoid+Pertussis | INJECTION | PARENTERAL/vaccine | J07AM02 | ||||||||
Diphteria Toxoid+Tetanus Toxoid+Pertussis+Haemophilus Influenza Type B | INJECTION | PARENTERAL/vaccine | J07 | 1388/10/30 | |||||||
Diphteria Toxoid+Tetanus Toxoid+Pertussis+Haemophilus Influenza Type B+Hepatitis B Vaccine | INJECTION | PARENTERAL/vaccine | J07C | 1388/10/30 | |||||||
Diphteria+Tetanus toxoids Adsorbed (Dt) | INJECTION | PARENTERAL/vaccine | J07AM02 | for Pediatrics | |||||||
Diphteria+Tetanus toxoids Adsorbed (Td) | INJECTION | PARENTERAL/vaccine | J07AM02 | for adults | |||||||
Dipyridamole | TABLET | 25 mg | ORAL | B01AC07 | |||||||
Dipyridamole | INJECTION | 5 mg/ml | PARENTERAL | B01AC07 | Hospital use only | 1369/01/26 | |||||
Dipyridamole | TABLET | 75 mg | ORAL | B01AC07 | |||||||
Dipyridamole+ASA | CAPSULE, EXTENDED RELEASE | ORAL | B01AC30 | Dipyridamole 200 mg+ASA25 mg | Need to be assessed by clinical trial before registration. | 1389/10/25 | |||||
Disopyramide | As Phosphate | CAPSULE | 100 mg | ORAL | C01BA03 | ||||||
Distilled Water | BULK | V03 | Bulk medicines | ||||||||
Disulfiram | TABLET | 200 mg | ORAL | N07BB01 | 1387/12/21 | ||||||
Disulfiram | TABLET | 250 mg | ORAL | N07BB01 | 1387/12/21 | ||||||
Disulfiram | TABLET | 500 mg | ORAL | N07BB01 | 1387/12/21 | ||||||
Dithranol | CREAM | 0.25% | TOPICAL | D05AC01 | 1361/10/19 | ||||||
Dithranol | BULK | V03 | Bulk medicines | 1365/10/14 | |||||||
Dobutamine | INJECTION, SOLUTION | 12.5 mg/ml | PARENTERAL | C01CA07 | As HCL | Hospital use only | |||||
Dobutamine | INJECTION, POWDER, LYOPHILIZED | 250 mg | PARENTERAL | C01CA07 | As HCL | Hospital use only | |||||
Docetaxel | INJECTION, SOLUTION | 20 mg/ml | PARENTERAL | L01CD02 | 1392/5/29 | ||||||
Docetaxel | INJECTION, SOLUTION | 10 mg/ml | PARENTERAL | L01CD02 | 1389/11/04 | ||||||
Docetaxel | INJECTION, POWDER | 20 mg | PARENTERAL | L01CD02 | |||||||
Docetaxel | INJECTION, POWDER | 80 mg | PARENTERAL | L01CD02 | 1375/12/12 | ||||||
Docusate Na+Sorbitol | ENEMA | RECTAL | A06AA02 | Docusate Na 0.01g+Sorbitol 13.4 g | 1372/07/11 | ||||||
Dolutegravir | As Sodium | TABLET | 50 mg | ORAL | J05AX12 | For Health Dept. of MOH only | 1396/05/28 | ||||
Domperidone | As Maleate | TABLET | 10 mg | ORAL | A03FA03 | 1386/04/26 | |||||
Domperidone | SUSPENSION | 1mg/ml | ORAL | A03FA03 | 1395/12/18 | ||||||
Donepezil | HCl | TABLET | 10 mg | ORAL | N06DA02 | 1383/12/16 | |||||
Donepezil | HCl | TABLET | 5 mg | ORAL | N06DA02 | 1383/12/16 | |||||
Donepezil | HCl | TABLET, ORALLY DISINTEGRATING | 10 mg | ORAL | N06DA02 | 1396/01/29 | |||||
Donepezil | HCl | TABLET, ORALLY DISINTEGRATING | 5 mg | ORAL | N06DA02 | 1396/01/29 | |||||
Dopamine | HCl | INJECTION | 40 mg/ml | PARENTERAL | C01CA04 | Hospital use only | |||||
Dorzolamide | As HCl | SOLUTION/ DROPS | 2% | OPHTHALMIC | S01EC03 | 1374/10/03 | |||||
Dorzolamide+Timolol | SOLUTION/ DROPS | OPHTHALMIC | S01ED51 | [Dorzolamide(As Hydrochloride) 2% + Timolol(As Maleate) 0.5%] | 1386/03/23 | ||||||
Doxapram | HCl | INJECTION | 20 mg/ml | PARENTERAL | R07AB01 | Hospital use only | |||||
Doxepin | As HCl | CAPSULE | 10 mg | ORAL | N06AA12 | 1381/10/08 | |||||
Doxepin | As HCl | TABLET | 10 mg | ORAL | N06AA12 | 1383/06/29 | |||||
Doxepin | As HCl | CAPSULE | 25 mg | ORAL | N06AA12 | 1381/10/08 | |||||
Doxepin | As HCl | TABLET | 25 mg | ORAL | N06AA02 | 1383/06/29 | |||||
Doxorubicin | HCl | INJECTION, POWDER | 10 mg | PARENTERAL | L01DB01 | ||||||
Doxorubicin | HCl | INJECTION, LIPOSOMAL | 2 mg/ml | PARENTERAL | L01DB01 | Pegylated | 1389/06/15 | ||||
Doxorubicin | HCl | INJECTION, SOLUTION, CONCENTRATE | 2 mg/ml | PARENTERAL | L01DB01 | ||||||
Doxorubicin | HCl | INJECTION, POWDER | 50 mg | PARENTERAL | L01DB01 | ||||||
Doxycycline | As Monohydrate | CAPSULE | 100 mg | ORAL | J01AA02 | ||||||
Doxycycline | As Hyclate or Monohydrate | TABLET | 100 mg | ORAL | J01AA02 | 1387/06/13 | |||||
Doxycycline | As Hyclate | CAPSULE | 100 mg | ORAL | J01AA02 | 1392/5/29 | |||||
Doxycycline | As Hyclate | CAPSULE, DELAYED RELEASE | 100 mg | ORAL | J01AA02 | 1396/04/18 | |||||
Doxycycline | INJECTION | 100 mg/ Vial | PARENTERAL | J01AA02 | Hospital use only | 1387/12/21 | |||||
Doxycycline | As Monohydrate | CAPSULE | 50 mg | ORAL | J01AA02 | 1386/08/09 | |||||
Droperidol | INJECTION | 1.25 mg/ml | PARENTERAL | N05AD08 | Hospital use only | 1396/03/21 | |||||
Droperidol | INJECTION | 2.5 mg/ml | PARENTERAL | N05AD08 | Hospital use only | 1362/08/15 | |||||
Droperidol Compound | INJECTION | PARENTERAL | N01AH51 | (Droperidol 25mg+Fentanyl(as citrate) 0.5mg)/10ml | Hospital use only | ||||||
Drospirenone+Ethinyl Estradiol | TABLET | ORAL | G03FA17 | (Drospirenone 3 mg + Ethinyl Estradiol 0.02 mg) | With obstetricians and General Practitioners prescriptions only | 1387/06/13 | |||||
Drospirenone+Ethinyl Estradiol | TABLET | ORAL | G03FA17 | (Drospirenone 3 mg + Ethinyl Estradiol 0.03 mg) | With obstetricians and General Practitioners prescriptions only | 1385/08/09 | |||||
Duloxetine | As HCl | CAPSULE, DELAYED RELEASE | 20 mg | ORAL | N06AX21 | 1390/03/07 | |||||
Duloxetine | As HCl | CAPSULE, DELAYED RELEASE | 30 mg | ORAL | N06AX21 | 1390/03/07 | |||||
Duloxetine | As HCl | CAPSULE, DELAYED RELEASE | 60 mg | ORAL | N06AX21 | 1390/03/07 | |||||
Dutasteride | CAPSULE, LIQUID FILLED | 0.5 mg | ORAL | G04CB02 | 1396/09/12 | ||||||
Dutasteride+Tamsulosin | CAPSULE | ORAL | G04CA52 | Dutastride 0.5 mg +Tamsulosin HCl 0.4 mg | 1396/12/08 | ||||||
Dutasteride+Tamsulosin | CAPSULE, EXTENDED RELEASE | ORAL | G04CA52 | Dutastride 0.5 mg +Tamsulosin HCl 0.4 mg | 1397/07/14 | ||||||
Dydrogesterone | TABLET | 10 mg | ORAL | G03DB01 | 1384/04/20 | ||||||
Dydrogesterone | TABLET | 5 mg | ORAL | G03DB01 | |||||||
Echothiophate | Iodide | SOLUTION/ DROPS | 0.06% | OPHTHALMIC | S01EB03 | ||||||
Echothiophate | Iodide | SOLUTION/ DROPS | 0.125% | OPHTHALMIC | S01EB03 | ||||||
Echothiophate | Iodide | SOLUTION/ DROPS | 0.25% | OPHTHALMIC | S01EB03 | ||||||
Edaravone | INJECTION, SOLUTION | 30 mg/20 ml | PARENTERAL | N07XX14 | ESALS | 1397/10/04 | |||||
Edetate Calcium Disodium | INJECTION | 50 mg/ml | PARENTERAL | V03AB03 | Hospital use only | 1362/01/14 | |||||
Edetate Calcium Disodium | INJECTION | 200 mg/ml | PARENTERAL | V03AB03 | Hospital use only | 1396/12/13 | |||||
Edetate Dicobalt | INJECTION | 15 mg/ml | PARENTERAL | V03AB03 | Hospital use only | 1362/01/21 | |||||
Edetate Disodium | INJECTION | 150 mg/ml | PARENTERAL | V03AB03 | Hospital use only | 1361/02/19 | |||||
Edetate Sodium | SOLUTION/ DROPS | OPHTHALMIC | S01XA05 | ||||||||
Edrophonium | Chloride | INJECTION | 10 mg/ml | PARENTERAL | V04CX | Hospital use only | |||||
Efavirens+Emtricitabine+Tenofovir | TABLET | ORAL | J05AR06 | Efavirens 600 mg+Emtricitabine 200 mg+Tenofovir disoproxil (as fumarate) 245 mg | Treatment of AIDS related complex. | For Health Dept. of MOH only | 1393/10/14 | ||||
Efavirenz | CAPSULE | 100 mg | ORAL | J05AG03 | Treatment of AIDS related complex. | For Health Dept. of MOH only | 1386/04/11 | ||||
Efavirenz | SOLUTION | 150 mg/5ml | ORAL | J05AG03 | Treatment of AIDS related complex. | For Health Dept. of MOH only | |||||
Efavirenz | CAPSULE | 200 mg | ORAL | J05AG03 | Treatment of AIDS related complex. | For Health Dept. of MOH only | 1386/04/11 | ||||
Efavirenz | TABLET | 200 mg | ORAL | J05AG03 | Treatment of AIDS related complex. | For Health Dept. of MOH only | 1386/06/10 | ||||
Efavirenz | CAPSULE | 50 mg | ORAL | J05AG03 | Treatment of AIDS related complex. | For Health Dept. of MOH only | 1386/04/11 | ||||
Efavirenz | TABLET | 600 mg | ORAL | J05AG03 | Treatment of AIDS related complex. | For Health Dept. of MOH only | 1386/04/11 | ||||
Eflornithine | HCl | CREAM | 13.90% | Topical | D11AX16 | for local production only | 1389/10/25 | ||||
Elosulfase alfa | INJECTION, SOLUTION, CONCENTRATE | 1 mg/ml | PARENTERAL | A16AB12 | Morquio A Syndrom | Orphan medicines | 1394/07/05 | ||||
Empagliflozin | TABLET | 10 mg | ORAL | A10BX12 | Diabetes Mellitus type 2 | 1396/11/29 | |||||
Empagliflozin | TABLET | 25 mg | ORAL | A10BX12 | Diabetes Mellitus type 2 | 1396/11/29 | |||||
Empagliflozin+Linagliptin | TABLET | ORAL | A10BD19 | Empagliflozin 10 mg+Linagliptin 5mg | Diabetes Mellitus type 2 | 1396/12/13 | |||||
Empagliflozin+Linagliptin | TABLET | ORAL | A10BD19 | Empagliflozin 25 mg+Linagliptin 5mg | Diabetes Mellitus type 2 | 1396/12/13 | |||||
Empagliflozin+Metformin | TABLET | ORAL | A10BD20 | Empagliflozin 5 mg+Metformin HCl 500 mg | Diabetes Mellitus type 2 | 1397/02/11 | |||||
Empagliflozin+Metformin | TABLET | ORAL | A10BD20 | Empagliflozin 12.5 mg+Metformin HCl 500 mg | Diabetes Mellitus type 2 | 1397/02/11 | |||||
Empagliflozin+Metformin | TABLET | ORAL | A10BD20 | Empagliflozin 5 mg+Metformin HCl 1000 mg | Diabetes Mellitus type 2 | 1397/02/11 | |||||
Empagliflozin+Metformin | TABLET | ORAL | A10BD20 | Empagliflozin 12.5 mg+Metformin HCl 1000 mg | Diabetes Mellitus type 2 | 1397/02/11 | |||||
Empagliflozin+Metformin | TABLET, EXTENDED RELEASE | ORAL | A10BD20 | Empagliflozin 10 mg+Metformin HCl 1000 mg | Diabetes Mellitus type 2 | 1397/09/03 | |||||
Empagliflozin+Metformin | TABLET, EXTENDED RELEASE | ORAL | A10BD20 | Empagliflozin 25 mg+Metformin HCl 1000 mg | Diabetes Mellitus type 2 | 1397/09/03 | |||||
Emtricitabine+Tenofovir | TABLET | ORAL | J05AR17 | Emtricitabine 200 mg+ Tenofovir Alafenamide (as Fumarate) 25 mg | For Health Dept. of MOH only | 1395/12/22 | |||||
Enalapril | TABLET | 10 mg | ORAL | C09AA02 | 1386/08/09 | ||||||
Enalapril | TABLET | 2.5 mg | ORAL | C09AA02 | 1386/08/09 | ||||||
Enalapril | TABLET | 20 mg | ORAL | C09AA02 | 1369/11/14 | ||||||
Enalapril | TABLET | 5 mg | ORAL | C09AA02 | 1369/11/14 | ||||||
Enflurane | INHALANT | RESPIRATORY | N01AB04 | Orphan medicines. Hospital use only | |||||||
Enoxaparin | Sodium | INJECTION | 100 mg/ml | PARENTERAL | B01AB05 | volumes of 1ml, 3 ml are for hospital use only | |||||
Entecavir | TABLET | 0.5 mg | ORAL | J05AF10 | Chronic hepatitis B | 1396/11/29 | |||||
Entecavir | TABLET | 1 mg | ORAL | J05AF10 | Chronic hepatitis B | 1396/11/29 | |||||
Eosin | BULK | V03 | Bulk medicines | 1376/12/10 | |||||||
Ephedrine | HCl | TABLET | 20 mg | ORAL | R03CA02 | ||||||
Ephedrine | HCl | TABLET | 15 mg | ORAL | R03CA02 | 1396/08/07 | |||||
Ephedrine | HCl | TABLET | 30 mg | ORAL | R03CA02 | 1396/08/07 | |||||
Ephedrine | HCl | INJECTION | 50 mg/ml | PARENTERAL | R03CA02 | Hospital use only | 1376/05/19 | ||||
Ephedrine | Sulfate | INJECTION | 50 mg/ml | PARENTERAL | R03CA02 | Hospital use only | |||||
Epinephrine | As Acid Tartrate or As HCl | SOLUTION/ DROPS | 1% | OPHTHALMIC | S01EA01 | 1360/09/15 | |||||
Epinephrine | As HCl | INJECTION | 0.1mg/ml | PARENTERAL | C01CA24 | ||||||
Epinephrine | As Acid Tartrate or As HCl | INJECTION | 1 mg/ml | PARENTERAL | C01CA24 | Hospital use only | 1374/06/26 | ||||
Epinephrine | INJECTION, SOLUTION | 0.15 mg/0.3 ml | PARENTERAL | C01CA24 | Allergic emergencies | 1395/03/31 | |||||
Epinephrine | INJECTION, SOLUTION | 0.3 mg/0.3 ml | PARENTERAL | C01CA24 | Allergic emergencies | 1395/03/31 | |||||
Epirubicin | HCl | INJECTION, POWDER | 10 mg | PARENTERAL | L01DB03 | Treatment of breast cancer | 1365/09/16 | ||||
Epirubicin | HCl | INJECTION, SOLUTION, CONCENTRATE | 2mg/ml | PARENTERAL | L01DB03 | Treatment of breast cancer | 1388/08/20 | ||||
Epirubicin | HCl | INJECTION, POWDER | 50 mg | PARENTERAL | L01DB03 | Treatment of breast cancer | 1365/09/16 | ||||
Eplerenone | TABLET | 25 mg | ORAL | C03DA04 | 1392/12/11 | ||||||
Eplerenone | TABLET | 50 mg | ORAL | C03DA04 | 1392/12/11 | ||||||
Epoetin | INJECTION | 1000 U/ ml | PARENTERAL | B03XA01 | Treatment of anemia | ||||||
Epoetin | INJECTION | 10000 U/ ml | PARENTERAL | B03XA01 | Treatment of anemia | ||||||
Epoetin | INJECTION | 2000 U/ 0. 4 ml | PARENTERAL | B03XA01 | Treatment of anemia | ||||||
Epoetin | INJECTION | 2000 U/ ml | PARENTERAL | B03XA01 | Treatment of anemia | ||||||
Epoetin | INJECTION | 20000 U/ ml | PARENTERAL | B03XA01 | Treatment of anemia | ||||||
Epoetin | INJECTION | 40,000 U/ ml | PARENTERAL | B03XA01 | Treatment of anemia | 1386/04/13 | |||||
Epoetin | INJECTION | 4000 U/ 0. 3 ml | PARENTERAL | B03XA01 | Treatment of anemia | ||||||
Epoetin | INJECTION | 4000 U/ 0. 4 ml | PARENTERAL | B03XA01 | Treatment of anemia | ||||||
Epoetin | INJECTION | 4000 U/ ml | PARENTERAL | B03XA01 | Treatment of anemia | ||||||
Epoetin | INJECTION | 2000 U/0.3 ml | PARENTERAL | B03XA01 | Treatment of anemia | 1396/03/13 | |||||
Epoetin | INJECTION | 10000 U/0.6 ml | PARENTERAL | B03XA01 | Treatment of anemia | 1396/03/13 | |||||
Epoetin | INJECTION | 20000 U/0.6 ml | PARENTERAL | B03XA01 | Treatment of anemia | 1396/03/13 | |||||
Epoetin | INJECTION | 40000 U/0.6 ml | PARENTERAL | B03XA01 | Treatment of anemia | 1396/03/13 | |||||
Epoprostenol | As Sodium | INJECTION, POWDER | 0.5 mg | PARENTERAL | B01AC09 | Orphan medicines | 1396/09/12 | ||||
Epoprostenol | As Sodium | INJECTION, POWDER | 1.5 mg | PARENTERAL | B01AC09 | Orphan medicines | 1396/09/12 | ||||
Eprosartan | As Mesylate | TABLET | 600 mg | ORAL | C09CA02 | 1388/02/30 | |||||
Eprosartan | As Mesylate | TABLET | 300 mg | ORAL | C09CA02 | 1388/02/30 | |||||
Eptifibatide | INJECTION | 0. 75mg/ ml | PARENTERAL | B01AC16 | 1387/12/21 | ||||||
Eptifibatide | INJECTION | 2mg/ ml | PARENTERAL | B01AC16 | 1387/12/21 | ||||||
Erbium [169Er] Citrate Colloid | INJECTION, COLLOIDAL SOLUTION | (5-10) mCi | INTRA-CAVITY | V10AX04 | Radiopharmaceuticals | 1389/10/25 | |||||
Ergotamine | Tartrate | TABLET | 2 mg | SUBLINGUAL | N02CA02 | 1377/07/26 | |||||
Ergotamine Compound | TABLET | ORAL | N02CA52 | Ergotamine tartrate 2 mg + Caffeine 100mg + Cyclizine Hcl 50 mg | 1382/04/01 | ||||||
Ergotamine+Caffeine | TABLET | ORAL | N02CA72 | Ergotamine tartrate 1mg+Caffeine 100mg | |||||||
Erlotinib | As HCl | TABLET | 100mg | ORAL | L01XE03 | ||||||
Erlotinib | As HCl | TABLET | 150mg | ORAL | L01XE03 | ||||||
Erlotinib | As HCl | TABLET | 25 mg | ORAL | L01XE03 | 1396/07/22 | |||||
Erythromycin | OINTMENT | 0.50% | OPHTHALMIC | S01AA17 | 1362/11/30 | ||||||
Erythromycin | GEL | 2% | TOPICAL | D10AF02 | 1373/05/02 | ||||||
Erythromycin | SWAB | 2% | TOPICAL | D10AF02 | 1397/10/04 | ||||||
Erythromycin | SOLUTION | 2% | TOPICAL | D10AF02 | 1376/04/29 | ||||||
Erythromycin | GEL | 4% | TOPICAL | D10AF02 | 1381/11/20 | ||||||
Erythromycin | SOLUTION | 4% | TOPICAL | D10AF02 | 1381/11/20 | ||||||
Erythromycin | As Lactobionate | INJECTION, POWDER | 1 g | PARENTERAL | J01FA01 | Hospital use only | 1371/09/15 | ||||
Erythromycin | As Ethylsuccinate | TABLET | 200 mg | ORAL | J01FA01 | 1360/08/24 | |||||
Erythromycin | As Ethylsuccinate | TABLET, CHEWABLE | 200 mg | ORAL | J01FA01 | 1372/09/21 | |||||
Erythromycin | As Ethylsuccinate | POWDER, FOR SUSPENSION | 200 mg/5ml | ORAL | J01FA01 | ||||||
Erythromycin | As Ethylsuccinate | TABLET | 400 mg | ORAL | J01FA01 | ||||||
Erythromycin | BULK | V03 | Bulk medicines | 1376/12/10 | |||||||
Erythromycin+Azelaic Acid | GEL | TOPICAL | D10AF52 | Erythromycin 2% + Azelaic Acid 5% | 1389/11/4 | ||||||
Erythromycin+Azelaic Acid | LOTION | TOPICAL | D10AF52 | Erythromycin 2% + Azelaic Acid 5% | 1389/11/4 | ||||||
Erythromycin+Benzoyl peroxide | GEL | TOPICAL | D10AF52 | Erythromycin 3% + Benzoyl Peroxide 5% | |||||||
Escitalopram | As Oxalate | TABLET | 10 mg | ORAL | N06AB10 | Antidepressant, Anxiety disorder | 1393/02/07 | ||||
Escitalopram | As Oxalate | TABLET | 5 mg | ORAL | N06AB10 | Antidepressant, Anxiety disorder | 1395/05/02 | ||||
Escitalopram | As Oxalate | TABLET | 20 mg | ORAL | N06AB10 | Antidepressant, Anxiety disorder | 1395/05/02 | ||||
Esmolol | HCl | INJECTION | 250 mg/ml | PARENTERAL | C07AB09 | Hospital use only | 1374/10/03 | ||||
Esmolol | HCl | INJECTION, POWDER | 2500 mg | PARENTERAL | C07AB09 | Hospital use only | 1395/11/06 | ||||
Esmolol | HCl | INJECTION | 10 mg/ml | PARENTERAL | C07AB09 | Hospital use only | Preservative Free | 1395/10/08 | |||
Esomeprazole | CAPSULE, DELAYED RELEASE | 20 mg | ORAL | A02BC05 | OTC medicines | 1387/12/21 | |||||
Esomeprazole | As Magnesium | CAPSULE, DELAYED RELEASE | 20 mg | ORAL | A02BC05 | OTC medicines | 1397/03/01 | ||||
Esomeprazole | TABLET, DELAYED RELEASE | 20 mg | ORAL | A02BC05 | OTC medicines | 1387/12/18 | |||||
Esomeprazole | CAPSULE, DELAYED RELEASE | 40 mg | ORAL | A02BC05 | 1387/12/21 | ||||||
Esomeprazole | As Magnesium | CAPSULE, DELAYED RELEASE | 40 mg | ORAL | A02BC05 | 1396/03/21 | |||||
Esomeprazole | TABLET, DELAYED RELEASE | 40 mg | ORAL | A02BC05 | 1387/12/18 | ||||||
Esomeprazole | As Magnesium | GRANULE FOR SUSPENSION, DELAYED RELEASE | 2.5 mg | ORAL | A02BC05 | 1397/06/24 | |||||
Esomeprazole | As Magnesium | GRANULE FOR SUSPENSION, DELAYED RELEASE | 5 mg | ORAL | A02BC05 | 1395/10/08 | |||||
Esomeprazole | As Magnesium | GRANULE FOR SUSPENSION, DELAYED RELEASE | 10 mg | ORAL | A02BC05 | 1395/10/08 | |||||
Estradiol | GEL | 0.06% | VAGINAL | G03CA03 | |||||||
Estradiol | GEL | 0.06% | TOPICAL | G03CA03 | |||||||
Estradiol | Valerate | TABLET | 1 mg | ORAL | G03CA03 | ||||||
Estradiol | As Hemihydrate | TABLET | 10 mcg | VAGINAL | G03CA03 | 1391/07/25 | |||||
Estradiol | Valerate | INJECTION | 10 mg/ml | PARENTERAL | G03CA03 | ||||||
Estradiol | Hemihydrate | PATCH, EXTENDED RELEASE | 100 mcg/24h | TRANSDERMAL | G03CA03 | 1382/02/21 | |||||
Estradiol | PATCH, EXTENDED RELEASE | 100 mcg/24h | TRANSDERMAL | G03CA03 | 1382/02/21 | ||||||
Estradiol | Valerate | TABLET | 2 mg | ORAL | G03CA03 | ||||||
Estradiol | PATCH, EXTENDED RELEASE | 25 mcg/24h | TRANSDERMAL | G03CA03 | 1382/02/21 | ||||||
Estradiol | Hemihydrate | PATCH, EXTENDED RELEASE | 25 mcg/24h | TRANSDERMAL | G03CA03 | 1382/02/21 | |||||
Estradiol | PATCH, EXTENDED RELEASE | 50 mcg/24h | TRANSDERMAL | G03CA03 | 1382/02/21 | ||||||
Estradiol | Hemihydrate | PATCH, EXTENDED RELEASE | 50 mcg/24h | TRANSDERMAL | G03CA03 | 1382/02/21 | |||||
Estradiol | GEL | 500 mcg | TOPICAL | G03CA03 | Estrogen replacement therapywith Turner syndrome | 1382/10/28 | |||||
Estramustine | Sodium Phosphate | CAPSULE | 140 mg | ORAL | L01XX11 | ||||||
Etanercept | INJECTION | 25 mg | PARENTERAL | L04AB01 | Reduction in signs and symptoms of moderately to severely active polyarticular-course juvenile rheumatoid arthritis in patients who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs. | 1386/12/06 | |||||
Etanercept | INJECTION, POWDER | 25 mg | PARENTERAL | L04AB01 | Reduction in signs and symptoms of moderately to severely active polyarticular-course juvenile rheumatoid arthritis in patients who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs. | ||||||
Etanercept | INJECTION | 50 mg/ml | PARENTERAL | L04AB01 | Reduction in signs and symptoms of moderately to severely active polyarticular-course juvenile rheumatoid arthritis in patients who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs. | 1389/08/24 | |||||
Ethacridine Lactate | BULK | V03 | Bulk medicines | Rivanol | 1376/12/10 | ||||||
Ethacrynic Acid | TABLET | 50 mg | ORAL | C03CC01 | |||||||
Ethambutol | HCl | TABLET | 400 mg | ORAL | J04AK02 | ||||||
Ethambutol+Isoniazid+Pirazinamide+Rifampin | TABLET | ORAL | J04AM06 | Ethambutol 275mg+Isoniazid 75mg+Pirazinamide 400mg +Rifampin 150mg | For Health Dept. of MOH only | ||||||
Ethambutol+Isoniazid+Rifampin | TABLET | ORAL | J04AM06 | Ethambutol 275mg+Isoniazid 75mg+Rifampin 150mg | For Health Dept. of MOH only | ||||||
Ethanol | BULK | V03 | Denaturated for Medical Use; Bulk medicines | 1375/08/28 | |||||||
Ethanol | BULK | V03 | Denaturated for Medical Use; Bulk medicines | ||||||||
Ether | INHALANT | RESPIRATORY | N01AA | Hospital use only | |||||||
Etherified Starch | INJECTION, SOLUTION | PARENTERAL | B05AA07 | ||||||||
Ethinylestradiol | TABLET | 0.05 mg | ORAL | G03CA01 | Treatment of Turner's syndrome | ||||||
Ethinylestradiol | TABLET | 0.5 mg | ORAL | L02AA03 | Treatment of Turner's syndrome | ||||||
Ethiodized Oil | INJECTION | 10ml | PARENTERAL | V08AD01 | 1369/07/15 | ||||||
Ethionamide | TABLET | 250 mg | ORAL | J04AD03 | 1380/04/17 | ||||||
Ethosuximide | CAPSULE, LIQUID FILLED | 250 mg | ORAL | N03AD01 | 1386/11/08 | ||||||
Ethosuximide | CAPSULE | 250 mg | ORAL | N03AD01 | |||||||
Ethosuximide | SYRUP | 250 mg/5ml | ORAL | N03AD01 | |||||||
Etidronate | Disodium | TABLET | 200 mg | ORAL | M05BA01 | Treatment of hypercalcemia of malignancy inadequately managed by dietary modification and/or oral hydration. | 1373/04/12 | ||||
Etomidate | INJECTION | 2 mg/ml | PARENTERAL | N01AX07 | Hospital use only | 1370/12/18 | |||||
Etoposide | CAPSULE | 100 mg | ORAL | L01CB01 | 1365/09/16 | ||||||
Etoposide | INJECTION, SOLUTION | 20 mg/ml | INTRAVENOUS DRIP | L01CB01 | 1365/09/16 | ||||||
Etoposide | CAPSULE | 50 mg | ORAL | L01CB01 | 1366/07/26 | ||||||
Everolimus | TABLET | 0.25 mg | ORAL | L04AA18 | Kidney, Liver, Heart transpalantation | 1390/07/05 | |||||
Everolimus | TABLET | 0.5 mg | ORAL | L04AA18 | Kidney, Liver, Heart transpalantation | 1390/07/05 | |||||
Everolimus | TABLET | 0.75 mg | ORAL | L04AA18 | Kidney, Liver, Heart transpalantation | 1390/07/05 | |||||
Everolimus | TABLET | 5 mg | ORAL | L01XE10 | Antineoplastic drugs | 1390/07/05 | |||||
Everolimus | TABLET | 10 mg | ORAL | L01XE10 | Antineoplastic drugs | 1395/05/02 | |||||
Exemestane | TABLET | 25 mg | ORAL | L02BG06 | Treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy. | 1382/04/01 | |||||
Exenatide | INJECTION, POWDER, EXTENDED RELEASE | 2 mg | PARENTERAL | A10BX04 | Type 2 Diabetes Mellitus | 1394/11/13 | |||||
Exenatide | INJECTION, | 250 mcg/ml | PARENTERAL | A10BX04 | Type 2 Diabetes Mellitus | 1396/04/18 | |||||
Expectorant | SYRUP | ORAL | R05CA10 | (Guaifenesin 100mg + Chlorpheniramine maleate 2mg + Pseudoephedrine HCl 30 mg ) / 5ml | OTC medicines | 1369/10/30 | |||||
Expectorant+Codeine | SYRUP | ORAL | R05CA10 | (Guaifenesin 100mg + Pseudoephedrine HCl 30 mg + Codeine phosphate 10mg)/5ml | 1383/09/02 | ||||||
Ezetimibe | TABLET | 10 mg | ORAL | C10AX09 | 1384/04/12 | ||||||
Factor IX | INJECTION, POWDER, LYOPHILIZED | 500 IU | PARENTERAL | B02BD09 | 1388/10/30 | ||||||
Factor IX | INJECTION, POWDER, LYOPHILIZED | 600 IU | PARENTERAL | B02BD09 | 1394/09/03 | ||||||
Factor IX | INJECTION, POWDER, LYOPHILIZED | 1000 IU | PARENTERAL | B02BD09 | 1394/07/18 | ||||||
Factor IX | INJECTION, POWDER, LYOPHILIZED | 1200 IU | PARENTERAL | B02BD09 | 1397/06/24 | ||||||
Factor VII | INJECTION, POWDER, For SOLUTION | 600 U | PARENTERAL | B02BD05 | Orphan medicines | Human Coagulation factor VII (IV Injection) | 1389/11/18 | ||||
Factor VIIa | INJECTION | 1 mg | PARENTERAL | B02BD05 | Orphan medicines | Room Temperature | |||||
Factor VIIa | INJECTION, POWDER, LYOPHILIZED | 1.2 mg | PARENTERAL | B02BD05 | Orphan medicines | ||||||
Factor VIIa | INJECTION | 2 mg | PARENTERAL | B02BD05 | Orphan medicines | Room Temperature | |||||
Factor VIIa | INJECTION, POWDER, LYOPHILIZED | 2.4 mg | PARENTERAL | B02BD05 | Orphan medicines | ||||||
Factor VIIa | INJECTION, POWDER, LYOPHILIZED | 4.8 mg | PARENTERAL | B02BD05 | Orphan medicines | ||||||
Factor VIIa | INJECTION, POWDER, LYOPHILIZED | 5 mg | PARENTERAL | B02BD05 | Orphan medicines | 1395/12/18 | |||||
Factor VIIa | INJECTION, POWDER, LYOPHILIZED | 8 mg | PARENTERAL | B02BD05 | Orphan medicines | 1395/12/18 | |||||
Factor VIII | INJECTION, POWDER, LYOPHILIZED | 250 IU | PARENTERAL | B02BD02 | |||||||
Factor VIII | INJECTION, POWDER, LYOPHILIZED | 500 U | PARENTERAL | B02BD02 | |||||||
Factor VIII | INJECTION, POWDER, LYOPHILIZED | 1000 U | PARENTERAL | B02BD02 | 1395/07/28 | ||||||
Factor VIII | INJECTION, POWDER, LYOPHILIZED | 2000 U | PARENTERAL | B02BD02 | 1395/09/13 | ||||||
Factor VIII+Von Willbrand | INJECTION, POWDER, LYOPHILIZED | PARENTERAL | B02BD06 | Factor VIII 1000 U +Von Willbrand factor 1000 U | Treatment of patients with von Willebrand's disease | 1391/10/03 | |||||
Factor VIII+Von Willbrand | INJECTION, POWDER, LYOPHILIZED | PARENTERAL | B02BD06 | Factor VIII 500 U +Von Willbrand factor 500 U | Treatment of patients with von Willebrand's disease | 1391/10/03 | |||||
Factor VIII+Von Willbrand | INJECTION, POWDER, LYOPHILIZED | PARENTERAL | B02BD06 | Factor VIII 250 U +Von Willbrand factor 600 U | Treatment of patients with von Willebrand's disease | 1394/11/13 | |||||
Factor VIII+Von Willbrand | INJECTION, POWDER, LYOPHILIZED | PARENTERAL | B02BD06 | Factor VIII 500 U +Von Willbrand factor 1200 U | Treatment of patients with von Willebrand's disease | 1394/11/13 | |||||
Factor VIII+Von Willbrand | INJECTION, POWDER, LYOPHILIZED | PARENTERAL | B02BD06 | Factor VIII 1000U +Von Willbrand factor 750 U | Treatment of patients with von Willebrand's disease | 1395/10/07 | |||||
Factor XIII | INJECTION, POWDER | PARENTERAL | B02BD07 | Human Fibrin-stabilising Factor | Orphan medicines | 1388/03/03 | |||||
Famotidine | TABLET | 20 mg | ORAL | A02BA03 | OTC medicines | ||||||
Famotidine | INJECTION , SOLUTION | 20 mg/50ml | INTRAVENOUS DRIP | A02BA03 | OTC medicines | 1391/05/02 | |||||
Famotidine | TABLET | 40 mg | ORAL | A02BA03 | |||||||
Famotidine+Calcium Carbonate+Magnesium Hydroxide | TABLET, CHEWABLE | ORAL | A02BA53 | Famotidine 10mg+Calcium Carbonate 800 mg+Magnesium Hydroxide 165 mg | OTC medicines | 1389/10/25 | |||||
Fampridine | TABLET, EXTENDED RELEASE | 10 mg | ORAL | N07XX07 | 1391/12/23 | ||||||
Febuxostat | TABLET | 40 mg | ORAL | M04AA03 | Hyperuricaemia in gout | 1393/05/12 | |||||
Febuxostat | TABLET | 80 mg | ORAL | M04AA03 | Hyperuricaemia in gout | 1393/05/12 | |||||
Febuxostat | TABLET | 120 mg | ORAL | M04AA03 | Hyperuricaemia in gout | 1395/03/19 | |||||
Fenofibrate | CAPSULE | 100 mg | ORAL | C10AB05 | 1382/10/07 | ||||||
Fenofibrate | CAPSULE | 200 mg | ORAL | C10AB05 | 1382/10/07 | ||||||
Fenofibrate | CAPSULE | 145 mg | ORAL | C10AB05 | 1395/08/15 | ||||||
Fenofibrate | TABLET | 145 mg | ORAL | C10AB05 | 1395/09/01 | ||||||
Fentanyl | PATCH | 100 mcg/h | TOPICAL | N02AB03 | 1385/02/12 | ||||||
Fentanyl | PATCH | 25 mcg/h | TRANSDERMAL | N02AB03 | |||||||
Fentanyl | PATCH | 50 mcg/h | TRANSDERMAL | N02AB03 | |||||||
Fentanyl | As Citrate | INJECTION | 50 mcg/ml | PARENTERAL | N01AH01 | Hospital use only | 1362/08/15 | ||||
Fentanyl | PATCH | 75 mcg/h | TOPICAL | N02AB03 | 1385/02/12 | ||||||
Ferric Carboxy Maltose | INJECTION | 50 mg ferric/ml | PARENTERAL | B03AC | 1391/02/25 | ||||||
Ferric Oxide Saccharated | INJECTION | 20 mg/ml | PARENTERAL | B03AC | 1380/09/04 | ||||||
Ferrous | sulfate | SYRUP | 200mg/5ml | ORAL | B03AA01 | 40 mg Fe 2+(Elemental)/5ml | 1363/05/21 | ||||
Ferrous-glycine-sulfate | CAPSULE, DELAYED RELEASE | 567.66 mg | ORAL | B03AA01 | 100 mg Fe 2+(base) | 1384/11/18 | |||||
Ferrous-glycine-sulfate+Folic Acid | CAPSULE | ORAL | B03AA02 | Ferrous-glycine-sulfate 454.13 mg + Folic Acid 1 mg; ( 80 mg Fe 2+ elemental ) | 1384/11/18 | ||||||
Fexofenadine | HCl | TABLET | 120 mg | ORAL | R06AX26 | OTC medicines | for local production only | 1390/03/23 | |||
Fexofenadine | HCl | TABLET | 180 mg | ORAL | R06AX26 | OTC medicines | for local production only | 1390/03/23 | |||
Fexofenadine | HCl | TABLET | 30 mg | ORAL | R06AX26 | OTC medicines | 1392/10/23 | ||||
Fexofenadine | HCl | SUSPENSION | 30 mg/5 ml | ORAL | R06AX26 | for local production only | 1390/09/21 | ||||
Fexofenadine | HCl | TABLET | 60 mg | ORAL | R06AX26 | OTC medicines | for local production only | 1390/03/23 | |||
Fibrinogen | INJECTION, POWDER | 1 g | PARENTERAL | B02BB01 | For the control of bleeding and prophylactic treatment of patients deficient in fibrinogen. | Hospital use only; Orphan medicines | 1360/02/02 | ||||
Fibrinolysin+ Desoxyribonuclease | OINTMENT | TOPICAL | B06AA02 | (Fibrinolysin 1U+Desoxyribonuclease 666U)/g Human | 1390/03/23 | ||||||
Filgrastim | INJECTION | 300 mcg/ml | PARENTERAL | L03AA02 | Reduction in the duration of neutropenia, fever, antibiotic use, and hospitalization, following induction and consolidation treatment for acute myeloid leukemia. Treatment of patients with AIDS who, in addition, are afflicted with cytomegalovirus retinitis and are being treated with ganciclovir. | 1374/02/09 | |||||
Filgrastim | INJECTION | 600 mcg/ml | PARENTERAL | L03AA02 | Reduction in the duration of neutropenia, fever, antibiotic use, and hospitalization, following induction and consolidation treatment for acute myeloid leukemia. Treatment of patients with AIDS who, in addition, are afflicted with cytomegalovirus retinitis and are being treated with ganciclovir. | ||||||
Finasteride | GEL | 1% | TOPICAL | D11AX10 | 1392/03/11 | ||||||
Finasteride | TABLET | 1 mg | ORAL | G04CB01 | |||||||
Finasteride | TABLET | 5 mg | ORAL | G04CB01 | 1374/07/09 | ||||||
Fingolimod | As HCl | CAPSULE | 0.5 mg | ORAL | L04AA27 | for local production only | 1390/03/07 | ||||
Flecainide | Acetate | TABLET | 100 mg | ORAL | C01BC04 | 1378/01/22 | |||||
Flecainide | Acetate | CAPSULE, EXTENDED RELEASE | 100 mg | ORAL | C01BC04 | 1396/05/28 | |||||
Flecainide | Acetate | CAPSULE, EXTENDED RELEASE | 200 mg | ORAL | C01BC04 | 1396/05/28 | |||||
Fluconazole | CAPSULE | 100 mg | ORAL | J02AC01 | |||||||
Fluconazole | TABLET | 100mg | ORAL | J02AC01 | 1371/10/27 | ||||||
Fluconazole | CAPSULE | 150 mg | ORAL | J02AC01 | |||||||
Fluconazole | TABLET | 150 mg | ORAL | J02AC01 | |||||||
Fluconazole | INJECTION | 2 mg/ml | PARENTERAL | J02AC01 | Hospital use only. | 1390/03/09 | |||||
Fluconazole | CAPSULE | 200 mg | ORAL | J02AC01 | |||||||
Fluconazole | TABLET | 200 mg | ORAL | J02AC01 | |||||||
Fluconazole | SUSPENSION | 200 mg/5ml | ORAL | J02AC01 | 1386/09/07 | ||||||
Fluconazole | TABLET | 50 mg | ORAL | J02AC01 | 1371/10/27 | ||||||
Fluconazole | CAPSULE | 50 mg | ORAL | J02AC01 | |||||||
Flucytosine | TABLET | 500 mg | ORAL | J02AX01 | 1368/04/18 | ||||||
Fludarabine | Phosphate | TABLET | 10 mg | ORAL | L01BB05 | 1391/11/02 | |||||
Fludarabine | Phosphate | INJECTION, SOLUTION | 25mg/ml | PARENTERAL | L01BB05 | (Chronic lymphocytic leukemia (CLL) , including refractory CLLa, treat and manage non- Hodykin lyxphome) | |||||
Fludarabine | Phosphate | INJECTION, POWDER | 50 mg | INTRAVENOUS DRIP | L01BB05 | Treatment of chronic lymphocytic leukemia (CLL), including refractory CLL. Treatment and management of patients with non-Hodgkins lymphoma. | |||||
Fluorodeoxyglucose [18F-FDG] | INJECTION, SOLUTION | 10 mCi | PARENTERAL | V09IX04 | Radiopharmaceuticals | 1389/10/25 | |||||
Fludrocortisone | Acetate | TABLET | 0.1 mg | ORAL | H02AA02 | ||||||
Flumazenil | INJECTION | 0.1 mg/ml | PARENTERAL | V03AB25 | Hospital use only | ||||||
Fluocinolone | Acetonide | CREAM | 0.03% | TOPICAL | D07AC04 | ||||||
Fluocinolone | Acetonide | OINTMENT | 0.03% | TOPICAL | D07AC04 | ||||||
Fluocinolone+ Hydroquinone+ Tretinoin | CREAM | TOPICAL | D10AD51 | Fluocinolone Acetonide 0.01%+ Hydroquinone 4%+ Tretinoin 0.05% | Hyperpigmented skin | 1395/03/09 | |||||
Fluorescein | As Sodium | INJECTION | 10% | PARENTERAL | S01JA01 | Hospital use only | |||||
Fluorescein | Sodium | STRIP | 1 mg/strip | OPHTHALMIC | S01JA01 | 1361/12/23 | |||||
Fluoride | Sodium | MOUTHWASH | 0.20% | DENTAL | A01AA01 | OTC medicines | 1373/03/22 | ||||
Fluoride | GEL | 1.23% | DENTAL | A01AA01 | OTC medicines | 1376/11/05 | |||||
Fluoride | As Sodium | TABLET | 0.25 mg | ORAL | A12CD01 | OTC medicines | 1369/07/15 | ||||
Fluoride | As Acidulated Phosphate | TABLET | 1 mg | ORAL | A12CD01 | OTC medicines | 1369/07/15 | ||||
Fluoride | Sodium | SOLUTION/ DROPS | 1.1 mg/ml | ORAL | A12CD01 | 1379/08/29 | |||||
Fluoride | Sodium | TABLET | 20 mg | ORAL | A12CD01 | 1373/04/12 | |||||
Fluoride | Sodium | SOLUTION/ DROPS | 550 mcg/0.15ml | ORAL | A12CD01 | ||||||
Fluorometholone | SUSPENSION/ DROPS | 0.10% | OPHTHALMIC | S01BA07 | |||||||
Fluorouracil | CREAM | 5% | TOPICAL | L01BC02 | |||||||
Fluorouracil | OINTMENT | 5% | TOPICAL | L01BC02 | 1386/01/22 | ||||||
Fluorouracil | INJECTION | 50 mg/ml | PARENTERAL | L01BC02 | For use in combination with interferon alpha-2a, recombinant, for the treatment of esophageal carcinoma. For use in combination with interferon alpha-2a, recombinant, for the treatment of advanced colorectal carcinoma. | ||||||
Fluoxetine | As HCl | CAPSULE | 10 mg | ORAL | N06AB03 | 1376/04/08 | |||||
Fluoxetine | As HCl | CAPSULE | 20 mg | ORAL | N06AB03 | 1371/06/08 | |||||
Fluoxetine | As HCl | CAPSULE, DELAYED RELEASE | 90 mg | ORAL | N06AB03 | 1396/04/31 | |||||
Fluoxetine | As HCl | SYRUP | 20 mg/5ml | ORAL | N06AB03 | Treatment of body dysmorphic disorder in children | |||||
Flupenthixol | As DiHCl | TABLET | 0.5 mg | ORAL | N05AF01 | ||||||
Flupenthixol | Decanoate | INJECTION | 20 mg/ml | PARENTERAL | N05AF01 | 1362/05/02 | |||||
Flupenthixol | As DiHCl | TABLET | 3 mg | ORAL | N05AF01 | ||||||
Fluphenazine | As DiHCl | TABLET | 1 mg | ORAL | N05AB02 | ||||||
Fluphenazine | As DiHCl | TABLET | 2.5 mg | ORAL | N05AB02 | 1362/02/04 | |||||
Fluphenazine | Decanoate | INJECTION | 25 mg/ml | PARENTERAL | N05AB02 | ||||||
Flurazepam | As HCl | CAPSULE | 15 mg | ORAL | N05CD01 | 1375/07/01 | |||||
Flutamide | TABLET | 250 mg | ORAL | L02BB01 | 1375/09/25 | ||||||
Fluticasone | Propionate | INHALER | 125 mcg/dose | RESPIRATORY | R03BA05 | 1378/05/10 | |||||
Fluticasone | Propionate | INHALER | 250 mcg/dose | RESPIRATORY | R03BA05 | 1380/05/31 | |||||
Fluticasone | Furoate | INHALER | 27.5 mcg/dose | INTRANASAL | R01AD08 | ||||||
Fluticasone | Propionate | INHALER | 50 mcg/ dose | NASAL | R01AD08 | 1380/05/31 | |||||
Fluticasone | Propionate | INHALER | 50 mcg/dose | RESPIRATORY | R03BA05 | 1380/05/31 | |||||
Fluvoxamine | Maleate | TABLET | 100 mg | ORAL | N06AB08 | 1383/09/16 | |||||
Fluvoxamine | Maleate | TABLET | 50 mg | ORAL | N06AB08 | ||||||
Folic Acid | TABLET | 1 mg | ORAL | B03BB01 | |||||||
Folic Acid | TABLET | 5 mg | ORAL | B03BB01 | 1378/05/10 | ||||||
Folic Acid | INJECTION | 5 mg/ml | PARENTERAL | B03BB01 | Hospital use only | 1372/01/29 | |||||
Follitropin Alfa | INJECTION | 600 IU/ml | PARENTERAL | G03GA05 | For the initiation and re-initiation of spermatogenesis in adult males with reproductive failure due to hypothalamic or pituitary dysfunction, hypogonadotropic hypogonadism. AMENDED indication 6/27/00: For the induction of spermatogenesis in men with primary testicular failure | 1385/10/20 | |||||
Follitropin Alfa | INJECTION, POWDER | 75 IU | PARENTERAL | G03GA05 | 1384/05/16 | ||||||
Follitropin Alfa+Lutropin Alfa | INJECTION, POWDER | PARENTERAL | G03GA30 | Follitropin Alfa 150U+Lutropin Alfa 75 U | Recombinant | 1392/08/20 | |||||
Follitropin Beta | INJECTION, SOLUTION | 50 IU/0.5 ml | PARENTERAL | G03GA06 | Recombinant | 1397/07/28 | |||||
Follitropin Beta | INJECTION, SOLUTION | 100 IU/0.5 ml | PARENTERAL | G03GA06 | Recombinant | 1397/07/28 | |||||
Follitropin Beta | INJECTION, SOLUTION | 200 IU/0.5 ml | PARENTERAL | G03GA06 | Recombinant | 1397/07/28 | |||||
Follitropin Beta | INJECTION | 75 IU | PARENTERAL | G03GA06 | Recombinant | ||||||
Follitropin Beta | INJECTION | 833 IU/ml | PARENTERAL | G03GA06 | Recombinant | 1390/1/29 | |||||
Fomepizole | INJECTION | 1 g/ml | PARENTERAL | V03AB34 | Treatment of methanol or ethylene glycol poisoning. | Hospital use only; Orphan medicines | 1385/02/12 | ||||
Formaldehyde | BULK | V03 | Bulk medicines | ||||||||
Formoterol | Fumarate | INHALER | 12 mcg | RESPIRATORY | R03AC13 | 1385/08/17 | |||||
Formoterol | Fumarate | INHALER | 12 mcg/capsule | RESPIRATORY | R03AC13 | 1384/02/11 | |||||
Formoterol | Fumarate | INHALER | 9 mcg | RESPIRATORY | R03AC13 | 1384/12/09 | |||||
Formoterol | Fumarate | INHALER | 4.5 mcg | RESPIRATORY | R03AC13 | 1384/12/09 | |||||
Formoterol | Fumarate | POWDER, INHALATION | 6 mcg/metered inhalation | RESPIRATORY | R03AC13 | 1396/01/29 | |||||
Fosfestrol | As Tetra Sodium | TABLET | 120 mg | ORAL | L02AA04 | ||||||
Fosfestrol | As Tetra Sodium | INJECTION | 50 mg/ml | PARENTERAL | L02AA04 | ||||||
Fosfomycin | As Trometamol | GRANULE, FOR SUSPENSION | 3 g | ORAL | J01XX01 | 1393/06/02 | |||||
Furazolidone | TABLET | 100 mg | ORAL | G01AX06 | 1359/11/08 | ||||||
Furazolidone | SUSPENSION | 50 mg/15ml | ORAL | G01AX06 | |||||||
Furosemide | INJECTION, SOLUTION | 10 mg/ml | INTRAVENOUS DRIP | C03CA01 | volume of 25 ml is for Hospital use only | 1366/10/20 | |||||
Furosemide | TABLET | 40 mg | ORAL | C03CA01 | |||||||
Furosemide | SOLUTION | 40 mg/5ml | ORAL | C03CA01 | 1395/09/01 | ||||||
Fusidate Sodium | OINTMENT | 2% | TOPICAL | D06AX01 | Topical Antibiotics | 1395/08/02 | |||||
Fusidic Acid | CREAM | 2% | TOPICAL | D06AX01 | Topical Antibiotics | 1395/08/02 | |||||
Fusidic Acid+Hydrocortisone | CREAM | TOPICAL | D07CA01 | Fusidic Acid 2%+Hydrocortisone 1% | Topical Antibiotics and Antiinflamatory | 1396/04/31 | |||||
Gabapentin | CAPSULE | 100 mg | ORAL | N03AX12 | Treatment of amyotrophic lateral sclerosis. | 1382/05/05 | |||||
Gabapentin | CAPSULE | 300 mg | ORAL | N03AX12 | Treatment of amyotrophic lateral sclerosis. | 1382/05/05 | |||||
Gabapentin | CAPSULE | 400 mg | ORAL | N03AX12 | Treatment of amyotrophic lateral sclerosis. | 1382/05/05 | |||||
Gabapentin | TABLET | 600 mg | ORAL | N03AX12 | Treatment of amyotrophic lateral sclerosis. | 1387/05/06 | |||||
Gabapentin | CAPSULE | 800 mg | ORAL | N03AX12 | Treatment of amyotrophic lateral sclerosis. | ||||||
Gabapentin | TABLET | 800 mg | ORAL | N03AX12 | Treatment of amyotrophic lateral sclerosis. | 1387/05/06 | |||||
Gadobutrol | INJECTION | 604.72 mg/ml (1mmol/ml) | PARENTERAL | V08CA09 | 1387/09/09 | ||||||
Gadodiamide | INJECTION | 287 mg/ml | PARENTERAL | V08CA03 | 1379/12/21 | ||||||
Gadopentetate | Dimeglumine | INJECTION | 469 mg/ml | PARENTERAL | V08CA01 | 137103/03 | |||||
Galantamine | As HBr | TABLET | 12 mg | ORAL | N06DA04 | 1383/07/12 | |||||
Galantamine | As HBr | CAPSULE, EXTENDED RELEASE | 16 mg | ORAL | N06DA04 | 1386/12/26 | |||||
Galantamine | As HBr | SOLUTION | 20 mg/5ml | ORAL | N06DA04 | 1383/07/12 | |||||
Galantamine | As HBr | CAPSULE, EXTENDED RELEASE | 24 mg | ORAL | N06DA04 | 1386/12/26 | |||||
Galantamine | As HBr | TABLET | 4 mg | ORAL | N06DA04 | 1383/07/12 | |||||
Galantamine | As HBr | TABLET | 8 mg | ORAL | N06DA04 | 1383/07/12 | |||||
Galantamine | As HBr | CAPSULE, EXTENDED RELEASE | 8 mg | ORAL | N06DA04 | 1386/12/26 | |||||
Gallium [68 Ga]-DOTATATE, DOTATOC or DOTANOC | INJECTION, SOLUTION | 5.5 mCi | PARENTERAL | V09X | Radiopharmaceuticals | 1391/09/01 | |||||
Gallium [67Ga] Citrate | INJECTION, SOLUTION | 5-10 mCi | PARENTERAL | V09HX01 | Radiopharmaceuticals | 1383/09/22 | |||||
Gallium [68Ga]-prostate specific membrane antigen, (68Ga-PSMA) | INJECTION, SOLUTION | 10 mCi | PARENTERAL | V09IX09 | Radiopharmaceuticals | 1397/02/18 | |||||
Galsulfase | INJECTION | 1mg/ml | PARENTERAL | A16AB08 | Orphan medicines | 1391/02/07 | |||||
Ganciclovir | GEL | 0.15% | OPHTHALMIC | S01AD09 | 1390/09/21 | ||||||
Ganciclovir | INJECTION, POWDER, LYOPHILIZED | 500 mg | PARENTERAL | J05AB06 | Treatment of acute herpetic keratitis (dendritic and geographic ulcers) | Hospital use only | 1378/08/23 | ||||
Ganirelix | As Acetate | INJECTION | 500 mcg/ml | PARENTERAL | H01CC01 | ||||||
Gaseous Gangrene Antitoxin | INJECTION | PARENTERAL | J06AA05 | Hospital use only | |||||||
Gefitinib | TABLET | 250mg | ORAL | L01XE02 | 1391/12/23 | ||||||
Gelatin Modified | INJECTION | 4% | PARENTERAL | B05AA06 | (Gelatin Succinylated 40g (4%) + Na+ 154 mmol + Cl- 120 mmol )/lit | Hospital use only | 1380/09/04 | ||||
Gelatin Modified | INJECTION | 4% | PARENTERAL | B05AA06 | (Gelatin Succinylated 40g (4%) + Na+ 151 mmol + Cl- 103 mmol )/lit | Hospital use only | 1396/11/29 | ||||
Gelatin Modified | INJECTION, SOLUTION | INTRAVENOUS DRIP | B05AA06 | (Gelatin Succinylate 30g + NaCl 4.51g + CaCl2,2H20 0.21g) / 1000 ml | Hospital use only | 1377/06/22 | |||||
Gemcitabine | As HCl | INJECTION, POWDER, LYOPHILIZED | 1 g | PARENTERAL | L01BC05 | 1380/03/27 | |||||
Gemcitabine | As HCl | INJECTION, SOLUTION, CONCENTRATE | 38 mg/ml | PARENTERAL | L01BC05 | 1390/03/23 | |||||
Gemcitabine | As HCl | INJECTION, POWDER, LYOPHILIZED | 200 mg | PARENTERAL | L01BC05 | 1380/03/27 | |||||
Gemcitabine | As HCl | INJECTION, SOLUTION, CONCENTRATE | 100mg/ml | PARENTERAL | L01BC05 | 1390/03/23 | 1394/06/10 | ||||
Gemfibrozil | CAPSULE | 300 mg | ORAL | C10AB04 | 1369/10/16 | ||||||
Gemfibrozil | TABLET | 450 mg | ORAL | C10AB04 | |||||||
Gemifloxacin | As Mesilate | TABLET | 320 mg | ORAL | J01MA15 | for local production only | 1389/05/30 | ||||
Gentamicin | As Sulfate | INJECTION | 0.8 mg/ml | PARENTERAL | J01GB03 | Hospital use only | for local production only ; in sodium chloride 0.9% (premixed) | 1390/03/09 | |||
Gentamicin | As Sulfate | INJECTION | 10 mg/ml | PARENTERAL | J01GB03 | 1390/12/22 | |||||
Gentamicin | As Sulfate | OINTMENT | 3 mg/g | OPHTHALMIC | S01AA11 | ||||||
Gentamicin | As Sulfate | SOLUTION/ DROPS | 3 mg/ml | OPHTHALMIC | S03AA06 | ||||||
Gentamicin | As Sulfate | INJECTION | 40 mg/ml | PARENTERAL | J01GB03 | 1390/12/22 | |||||
Gentian Violet | SOLUTION | 1% | TOPICAL | D01AE02 | Crystal Violet 1 g + Ethanol 96% (8-10)ml + water qs to 100 ml | ||||||
Gentian Violet | BULK | V03 | Bulk medicines | 1361/09/28 | |||||||
Germanium [68Ge]/Gallium [68Ga] | GENERATOR | (10-100) mCi | Not for direct patient administration, only for preparation of radiopharmaceuticals | V09X | Radiopharmaceuticals | 1391/09/01 | |||||
Gestonorone | Caproate | INJECTION | 100 mg/ml | PARENTERAL | L02AB03 | 1368/04/18 | |||||
Glatiramer | Acetate | INJECTION | 20 mg/ml | PARENTERAL | L03AX13 | 1389/03/29 | |||||
Glatiramer | Acetate | INJECTION | 40 mg/ml | PARENTERAL | L03AX13 | 1393/02/07 | |||||
Glibenclamide | TABLET | 5 mg | ORAL | A10BB01 | Type 2 Diabetes Mellitus | ||||||
Gliclazide | TABLET, EXTENDED RELEASE | 30 mg | ORAL | A10BB09 | Type 2 Diabetes Mellitus | 1383/07/12 | |||||
Gliclazide | TABLET, EXTENDED RELEASE | 60 mg | ORAL | A10BB09 | Type 2 Diabetes Mellitus | 1394/03/31 | |||||
Gliclazide | TABLET | 80 mg | ORAL | A10BB09 | Type 2 Diabetes Mellitus | 1372/07/11 | |||||
Glimepiride | TABLET | 1 mg | ORAL | A10BB12 | Type 2 Diabetes Mellitus | 1395/12/22 | |||||
Glimepiride | TABLET | 2 mg | ORAL | A10BB12 | Type 2 Diabetes Mellitus | 1395/12/22 | |||||
Glimepiride | TABLET | 3 mg | ORAL | A10BB12 | Type 2 Diabetes Mellitus | 1395/12/22 | |||||
Glimepiride | TABLET | 4 mg | ORAL | A10BB12 | Type 2 Diabetes Mellitus | 1395/12/22 | |||||
Glucagon | As HCl | INJECTION, POWDER | 1 mg | PARENTERAL | H04AA01 | Hospital use only | |||||
Glycerin | SUPPOSITORY | 1 g | RECTAL | A06AX01 | OTC medicines | Equal to 700 mg Glycerin | |||||
Glycerin | SUPPOSITORY | 1.2 mg | RECTAL | A06AX01 | OTC medicines | ||||||
Glycerin | SUPPOSITORY | 2 g | RECTAL | A06AX01 | OTC medicines | Equal to 1.4 g Glycerin | |||||
Glycerin | SUPPOSITORY | 4 g | RECTAL | A06AX01 | OTC medicines | 1395/11/12 | |||||
Glycerin | SUPPOSITORY | 3.4 mg | RECTAL | A06AX01 | OTC medicines | ||||||
Glycerin | BULK | V03 | Bulk medicines | 1376/12/10 | |||||||
Glycine | SOLUTION | 1.50% | IRRIGATION | B05CX03 | Aminoacetic Acid | ||||||
Glycine | POWDER | 1 g | ORAL | B05CX03 | for treatment of pateints with Isovaleric Acidemia | 1387/11/06 | |||||
Glycolic Acid | SOLUTION | 70% | TOPICAL | D | 1387/06/13 | ||||||
Glycolic Acid | BULK | V03 | Bulk medicines | ||||||||
Glycopyrronium | Bromide | INJECTION | 200 mcg/ml | PARENTERAL | A03AB02 | 1385/06/14 | |||||
Gold Sodium Thiomalate | INJECTION | 100 mg/ml | PARENTERAL | M01CB01 | |||||||
Gold Sodium Thiomalate | INJECTION | 20 mg/ml | PARENTERAL | M01CB01 | 1368/02/10 | ||||||
Gold Sodium Thiomalate | INJECTION | 40 mg/ml | PARENTERAL | M01CB01 | |||||||
Gold Sodium Thiomalate | INJECTION | 50 mg/ml | PARENTERAL | M01CB01 | 1368/02/10 | ||||||
Gonadorelin | INJECTION, POWDER | 100 mcg | PARENTERAL | V04CM01 | 1372/06/07 | ||||||
Gonadorelin | Acetate | INJECTION, POWDER | 0.8 mg | PARENTERAL | H01CA01 | For induction of ovulation in women with hypothalamic amenorrhea due to a deficiency or absence in the quantity or pulse pattern of endogenous GnRH secretion. | 1371/03/03 | ||||
Gonadorelin | Acetate | INJECTION, POWDER | 3.2 mg | PARENTERAL | H01CA01 | For induction of ovulation in women with hypothalamic amenorrhea due to a deficiency or absence in the quantity or pulse pattern of endogenous GnRH secretion. | 1371/03/03 | ||||
Goserelin | As Acetate | IMPLANT | 10.8mg | PARENTERAL | L02AE03 | 1391/12/23 | |||||
Goserelin | As Acetate | IMPLANT | 3.6mg | PARENTERAL | L02AE03 | 1391/12/23 | |||||
Granisetron | As HCl | TABLET | 1 mg | ORAL | A04AA02 | 1372/07/11 | |||||
Granisetron | As HCl | INJECTION, SOLUTION | 1 mg/ml | INTRAVENOUS DRIP | A04AA02 | 1372/07/11 | |||||
Granisetron | PATCH, EXTENDED RELEASE | 3.1mg/24h (34.3 mg/52 cm2 | TRANSDERMAL | A04AA02 | 1390/09/21 | ||||||
Guaifenesin | CAPSULE, LIQUID FILLED | 100 mg | ORAL | R05CA03 | OTC medicines | for local production only | 1390/09/21 | ||||
Guaifenesin | SYRUP | 100 mg/5ml | ORAL | R05CA03 | OTC medicines | 1369/10/30 | |||||
Guaifenesin | CAPSULE, LIQUID FILLED | 200 mg | ORAL | R05CA03 | OTC medicines | for local production only | 1390/09/21 | ||||
Haemophilus Influenza Type B | INJECTION, POWDER | PARENTERAL | J07AG01 | vaccine | 1387/05/01 | ||||||
Haemophilus Influenza Type B | INJECTION, SOLUTION | PARENTERAL | J07AG01 | vaccine | 1388/09/17 | ||||||
Haloperidol | TABLET | 0.5 mg | ORAL | N05AD01 | |||||||
Haloperidol | TABLET | 2 mg | ORAL | N05AD01 | 1378/01/22 | ||||||
Haloperidol | As Lacate | SOLUTION | 2 mg/ml | ORAL | N05AD01 | ||||||
Haloperidol | TABLET | 5 mg | ORAL | N05AD01 | 1360/10/27 | ||||||
Haloperidol | As Lacate | INJECTION | 5 mg/ml | PARENTERAL | N05AD01 | ||||||
Haloperidol | As Decanoate | INJECTION | 50 mg/ml | PARENTERAL | N05AD01 | 1368/04/18 | |||||
Halothane | INHALANT | 250 ml/bottle | RESPIRATORY | N01AB01 | Hospital use only | ||||||
Hematinic | CAPSULE, LIQUID FILLED | ORAL | B03AE02 | VIT. B12 15mcg+Ferrous Fumarate 350 mg+VIT.C 150mg+Folic Acid 1mg | OTC medicines | 1385/09/15 | |||||
Hematinic | CAPSULE | ORAL | B03AE02 | VIT. B12 15mcg+Ferrous Fumarate 350 mg+VIT.C 150mg+Folic Acid 1mg | OTC medicines | ||||||
Hemodialysis Concentrated I | SOLUTION, CONCENTRATE | UNASSIGNED | B05ZA | (Na+4725mEq + Mg2+35mEq + K+ 35mEq + Ca2+ 87.5mEq + Cl- 3657.5mEq + Acetate 1225 mEq + Dextrose 70 g)/ L; Dextrose anhydrous or monohydrate Eq. to 70 g Dextrose/1000 ml | 1360/02/02 | ||||||
Hemodialysis Concentrated I ,Acidic | SOLUTION, CONCENTRATE | UNASSIGNED | B05ZA | (Na+3710mEq + Mg++35mEq + K+ 35mEq + Ca++ 87.5mEq + Cl- 3902.5 mEq + CH3Coo- 122.5 mEq + Dextrose 70 g)/ L Dextrose anhydrous or monohydrate Eq. to 70 g Dextrose/1000 ml | 1393/10/14 | ||||||
Hemodialysis Concentrated I,without Dextrose | SOLUTION, CONCENTRATE | UNASSIGNED | B05ZA | (Na+ 4725 mEq + Mg2+35 mEq + K+ 35mEq + Ca2+ 87.5 mEq + Cl- 3657.5 mEq + Acetate 1225mEq )/ L | 1362/11/09 | ||||||
Hemodialysis Concentrated II | SOLUTION, CONCENTRATE | UNASSIGNED | B05ZA | (Na+ 4725 mEq+MG2+ 35mEq + K+ 70mEq+Ca2+ 87.5mEq+ Cl- 3692.5 mEq + Acetate 1225mEq + Dextrose 70 g) / L Dextrose anhydrous or monohydrate Eq. to 70 g Dextrose/1000 ml | 1360/02/02 | ||||||
Hemodialysis Concentrated II ,Acidic | SOLUTION, CONCENTRATE | UNASSIGNED | B05ZA | (Na+3710mEq + Mg2+35mEq + K+ 70mEq + Ca2+ 87.5mEq + Cl- 3902.5 mEq + CH3Coo- 122.5 mEq + Dextrose 70 g)/ L Dextrose anhydrous or monohydrate Eq. to 70 g Dextrose/1000 ml | 1381/09/24 | ||||||
Hemodialysis Concentrated III | SOLUTION, CONCENTRATE | UNASSIGNED | B05ZA | (Na+4725mEq + Mg2+35mEq + K+ 105mEq + Ca2+ 87.5mEq + Cl- 3745 mEq + Acetate 1225 mEq + Dextrose 70 g)/ L Dextrose anhydrous or monohydrate Eq. to 70 g Dextrose/1000 ml | |||||||
Hemodialysis Concentrated III ,Acidic | SOLUTION, CONCENTRATE | UNASSIGNED | B05ZA | (Na+3710mEq + Mg++35mEq + K+ 105mEq + Ca++ 87.5mEq + Cl- 3902.5 mEq + CH3Coo- 122.5 mEq + Dextrose 70 g)/ L Dextrose anhydrous or monohydrate Eq. to 70 g Dextrose/1000 ml | 1393/10/14 | ||||||
Hemofiltration+Haemodiafiltration | SOLUTION | UNASSIGNED | B05ZB | (Na+125-150mEq + Mg2+0.5-3 mEq + K+0- 4.5 mEq + Ca2+ 2-5 mEq + Cl- 90-120 mEq + Acetate and or lactate and or Hydrogen Carbonate 30-60 mEq + Glucose 0-25 mmol)/ L | 1392/06/12 | ||||||
Heparin | Sodium | INJECTION | 10,000 U/ml | PARENTERAL | B01AB01 | Hospital use only | |||||
Heparin | Sodium | INJECTION | 5000 U/ml | PARENTERAL | B01AB01 | Hospital use only | |||||
Heparin | Sodium | INJECTION | 1000 U/ml | PARENTERAL | B01AB01 | Hospital use only | without preservative | 1396/08/07 | |||
Hepatitis B immune globulin | INJECTION | At least 200 IU/ml | PARENTERAL | J06BB04 | Prophylaxis against hepatitis B virus reinfection in liver transplant patients. | ||||||
Hepatitis B Immune Globulin(humam | INJECTION | 50 IU/ml | PARENTERAL | J06BB04 | |||||||
Hepatitis B Virus | INJECTION | PARENTERAL | J07BC01 | vaccine | 1372/08/23 | ||||||
Hexamethylmelamine | CAPSULE | 100 mg | ORAL | L01XX03 | |||||||
Homatropine | HBr | SOLUTION/ DROPS | 2% | OPHTHALMIC | S01FA05 | ||||||
Human Papiloma Virus | INJECTION | PARENTERAL | J07BM01 | 2 Valents | 1390/07/05 | ||||||
Human Papiloma Virus | INJECTION | PARENTERAL | J07BM01 | 4 Valents | 1390/07/05 | ||||||
Human Papiloma Virus | INJECTION | PARENTERAL | J07BM01 | 9 Valents | 1395/12/18 | ||||||
Hydralazine | HCl | TABLET | 10 mg | ORAL | C02DB02 | ||||||
Hydralazine | HCl | INJECTION, POWDER | 20 mg | PARENTERAL | C02DB02 | Hospital use only | |||||
Hydralazine | HCl | INJECTION, SOLUTION, CONCENTRATE | 20 mg | PARENTERAL | C02DB02 | Hospital use only | |||||
Hydralazine | HCl | TABLET | 25 mg | ORAL | C02DB02 | ||||||
Hydralazine | HCl | TABLET | 50 mg | ORAL | C02DB02 | 1359/09/12 | |||||
Hydrochloric Acid | BULK | V03 | Bulk medicines | ||||||||
Hydrochlorothiazide | TABLET | 50 mg | ORAL | C03AA03 | Oedema, Hypertension | ||||||
Hydrochlorothiazide | TABLET | 25 mg | ORAL | C03AA03 | Oedema, Hypertension | 1394/07/05 | |||||
Hydrochlorothiazide | TABLET | 12.5 mg | ORAL | C03AA03 | Oedema, Hypertension | 1394/07/05 | |||||
Hydrocortisone | CREAM | 1% | TOPICAL | D07AA02 | |||||||
Hydrocortisone | Acetate | CREAM | 1% | TOPICAL | D07AA02 | 1388/10/30 | |||||
Hydrocortisone | Acetate | OINTMENT | 1% | OPHTHALMIC | S01BA02 | ||||||
Hydrocortisone | Acetate | OINTMENT | 1% | TOPICAL | D07AA02 | ||||||
Hydrocortisone | TABLET | 10 mg | ORAL | H02AB09 | 1371/08/24 | ||||||
Hydrocortisone | As Sodium Phosphate | INJECTION, POWDER | 100 mg | PARENTERAL | H02AB09 | ||||||
Hydrocortisone | As Sodium succinate | INJECTION, POWDER | 100 mg | PARENTERAL | H02AB09 | 1368/12/13 | |||||
Hydrocortisone | ENEMA | 100 mg/60ml | RECTAL | A07EA02 | 1364/04/30 | ||||||
Hydrocortisone | As Sodium Phosphate | INJECTION | 50 mg/ml | PARENTERAL | H02AB09 | ||||||
Hydrocortisone | As Sodium succinate | INJECTION | 50 mg/ml | PARENTERAL | H02AB09 | 1380/07/18 | |||||
Hydrocortisone+Acetic Acid | SOLUTION/ DROPS | OTIC | S02CA03 | Hydrocortisone 1% + Acetic Acid 2% | 1386/12/06 | ||||||
Hydrogen Peroxide Concentrate | BULK | 30% w/w | V03 | Bulk medicines | |||||||
Hydromorphone | TABLET | 2 mg | ORAL | N02AA03 | 1387/10/15 | ||||||
Hydromorphone | TABLET | 4 mg | ORAL | N02AA03 | 1387/10/15 | ||||||
Hydrophilic Petrolatum | BULK | V03 | White Petrolatum86%+White Wax8%+Strearyl Alcohol3%+Cholestrol3% | Bulk medicines | |||||||
Hydroquinone | CREAM | 2% | TOPICAL | D11AX11 | 1369/10/30 | ||||||
Hydroquinone | CREAM | 4% | TOPICAL | D11AX11 | 1378/02/19 | ||||||
Hydroquinone | BULK | V03 | Bulk medicines | ||||||||
Hydroxychloroquine | Sulfate | TABLET | 200 mg | ORAL | P01BA02 | 1371/08/03 | |||||
Hydroxyprogesteron | Caproate | INJECTION | 250 mg/ml | PARENTERAL | G03DA03 | 1382/03/04 | |||||
Hydroxyurea | CAPSULE | 250 mg | ORAL | L01XX05 | Treatment of pediatric patients with sickle cell anemia. Treatment of patients with sickle cell anemia as shown by the presence of hemoglobin S. | 1385/03/23 | |||||
Hydroxyurea | CAPSULE | 500 mg | ORAL | L01XX05 | Treatment of pediatric patients with sickle cell anemia. Treatment of patients with sickle cell anemia as shown by the presence of hemoglobin S. | ||||||
Hydroxyzine | HCl | TABLET | 10 mg | ORAL | N05BB01 | ||||||
Hydroxyzine | HCl | SYRUP | 10 mg/5ml | ORAL | N05BB01 | ||||||
Hydroxyzine | HCl | TABLET | 25 mg/ml | ORAL | N05BB01 | ||||||
Hyoscine-n-butyl | Bromide | SUPPOSITORY | 10 mg | RECTAL | A03BB01 | ||||||
Hyoscine-n-butyl | Bromide | TABLET | 10 mg | ORAL | A03BB01 | ||||||
Hyoscine-n-butyl | Bromide | INJECTION | 20 mg/ml | PARENTERAL | A03BB01 | ||||||
Hyoscine-n-butyl | Bromide | SUPPOSITORY | 7.5 mg | RECTAL | A03BB01 | ||||||
Ibuprofen | GEL | 5% | TOPICAL | M02AA13 | OTC medicines | 1389/06/15 | |||||
Ibuprofen | As Lysine | INJECTION | 10 mg/ml | PARENTERAL | C01EB16 | Hospital use only | 1390/09/21 | ||||
Ibuprofen | SUSPENSION | 100 mg/5ml | ORAL | M01AE01 | 1373/05/30 | ||||||
Ibuprofen | SUSPENSION | 40 mgml | ORAL | M01AE01 | 1396/04/18 | ||||||
Ibuprofen | INJECTION | 100mg/ml | PARENTERAL | M01AE01 | Hospital use only | 1390/06/14 | |||||
Ibuprofen | CAPSULE, LIQUID FILLED | 200 mg | ORAL | M01AE01 | OTC medicines | 1383/04/29 | |||||
Ibuprofen | TABLET | 200 mg | ORAL | M01AE01 | OTC medicines | 1369/10/30 | |||||
Ibuprofen | TABLET, EXTENDED RELEASE | 800 mg | ORAL | M01AE01 | 1397/02/11 | ||||||
Ibuprofen | TABLET, ORALLY DISINTEGRATING | 200 mg | ORAL | M01AE01 | OTC medicines | 1396/11/29 | |||||
Ibuprofen | CAPSULE, LIQUID FILLED | 400 mg | ORAL | M01AE01 | 1383/04/29 | ||||||
Ibuprofen | TABLET | 400 mg | ORAL | M01AE01 | |||||||
Ibuprofen | GRANULE, EFFERVESCENT | 600 mg | ORAL | M01AE01 | 1397/07/14 | ||||||
Ibuprofen | As Lysine | TABLET | 200 mg | ORAL | M01AE01 | 1392/07/22 | |||||
Ibuprofen | As Lysine | TABLET | 400 mg | ORAL | M01AE01 | 1392/07/22 | |||||
Ibuprofen | As Lysine | INJECTION , SOLUTION | 400 mg/3ml | PARENTERAL | M01AE01 | Hospital use only | 1392/05/29 | ||||
Ibuprofen | INJECTION | 5mg/ml | INTRAVENOUS | C01EB16 | For diagnosis of PDA (Patent ductus arterious) | Hospital use only | 1386/11/03 | ||||
Ichthammol | OINTMENT | 10% | TOPICAL | D10BX | Ichthyol | 1369/10/30 | |||||
Ichthammol | OINTMENT | 20% | TOPICAL | D10BX | Ichthyol | 1397/03/01 | |||||
Ichthammol | BULK | V03 | Bulk medicines | Ichthyol | |||||||
Idarubicin | HCl | INJECTION, POWDER, LYOPHILIZED | 10 mg | PARENTERAL | L01DB06 | Treatment of acute lymphoblastic leukemia in pediatric patients. Treatment of acute myelogenous leukemia, also referred to as acute nonlymphocytic leukemia. | Orphan medicines | 1371/04/14 | |||
Idarubicin | HCl | INJECTION, POWDER, LYOPHILIZED | 5 mg | PARENTERAL | L01DB06 | Treatment of acute lymphoblastic leukemia in pediatric patients. Treatment of acute myelogenous leukemia, also referred to as acute nonlymphocytic leukemia. | Orphan medicines | 1371/04/14 | |||
Idarubicin | HCl | INJECTION, SOLUTION | 1mg/ml | PARENTERAL | L01DB06 | Treatment of acute lymphoblastic leukemia in pediatric patients. Treatment of acute myelogenous leukemia, also referred to as acute nonlymphocytic leukemia. | Orphan medicines | 1395/09/01 | |||
Idarucizumab | INJECTION, SOLUTION | 2.5 g/50 ml | PARENTERAL | V03AB37 | Antidote for Dabigatran | 1397/05/10 | |||||
Idoxuridine | SOLUTION/ DROPS | 0.10% | OPHTHALMIC | S01AD01 | |||||||
Ifosfamide | INJECTION, POWDER | 1 g | PARENTERAL | L01AA06 | Treatment of testicular cancer. Treatment of bone sarcomas Treatment of soft tissue sarcomas | 1365/01/24 | |||||
Ifosfamide | INJECTION, POWDER | 2 g | PARENTERAL | L01AA06 | Treatment of testicular cancer. Treatment of bone sarcomas Treatment of soft tissue sarcomas | 1365/01/24 | |||||
Ifosfamide | INJECTION, SOLUTION | 40mg/ml | PARENTERAL | L01AA06 | Treatment of testicular cancer. Treatment of bone sarcomas Treatment of soft tissue sarcomas | In 25 ml final dose reach to 1 gr | 1391/10/03 | ||||
Ifosfamide | INJECTION, SOLUTION | 50mg/ml | PARENTERAL | L01AA06 | Treatment of testicular cancer. Treatment of bone sarcomas Treatment of soft tissue sarcomas | In 20 ml final dose reach to 1 gr | |||||
Igm-enriched Human (Immune globulin) | INJECTION | PARENTERAL | J06BA02 | Hospital use only | |||||||
Imatinib | TABLET | 100 mg | ORAL | L01XE01 | Treatment of idiopathic hypereosinophilic syndrome including acute and chronic eosinophilic leukemia Treatment of Philadelphia-positive ALL Treatment of dermatofibrosarcoma protuberans Treatment of gastrointestinal stromal tumors | 1384/02/12 | |||||
Imatinib | As Mesylate | CAPSULE | 100 mg | ORAL | L01XE01 | Treatment of idiopathic hypereosinophilic syndrome including acute and chronic eosinophilic leukemia Treatment of Philadelphia-positive ALL Treatment of dermatofibrosarcoma protuberans Treatment of gastrointestinal stromal tumors | 1380/08/27 | ||||
Imatinib | As Mesylate | CAPSULE | 400 mg | ORAL | L01XE01 | Treatment of idiopathic hypereosinophilic syndrome including acute and chronic eosinophilic leukemia Treatment of Philadelphia-positive ALL Treatment of dermatofibrosarcoma protuberans Treatment of gastrointestinal stromal tumors | 1395/07/17 | ||||
Imatinib | As Mesylate | TABLET | 400 mg | ORAL | L01XE01 | Treatment of idiopathic hypereosinophilic syndrome including acute and chronic eosinophilic leukemia; treatment of Philadelphia-positive ALL Treatment of dermatofibrosarcoma protuberans Treatment of gastrointestinal stromal tumors | 1392/09/25 | ||||
Imatinib | CAPSULE | 50 mg | ORAL | L01XE01 | Treatment of idiopathic hypereosinophilic syndrome including acute and chronic eosinophilic leukemia Treatment of Philadelphia-positive ALL Treatment of dermatofibrosarcoma protuberans Treatment of gastrointestinal stromal tumors | 1380/08/27 | |||||
Imiglucerase | INJECTION, POWDER | 200 U | PARENTERAL | A16AB02 | Replacement therapy in patients with types I, II, and III Gaucher's disease. | Orphan medicines | 1382/03/04 | ||||
Imiglucerase | INJECTION, POWDER | 400 U | PARENTERAL | A16AB02 | Replacement therapy in patients with types I, II, and III Gaucher's disease. | Orphan medicines | 1385/03/23 | ||||
Imipenem+Cilastatin | INJECTION, POWDER | PARENTERAL | J01DH51 | Imipenem(as Monohydrate) 250 mg + Cilastatin(as Sodium) 250 mg | Hospital use only | 1383/07/12 | |||||
Imipenem+Cilastatin | INJECTION, POWDER | PARENTERAL | J01DH51 | Imipenem(as Monohydrate) 500 mg + Cilastatin(as Sodium) 500 mg | Hospital use only | 1383/07/12 | |||||
Imipenem+Cilastatin | INJECTION, POWDER | PARENTERAL | J01DH51 | Imipenem(as Monohydrate) 750 mg + Cilastatin(as Sodium) 750 mg | Hospital use only | 1383/07/12 | |||||
Imipramine | HCl | TABLET | 10 mg | ORAL | N06AA02 | ||||||
Imipramine | HCl | INJECTION | 12.5 mg/ml | PARENTERAL | N06AA02 | Hospital use only | |||||
Imipramine | HCl | TABLET | 25 mg | ORAL | N06AA02 | ||||||
Imipramine | HCl | TABLET | 50 mg | ORAL | N06AA02 | 1372/04/27 | |||||
Imiquimod | CREAM | 5% | TOPICAL | D06BB10 | 1385/02/12 | ||||||
Immune Globulin | INJECTION, POWDER, LYOPHILIZED | PARENTERAL | J06BA02 | Treatment of multifocal motor neuropathy, Guillain Barre Syndrome, polymyositis/dermatomyositis | Hospital use only | 1361/08/20 | |||||
Immune Globulin | INJECTION | 100 mg/ml | PARENTERAL | J06BA02 | Treatment of multifocal motor neuropathy, Guillain Barre Syndrome, polymyositis/dermatomyositis | Hospital use only | |||||
Immune Globulin | INJECTION | 200 mg/ml | PARENTERAL | J06BA01 | Treatment of multifocal motor neuropathy, Guillain Barre Syndrome, polymyositis/dermatomyositis | Hospital use only | Subcutaneous | 1395/03/19 | |||
Immune Globulin | INJECTION | 120 mg/ml | INTRAVENOUS | J06BA02 | Treatment of multifocal motor neuropathy, Guillain Barre Syndrome, polymyositis/dermatomyositis | Hospital use only | |||||
Immune Globulin | INJECTION | 50 mg/ml | INTRAVENOUS | J06BA02 | Treatment of multifocal motor neuropathy, Guillain Barre Syndrome, polymyositis/dermatomyositis | Hospital use only | |||||
Indapamide | TABLET, EXTENDED RELEASE | 1.5 mg | ORAL | C03BA11 | 1383/08/10 | ||||||
Indapamide | TABLET | 2.5 mg | ORAL | C03BA11 | 1395/12/22 | ||||||
Indium [111In] Ibritumomab Tiuxetan | INJECTION, SOLUTION | 5 mCi | PARENTERAL | V09 | Radiopharmaceuticals | 1389/10/25 | |||||
Indium [111In]-Oxyquinoline, (111In-Oxine) | INJECTION, SOLUTION | 1 mCi/ml | Not for direct patient administration, only for preparation of radiolabeled cells | V09 | Radiopharmaceuticals | 1389/10/25 | |||||
Indium [111In]-Pentetate, (111In-DTPA) | INJECTION, SOLUTION | 1 mCi/ml | PARENTERAL | V09AX01 | Radiopharmaceuticals | 1389/10/25 | |||||
Indocyanine Green | INJECTION, POWDER | 25 mg | PARENTERAL | V04CX | Orphan medicines | 1385/06/14 | |||||
Indometacin | SUPPOSITORY | 100 mg | RECTAL | M01AB01 | |||||||
Indometacin | CAPSULE | 25 mg | ORAL | M01AB01 | |||||||
Indometacin | INJECTION, SOLUTION | 25 mg/ml | PARENTERAL | M01AB01 | For diagnosis of PDA (Patent ductus arterious) | Hospital use only | 1390/03/07 | ||||
Indometacin | SUPPOSITORY | 50 mg | RECTAL | M01AB01 | 1368/03/07 | ||||||
Indometacin | CAPSULE, EXTENDED RELEASE | 75 mg | ORAL | M01AB01 | |||||||
Indometacin | TABLET, EXTENDED RELEASE | 75 mg | ORAL | M01AB01 | |||||||
Indometacin | TABLET, EXTENDED RELEASE | 80 mg | ORAL | M01AB01 | |||||||
Infliximab | INJECTION, POWDER | 100 mg | PARENTERAL | L04AB02 | Treatment of moderately to severely active Crohn's disease for the reduction of the signs and symptoms, in patients who have an inadequate response to conventional therapy; and treatment of patients with fistulizing Crohn's disease. Treatment of chronic sarcoidosis Treatment of giant cell arteritis | Orphan medicines | 1384/08/08 | ||||
Influenza Virus | INJECTION | PARENTERAL | J07BB01 | vaccine | |||||||
Insulin (Regular) | INJECTION | 100 IU/ml | PARENTERAL | A10AB01 | 1385/08/17 | ||||||
Insulin Aspart | INJECTION, SUSPENSION | 100 IU/ml | PARENTERAL | A10AB05 | 30% soluble Insulin Aspart + 70% Insulin Aspart crystallised with Protamine | 1384/12/09 | |||||
Insulin Aspart | INJECTION, SOLUTION | 100 IU/ml | PARENTERAL | A10AB05 | 1384/12/09 | ||||||
Insulin Biphasic Isophane | INJECTION, SUSPENSION | 100 IU/ml | PARENTERAL | A10AB30 | ( Isophane Insulin 75% + Insulin Regular 25%) | 1385/12/02 | |||||
Insulin Biphasic Isophane | INJECTION | 100 IU/ml | PARENTERAL | A10AB30 | Isophane Insulin 70% + Insulin Reg 30% | ||||||
Insulin Detemir | INJECTION, SOLUTION | 100 IU/ml | PARENTERAL | A10AE05 | 1392/12/11 | ||||||
Insulin Glargine | INJECTION | 100 IU/ml | PARENTERAL | A10AE01 | Diabetes Mellitus | Recombinant | 1385/10/05 | ||||
Insulin Glargine | INJECTION | 300 IU/ml | PARENTERAL | A10AE04 | Diabetes Mellitus | Recombinant | 1394/11/13 | ||||
Insulin Glulisin | INJECTION, SOLUTION | 100 IU/ml | PARENTERAL | A10AB06 | 1392/12/11 | ||||||
Insulin Isophane | INJECTION | 100 IU/ml | PARENTERAL | A10AE01 | NPH | 1385/08/17 | |||||
Insulin Lispro | INJECTION, SOLUTION | 100 IU/ml | PARENTERAL | A10AB04 | Diabetes Mellitus | Human Recombinant | 1396/12/08 | ||||
Insulin Biphasic Lispro | INJECTION, SUSPENSION | 100 IU/ml | PARENTERAL | A10AD04 | Insulin Lispro 25% + Insulin Lispro Protamine 75% | Diabetes Mellitus | Human Recombinant | 1396/12/08 | |||
Insulin Biphasic Lispro | INJECTION, SUSPENSION | 100 IU/ml | PARENTERAL | A10AD04 | Insulin Lispro 50% + Insulin Lispro Protamine 50% | Diabetes Mellitus | Human Recombinant | 1396/12/08 | |||
Insulin Zinc | INJECTION | 100 IU/ml | PARENTERAL | A10AE01 | |||||||
Interferon Alfa-2a | INJECTION | 6 Million U/ml | PARENTERAL | L03AB04 | For the concomitant administration with fluorouracil for the treatment of advanced colorectal cancer. Treatment of AIDS related Kaposi's sarcoma. For the treatment of metastatic malignant melanoma in combination with Teceleukin. | ||||||
Interferon Alfa-2a | INJECTION | 9 Million U/ml | PARENTERAL | L03AB04 | For the concomitant administration with fluorouracil for the treatment of advanced colorectal cancer. Treatment of AIDS related Kaposi's sarcoma. For the treatment of metastatic malignant melanoma in combination with Teceleukin. | ||||||
Interferon Alfa-2b | INJECTION, POWDER | 10 Million U | PARENTERAL | L03AB05 | Treatment of AIDS-related Kaposi's sarcoma. Treatment of acute hepatitis B. Treatment of primary malignant brain tumors. Treatment of carcinoma in situ of the urinary bladder. Treatment of chronic delta hepatitis. | ||||||
Interferon Alfa-2b | INJECTION | 10MillionU/ml | PARENTERAL | L03AB05 | Treatment of AIDS-related Kaposi's sarcoma. Treatment of acute hepatitis B. Treatment of primary malignant brain tumors. Treatment of carcinoma in situ of the urinary bladder. Treatment of chronic delta hepatitis. | ||||||
Interferon Alfa-2b | INJECTION | 3 Million U | PARENTERAL | L03AB05 | Treatment of AIDS-related Kaposi's sarcoma. Treatment of acute hepatitis B. Treatment of primary malignant brain tumors. Treatment of carcinoma in situ of the urinary bladder. Treatment of chronic delta hepatitis. | 1391/02/25 | |||||
Interferon Alfa-2b | INJECTION | 5 Million U | PARENTERAL | L03AB05 | Treatment of AIDS-related Kaposi's sarcoma. Treatment of acute hepatitis B. Treatment of primary malignant brain tumors. Treatment of carcinoma in situ of the urinary bladder. Treatment of chronic delta hepatitis. | 1391/02/25 | |||||
Interferon Beta-1a | INJECTION | 12 Million U, 44 mcg | PARENTERAL | L03AB07 | For the systemic treatment of cutaneous malignant melanoma. Treatment of symptomatic patients with AIDS including all patients with CD4 T-cell counts less than 200 cells per mm3. Treatment of acute non-A, non-B hepatitis. | ||||||
Interferon Beta-1a | INJECTION | 12 MillionU/ml, 30 mcg | PARENTERAL | L03AB07 | For the systemic treatment of cutaneous M Melanoma Treatment of symptomatic patients with AIDS including all patients with CD4 T-cell counts less than 200 cells Treatment of acute non-A, non-B hepatitis. | ||||||
Interferon Beta-1a | INJECTION, POWDER | 6 Million U, 30 mcg | PARENTERAL | L03AB07 | For the systemic treatment of cutaneous M Melanoma Treatment of symptomatic patients with AIDS including all patients with CD4 T-cell counts less than 200 cells Treatment of acute non-A, non-B hepatitis. | ||||||
Interferon Beta-1b | INJECTION, POWDER | 250 mcg | PARENTERAL | L03AB07 | For the systemic treatment of cutaneous M Melanoma Treatment of symptomatic patients with AIDS including all patients with CD4 T-cell counts less than 200 cells Treatment of acute non-A, non-B hepatitis. | ||||||
Interferon Beta-1b | INJECTION, POWDER | 9.6 Million U, 300 mcg | PARENTERAL | L03AB08 | For the systemic treatment of cutaneous M Melanoma Treatment of symptomatic patients with AIDS including all patients with CD4 T-cell counts less than 200 cells Treatment of acute non-A, non-B hepatitis. | ||||||
Interferon Gamma-1b | INJECTION | 100 mcg | PARENTERAL | L03AB03 | renal cell carcinoma/chronic granuloma+ous diseasea/delaying time to dieseas progressin in patients with severe, malignant osteoperosisa, diopathic pulomonary fibrosis | ||||||
Iobenguane [123I], (123I-MIBG) | INJECTION, SOLUTION | 10 mCi | PARENTERAL | V09 | Radiopharmaceuticals | 1389/10/25 | |||||
Iobenguane [131I], (131I-MIBG) | INJECTION, SOLUTION | (50-300) mCi | PARENTERAL | V10XA02 | Radiopharmaceuticals | 1389/10/25 | |||||
Iobenguane [131I], (131I-MIBG) | INJECTION, SOLUTION | 1 mCi | PARENTERAL | V09IX02 | Radiopharmaceuticals | 1389/10/25 | |||||
Iodide [131I] Sodium | SOLUTION | (50-200) mCi | ORAL | V09FX03 | Radiopharmaceuticals | 1383/09/22 | |||||
Iodide [131I] Sodium | CAPSULE | (5-100) micCi | ORAL | V09FX03 | Radiopharmaceuticals | 1383/09/22 | |||||
Iodide [131I] Sodium | CAPSULE | (5-200) mCi | ORAL | V09FX03 | Radiopharmaceuticals | 1383/09/22 | |||||
Iodixanol | INJECTION | 150 mgI/ml | PARENTERAL | V08AB09 | 1379/12/21 | ||||||
Iodixanol | INJECTION | 270 mgI/ml | PARENTERAL | V08AB09 | 1379/12/21 | ||||||
Iodixanol | INJECTION | 320 mgI/ml | PARENTERAL | V08AB09 | 1379/12/21 | ||||||
Iodoquinol | TABLET | 210 mg | ORAL | G01AC01 | Diiodohydroxyquinoline | 1367/12/14 | |||||
Iohexol | INJECTION | 240 mgI/ml | PARENTERAL | V08AB02 | 518 mg/ml | 1367/09/20 | |||||
Iohexol | INJECTION | 300 mgI/ml | PARENTERAL | V08AB02 | 647 mg/ml | 1371/04/14 | |||||
Iohexol | INJECTION | 350 mgI/ml | PARENTERAL | V08AB02 | 755 mg/ml | 1371/07/19 | |||||
Iopamidol | INJECTION | 300 mgI/ml | PARENTERAL | V08AB04 | 612mg/ml | 1383/11/04 | |||||
Iopamidol | SOLUTION | 300mgI/ml | ORAL | V08AB04 | 1382/04/01 | ||||||
Iopamidol | INJECTION | 370 mgI/ml | PARENTERAL | V08AB04 | 755 mg/ml | 1383/11/04 | |||||
Iopanoic Acid | TABLET | 500 mg | ORAL | V08AC06 | |||||||
Iopromide | INJECTION | 240 mgI/ml | PARENTERAL | V08AB05 | 1372/08/23 | ||||||
Iopromide | INJECTION | 300 mgI/ml | PARENTERAL | V08AB05 | 1386/11/08 | ||||||
Iopromide | INJECTION | 300 mgI/ml | PARENTERAL | V08AB05 | 1372/08/23 | ||||||
Iopromide | INJECTION | 370 mgI/ml | PARENTERAL | V08AB05 | 1372/08/23 | ||||||
Iotroxate | Meglumine | INJECTION | 50 mgI/ml | PARENTERAL | V08AC02 | ||||||
Ipecac | SYRUP | 0.14% | ORAL | V03AB01 | 0.14%Total Alkaloids | 1369/10/30 | |||||
Ipratropium | Bromide | INHALER | 20 mcg/dose | RESPIRATORY | R03BB01 | ||||||
Ipratropium | Bromide | NEBULISATION | 250 mcg/ml | RESPIRATORY | R03BB01 | Nebulisation | |||||
Ipratropium | Bromide | INHALER | 40 mcg/dose | RESPIRATORY | R03BB01 | 1376/06/09 | |||||
Ipratropium | Bromide | SPRAY, METERED | 21 mcg/spray | NASAL | R03BB01 | 1396/03/13 | |||||
Ipratropium | Bromide | SPRAY, METERED | 42 mcg/spray | NASAL | R03BB01 | 1396/03/13 | |||||
Ipratropium+Fenoterol | AEROSOL, METERED | RESPIRATORY | R03AL01 | (Ipratropium bromide 20 mcg + Fenoterol hydrobromide 50 mcg)/dose | HFA only | 1389/08/24 | |||||
Ipratropium+Salbutamol | AEROSOL, METERED | RESPIRATORY | R03AL02 | (Ipratropium bromide 20 mcg + Salbutamol ( As sulfate ) 100 mcg)/dose | |||||||
Ipratropium+Salbutamol | NEBULISATION | RESPIRATORY | R03AL02 | (Ipratropium bromide 200 mcg + Salbutamol ( As sulfate ) 1 mg)/ml | 1387/03/08 | ||||||
Irinotecan | HCl | INJECTION, POWDER | 100mg | INTRAVENOUS DRIP | L01XX19 | ||||||
Irinotecan | HCl | INJECTION | 20 mg/ml | PARENTERAL | L01XX19 | 1390/01/29 | |||||
Irinotecan | HCl | INJECTION, POWDER | 40mg | INTRAVENOUS DRIP | L01XX19 | ||||||
Iron | as isomaltoside | INJECTION | 100mg/ml | PARENTERAL | B03AC | Hospital use only | for local production only | 1391/05/02 | |||
Iron | As Sucrose | INJECTION | 20 mg/ml | INTRAVENOUS | B03AC03 | Hospital use only | |||||
Iron | SOLUTION/ DROPS | 25 mg/ml | ORAL | B03AA02 | OTC medicines | ||||||
Iron | As Sorbitol | INJECTION | 50 mg/ml | INTRAMUSCULAR | B03AC03 | Hospital use only | 1364/03/12 | ||||
Isocarboxazid | TABLET | 10 mg | ORAL | N06AF01 | 1371/06/08 | ||||||
Isoflurane | INHALANT | RESPIRATORY | N01AB06 | Hospital use only | 1363/05/28 | ||||||
Isoniazid | TABLET | 100 mg | ORAL | J04AC01 | |||||||
Isoniazid | INJECTION | 100 mg/ml | PARENTERAL | J04AC01 | Hospital use only | ||||||
Isoniazid | TABLET | 300 mg | ORAL | J04AC01 | |||||||
Isoniazid+Prazinamide+Rifampin | TABLET | ORAL | J04AM05 | Isoniazid 50 mg + Pyrazinamide 300 mg + Rifampin 120 mg | For Health Dept. of MOH only | 1378/05/10 | |||||
Isoniazid+Rifampin | TABLET | ORAL | J04AM02 | Isoniazid 75 mg + Rifampin 150 mg | For Health Dept. of MOH only | ||||||
Isopropyl Alcohol | BULK | V03 | Bulk medicines | ||||||||
Isoproterenol | HCl | INJECTION | 0.2 mg/ml | PARENTERAL | R03CB01 | Hospital use only | |||||
Isoproterenol | HCl | INJECTION | 1 mg/ml | PARENTERAL | R03CB01 | Hospital use only | |||||
Isosorbide | Dinitrate | SPRAY | 1.25mg/Dose | TOPICAL | C01DA08 | 1387/05/16 | |||||
Isosorbide | Dinitrate | TABLET | 10 mg | ORAL | C01DA08 | ||||||
Isosorbide | Dinitrate | TABLET, EXTENDED RELEASE | 40 mg | ORAL | C01DA08 | 1364/11/06 | |||||
Isosorbide | Dinitrate | TABLET | 5 mg | SUBLINGUAL | C01DA08 | ||||||
Isosorbide | Mononitrate | CAPSULE, EXTENDED RELEASE | 50 mg | ORAL | C01DA08 | Modified(30/70) | 1386/07/18 | ||||
Isosorbide | Mononitrate | TABLET, EXTENDED RELEASE | 60 mg | ORAL | C01DA08 | ||||||
Isotretinoin | GEL | 0.05% | TOPICAL | D10AD04 | 1384/04/20 | ||||||
Isotretinoin | CAPSULE | 10 mg | ORAL | D10BA01 | 1385/11/04 | ||||||
Isotretinoin | CAPSULE, LIQUID FILLED | 16 mg | ORAL | D10BA01 | 1389/09/22 | ||||||
Isotretinoin | CAPSULE, LIQUID FILLED | 20 mg | ORAL | D10BA01 | |||||||
Isotretinoin | CAPSULE, LIQUID FILLED | 8 mg | ORAL | D10BA01 | 1389/09/22 | ||||||
Isoxsuprine | HCl | TABLET | 10 mg | ORAL | C04AA01 | ||||||
Itraconazole | CAPSULE | 100 mg | ORAL | J02AC02 | 1374/04/18 | ||||||
Itraconazole | SOLUTION | 10 mg/ml | ORAL | J02AC02 | 1395/10/08 | ||||||
Ivabradine | As HCl | TABLET | 5 mg | ORAL | C01EB17 | Chronic heart failure, Angina pectoris | 1396/11/29 | ||||
Ivabradine | As HCl | TABLET | 7.5 mg | ORAL | C01EB17 | Chronic heart failure, Angina pectoris | 1396/11/29 | ||||
Ivermectin | TABLET | 3 mg | ORAL | P02CF01 | Anthelmintic | 1394/11/13 | |||||
Ivermectin | TABLET | 6 mg | ORAL | P02CF01 | Anthelmintic | 1394/11/13 | |||||
Ivermectin | LOTION | 0.50% | TOPICAL | P02CF01 | W/W | 1396/09/12 | |||||
Ivermectin | CREAM | 1.00% | TOPICAL | D11AX22 | Inflammatory lesions of rosacea | W/W | 1397/02/02 | ||||
Ketamine | As HCl | INJECTION | 50 mg/ml | PARENTERAL | N01AX03 | Hospital use only | 1372/11/17 | ||||
Ketoconazole | CREAM | 2% | TOPICAL | D01AC08 | 1368/11/15 | ||||||
Ketoconazole | LOTION | 2% | TOPICAL | D01AC08 | 1387/02/18 | ||||||
Ketoconazole | SHAMPOO | 2% | TOPICAL | D01AC08 | 1372/11/17 | ||||||
Ketoconazole | TABLET | 200 mg | ORAL | J02AB02 | 1368/11/15 | ||||||
Ketoconazole | BULK | V03 | Bulk medicines | 1376/12/10 | |||||||
Ketorolac | Trometamol | SOLUTION/ DROPS | 0.50% | OPHTHALMIC | S01BC05 | 1386/11/03 | |||||
Ketorolac | Trometamol | SOLUTION/ DROPS | 0.45% | OPHTHALMIC | S01BC05 | 1396/03/13 | |||||
Ketorolac | Trometamol | TABLET | 10 mg | ORAL | M01AB15 | for local production only | 1389/05/30 | ||||
Ketorolac | Trometamol | INJECTION | 15 mg/ml | PARENTERAL | M01AB15 | 1392/05/29 | |||||
Ketorolac | Trometamol | INJECTION, SOLUTION | 30 mg/ml | PARENTERAL | M01AB15 | Hospital use only | 1389/05/30 | ||||
Ketotifen | As Fumarate | SOLUTION/ DROPS | 0.03% | OPHTHALMIC | S01GX08 | 1386/03/23 | |||||
Ketotifen | As Fumarate | TABLET | 1 mg | ORAL | R06AX17 | 1373/12/21 | |||||
Ketotifen | As Fumarate | SOLUTION/ DROPS | 1 mg/ ml | ORAL | R06AX17 | 1388/08/20 | |||||
Ketotifen | As Fumarate | SYRUP | 1 mg/5 ml | ORAL | R06AX17 | 1373/12/21 | |||||
Kojic Acid | BULK | V03 | Bulk medicines | ||||||||
Labetalol | HCl | INJECTION | 5 mg/ml | PARENTERAL | C07AG01 | Hospital use only | 1386/12/07 | ||||
Lacosamide | TABLET | 50 mg | ORAL | N03AX18 | Control of epilepsies | 1397/07/28 | |||||
Lacosamide | TABLET | 100 mg | ORAL | N03AX18 | Control of epilepsies | 1397/07/28 | |||||
Lacosamide | TABLET | 150 mg | ORAL | N03AX18 | Control of epilepsies | 1397/07/28 | |||||
Lacosamide | TABLET | 200 mg | ORAL | N03AX18 | Control of epilepsies | 1397/07/28 | |||||
Lactic Acid | BULK | V03 | Bulk medicines | ||||||||
Lactose | BULK | V03 | Bulk medicines | ||||||||
Lactulose | POWDER, FOR SOLUTION | 10 g | ORAL | A06AD11 | |||||||
Lactulose | SYRUP | 10 g/15 ml | ORAL | A06AD11 | |||||||
Lamivudine | SOLUTION | 10 mg/ml | ORAL | J05AF05 | |||||||
Lamivudine | TABLET | 100 mg | ORAL | J05AF05 | 1379/06/20 | ||||||
Lamivudine | TABLET | 150 mg | ORAL | J05AF05 | |||||||
Lamivudine+Zidovudine | TABLET | ORAL | J05AR01 | Lamivudine 150 mg+Zidovudine300 mg | For Health Dept. of MOH only | 1393/10/14 | |||||
Lamotrigine | SOLUTION | 10 mg/ml | ORAL | N03AX09 | |||||||
Lamotrigine | TABLET | 100 mg | ORAL | N03AX09 | |||||||
Lamotrigine | TABLET | 25 mg | ORAL | N03AX09 | |||||||
Lamotrigine | TABLET | 50 mg | ORAL | N03AX09 | |||||||
Lanolin | BULK | V03 | Bulk medicines | ||||||||
Lanreotide | As Acetate | INJECTION, SOLUTION, EXTENDED RELEASE | 120 mg | PARENTERAL | H01CB03 | 1393/06/02 | |||||
Lanreotide | As Acetate | INJECTION, SOLUTION, EXTENDED RELEASE | 60 mg | PARENTERAL | H01CB03 | 1393/06/02 | |||||
Lanreotide | As Acetate | INJECTION, SOLUTION, EXTENDED RELEASE | 90 mg | PARENTERAL | H01CB03 | 1393/06/02 | |||||
Lansoprazole | CAPSULE, DELAYED RELEASE | 15 mg | ORAL | A02BC03 | 1387/12/21 | ||||||
Lansoprazole | CAPSULE, DELAYED RELEASE | 30 mg | ORAL | A02BC03 | 1387/12/21 | ||||||
Laronidase | INJECTION | 2.9mg/ml | PARENTERAL | A16AB05 | for treatment of mocopolysacoidosis | Orphan medicines | 1387/11/06 | ||||
Latanoprost | SOLUTION | 50 mcg/ml | OPHTHALMIC | S01EE01 | 1379/11/09 | ||||||
Latanoprost+Timolol | SOLUTION/ DROPS | OPHTHALMIC | S01ED51 | Latanoprost 50 mcg + Timolol (As Maleate) 5 mg | 1387/05/06 | ||||||
L-Carnitine | TABLET, CHEWABLE | 1 g | ORAL | A16AA01 | |||||||
L-Carnitine | As L-Tartrate | TABLET, CHEWABLE | 1 g | ORAL | A16AA01 | 1388/08/20 | |||||
L-Carnitine | SOLUTION | 100 mg/ml | ORAL | A16AA01 | |||||||
L-Carnitine | INJECTION | 200 mg/ml | PARENTERAL | A16AA01 | Hospital use only | ||||||
L-Carnitine | TABLET | 250 mg | ORAL | A16AA01 | |||||||
L-Carnitine | As L-Tartrate | TABLET | 250 mg | ORAL | A16AA01 | 1388/08/20 | |||||
L-Carnitine | TABLET | 330 mg | ORAL | A16AA01 | 1388/10/30 | ||||||
Ledipasvir+Sofosbuvir | TABLET | ORAL | J05AX | Ledipasvir 90 mg+Sofosbuvir 400 mg | Hepatitis C infection | 1394/03/31 | |||||
Leflunomide | TABLET | 10 mg | ORAL | L04AA13 | Arthritis rheumatoid | 1395/12/22 | |||||
Leflunomide | TABLET | 20 mg | ORAL | L04AA13 | Arthritis rheumatoid | 1395/12/22 | |||||
Leishmanin | SUSPENSION | INTRADERMAL | V04CX | 1386/11/08 | |||||||
Lenalidomide | CAPSULE | 10 mg | ORAL | L04AX04 | for multiple myolema; and myeloma depylastic | 1393/02/07 | |||||
Lenalidomide | CAPSULE | 15 mg | ORAL | L04AX04 | for multiple myolema; and myeloma depylastic | 1393/02/07 | |||||
Lenalidomide | CAPSULE | 25 mg | ORAL | L04AX04 | for multiple myolema; and myeloma depylastic | 1393/02/07 | |||||
Lenalidomide | CAPSULE | 5 mg | ORAL | L04AX04 | for multiple myolema; and myeloma depylastic | 1393/02/07 | |||||
Letrozole | TABLET | 2.5 mg | ORAL | L02BG04 | 1381/06/18 | ||||||
Leucovorin | INJECTION | 125mg/ml | PARENTERAL | V03AF03 | For rescue use after high dose methotrexate therapy in the treatment of osteosarcoma. | ||||||
Leucovorin | INJECTION | 3 mg/ml | PARENTERAL | V03AF03 | For rescue use after high dose methotrexate therapy in the treatment of osteosarcoma. | ||||||
Leucovorin | INJECTION, POWDER | 30 mg | PARENTERAL | V03AF03 | For rescue use after high dose methotrexate therapy in the treatment of osteosarcoma. | ||||||
Leuprorelin | Acetate | INJECTION, POWDER | 3.75 mg | PARENTERAL | L02AE02 | Treatment of central precocious puberty. | |||||
Leuprorelin | Acetate | INJECTION, POWDER, EXTENDED RELEASE | 3.75 mg | PARENTERAL | L02AE02 | Prostate Cancer | 1396/12/23 | ||||
Leuprorelin | Acetate | INJECTION, POWDER, EXTENDED RELEASE | 7.5 mg | PARENTERAL | L02AE02 | Prostate Cancer | 1387/02/04 | ||||
Leuprorelin | Acetate | INJECTION, POWDER, EXTENDED RELEASE | 11.25 mg | PARENTERAL | L02AE02 | Prostate Cancer | 1396/12/23 | ||||
Leuprorelin | Acetate | INJECTION, POWDER, EXTENDED RELEASE | 22.5 mg | PARENTERAL | L02AE02 | Prostate Cancer | 1394/07/05 | ||||
Leuprorelin | Acetate | INJECTION, POWDER, EXTENDED RELEASE | 45 mg | PARENTERAL | L02AE02 | Prostate Cancer | 1395/05/02 | ||||
Levamisole | As HCl | SYRUP | 40 mg/5ml | ORAL | P02CE01 | ||||||
Levamisole | As HCl | TABLET | 50 mg | ORAL | P02CE01 | ||||||
Levetiracetam | INJECTION, SOLUTION, CONCENTRATE | 100 mg/ml | PARENTERAL | N03AX14 | 1392/09/25 | ||||||
Levetiracetam | INJECTION, SOLUTION | 500 mg/100 ml | PARENTERAL | N03AX14 | In Sodium Chloride | 1395/04/09 | |||||
Levetiracetam | INJECTION, SOLUTION | 1500 mg/100 ml | PARENTERAL | N03AX14 | In Sodium Chloride | 1395/12/22 | |||||
Levetiracetam | TABLET | 1000 mg | ORAL | N03AX14 | 1391/06/13 | ||||||
Levetiracetam | TABLET | 250 mg | ORAL | N03AX14 | 1387/12/21 | ||||||
Levetiracetam | TABLET | 500 mg | ORAL | N03AX14 | 1387/12/21 | ||||||
Levetiracetam | SOLUTION | 100 mg/ml | ORAL | N03AX14 | 1388/02/30 | ||||||
Levetiracetam | TABLET | 750 mg | ORAL | N03AX14 | 1388/08/20 | ||||||
Levocetirizine | DiHCl | TABLET | 5 mg | ORAL | R06AE09 | 1386/09/07 | |||||
Levodopa | TABLET | 500 mg | ORAL | N04BA01 | |||||||
Levodopa+ Carbidopa+ Entacapon | TABLET | ORAL | N04BA03 | Levodopa 100mg+ Carbidopa 25 mg+ Entacapon 200 mg | 1387/12/21 | ||||||
Levodopa+ Carbidopa+ Entacapon | TABLET | ORAL | N04BA03 | Levodopa 125mg+ Carbidopa31.25 mg+ Entacapon 200 mg | 1389/8/24 | ||||||
Levodopa+ Carbidopa+ Entacapon | TABLET | ORAL | N04BA03 | Levodopa 150mg+ Carbidopa 37.5 mg+ Entacapon 200 mg | 1387/12/21 | ||||||
Levodopa+ Carbidopa+ Entacapon | TABLET | ORAL | N04BA03 | Levodopa 200mg+ Carbidopa 50 mg+ Entacapon 200 mg | 1389/08/24 | ||||||
Levodopa+ Carbidopa+ Entacapon | TABLET | ORAL | N04BA03 | Levodopa 50mg+ Carbidopa 12.5mg+ Entacapon 200 mg | 1387/12/21 | ||||||
Levodopa+ Carbidopa+ Entacapon | TABLET | ORAL | N04BA03 | Levodopa 75mg+ Carbidopa 18.75 mg+ Entacapon 200 mg | 1389/08/24 | ||||||
Levodopa+Benserazide | TABLET | ORAL | N04BA02 | Levodopa 100 mg+Benserazide (as Hydrochloride) 25 | 1365/11/05 | ||||||
Levodopa+Benserazide | TABLET | ORAL | N04BA02 | Levodopa 200 mg+Benserazide (as Hydrochloride) 50 | |||||||
Levodopa+Benserazide | TABLET | ORAL | N04BA02 | Levodopa 50 mg+Benserazide (as Hydrochloride) 12.5 | 1365/11/05 | ||||||
Levodopa+Carbidopa | TABLET | ORAL | N04BA02 | Levodopa 100 mg+Carbidopa (as Monohydrate) 10 mg | |||||||
Levodopa+Carbidopa | TABLET | ORAL | N04BA02 | Levodopa 100 mg+Carbidopa (as Monohydrate) 25 mg | |||||||
Levodopa+Carbidopa | TABLET, EXTENDED RELEASE | ORAL | N04BA02 | Levodopa 100 mg+Carbidopa (as Monohydrate) 25 mg | 1392/05/29 | ||||||
Levodopa+Carbidopa | TABLET, EXTENDED RELEASE | ORAL | N04BA02 | Levodopa 200 mg+Carbidopa (as Monohydrate) 50 mg | 1392/05/29 | ||||||
Levodopa+Carbidopa Forte | TABLET | ORAL | N04BA02 | Levodopa 250 mg+Carbidopa (as Monohydrate) 25 mg | |||||||
Levofloxacin | Hemihydrate | SOLUTION/ DROPS | 0.50% | OPHTHALMIC | S01AX19 | 1390/01/29 | |||||
Levofloxacin | TABLET | 250 mg | ORAL | J01MA12 | for local production only | 1389/10/25 | |||||
Levofloxacin | INJECTION, SOLUTION CONCENTRATE | 25mg/ml | PARENTRAL | J01MA12 | Hospital use only. | 1392/04/04 | |||||
Levofloxacin | TABLET | 500 mg | ORAL | J01MA12 | for local production only | 1389/10/25 | |||||
Levofloxacin | INJECTION , SOLUTION | 5 mg/ml | INTRAVENOUS DRIP | J01MA12 | Hospital use only | 1391/05/02 | |||||
Levofloxacin | TABLET | 750 mg | ORAL | J01MA12 | for local production only | 1389/10/25 | |||||
Levonorgestrel | TABLET | 1.5 mg | ORAL | G03AC03 | OTC medicines | 1388/09/04 | |||||
Levonorgestrel | IMPLANT | 2 X 75 mg | TRANSDERMAL | G03AC03 | for local production only | 1390/01/29 | |||||
Levonorgestrel | TABLET | 30 mcg | ORAL | G03AC03 | |||||||
Levonorgestrel | IMPLANT | 6 X 36 mg | TRANSDERMAL | G03AC03 | 1371/08/24 | ||||||
Levonorgestrel | TABLET | 750 mcg | ORAL | G03AC03 | OTC medicines | 1381/06/31 | |||||
Levothyroxine | Sodium | CAPSULE, LIQUID FILLED | 100 mcg | ORAL | H03AA01 | 1386/07/18 | |||||
Levothyroxine | Sodium | TABLET | 100 mcg | ORAL | H03AA01 | ||||||
Levothyroxine | Sodium | SOLUTION | 20 mcg/ml | ORAL | H03AA01 | 1396/02/02 | |||||
Levothyroxine | Sodium | CAPSULE, LIQUID FILLED | 50 mcg | ORAL | H03AA01 | 1386/07/18 | |||||
Levothyroxine | Sodium | TABLET | 50 mcg | ORAL | H03AA01 | 1378/08/23 | |||||
Levothyroxine | Sodium | TABLET | 75 mcg | ORAL | H03AA01 | 1386/04/27 | |||||
Levothyroxine | Sodium | TABLET | 25 mcg | ORAL | H03AA01 | 1395/06/24 | |||||
Levothyroxine | Sodium | TABLET | 150 mcg | ORAL | H03AA01 | 1395/06/24 | |||||
Lidocaine | HCl | INJECTION | 1% | PARENTERAL | C01BB01 | Hospital use only | |||||
Lidocaine | HCl | INJECTION | 2% | PARENTERAL | C01BB01 | Cartridge (carpool) | |||||
Lidocaine | HCl | INJECTION | 2% | PARENTERAL | C01BB01 | Hospital use only | |||||
Lidocaine | HCl | GEL | 2% | TOPICAL | D04AB01 | OTC medicines | |||||
Lidocaine | CREAM | 4% | TOPICAL | D04AB01 | OTC medicines | 1396/09/19 | |||||
Lidocaine | HCl | INJECTION, SOLUTION | 4% | PARENTERAL | N01BB52 | Hospital use only | 1368/07/16 | ||||
Lidocaine | HCl | SOLUTION | 4% | TOPICAL | D04AB01 | ||||||
Lidocaine | HCl | INJECTION | 5% | INTRASPINAL | N01BB52 | Lidocaine HCl 5%+Dextrose 7.5% | Hospital use only | 1362/09/27 | |||
Lidocaine | HCl | SPRAY | 6.50% | TOPICAL | D04AB01 | 1384/12/09 | |||||
Lidocaine | HCl | INJECTION, SOLUTION | 20% | PARENTERAL | C01BB01 | Hospital use only | |||||
Lidocaine | SPRAY | 10 mg/dose | TOPICAL | D04AB01 | 10% | 1386/11/08 | |||||
Lidocaine | PATCH | 5% | TOPICAL | D04AB01 | 1395/11/06 | ||||||
Lidocaine+Epinephrine | INJECTION | PARENTERAL | N01BB52 | (Lidocaine HCl 20mg+Epinephrine (As Bitartrate) 12.5 mcg)/ ml | Hospital use only | ||||||
Lidocaine+Epinephrine | INJECTION | PARENTERAL | N01BB52 | Lidocaine HCl 10mg+Epinephrine (As Bitartrate) 5mcg/ml | Hospital use only | ||||||
Lidocaine+Chlorhexidine | GEL | TOPICAL | N01BB52 | Lidocaine Hydrochloride 2%+Chlorhexidine Dihydrochloride 0.05% | 1384/12/09 | ||||||
Lidocaine+Hydrocortisone | OINTMENT | RECTAL | N01BB52 | Lidocaine 5%+Hydrocortisone Acetate 0.5% | 1368/08/07 | ||||||
Lidocaine+Prilocaine | CREAM | TOPICAL | N01BB52 | Lidocaine 2.5% + Prilocaine 2.5% | 1379/01/29 | ||||||
Lidocaine+Tetracaine | CREAM | TOPICAL | N01BB52 | Lidocaine7% + Tetracaine 7% | 1396/06/25 | ||||||
Linagliptin | TABLET | 5 mg | ORAL | A10BH05 | Type 2 Diabetes Mellitus | 1395/08/02 | |||||
Lindane | LOTION | 1% | TOPICAL | P03AB02 | |||||||
Lindane | SHAMPOO | 1% | TOPICAL | P03AB02 | |||||||
Linezolid | POWDER, FOR SUSPENSION | 100 mg/5ml | ORAL | J01XX08 | 1391/12/23 | ||||||
Linezolid | TABLET | 400 mg | ORAL | J01XX08 | 1391/12/23 | ||||||
Linezolid | TABLET | 600 mg | ORAL | J01XX08 | 1391/12/23 | ||||||
Linezolid | INJECTION, SOLUTION | 2 mg/ml | PARENTERAL | J01XX08 | Hospital use only | 1391/12/23 | |||||
Liothyronine | Sodium | TABLET | 25 mcg | ORAL | H03AA02 | ||||||
Lipid Infusion | INJECTION, SOLUTION | 10% | INTRAVENOUS DRIP | B05BA02 | |||||||
Lipid Infusion | INJECTION, SOLUTION | 20% | INTRAVENOUS DRIP | B05BA02 | Hospital use only | 1381/02/09 | |||||
Liraglutide | INJECTION, SOLUTION | 6 mg/ml | PARENTERAL | A10BX07 | Disposable pen | 1391/02/07 | |||||
Lisdexamfetamine | Mesilate | CAPSULE | 10 mg | ORAL | N06BA12 | ADHD | 1396/11/29 | ||||
Lisdexamfetamine | Mesilate | CAPSULE | 20 mg | ORAL | N06BA12 | ADHD | 1396/11/29 | ||||
Lisdexamfetamine | Mesilate | CAPSULE | 30 mg | ORAL | N06BA12 | ADHD | 1396/11/29 | ||||
Lisdexamfetamine | Mesilate | CAPSULE | 40 mg | ORAL | N06BA12 | ADHD | 1396/11/29 | ||||
Lisdexamfetamine | Mesilate | CAPSULE | 50 mg | ORAL | N06BA12 | ADHD | 1396/11/29 | ||||
Lisdexamfetamine | Mesilate | CAPSULE | 60 mg | ORAL | N06BA12 | ADHD | 1396/11/29 | ||||
Lisdexamfetamine | Mesilate | CAPSULE | 70 mg | ORAL | N06BA12 | ADHD | 1396/11/29 | ||||
Lisinopril | TABLET | 10 mg | ORAL | C09AA03 | 1382/03/04 | ||||||
Lisinopril | TABLET | 20 mg | ORAL | C09AA03 | 1382/03/04 | ||||||
Lisinopril | TABLET | 5 mg | ORAL | C09AA03 | 1382/03/04 | ||||||
Lisinopril+Hydrochlorothiazide | TABLET | ORAL | C09BA03 | Lisinopril 10mg + Hydrochlorothiazide 12.5mg | 1387/07/07 | ||||||
Lisinopril+Hydrochlorothiazide | TABLET | ORAL | C09BA03 | Lisinopril 20mg + Hydrochlorothiazide 12.5mg | 1387/07/07 | ||||||
Lisinopril+Hydrochlorothiazide | TABLET | ORAL | C09BA03 | Lisinopril 20mg + Hydrochlorothiazide 25mg | 1387/07/07 | ||||||
Lithium | Carbonate | TABLET | 300 mg | ORAL | N05AN01 | ||||||
Lithium | Carbonate | CAPSULE, EXTENDED RELEASE | 400 mg | ORAL | N05AN01 | ||||||
Lithium | Carbonate | TABLET, EXTENDED RELEASE | 400 mg | ORAL | N05AN01 | ||||||
Lithium | Carbonate | TABLET, EXTENDED RELEASE | 450 mg | ORAL | N05AN01 | 1397/09/27 | |||||
Lomustine | CAPSULE | 40 mg | ORAL | L01AD02 | |||||||
Loperamide | HCl | SOLUTION | 1 mg/5ml | ORAL | A07DA03 | OTC medicines | 1383/10/28 | ||||
Loperamide | HCl | CAPSULE | 2 mg | ORAL | A07DA03 | OTC medicines | |||||
Loperamide | HCl | TABLET | 2 mg | ORAL | A07DA03 | OTC medicines | |||||
Lopinavir+Ritonavir | SOLUTION | ORAL | J05AE | (Lopinavir 400mg+Ritonavir 100mg)/5ml | for Health Dept. of MOH only | 1386/04/11 | |||||
Lopinavir+Ritonavir | SOLUTION | ORAL | J05AR10 | (Lopinavir80 mg+Ritonavir 20 mg)/ml | for Health Dept. of MOH only | 1393/10/14 | |||||
Lopinavir+Ritonavir | TABLET | ORAL | J05AR10 | Lopinavir 100 mg+Ritonavir 25 mg | for Health Dept. of MOH only | 1393/10/14 | |||||
Lopinavir+Ritonavir | CAPSULE, LIQUID FILLED | ORAL | J05AR10 | Lopinavir 133.3mg+Ritonavir 33.3mg | for Health Dept. of MOH only | 1386/04/11 | |||||
Lopinavir+Ritonavir | TABLET | ORAL | J05AR10 | Lopinavir 200mg+Ritonavir 50mg | for Health Dept. of MOH only | 1386/04/11 | |||||
Loratadine | CAPSULE, LIQUID FILLED | 10 mg | ORAL | R06AX13 | for local production only | 1390/03/23 | |||||
Loratadine | TABLET | 10 mg | ORAL | R06AX13 | |||||||
Loratadine | TABLET, ORALLY DISINTEGRATING | 10 mg | ORAL | R06AX13 | 1385/02/12 | ||||||
Loratadine | SYRUP | 5 mg/5ml | ORAL | R06AX13 | |||||||
Loratadine+Pseudoephedrine | TABLET, EXTENDED RELEASE | ORAL | R01BA52 | Loratadine 5 mg + Pseudoephedrine Sulfate 120 mg | for local production only | 1389/07/17 | |||||
Lorazepam | TABLET | 1 mg | ORAL | N05BA06 | 1366/07/19 | ||||||
Lorazepam | TABLET | 2 mg | ORAL | N05BA06 | 1366/07/19 | ||||||
Lorazepam | INJECTION | 2 mg/ml | PARENTERAL | N05BA06 | Hospital use only | 1374/12/20 | |||||
Lorazepam | INJECTION | 4 mg/ml | PARENTERAL | N05BA06 | Hospital use only | 1382/09/03 | |||||
Lorenzos Oil | OIL | 500 ml | ORAL | Treatment of early stages of Adrenoleucodystrophy | 1387/11/06 | ||||||
Losartan | Potassium | TABLET | 12.5 mg | ORAL | C09CA01 | 1397/04/30 | |||||
Losartan | Potassium | TABLET | 25 mg | ORAL | C09CA01 | 1377/11/18 | |||||
Losartan | Potassium | TABLET | 50 mg | ORAL | C09CA01 | ||||||
Losartan | Potassium | TABLET | 100 mg | ORAL | C09CA01 | 1397/04/30 | |||||
Losartan+Hydrochlorothiazide | TABLET | ORAL | C03AX01 | Losartan Potassium 50mg + Hydrochlorothiazide 12.5mg | 1387/08/01 | ||||||
Loteprednol | Etabonate | SUSPENSION/ DROPS | 0.50% | OPHTHALMIC | S01BA14 | 1388/05/11 | |||||
Loteprednol | Etabonate | OINTMENT | 0.50% | OPHTHALMIC | S01BA14 | 1395/12/22 | |||||
Lovastatin | TABLET | 20 mg | ORAL | C10AA02 | 1369/10/16 | ||||||
Low Sodium Salt | POWDER | 5 g | ORAL | A12CA | [Kcl(670 mg-700 mg) + Nacl(300 mg-330 mg) + Mgco3 (4 mg-5 mg)] / g sachet | ||||||
Lutetium [177Lu]-DOTATATE | INJECTION, SOLUTION | 200 mCi | PARENTERAL | V10XX04 | Radiopharmaceuticals | 1397/02/18 | |||||
Lutetium [177Lu]-prostate specific membrane antigen, (177Lu-PSMA) | INJECTION, SOLUTION | 200 mCi | PARENTERAL | V10XX04 | Radiopharmaceuticals | 1397/02/18 | |||||
Lutetium [177Lu]-Ethylenediamine tetramethylene phosphonate, (177Lu-EDTMP) | INJECTION, SOLUTION | 1 mCi/kg | PARENTERAL | V10B | Radiopharmaceuticals | 1391/09/01 | |||||
Lutropin Alfa | INJECTION, POWDER | 75 IU | PARENTERAL | G03GA07 | 1385/12/02 | ||||||
Lynestrenol | TABLET | 0.5 mg | ORAL | G03AC02 | With obstetricians and General Practitioners prescriptions only | 1371/03/03 | |||||
Macitentan | TABLET | 10 mg | ORAL | C02KX04 | PAH | Pulmonologist prescription only, Local production only | 1397/10/04 | ||||
Mafenide | Acetate | CREAM | 112 mg/g | TOPICAL | D06BA03 | eq to 85 mg ( Base )/g | 1381/04/23 | ||||
Magnesium Hydroxide | SUSPENSION | 8% | ORAL | A02AA04 | OTC medicines | 1369/10/30 | |||||
Magnesium Oxide | TABLET | 400 mg | ORAL | A02AA04 | 250 mg elemental | ||||||
Magnesium Sulfate | INJECTION | 10% | PARENTERAL | A12CC02 | 1385/11/18 | ||||||
Magnesium Sulfate | INJECTION | 20% | PARENTERAL | A12CC02 | 1385/11/18 | ||||||
Magnesium Sulfate | INJECTION | 50% | PARENTERAL | A12CC02 | Hospital use only | 1385/11/18 | |||||
Mannitol | INJECTION, SOLUTION | 10% | INTRAVENOUS DRIP | B05BC01 | |||||||
Mannitol | INJECTION, SOLUTION | 20% | INTRAVENOUS DRIP | B05BC01 | Hospital use only | ||||||
Maprotiline | HCl | TABLET | 25 mg | ORAL | N06AA21 | 1371/06/08 | |||||
Maprotiline | HCl | TABLET | 75 mg | ORAL | N06AA21 | 1371/06/08 | |||||
Measles Vaccine | INJECTION | PARENTERAL | J07BD01 | (Rubeola) Virus live Attenuated vaccine | |||||||
Measles Immune globulin | INJECTION | 200 IU/ml | PARENTERAL | J06BB14 | |||||||
Measles+Mumps+Rubella Vaccine | INJECTION, POWDER, LYOPHILIZED | PARENTERAL | J07BD52 | MMR vaccine | |||||||
Measles+Rubella Vaccine | INJECTION, POWDER, LYOPHILIZED | PARENTERAL | J07BD53 | MR vaccine; Virus alive | |||||||
Mebendazole | TABLET, CHEWABLE | 100 mg | ORAL | P02CA01 | OTC medicines | ||||||
Mebeverine | HCl | TABLET | 135 mg | ORAL | A03AA04 | ||||||
Mebeverine | HCl | CAPSULE, EXTENDED RELEASE | 200 mg | ORAL | A03AA04 | 1385/08/17 | |||||
Medroxyprogesterone | Acetate | INJECTION | 100 mg/ml | PARENTERAL | L02AB02 | Treatment of immune thrombocytopenic purpura. | |||||
Medroxyprogesterone | Acetate | INJECTION | 150 mg/ml | PARENTERAL | G03AC06 | Treatment of immune thrombocytopenic purpura. | 1371/03/03 | ||||
Medroxyprogesterone | Acetate | INJECTION | 160 mg/ml | PARENTERAL | G03AC06 | Endometriosis, Contraception | 1396/05/28 | ||||
Medroxyprogesterone | Acetate | TABLET | 250 mg | ORAL | G03AC06 | With obstetricians and General Practitioners prescriptions only | 1363/06/11 | ||||
Medroxyprogesterone | Acetate | TABLET | 5 mg | ORAL | G03DA02 | With obstetricians and General Practitioners prescriptions only | |||||
Medroxyprogestrone+Estradiol | INJECTION | PARENTERAL | G03AA08 | Depot Medroxyprogesterone Acetate 25mg + Estradiol Cypionate 5mg/0.5ml | |||||||
Mefenamic Acid | CAPSULE | 250 mg | ORAL | M01AG01 | 1368/09/19 | ||||||
Mefloquine | TABLET | 250 mg | ORAL | P01BC02 | 1383/04/07 | ||||||
Megestrol | Acetate | TABLET | 15 mg | ORAL | L02AB01 | Treatment of anorexia, cachexia, or an unexplained significant weight loss in patients with a diagnosis of acquired immune deficiency syndrome. | |||||
Megestrol | Acetate | TABLET | 20 mg | ORAL | L02AB01 | Treatment of anorexia, cachexia, or an unexplained significant weight loss in patients with a diagnosis of acquired immune deficiency syndrome. | |||||
Megestrol | Acetate | TABLET | 40 mg | ORAL | L02AB01 | Treatment of anorexia, cachexia, or an unexplained significant weight loss in patients with a diagnosis of acquired immune deficiency syndrome. | |||||
Megestrol | Acetate | SUSPENSION | 40 mg/ml | ORAL | L02AB01 | Treatment of anorexia, cachexia, or an unexplained significant weight loss in patients with a diagnosis of acquired immune deficiency syndrome. | |||||
Meglumine | Antimonate | INJECTION | 300 mg/ml | PARENTERAL | P01CB01 | ||||||
Meglumine | Gadoterate | INJECTION | 377 mg/ml | PARENTERAL | V08CA01 | ||||||
Meglumine Compound | INJECTION | PARENTERAL | V08AA01 | Meglumine Diatrizoate 52.1%+Sodium Diatrizoate 7.9% | |||||||
Meglumine Compound | SOLUTION | ORAL | V08AA01 | Meglumine Diatrizoate 66%+Sodium Diatrizoate 10% | |||||||
Meglumine+Ioxaglate | INJECTION | PARENTERAL | V08AB03 | Meglumine Ioxaglate 393 mg/ml + Sodium Ioxaglate 196.5 mg/ml | |||||||
Meloxicam | TABLET | 15 mg | ORAL | M01AC06 | 1387/09/09 | ||||||
Meloxicam | TABLET | 7.5 mg | ORAL | M01AC06 | 1387/09/09 | ||||||
Meloxicam | TABLET, ORALLY DISINTEGRATING | 15 mg | ORAL | M01AC06 | 1396/02/02 | ||||||
Meloxicam | TABLET, ORALLY DISINTEGRATING | 7.5 mg | ORAL | M01AC06 | 1396/02/02 | ||||||
Melphalan | TABLET | 2 mg | ORAL | L01AA03 | |||||||
Melphalan | INJECTION, POWDER | 50 mg | PARENTERAL | L01AA03 | Treatment of patients with multiple myeloma for whom ORAL therapy is inappropriate. For use in hyperthermic regional limb perfusion to treat metastatic melanoma of the extremity. | 1373/08/01 | |||||
Memantine | HCl | TABLET | 10 mg | ORAL | N06DX01 | 1385/04/13 | |||||
Memantine | HCl | SOLUTION | 10mg/g | ORAL | N06DX01 | for local production only | 1390/09/21 | ||||
Memantine | HCl | CAPSULE,EXTENDED RELEASE | 14 mg | ORAL | N06DX01 | 1390/01/29 | |||||
Memantine | HCl | SOLUTION | 2 mg/ml | ORAL | N06DX01 | 1390/01/29 | |||||
Memantine | HCl | TABLET | 20 mg | ORAL | N06DX01 | 1390/01/29 | |||||
Memantine | HCl | CAPSULE,EXTENDED RELEASE | 21 mg | ORAL | N06DX01 | 1390/01/29 | |||||
Memantine | HCl | TABLET | 5 mg | ORAL | N06DX01 | 1385/04/13 | |||||
Meningococcal Vaccine | INJECTION | PARENTERAL | J07AH05 | Meningococcal AC conjugate (2 Valents) | 1391/02/25 | ||||||
Meningococcal Vaccine | INJECTION | PARENTERAL | J07AH05 | Meningococcal AC polysaccharide (2 Valents) | 1391/02/25 | ||||||
Meningococcal Vaccine | INJECTION | PARENTERAL | J07AH05 | Meningococcal ACWY polysaccharide (4 Valents) | 1391/02/25 | ||||||
Meningococcal Vaccine | INJECTION | PARENTERAL | J07AH05 | Meningococcal ACWY conjugate (4 Valents) | 1391/02/25 | ||||||
Menotropins | INJECTION, POWDER, LYOPHILIZED | PARENTERAL | G03GA02 | 150 IU FSH+150 IU LH | 1393/06/02 | ||||||
Menotropins | INJECTION, POWDER, LYOPHILIZED | PARENTERAL | G03GA02 | 75 IU FSH+75 IU LH | 1359/07/13 | ||||||
Menotropins | INJECTION, POWDER, LYOPHILIZED | PARENTERAL | G03GA02 | 600 IU FSH+600 IU LH | 1396/08/29 | ||||||
Menotropins | INJECTION, POWDER, LYOPHILIZED | PARENTERAL | G03GA02 | 1200 IU FSH+1200 IU LH | 1396/08/29 | ||||||
Menthol | BULK | V03 | Bulk medicines | ||||||||
Menthol Salicylate | OINTMENT | TOPICAL | M02AC | Methyl Salicylate 15%+Menthol 10% | OTC medicines | 1369/10/30 | |||||
Menthol+Zinc oxide+Calamine | OINTMENT | TOPICAL | D02AB | (Menthol 0.44 g + Zinc oxide 20.625 g + Calamine 10 g)/100g | OTC medicines | for local production only | 1389/07/17 | ||||
Mepivacaine | HCl | INJECTION | 2% | PARENTERAL | N01BB03 | Hospital use only | |||||
Mepivacaine | HCl | INJECTION | 3% | PARENTERAL | N01BB03 | Dentistry applications only | 3/23/1990 | ||||
Mequinol | OINTMENT | 10% | TOPICAL | D11AX06 | 1380/03/27 | ||||||
Mequinol+Tretinoin | SOLUTION | TOPICAL | D10AD51 | Mequinol 2% + Tretinoin 0. 01% | 1380/06/03 | ||||||
Mercaptopurine | TABLET | 50 mg | ORAL | L01BB02 | Orphan medicines | ||||||
Meropenem | As Trihydrate | INJECTION, POWDER | 1 g | PARENTERAL | J01DH02 | Management of acute pulmonary exacerbations, in cystic fibrosis patients, due to respiratory tract infection with susceptible organisms. | Hospital use only | ||||
Meropenem | As Trihydrate | INJECTION, POWDER | 500 mg | PARENTERAL | J01DH02 | Management of acute pulmonary exacerbations, in cystic fibrosis patients, due to respiratory tract infection with susceptible organisms. | Hospital use only. | 1383/07/12 | |||
Mesalazine | GRANULE, EXTENDED RELEASE | 1 g | ORAL | A07EC02 | sachet | 1380/12/05 | |||||
Mesalazine | TABLET, EXTENDED RELEASE | 1 g | ORAL | A07EC02 | 1393/03/04 | ||||||
Mesalazine | ENEMA | 1 g/100ml | RECTAL | A07EC02 | 1393/03/04 | ||||||
Mesalazine | ENEMA, FOAM | 1 g/application aerosol can | RECTAL | A07EC02 | 1395/11/06 | ||||||
Mesalazine | ENEMA | 4 g/100ml | RECTAL | A07EC02 | |||||||
Mesalazine | SUPPOSITORY, EXTENDED RELEASE | 1000 mg | RECTAL | A07EC02 | 1386/01/22 | ||||||
Mesalazine | GRANULE, EXTENDED RELEASE | 2 g | ORAL | A07EC02 | sachet | 1393/03/04 | |||||
Mesalazine | GRANULE, EXTENDED RELEASE | 4 g | ORAL | A07EC02 | sachet | 1396/11/29 | |||||
Mesalazine | TABLET, DELAYED RELEASE | 250 mg | ORAL | A07EC02 | |||||||
Mesalazine | TABLET, EXTENDED RELEASE | 250 mg | ORAL | A07EC02 | |||||||
Mesalazine | TABLET, DELAYED RELEASE | 400 mg | ORAL | A07EC02 | 1380/09/04 | ||||||
Mesalazine | SUPPOSITORY | 500 mg | RECTAL | A07EC02 | |||||||
Mesalazine | TABLET, DELAYED RELEASE | 500 mg | ORAL | A07EC02 | |||||||
Mesalazine | TABLET, EXTENDED RELEASE | 500 mg | ORAL | A07EC02 | |||||||
Mesalazine | CAPSULE, EXTENDED RELEASE | 500 mg | ORAL | A07EC02 | 1392/05/01 | ||||||
Mesalazine | TABLET, EXTENDED RELEAS | 1200 mg | ORAL | A07EC02 | 1397/04/30 | ||||||
Mesalazine | TABLET, DELAYED RELEASE | 800 mg | ORAL | A07EC02 | 1385/05/10 | ||||||
Mesna | INJECTION | 100 mg/ml | PARENTERAL | V03AF01 | For use as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis. Inhibition of the urotoxic effects induced by oxazaphosphorine compounds such as cyclophosphamide. | 1365/01/24 | |||||
Metaproterenol | Sulfate | INJECTION | 0.5 mg/ml | PARENTERAL | R03CB03 | Hospital use only | |||||
Metaproterenol | Sulfate | TABLET | 20 mg | ORAL | R03CB03 | ||||||
Metformin | HCl | TABLET | 1000 mg | ORAL | A10BA02 | 1385/08/17 | |||||
Metformin | HCl | TABLET, EXTENDED RELEASE | 1000 mg | ORAL | A10BA02 | 1391/07/25 | |||||
Metformin | HCl | TABLET, EXTENDED RELEASE | 750 mg | ORAL | A10BA02 | 1395/03/19 | |||||
Metformin | HCl | TABLET, EXTENDED RELEASE | 500 mg | ORAL | A10BA02 | 1391/07/25 | |||||
Metformin | HCl | TABLET | 500 mg | ORAL | A10BA02 | 1361/05/31 | |||||
Metformin | HCl | TABLET | 850 mg | ORAL | A10BA02 | 1396/08/29 | |||||
Metformin | HCl | SOLUTION | 500 mg/5ml | ORAL | A10BA02 | 1395/09/01 | |||||
Metformin+Glibenclamide | TABLET | ORAL | A10BD02 | Metformin HCl 500 mg+ Glibenclamide 2.5 mg | 1389/06/29 | ||||||
Metformin+Glibenclamide | TABLET | ORAL | A10BD02 | Metformin HCl 500 mg+ Glibenclamide 5 mg | 1389/06/29 | ||||||
Metformin+Glibenclamide | TABLET | ORAL | A10BD02 | Metformin HCl 1000 mg+ Glibenclamide 5 mg | 1396/03/13 | ||||||
Metformin+Pioglitazone | TABLET | ORAL | A10BD05 | Metformin HCL 500 mg + Pioglitazone 15 mg | 1389/08/24 | ||||||
Metformin+Linagliptin | TABLET | ORAL | A10BD11 | Metformin HCL 500 mg + Linagliptin2.5 mg | 1396/04/31 | ||||||
Metformin+Linagliptin | TABLET | ORAL | A10BD11 | Metformin HCL 1000 mg + Linagliptin2.5 mg | 1396/04/31 | ||||||
Metformin+Linagliptin | TABLET, EXTENDED RELEASE | ORAL | A10BD11 | Metformin HCL 1000 mg + Linagliptin 5 mg | 1396/08/29 | ||||||
Metformin+Linagliptin | TABLET, EXTENDED RELEASE | ORAL | A10BD11 | Metformin HCL 1000 mg + Linagliptin 2.5 mg | 1396/08/29 | ||||||
Methacholine | Chloride | INHALER | 100 mg/20ml | RESPIRATORY | V04CX | 1386/11/03 | |||||
Methadone | HCl | POWDER | 1 g | ORAL | N07BC02 | Sachet | 1384/11/18 | ||||
Methadone | HCl | INJECTION | 10 mg/ml | PARENTERAL | N07BC02 | Hospital use only | |||||
Methadone | HCl | TABLET | 20 mg | ORAL | N07BC02 | 1382/12/25 | |||||
Methadone | HCl | TABLET, DISPERSIBLE | 20 mg | ORAL | N07BC02 | 1386/12/06 | |||||
Methadone | HCl | SOLUTION | 25 mg/5ml | ORAL | N07BC02 | 1384/02/12 | |||||
Methadone | HCl | TABLET, DISPERSIBLE | 40 mg | ORAL | N07BC02 | 1386/12/06 | |||||
Methadone | HCl | TABLET | 40 mg | ORAL | N07BC02 | 1382/12/25 | |||||
Methadone | HCl | TABLET | 5 mg | ORAL | N07BC02 | ||||||
Methadone | HCl | INJECTION | 5 mg/ml | PARENTERAL | N07BC02 | Hospital use only | 1369/01/26 | ||||
Methadone | HCl | SOLUTION | 5mg/5ml | ORAL | N07BC02 | ||||||
Methimazole | TABLET | 5 mg | ORAL | H03BB02 | |||||||
Methocarbamol | INJECTION | 100 mg/ml | PARENTERAL | M03EA03 | |||||||
Methocarbamol | TABLET | 500 mg | ORAL | M03EA03 | |||||||
Methocarbamol | TABLET | 750 mg | ORAL | M03EA03 | 1396/02/02 | ||||||
Methotrexate | As Sodium | INJECTION, POWDER, LYOPHILIZED | 1 g | PARENTERAL | L01BA01 | with and without preservative | 1375/07/29 | ||||
Methotrexate | As Sodium | INJECTION, SOLUTION | 10 mg/ml | PARENTERAL | L01BA01 | with and without preservative | |||||
Methotrexate | As Sodium | INJECTION, SOLUTION | 20 mg/ml | PARENTERAL | L01BA01 | without preservative | 1396/06/25 | ||||
Methotrexate | As Sodium | INJECTION, SOLUTION | 100 mg/ml | PARENTERAL | L01BA01 | with and without preservative | |||||
Methotrexate | As Sodium | INJECTION, SOLUTION | 50 mg/ml | PARENTERAL | L01BA01 | without preservative | 1395/09/01 | ||||
Methotrexate | As Sodium | INJECTION, SOLUTION | 2.5 mg/ml | PARENTERAL | L01BA01 | with and without preservative | 1375/07/29 | ||||
Methotrexate | As Sodium | TABLET | 2.5 mg | ORAL | L01BA01 | 1389/6/29 | |||||
Methotrexate | TABLET | 2.5 mg | ORAL | L01BA01 | |||||||
Methotrexate | As Sodium | INJECTION, SOLUTION | 25 mg/ml | PARENTERAL | L01BA01 | with and without preservative | 1375/07/29 | ||||
Methotrexate | INJECTION, SOLUTION | 25 mg/ml | PARENTERAL | L01BA01 | without preservative | 1397/04/03 | |||||
Methotrexate | As Sodium | INJECTION, POWDER, LYOPHILIZED | 5 mg | PARENTERAL | L01BA01 | with and without preservative | |||||
Methotrexate | As Sodium | INJECTION, SOLUTION | 5 mg/ml | PARENTERAL | L01BA01 | with and without preservative | 1375/07/29 | ||||
Methotrexate | As Sodium | INJECTION, POWDER, LYOPHILIZED | 50 mg | PARENTERAL | L01BA01 | with and without preservative | 1369/09/18 | ||||
Methotrexate | TABLET | 5mg | ORAL | L01BA01 | 1385/05/10 | ||||||
Methoxsalen | SOLUTION | 1% | TOPICAL | D05AD02 | 1373/09/20 | ||||||
Methoxsalen | TABLET | 10 mg | ORAL | D05AD02 | For use in conjunction with the UVAR photopheresis system to treat graft versus host disease. | ||||||
Methoxy Polyethylen Glycol-Epoetin Beta | INJECTION, SOLUTION | 50 mcg/0.3 ml | PARENTERAL | B03XA03 | Hypoplastic, Haemolytic, Renal Anaemia | 1394/11/13 | |||||
Methoxy Polyethylen Glycol-Epoetin Beta | INJECTION, SOLUTION | 100 mcg/0.3 ml | PARENTERAL | B03XA03 | Hypoplastic, Haemolytic, Renal Anaemia | 1394/11/13 | |||||
Methoxy Polyethylen Glycol-Epoetin Beta | INJECTION, SOLUTION | 200 mcg/0.3 ml | PARENTERAL | B03XA03 | Hypoplastic, Haemolytic, Renal Anaemia | 1394/11/13 | |||||
Methyl Salicylate | OINTMENT | 30% | TOPICAL | M02AC | OTC medicines | 1369/10/30 | |||||
Methylcellulose | GRANULE | ORAL | A06AC06 | 1376/11/02 | |||||||
Methyldopa | TABLET | 250 mg | ORAL | C02AB02 | |||||||
Methylene Blue | INJECTION | 10 mg/ml | PARENTERAL | V03AB17 | |||||||
Methylergonovine | Maleate | TABLET | 0.125 mg | ORAL | G02AB01 | ||||||
Methylergonovine | Maleate | INJECTION | 0.2 mg/ml | PARENTERAL | G02AB01 | ||||||
Methylphenidate | HCl | TABLET | 10 mg | ORAL | N06BA04 | ||||||
Methylphenidate | HCl | TABLET, EXTENDED RELEASE | 20 mg | ORAL | N06BA04 | 1385/03/23 | |||||
Methylphenidate | HCl | TABLET, EXTENDED RELEASE | 18 mg | ORAL | N06BA04 | 1395/05/03 | |||||
Methylphenidate | HCl | TABLET, EXTENDED RELEASE | 27 mg | ORAL | N06BA04 | 1395/05/03 | |||||
Methylphenidate | HCl | TABLET, EXTENDED RELEASE | 36 mg | ORAL | N06BA04 | 1395/05/03 | |||||
Methylphenidate | HCl | TABLET, EXTENDED RELEASE | 54 mg | ORAL | N06BA04 | 1395/05/03 | |||||
Methylphenidate | HCl | CAPSULE, EXTENDED RELEASE | 30 mg | ORAL | N06BA04 | 1395/05/03 | |||||
Methylprednisolone | As Sodium Succinate | INJECTION, POWDER | 1000 mg | PARENTERAL | H02AB04 | Hospital use only | 1382/08/12 | ||||
Methylprednisolone | As Sodium Succinate | INJECTION, POWDER | 250 mg | PARENTERAL | H02AB04 | Hospital use only | 1382/08/12 | ||||
Methylprednisolone | As Sodium Succinate | INJECTION, POWDER | 40 mg | PARENTERAL | H02AB04 | 1384/05/16 | |||||
Methylprednisolone | Acetate | INJECTION | 40 mg/ml | PARENTERAL | H02AB04 | 1383/10/06 | |||||
Methylprednisolone | As Sodium succinate | INJECTION, POWDER | 500 mg | PARENTERAL | H02AB04 | Hospital use only | 1364/11/13 | ||||
Methyltestosterone | TABLET | 25 mg | ORAL | G03BA02 | |||||||
Metoclopramide | HCl | CAPSULE, LIQUID FILLED | 10 mg | ORAL | A03FA01 | 1385/11/18 | |||||
Metoclopramide | HCl | TABLET | 10 mg | ORAL | A03FA01 | ||||||
Metoclopramide | HCl | SOLUTION/ DROPS | 4 mg/ml, 15ml | ORAL | A03FA01 | ||||||
Metoclopramide | HCl | INJECTION | 5 mg/ml | PARENTERAL | A03FA01 | ||||||
Metoprolol | Tartrate | TABLET | 100 mg | ORAL | C07AB02 | 1380/06/25 | |||||
Metoprolol | Succinate | TABLET, EXTENDED RELEASE | 190 mg | ORAL | C07AB02 | 1385/11/24 | |||||
Metoprolol | Tartrate | INJECTION | 1mg/ml | PARENTERAL | C07AB02 | Hospital use only | 1379/04/06 | ||||
Metoprolol | Succinate | TABLET, EXTENDED RELEASE | 23.75 mg | ORAL | C07AB02 | 1385/11/24 | |||||
Metoprolol | Succinate | TABLET, EXTENDED RELEASE | 47.5 mg | ORAL | C07AB02 | 1385/11/24 | |||||
Metoprolol | Tartrate | TABLET | 50 mg | ORAL | C07AB02 | 1377/11/18 | |||||
Metoprolol | Succinate | TABLET, EXTENDED RELEASE | 95 mg | ORAL | C07AB02 | 1385/11/24 | |||||
Metronidazole | GEL | 0.75% | TOPICAL | D06BX01 | Treatment of grade III and IV, anaerobically infected, decubitus ulcers. Treatment of acne rosacea. | 1376/03/25 | |||||
Metronidazole | GEL | 0.75% | VAGINAL | G01AF01 | |||||||
Metronidazole | As Benzoate | SUSPENSION | 125 mg/5ml | ORAL | P01AB01 | ||||||
Metronidazole | TABLET | 250 mg | ORAL | P01AB01 | |||||||
Metronidazole | TABLET | 500 mg | ORAL | P01AB01 | 1395/05/03 | ||||||
Metronidazole | INJECTION, SOLUTION | 5 mg/ml | INTRAVENOUS DRIP | J01XD01 | Hospital use only | 1363/03/06 | |||||
Metronidazole | SUPPOSITORY | 500 mg | VAGINAL | G01AF01 | |||||||
Metronidazole | TABLET | 500 mg | VAGINAL | G01AF01 | 1363/04/31 | ||||||
Metyrapone | TABLET | 250 mg | ORAL | V04CD01 | |||||||
Mexiletine | CAPSULE | 100 mg | ORAL | C01BB02 | 1377/02/09 | ||||||
Mexiletine | CAPSULE | 200 mg | ORAL | C01BB02 | |||||||
Miconazole | Nitrate | CREAM | 2% | TOPICAL | D01AC02 | ||||||
Miconazole | Nitrate | CREAM | 2% | VAGINAL | G01AF04 | ||||||
Miconazole | Nitrate | SUPPOSITORY | 100 mg | VAGINAL | G01AF04 | 1382/07/13 | |||||
Microfibrillar Collagen Hemostat | TAMPON | 14.8 mg/cm3 | TOPICAL | B02BC07 | 0.15 cm thikness - Registered as ANTEMA | ||||||
Microfibrillar Collagen Hemostat | TAMPON | 15.5 mg/cm3 | TOPICAL | B02BC07 | Cillender 8 cm x 3 cm diameter - Registered as ANTEMA | ||||||
Microfibrillar Collagen Hemostat | TAMPON | 22.3mg/cm3 | TOPICAL | B02BC07 | 0.5 cm thickness - Registered as ANTEMA | ||||||
Midazolam | As HCl | INJECTION | 1 mg/ml | PARENTERAL | N05CD08 | Treatment of bouts of increased seizure activity in selected refractory patients with epilepsy who are on stable regimens of anti-epileptic drugs and who require intermittent use of midazolam | Hospital use only | 1391/02/25 | |||
Midazolam | As HCl | SOLUTION | 10 mg/ml, 5ml | BUCCAL | N05CD08 | Hospital use only | 1391/02/25 | ||||
Midazolam | As HCl | SYRUP | 2 mg/ml | ORAL | N05CD08 | Hospital use only | 1391/02/25 | ||||
Midazolam | As HCl | INJECTION | 5 mg/ml | PARENTERAL | N05CD08 | Treatment of bouts of increased seizure activity in selected refractory patients with epilepsy who are on stable regimens of anti-epileptic drugs and who require intermittent use of midazolam | Hospital use only | 1391/02/25 | |||
Midodrine | HCl | TABLET | 2. 5 mg | ORAL | C01CA17 | Hospital use only; Orphan medicines | 1387/12/21 | ||||
Midodrine | HCl | TABLET | 5 mg | ORAL | C01CA17 | Hospital use only; Orphan medicines | 1387/12/21 | ||||
Miglustat | CAPSULE | 100 mg | ORAL | A16AX06 | Mild to moderate type I Gaucher's disease | Hospital use only; Orphan medicines | 1395/08/16 | ||||
Milrinone | As Lactate | INJECTION, SOLUTION | 1 mg/ml | PARENTERAL | C01CE02 | Hospital use only | 1379/02/04 | ||||
Miltefosine | CAPSULE | 50 mg | ORAL | L01XX09 | Antileishmania | for Health Dept. of MOH only | 1394/11/13 | ||||
Mineral Oil | BULK | V03 | Bulk medicines | liquid Paraffin | |||||||
Minoxidil | AEROSOL ,FOAM | 2% | TOPICAL | D11AX01 | Androgenetic Alopecia | OTC medicines | 1391/05/02 | ||||
Minoxidil | AEROSOL, FOAM | 5% | TOPICAL | D11AX01 | Androgenetic Alopecia | OTC medicines | 1391/05/02 | ||||
Minoxidil | TABLET | 10 mg | ORAL | C02DC01 | |||||||
Minoxidil | SOLUTION | 20 mg/ml | TOPICAL | D11AX01 | Androgenetic Alopecia | OTC medicines | 1371/08/03 | ||||
Minoxidil | SOLUTION | 50 mg/ml | TOPICAL | D11AX01 | Androgenetic Alopecia | OTC medicines | |||||
Minoxidil | BULK | V03 | Bulk medicines | 1376/12/10 | |||||||
Minoxidil+Azelaic Acid+Betamethasone | SOLUTION | TOPICAL | D11AX | Minoxidil 5% + Azelaic Acid 5% + Betamethasone Valerate 0.025% | 1389/11/04 | ||||||
Minoxidil+Azelaic Acid+Betamethasone+Tretinoin | SOLUTION | TOPICAL | D11AX | Minoxidil 5% + Azelaic Acid 5% + Tretinoin 0.025% + Betamethasone Valerate 0.025% | 1389/11/04 | ||||||
Mirtazapine | TABLET | 7.5 mg | ORAL | N06AX11 | 1396/05/09 | ||||||
Mirtazapine | TABLET | 15 mg | ORAL | N06AX11 | 1396/05/09 | ||||||
Mirtazapine | TABLET | 30 mg | ORAL | N06AX11 | 1396/05/09 | ||||||
Mirtazapine | TABLET | 45 mg | ORAL | N06AX11 | 1396/05/09 | ||||||
Mirtazapine | TABLET, ORALLY DISINTEGRATING | 15 mg | ORAL | N06AX11 | 1396/05/09 | ||||||
Mirtazapine | TABLET, ORALLY DISINTEGRATING | 30 mg | ORAL | N06AX11 | 1396/05/09 | ||||||
Mirtazapine | TABLET, ORALLY DISINTEGRATING | 45 mg | ORAL | N06AX11 | 1396/05/09 | ||||||
Misoprostol | TABLET | 200 mcg | ORAL | G02AD06 | Treatment of intrauterine fetal death not accompanied by complete expulsion of the products of conception in the second and third trimesters of pregnancy. | Hospital use only | With obstetricians prescriptions only | 1387/03/28 | |||
Mitomycin | INJECTION, POWDER | 10 mg | PARENTERAL | L01DC03 | |||||||
Mitomycin | INJECTION, POWDER | 2 mg | PARENTERAL | L01DC03 | |||||||
Mitomycin | INJECTION, POWDER | 40 mg | INTRACAVITARY | L01DC03 | 1386/11/08 | ||||||
Mitomycin | INJECTION, POWDER | 20 mg | INTRACAVITARY | L01DC03 | 1396/04/27 | ||||||
Mitomycin | INJECTION, POWDER | 5 mg | PARENTERAL | L01DC03 | |||||||
Mitotane | TABLET | 500 mg | ORAL | L01XX23 | 1361/09/14 | ||||||
Mitoxantrone | As HCl | INJECTION | 2 mg/ml | PARENTERAL | L01DB07 | Treatment of hormone refractory prostate cancer. Treatment of progressive-relapsing multiple sclerosis. | 1365/09/16 | ||||
Mivacurium | Chloride | INJECTION, POWDER | 2 mg/ml | PARENTERAL | M03AC10 | Hospital use only | 1382/03/04 | ||||
Moclobemide | TABLET | 150 mg | ORAL | N06AG02 | 1376/02/28 | ||||||
Modafinil | TABLET | 100 mg | ORAL | N06BA07 | should be labelled as under control medicine | 1387/12/21 | |||||
Modafinil | TABLET | 200 mg | ORAL | N06BA07 | should be labelled as under control medicine | 1388/08/20 | |||||
Molgramostim (GMCSF) | INJECTION, POWDER | 0.15 mg | PARENTERAL | L03AA03 | Treatment of AIDS patients with neutropenia due to the disease, AZTor ganciclovir. Treatment of aplastic anemia. | ||||||
Molgramostim (GMCSF) | INJECTION, POWDER | 0.4 mg | PARENTERAL | L03AA03 | Treatment of AIDS patients with neutropenia due to the disease, AZTor ganciclovir. Treatment of aplastic anemia. | ||||||
Molybdenum (99Mo)/Technetium [99mTc] | GENERATOR | 100-3000 mCi | INTRAVENOUS BOLUS | V09FX01 | Hospital use only | Radiopharmaceuticals | |||||
Mometasone | Furoate | SPRAY, SUSPENSION | 0.05% | NASAL | R01AD09 | 1386/12/07 | |||||
Mometasone | Furoate | OINTMENT | 0. 1% | TOPICAL | D07AC13 | 1388/02/02 | |||||
Mometasone | Furoate | CREAM | 0. 1% | TOPICAL | D07AC13 | 1388/02/02 | |||||
Mometasone | Furoate | LOTION | 0. 1% | TOPICAL | D07AC13 | 1388/02/02 | |||||
Mometasone | Furoate | POWDER, INHALATION | 100 mcg | RESPIRATORY | R03BA07 | 1392/05/29 | |||||
Mometasone | Furoate | POWDER, INHALATION | 200 mcg | RESPIRATORY | R03BA07 | 1392/05/29 | |||||
Mometasone | Furoate | POWDER, INHALATION | 400 mcg | RESPIRATORY | R03BA07 | 1392/05/29 | |||||
Mometasone+Formoterol | AEROSOL, INHALATION | RESPIRATORY | R03AK07 | Mometasone Furoate100 mcg+Formoterol Fumarate 5mcg | 1392/05/29 | ||||||
Mometasone+Formoterol | AEROSOL, INHALATION | RESPIRATORY | R03AK07 | Mometasone Furoate200 mcg+Formoterol Fumarate 5mcg | 1392/05/29 | ||||||
Mometasone+Formoterol | AEROSOL, INHALATION | RESPIRATORY | R03AK07 | Mometasone Furoate50 mcg+Formoterol Fumarate 5mcg | 1392/05/29 | ||||||
Monobenzone | CREAM | 20% | TOPICAL | D11AX13 | |||||||
Montelukast | As Sodium | TABLET | 10 mg | ORAL | R03DC03 | 1384/02/26 | |||||
Montelukast | As Sodium | GRANULE | 4 mg | ORAL | R03DC03 | Sachet | |||||
Montelukast | As Sodium | TABLET, CHEWABLE | 5 mg | ORAL | R03DC03 | 1379/06/20 | |||||
Morphine | Sulfate | SUPPOSITORY | 10 mg | RECTAL | N02AA01 | 1385/10/05 | |||||
Morphine | Sulfate | TABLET | 10 mg | ORAL | N02AA01 | ||||||
Morphine | HCl | INJECTION | 10 mg/ml | PARENTERAL | N02AA01 | Hospital use only | for local production only; Without preservative | 1389/8/24 | |||
Morphine | Sulfate | INJECTION | 10 mg/ml | PARENTERAL | N02AA01 | Hospital use only | 1389/08/24 | ||||
Morphine | Sulfate | INJECTION | 25mg/ml | PARENTERAL | N02AA01 | Hospital use only | 1387/10/15 | ||||
Morphine | Sulfate | INJECTION | 50mg/ml | PARENTERAL | N02AA01 | Hospital use only | 1387/10/15 | ||||
Moxifloxacin | As HCl | SOLUTION | 0.50% | OPHTHALMIC | S01AE07 | 1390/07/04 | |||||
Moxifloxacin | As HCl | TABLET | 400 mg | ORAL | J01MA14 | Hospital use only | for local production only; With infectious diseases specialists and pulmonologists prescriptions only | 1390/003/07 | |||
Multivitamin Pediatric | INJECTION | INTRAVENOUS | A11AE | (Vit.B1 2.5mg + Vit.B2 3.6mg + Vit. B6 4mg + Vit. B12 5mcg + Niacin 40mg + Pantothenic Acid 15mg + Biotin 60mcg + Vit.C 100mg+Folic Acid 400mcg)/10ml INTERAVENOUS | Hospital use only | With pediatricians prescriptions only | 1386/06/28 | ||||
Multivitamin Infant Oily | INJECTION, EMULSION | INTRAVENOUS | B05XC | Nutrient | Hospital use only | With pediatricians prescriptions only, Should be reconstitute in intralipid | 1396/11/29 | ||||
Multivitamin Adult Oily | INJECTION, EMULSION | INTRAVENOUS | B05XC | Nutrient | Hospital use only | Should be reconstitute in intralipid | 1396/11/29 | ||||
Multivitamin Therapeutic | CAPSULE | ORAL | A11AA | Vit.A 25000 IU+Vit.B1 20 mg+Vit.B2 5mg+Nicotinamide50 mg+Vit.B6 10mg+Vit.B12 5mcg+Vit.C 150mg+Biotin 0.25mg+Vit.D 1000IU+ Vit.E 10mg(IU)+Folic Acid 1mg+Calcium Pantothenate 11.6mg+Ca 100mg +Mg(As MgO) 5mg +Mn 0.5mg+Mo 0.1mg+Iron 10mg+Zn 0.5mg+P 77.27mg+Cu | |||||||
Multivitamin Therapeutic | TABLET | ORAL | A11AA | Vit.A25000 IU+Vit.B1 20mg+Vit.B2 5mg+Nicotinamide 50mg+Vit. B6 10mg+Vit. B12 5mcg+ Vit.C 150mg+Biotin 0.25mg+Vit.D 500IU+Vit.E 10mg(IU)+Folic Acid 1mg+Calcium Pantothenate 11.6mg +Ca HPO4,2H2O129mg +MnSO4,4H2O 2.05mg+MgO 30mg+CuSO4,5H2O 3.9mg+Sodium molib | |||||||
Mumps Mirus Vaccine | INJECTION, POWDER | PARENTERAL | J07BX | Live | |||||||
Mupirocin | As Calcium | OINTMENT | 2% | NASAL | R01AX06 | 1378/02/19 | |||||
Mupirocin | OINTMENT | 2% | TOPICAL | D06AX09 | 1372/10/19 | ||||||
Mycophenolate Mofetil | CAPSULE | 250 mg | ORAL | L04AA06 | |||||||
Mycophenolate Mofetil | TABLET | 500 mg | ORAL | L04AA06 | |||||||
Mycophenolate Mofetil | POWDER FOR SUSPENSION | 200 mg/ml | ORAL | L04AA06 | 1396/05/28 | ||||||
Mycophenolic acid | TABLET, DELAYED RELEASE | 360 mg | ORAL | L04AA06 | Treatment of pemphigus vulgaris Treatment of myasthenia gravis | 1384/08/22 | |||||
Mycophenolic acid | TABLET, DELAYED RELEASE | 180 mg | ORAL | L04AA06 | Treatment of pemphigus vulgaris Treatment of myasthenia gravis | ||||||
Nafcillin | Sodium | INJECTION, POWDER | 500 mg | PARENTERAL | J01CF06 | Hospital use only | 1364/12/04 | ||||
Nalidixic Acid | TABLET | 500 mg | ORAL | J01MB02 | |||||||
Nalidixic Acid | SUSPENSION | 60 mg/ml | ORAL | J01MB02 | 1366/07/26 | ||||||
Naloxone | HCl | INJECTION | 0.4 mg/ml | PARENTERAL | V03AB15 | Hospital use only | |||||
Naltrexone | HCl | CAPSULE | 25 mg | ORAL | N07BB04 | ||||||
Naltrexone | INJECTION, POWDER | 380 mg/vial | PARENTRAL | N07BB04 | Hospital use only | 1392/05/01 | |||||
Naltrexone | HCl | CAPSULE | 50 mg | ORAL | N07BB04 | ||||||
Nandrolone | Decanoate | INJECTION | 25 mg/ml | PARENTERAL | A14AB01 | ||||||
Nandrolone | Phenpropionate | INJECTION | 25 mg/ml | PARENTERAL | A14AB01 | ||||||
Naphazoline | HCl | SOLUTION/ DROPS | 0.05% | NASAL | R01AA08 | ||||||
Naphazoline | HCl | SPRAY | 0.05% | NASAL | R01AA08 | 1384/03/09 | |||||
Naphazoline | Nitrate | SOLUTION/ DROPS | 0.05% | NASAL | R01AA08 | ||||||
Naphazoline | HCl | SOLUTION/ DROPS | 0.1% | OPHTHALMIC | S01GA01 | ||||||
Naphazoline | Nitrate | SOLUTION/ DROPS | 0.1% | OPHTHALMIC | S01GA01 | ||||||
Naphazoline+Antazoline | SOLUTION/ DROPS | OPHTHALMIC | S01GA51 | Naphazoline HCl 0.05%+Antazoline Phosphate 0.5% | 1360/09/22 | ||||||
Naproxen | CAPSULE, LIQUID FILLED | 200 mg | ORAL | M01AE02 | 1389/03/31 | ||||||
Naproxen | TABLET | 250 mg | ORAL | M01AE02 | 1373/05/30 | ||||||
Naproxen | TABLET | 375 mg | ORAL | M01AE02 | 1386/07/18 | ||||||
Naproxen | SUPPOSITORY | 500 mg | RECTAL | M01AE02 | 1379/09/27 | ||||||
Naproxen | TABLET, DELAYED RELEASE | 500 mg | ORAL | M01AE02 | 1374/02/09 | ||||||
Natalizumab | INJECTION, SOLUTION,CONCENTRATE | 20 mg/ ml | PARENTERAL | L04AA23 | 1390/07/05 | ||||||
Natamycin | SOLUTION/ DROPS | 5% | OPHTHALMIC | S01AA10 | 1368/07/16 | ||||||
Nelfinavir | As Mesylate | TABLET | 250 mg | ORAL | J05AE04 | 1379/05/02 | |||||
Nelfinavir | As Mesylate | POWDER | 50 mg/g | ORAL | J05AE04 | for Health Dept. of MOH only | 1385/09/07 | ||||
Nelfinavir | As Mesylate | TABLET | 625 mg | ORAL | J05AE04 | for Health Dept. of MOH only | 1383/08/04 | ||||
Neomycin | Sulfate | SOLUTION | 125 mg/5ml | ORAL | J01GB05 | 1368/05/09 | |||||
Neomycin | Sulfate | TABLET | 500 mg | ORAL | J01GB05 | ||||||
Neostigmine | Methylsulfate | INJECTION | 0.5 mg/ml | PARENTERAL | N07AA01 | Hospital use only | |||||
Neostigmine | Bromide | TABLET | 15 mg | ORAL | N07AA01 | 1379/04/06 | |||||
Neostigmine | Methylsulfate | INJECTION | 2.5 mg/ml | PARENTERAL | N07AA01 | Hospital use only | 1362/11/23 | ||||
Nevirapine | TABLET | 200 mg | ORAL | J05AG01 | Treatment of AIDS related complex. | for Health Dept. of MOH only | |||||
Nevirapine | SUSPENSION | 50 mg/5ml | ORAL | J05AG01 | Treatment of AIDS related complex. | for Health Dept. of MOH only | |||||
Niacinamide | TABLET | 500 mg | ORAL | A11HA01 | 1369/10/30 | ||||||
Niclosamide | TABLET, CHEWABLE | 500 mg | ORAL | P02DA01 | |||||||
Nicorandil | TABLET | 10 mg | ORAL | C01DX16 | 1387/12/21 | ||||||
Nicorandil | TABLET | 20 mg | ORAL | C01DX16 | 1387/12/21 | ||||||
Nicotine | LOZENGE | 1 mg/ml | ORAL | N07BA01 | For local production only | 1391/06/13 | |||||
Nicotine | SPRAY | 10 mg/ml | NASAL | N07BA01 | OTC medicines | 1385/09/15 | |||||
Nicotine | PATCH, EXTENDED RELEASE | 14mg/24h | TRANSDERMAL | N07BA01 | OTC medicines | 1386/04/13 | |||||
Nicotine | PATCH, EXTENDED RELEASE | 15 mg/16h | TRANSDERMAL | N07BA01 | OTC medicines | ||||||
Nicotine | LOZENGE | 2 mg | ORAL | N07BA01 | OTC medicines | 1391/06/13 | |||||
Nicotine | GUM | 2 mg | ORAL | N07BA01 | OTC medicines | 1372/04/27 | |||||
Nicotine | TABLET | 2 mg | SUBLINGUAL | N07BA01 | OTC medicines | 1378/08/23 | |||||
Nicotine | PATCH, EXTENDED RELEASE | 21mg/24h | TRANSDERMAL | N07BA01 | OTC medicines | 1386/04/13 | |||||
Nicotine | LOZENGE | 4 mg | ORAL | N07BA01 | OTC medicines | 1391/06/13 | |||||
Nicotine | PATCH, EXTENDED RELEASE | 7mg/24h | TRANSDERMAL | N07BA01 | OTC medicines | 1386/04/13 | |||||
Nicotinic Acid | TABLET | 100 mg | ORAL | C10AD02 | 1363/04/03 | ||||||
Nicotinic Acid | TABLET | 25 mg | ORAL | C04AC01 | 1369/10/30 | ||||||
Nicotinic Acid | TABLET | 500 mg | ORAL | C10AD02 | 1376/06/30 | ||||||
Nifedipine | CAPSULE | 10 mg | ORAL | C08CA05 | |||||||
Nifedipine | TABLET | 10 mg | ORAL | C08CA05 | 1365/02/21 | ||||||
Nifedipine | CAPSULE, EXTENDED RELEASE | 20 mg | ORAL | C08CA05 | 1383/08/18 | ||||||
Nifedipine | TABLET, EXTENDED RELEASE | 20 mg | ORAL | C08CA05 | 1382/01/24 | ||||||
Nifedipine | TABLET, EXTENDED RELEASE | 60 mg | ORAL | C08CA05 | 1396/11/29 | ||||||
Nifedipine | CAPSULE | 30 mg | ORAL | C08CA05 | |||||||
Nifedipine | TABLET | 30 mg | ORAL | C08CA05 | 1377/11/18 | ||||||
Nilotinib | As HCl | CAPSULE | 150 mg | ORAL | L01XE08 | For local production only | 1390/03/23 | ||||
Nilotinib | As HCl | CAPSULE | 200 mg | ORAL | L01XE08 | 1388/05/11 | |||||
Nimodipine | INJECTION, SOLUTION | 0.2 mg/ml | INTRAVENOUS DRIP | C08CA06 | Hospital use only | ||||||
Nimodipine | TABLET | 30 mg | ORAL | C08CA06 | |||||||
Nitisinone | CAPSULE | 10 mg | ORAL | A16AX04 | Orphan medicines; for treatment of Tyrosinemia type I patients | 1387/11/06 | |||||
Nitisinone | TABLET | 10 mg | ORAL | A16AX04 | Orphan medicines; for treatment of Tyrosinemia type I patients | 1387/11/06 | |||||
Nitisinone | TABLET | 2 mg | ORAL | A16AX04 | Orphan medicines; for treatment of Tyrosinemia type I patients | 1387/11/06 | |||||
Nitisinone | CAPSULE | 2 mg | ORAL | A16AX04 | Orphan medicines; for treatment of Tyrosinemia type I patients | 1387/11/06 | |||||
Nitisinone | CAPSULE | 5 mg | ORAL | A16AX04 | Orphan medicines; for treatment of Tyrosinemia type I patients | 1387/11/06 | |||||
Nitisinone | TABLET | 5 mg | ORAL | A16AX04 | Orphan medicines; for treatment of Tyrosinemia type I patients | 1387/11/06 | |||||
Nitrazepam | TABLET | 5 mg | ORAL | N05CD02 | 1382/04/01 | ||||||
Nitrofurantoin | TABLET | 100 mg | ORAL | J01XB01 | |||||||
Nitrofurantoin | SUSPENSION | 25 mg/5ml | ORAL | J01XE01 | |||||||
Nitrofurazone | CREAM | 0.20% | TOPICAL | D09AA03 | |||||||
Nitroglycerin | OINTMENT | 2% | TOPICAL | C01DA02 | |||||||
Nitroglycerin | CAPSULE, LIQUID FILLED | 0.4 mg | SUBLINGUAL | C01DA02 | |||||||
Nitroglycerin | TABLET | 0.4 mg | ORAL | C01DA02 | |||||||
Nitroglycerin | INJECTION | 1 mg/ml | PARENTERAL | C01DA02 | Hospital use only | ||||||
Nitroglycerin | PLASTER | 10 mg/24h | TRANSDERMAL | C01DA02 | 1368/07/16 | ||||||
Nitroglycerin | PATCH, EXTENDED RELEASE | 10 mg/24h | TRANSDERMAL | C01DA02 | 1387/07/07 | ||||||
Nitroglycerin | CAPSULE, EXTENDED RELEASE | 2.5 mg | ORAL | C01DA02 | |||||||
Nitroglycerin | TABLET, EXTENDED RELEASE | 2.5 mg | ORAL | C01DA02 | |||||||
Nitroglycerin | CAPSULE, EXTENDED RELEASE | 2.6 mg | ORAL | C01DA02 | |||||||
Nitroglycerin | TABLET, EXTENDED RELEASE | 2.6 mg | ORAL | C01DA02 | 1370/02/29 | ||||||
Nitroglycerin | SPRAY | 400 mcg/dose | RESPIRATORY | C01DA02 | 1377/11/18 | ||||||
Nitroglycerin | PLASTER | 5 mg/24h | TRANSDERMAL | C01DA02 | 1368/07/16 | ||||||
Nitroglycerin | PATCH, EXTENDED RELEASE | 5 mg/24h | TRANSDERMAL | C01DA02 | 1387/07/07 | ||||||
Nitroglycerin | OINTMENT | 0.40% | TOPICAL | C01DA02 | 1395/10/07 | ||||||
Nitroglycerin | INJECTION | 5 mg/ml | PARENTERAL | C01DA02 | Hospital use only | 1382/02/28 | |||||
Nitroglycerin | CAPSULE, EXTENDED RELEASE | 6.4 mg | ORAL | C01DA02 | |||||||
Nitroglycerin | TABLET, EXTENDED RELEASE | 6.4 mg | ORAL | C01DA02 | 1361/06/07 | ||||||
Nitroglycerin | CAPSULE, EXTENDED RELEASE | 6.5 mg | ORAL | C01DA02 | |||||||
Nitroglycerin | TABLET, EXTENDED RELEASE | 6.5 mg | ORAL | C01DA02 | |||||||
Nitroprusside | Sodium | INJECTION, POWDER | 50 mg | PARENTERAL | C02DD01 | Treatment and prevention of cerebral vasospasm following subarachnoid hemorrhage. | |||||
Nitrous Oxide | INHALER | 1000 PPM | RESPIRATORY | N01AX13 | |||||||
Nitrous Oxide | INHALANT | RESPIRATORY | N01AX13 | ||||||||
Nitrous oxide+Oxygen | GAS, MEDICINAL | INHALATION | N01AX63 | Nitrous oxide 50%v/v+Oxygen 50%V/V | Hospital use only | for local production only | 1389/05/30 | ||||
Nonoxynol-9 | CREAM | 5% | VAGINAL | G02BB | 1369/10/30 | ||||||
Norepinephrine | As Bitartrate | INJECTION | 0.10% | PARENTERAL | C01CA03 | Hospital use only | |||||
Nortriptyline | As HCl | TABLET | 10 mg | ORAL | N06AA10 | 1362/03/08 | |||||
Nortriptyline | As HCl | TABLET | 25 mg | ORAL | N06AA10 | 1362/03/08 | |||||
Nystatin | TABLET | 500,000 U | ORAL | A03AA03 | |||||||
Nystatin | TABLET | 100,000 U | VAGINAL | G01AA01 | 1359/06/08 | ||||||
Nystatin | OINTMENT | 100,000 U/g | TOPICAL | D01AA01 | |||||||
Nystatin | POWDER, FOR SUSPENSION | 100,000 U/ml | LOCAL ORAL | A07AA03 | |||||||
Obidoxime | Chloride | INJECTION | 250 mg/ml | PARENTERAL | V03AB13 | Hospital use only | 1365/11/19 | ||||
Obidoxime | Chloride | INJECTION | 275 mg/ml | PARENTERAL | V03AB13 | Hospital use only | |||||
Ocrelizumab | INJECTION, SOLUTION, CONCENTRATE | 30 mg/ml | PARENTERAL | L04AA36 | Relapsing Remitting Multiple Sclerosis, Primary Progressive Multiple Sclerosis | 1397/06/24 | |||||
Octreotide | As Acetate | INJECTION | 100 mcg/ml | PARENTERAL | H01CB02 | Treatment of acromegaly. Treatment of diarrhea associated with vasoactive intestinal peptide tumors (VIPoma). Treatment of severe diarrhea and flushing associated with malignant carcinoid tumors. | Hospital use only | ||||
Octreotide | As Acetate | INJECTION,POWDER,EXTENDED RELEASE | 20 mg | PARENTERAL | H01CB02 | Treatment of acromegaly. Treatment of diarrhea associated with vasoactive intestinal peptide tumors (VIPoma). Treatment of severe diarrhea and flushing associated with malignant carcinoid tumors. | Hospital use only | ||||
Octreotide | As Acetate | INJECTION | 200 mcg/ml | PARENTERAL | H01CB02 | Treatment of acromegaly. Treatment of diarrhea associated with vasoactive intestinal peptide tumors (VIPoma). Treatment of severe diarrhea and flushing associated with malignant carcinoid tumors. | Hospital use only | ||||
Octreotide | As Acetate | INJECTION,POWDER,EXTENDED RELEASE | 30 mg | PARENTERAL | H01CB02 | Treatment of acromegaly. Treatment of diarrhea associated with vasoactive intestinal peptide tumors (VIPoma). Treatment of severe diarrhea and flushing associated with malignant carcinoid tumors. | Hospital use only | 1389/03/31 | |||
Octreotide | As Acetate | INJECTION | 50 mcg/ml | PARENTERAL | H01CB02 | Treatment of acromegaly. Treatment of diarrhea associated with vasoactive intestinal peptide tumors (VIPoma). Treatment of severe diarrhea and flushing associated with malignant carcinoid tumors. | Hospital use only | 1382/04/29 | |||
Ofloxacin | SOLUTION/ DROPS | 0.3% | OTIC | S02AA16 | 1381/10/08 | ||||||
Ofloxacin | TABLET | 200 mg | ORAL | J01MA01 | |||||||
Ofloxacin | TABLET | 300 mg | ORAL | J01MA01 | 1380/02/30 | ||||||
Ofloxacin | SOLUTION/ DROPS | 3mg/ml | OPHTALMIC | S01AE01 | 1391/06/13 | ||||||
Ofloxacin | TABLET | 400 mg | PARENTERAL | J01MA01 | 1386/09/07 | ||||||
Olanzapine | INJECTION, POWDER, FOR SOLUTION | 10 mg | PARENTERAL | N05AH03 | 1392/03/21 | ||||||
Olanzapine | TABLET | 10 mg | ORAL | N05AH03 | |||||||
Olanzapine | TABLET | 15 mg | ORAL | N05AH03 | 1382/09/03 | ||||||
Olanzapine | TABLET | 2.5 mg | ORAL | N05AH03 | 1382/09/03 | ||||||
Olanzapine | TABLET | 5 mg | ORAL | N05AH03 | 1379/06/20 | ||||||
Olopatadine | HCl | SPRAY | 0.6%(665 mcg/puff) | INTRANASAL | R01AC08 | 1390/06/14 | |||||
Olopatadine | As HCl | SOLUTION/ DROPS | 5 mg/ 5 ml | OPHTALMIC | S01GX09 | 1388/04/21 | |||||
Omalizumab | INJECTION, POWDER | 150 mg | PARENTERAL | R03DX05 | 1391/12/23 | ||||||
Omalizumab | INJECTION, POWDER | 75mg | PARENTERAL | R03DX05 | 1391/12/23 | ||||||
Omeprazole | POWDER, FOR SUSPENSION | 20 mg | ORAL | A02BC01 | sachet | 1386/09/07 | |||||
Omeprazole | As Magnesium | POWDER, FOR SUSPENSION, DELAYED RELEASE | 10 mg | ORAL | A02BC01 | sachet | 1395/06/24 | ||||
Omeprazole | As Magnesium | POWDER, FOR SUSPENSION, DELAYED RELEASE | 2.5 mg | ORAL | A02BC01 | sachet | 1395/06/24 | ||||
Omeprazole | CAPSULE, DELAYED RELEASE PELLETS | 20 mg | ORAL | A02BC01 | |||||||
Omeprazole | As Magnesium | CAPSULE, DELAYED RELEASE PELLETS | 20 mg | ORAL | A02BC01 | 1396/03/21 | |||||
Omeprazole | As Magnesium | TABLET, DELAYED RELEASE | 20 mg | ORAL | A02BC01 | 1396/08/29 | |||||
Omeprazole | As Sodium | INJECTION, POWDER | 40 mg | PARENTERAL | A02BC01 | PPI | 1396/11/29 | ||||
Ondansetron | As HCl | INJECTION, SOLUTION | 32 mg/50ml | INTRAVENOUS DRIP | A04AA01 | 1391/10/03 | |||||
Ondansetron | As HCl | TABLET | 4 mg | ORAL | A04AA01 | 1377/06/22 | |||||
Ondansetron | As HCl | TABLET | 8 mg | ORAL | A04AA01 | 1396/12/08 | |||||
Ondansetron | TABLET, ORALLY DISINTEGRATING | 4 mg | ORAL | A04AA01 | ODT | 1395/12/18 | |||||
Ondansetron | TABLET, ORALLY DISINTEGRATING | 8 mg | ORAL | A04AA01 | ODT | 1395/12/18 | |||||
Ondansetron | As HCl | FILM | 4 mg | ORAL | A04AA01 | ORALLY DISINTEGRATING | 1396/03/21 | ||||
Ondansetron | As HCl | FILM | 8 mg | ORAL | A04AA01 | ORALLY DISINTEGRATING | 1396/03/21 | ||||
Ondansetron | As HCl | SOLUTION | 4 mg/5ml | ORAL | A04AA01 | 1382/02/21 | |||||
Ondansetron | As HCl | INJECTION | 2 mg/ml | PARENTERAL | A04AA01 | 1377/06/22 | |||||
Ophthalmic Bath Solution 1 | SOLUTION | OPHTHALMIC | S01AX07 | Boric Acid 1610 mg/100 ml | OTC medicines | 1369/10/30 | |||||
Ophthalmic Bath Solution 2 | SOLUTION | OPHTHALMIC | S01X | NaCl 0.49% or 0.64% + KCl 0.075% + MgCl2, 6H2O 0.03% + CaCl2, 2 H2O 0.048% +Sodium Citrate, 2 H2O 0.17% + Sodium Acetate, 3H2O 0.39% | OTC medicines | Balanced Salt Solution | 1360/09/22 | ||||
Ophthalmic Bath Solution 3 | SOLUTION | OPHTHALMIC | S01X | Part 1:480ml (NaCl 7.44mg+KCl 0.395mg + Na2HPO4 0.433mg+ NaHCO3 2.19mg)/ml, Part 2:20ml (Glutathion Disulfide 4.6mg + Dextrose 23 mg +Calcium Chloride,2H2O 3.85mg + Magnesium Chloride,6H2O 5mg)/ml | OTC medicines | Balanced Salt Solution+Glutathion | 1361/12/23 | ||||
Opium | TINCTURE | 10 mg/ml | ORAL | N02AA02 | For abuse and addiction treatment centers | 1389/03/29 | |||||
Orlistat | CAPSULE | 120 mg | ORAL | A08AB01 | 1381/06/10 | ||||||
Orlistat | CAPSULE | 60 mg | ORAL | A08AB01 | OTC medicines | 1387/03/28 | |||||
Oseltamivir | CAPSULE | 30 mg | ORAL | J05AH02 | For Health Dept. of MOH only | 1388/08/20 | |||||
Oseltamivir | CAPSULE | 45 mg | ORAL | J05AH02 | For Health Dept. of MOH only | 1388/08/20 | |||||
Oseltamivir | As phosphate | POWDER, FOR SOLUTION | 30 mg/5ml | ORAL | J05AH02 | For Health Dept. of MOH only | 1395/05/03 | ||||
Oseltamivir | As phosphate | POWDER, FOR SOLUTION | 60 mg/5ml | ORAL | J05AH02 | For Health Dept. of MOH only | |||||
Oseltamivir | As phosphate | POWDER, FOR SUSPENSION | 60 mg/5ml | ORAL | J05AH02 | For Health Dept. of MOH only | 1391/06/13 | ||||
Oseltamivir | As phosphate | CAPSULE | 75 mg | ORAL | J05AH02 | For Health Dept. of MOH only | 1384/04/12 | ||||
Oxaliplatin | INJECTION, POWDER, LYOPHILIZED | 100 mg | PARENTERAL | L01XA03 | 1380/02/09 | ||||||
Oxaliplatin | INJECTION, SOLUTION, CONCENTRATE | 5 mg/ml | PARENTERAL | L01XA03 | |||||||
Oxaliplatin | INJECTION, POWDER, LYOPHILIZED | 50 mg | PARENTERAL | L01XA03 | 1380/02/09 | ||||||
Oxandrolone | TABLET | 2.5 mg | ORAL | A14AA08 | 1378/08/23 | ||||||
Oxandrolone | TABLET | 10 mg | ORAL | A14AA08 | 1397/06/24 | ||||||
Oxazepam | TABLET | 10 mg | ORAL | N05BA04 | |||||||
Oxcarbazepine | TABLET | 150 mg | ORAL | N03AF02 | 1380/11/28 | ||||||
Oxcarbazepine | TABLET | 300 mg | ORAL | N03AF02 | 1380/11/28 | ||||||
Oxcarbazepine | TABLET | 600 mg | ORAL | N03AF02 | 1380/11/28 | ||||||
Oxybutynin | HCl | TABLET, EXTENDED RELEASE | 10 mg | ORAL | G04BD04 | 1392/07/22 | |||||
Oxybutynin | HCl | TABLET, EXTENDED RELEASE | 15 mg | ORAL | G04BD04 | 1392/07/22 | |||||
Oxybutynin | HCl | TABLET | 5 mg | ORAL | G04BD04 | ||||||
Oxycodone | HCl | TABLET, EXTENDED RELEASE | 10 mg | ORAL | N02AA05 | Narcotic medicines; Should be labelled as under control medicines | 1388/08/20 | ||||
Oxycodone | HCl | TABLET | 15 mg | ORAL | N02AA05 | Narcotic medicines; Should be labelled as under control medicines | 1383/11/04 | ||||
Oxycodone | HCl | TABLET, EXTENDED RELEASE | 20 mg | ORAL | N02AA05 | Narcotic medicines; Should be labelled as under control medicines | 1388/08/20 | ||||
Oxycodone | HCl | TABLET | 30 mg | ORAL | N02AA05 | Narcotic medicines; Should be labelled as under control medicines | 1383/11/04 | ||||
Oxycodone | HCl | TABLET, EXTENDED RELEASE | 40 mg | ORAL | N02AA05 | Narcotic medicines; Should be labelled as under control medicines | 1388/08/20 | ||||
Oxycodone | HCl | TABLET | 5 mg | ORAL | N02AA05 | Narcotic medicines; Should be labelled as under control medicines | 1383/11/04 | ||||
Oxycodone | HCl | TABLET, EXTENDED RELEASE | 80 mg | ORAL | N02AA05 | Narcotic medicines; Should be labelled as under control medicines | 1388/08/20 | ||||
Oxygen | GAS, MEDICINAL | INHALATION | 1396/03/21 | ||||||||
Oxymetazoline | HCl | SPRAY | 0.05% | NASAL | S01GA04 | for local production only | 1389/06/29 | ||||
Oxymetazoline | HCl | SPRAY | 0.10% | NASAL | S01GA04 | for local production only | 1389/06/29 | ||||
Oxymetholone | TABLET | 50 mg | ORAL | A14AA05 | |||||||
Oxytocin | INJECTION | 10 U/ml | PARENTERAL | H01BB02 | Hospital use only | ||||||
Oxytocin | INJECTION | 5 U/ml | PARENTERAL | H01BB02 | Hospital use only | ||||||
Paclitaxel | INJECTION, POWDER FOR SUSPENSION | 100 mg | PARENTERAL | L01CD01 | Albumin band (Nano) | 1392/06/12 | |||||
Paclitaxel | INJECTION | 6 mg/ml | PARENTERAL | L01CD01 | Treatment of AIDS-related Kaposi's sarcoma. Treatment of non-superficial urothelial cancer | 1381/05/20 | |||||
Pamidronate | Disodium | INJECTION | 15 mg/ml | PARENTERAL | M05BA03 | 1385/08/17 | |||||
Pamidronate | Disodium | INJECTION | 3 mg/ml | PARENTERAL | M05BA03 | ||||||
Pamidronate | Disodium | INJECTION, POWDER, LYOPHILIZED | 30 mg | PARENTERAL | M05BA03 | 1382/03/04 | |||||
Pamidronate | Disodium | INJECTION, POWDER, LYOPHILIZED | 90 mg | PARENTERAL | M05BA03 | 1382/03/04 | |||||
Pamidronate | Disodium | INJECTION, SOLUTION, CONCENTRATE | 9mg/ml | PARENTERAL | M05BA03 | ||||||
Pancreatin | TABLET, DELAYED RELEASE | ORAL | A09AA02 | OTC medicines | 1369/10/30 | ||||||
Pancreatin | CAPSULE | ORAL | A09AA02 | ||||||||
Pancuronium | Bromide | INJECTION | 2 mg/ml | PARENTERAL | M03AC01 | Hospital use only | 1371/08/03 | ||||
Panitumumab | INJECTION, SOLUTION, CONCENTRATE | 20mg/ml | PARENTERAL | L01XC08 | Metastatic colorectal cancer | 1395/12/22 | |||||
Pantoprazole | As Sodium sesquihydrate | CAPSULE, DELAYED RELEASE | 15 mg | ORAL | A02BC02 | 1385/08/17 | |||||
Pantoprazole | As Sodium sesquihydrate | TABLET, DELAYED RELEASE | 20 mg | ORAL | A02BC02 | 1382/04/15 | |||||
Pantoprazole | As Sodium sesquihydrate | CAPSULE, DELAYED RELEASE | 20 mg | ORAL | A02BC02 | 1386/06/28 | |||||
Pantoprazole | As Sodium | INJECTION, POWDER, LYOPHILIZED | 40 mg | INTRAVENOUS DRIP | A02BC02 | 1382/03/04 | |||||
Pantoprazole | As Sodium sesquihydrate | TABLET, DELAYED RELEASE | 40 mg | ORAL | A02BC02 | 1382/04/15 | |||||
Pantoprazole | As Sodium sesquihydrate | CAPSULE, DELAYED RELEASE | 40 mg | ORAL | A02BC02 | 1386/06/28 | |||||
Papaverine | HCl | INJECTION | 40 mg/ml | PARENTERAL | G04BE02 | Hospital use only | 1375/12/12 | ||||
Para aminosalicylic acid | GRANULE | 4 g | ORAL | J04AA01 | Treatment of tuberculosis infections | ||||||
Para-Aminobenzoic Acid | BULK | V03 | Bulk medicines | ||||||||
Parathormon | INJECTION | 100 uspU/ml | PARENTERAL | H05AA01 | Hospital use only | 1361/09/14 | |||||
Paromomycin | As Sulfate | SYRUP | 125 mg/ 5ml | ORAL | A07AA06 | 1359/07/13 | |||||
Paromomycin | As Sulfate | CAPSULE | 250 mg | ORAL | A07AA06 | 1359/07/13 | |||||
Paromomycin+Urea | OINTMENT | TOPICAL | D06AX | (Paromomycin 15 g + Urea 10 g ) / 100 g | |||||||
Paroxetine | As HCl | TABLET | 20 mg | ORAL | N06AB05 | 1393/02/07 | |||||
Paroxetine | As HCl | TABLET | 40 mg | ORAL | N06AB05 | 1393/02/07 | |||||
Paroxetine | As Mesilate | TABLET | 20 mg | ORAL | N06AB05 | 1395/12/22 | |||||
Patent Blue V | INJECTION | PARENTERAL | V04CX | 1363/05/21 | |||||||
Pediatric Grippe | SYRUP | ORAL | R06AB54 | (Chlorpheniramine Maleate 0.67mg + Pseudoephedrine HCl 10 mg)/5ml | OTC medicines | ||||||
Pegaspargase | INJECTION, POWDER | 3750 IU | PARENTERAL | L01XX24 | Orphan medicines | ||||||
Pegaspargase | INJECTION | 750 IU/ml | PARENTERAL | L01XX24 | treatment of Acute lymphocytic leukemia | Orphan medicines | 1383/06/01 | ||||
Pegfilgrastim | INJECTION, SOLUTION | 10 mg/ml | PARENTERAL | L03AA13 | 1393/03/25 | ||||||
Peginterferon Alfa-2a | INJECTION | 180 mcg/ml | PARENTERAL | L03AB11 | Treatment of chronic myelogenous leukemia. Treatment of renal cell carcinoma. | 1383/02/13 | |||||
Peginterferon Alfa-2a | INJECTION | 270 mcg/ml | PARENTERAL | L03AB11 | Treatment of chronic myelogenous leukemia. Treatment of renal cell carcinoma. | 1386/03/23 | |||||
Peginterferon Alfa-2a | INJECTION | 360 mcg/ml | PARENTERAL | L03AB11 | Treatment of chronic myelogenous leukemia. Treatment of renal cell carcinoma. | ||||||
Peginterferon Alfa-2b | INJECTION, POWDER, LYOPHILIZED | 100 mcg | PARENTERAL | L03AB10 | Treatment of chronic myelogenous leukemia. Treatment of renal cell carcinoma. | 1384/05/16 | |||||
Peginterferon Alfa-2b | INJECTION, POWDER, LYOPHILIZED | 120 mcg | PARENTERAL | L03AB10 | Treatment of chronic myelogenous leukemia. Treatment of renal cell carcinoma. | 1384/05/16 | |||||
Peginterferon Alfa-2b | INJECTION, POWDER, LYOPHILIZED | 150 mcg | PARENTERAL | L03AB10 | Treatment of chronic myelogenous leukemia. Treatment of renal cell carcinoma. | 1384/05/16 | |||||
Peginterferon Alfa-2b | INJECTION, POWDER, LYOPHILIZED | 50 mcg | PARENTERAL | L03AB10 | Treatment of chronic myelogenous leukemia. Treatment of renal cell carcinoma. | 1384/05/16 | |||||
Peginterferon Alfa-2b | INJECTION, POWDER, LYOPHILIZED | 80 mcg | PARENTERAL | L03AB10 | Treatment of chronic myelogenous leukemia. Treatment of renal cell carcinoma. | 1384/05/16 | |||||
Peginterferon Beta-1a | INJECTION | 125 mcg/ 0.5 ml | PARENTERAL | L03AB13 | Treatment of relapsing-remitting multiple sclerosis | 1395/12/22 | |||||
Peginterferon Beta-1a | INJECTION | 94 mcg/ 0.5 ml | PARENTERAL | L03AB13 | Treatment of relapsing-remitting multiple sclerosis | 1395/12/22 | |||||
Peginterferon Beta-1a | INJECTION | 63 mcg/ 0.5 ml | PARENTERAL | L03AB13 | Treatment of relapsing-remitting multiple sclerosis | 1395/12/22 | |||||
Pemetrexed | as disodium | INJECTION, POWDER, LYOPHILIZED | 100 mg | PARENTERAL | L01BA04 | 1390/07/05 | |||||
Pemetrexed | as disodium | INJECTION, POWDER, LYOPHILIZED | 500 mg | PARENTERAL | L01BA04 | 1390/07/05 | |||||
Penicillamine | CAPSULE | 250 mg | ORAL | M01CC01 | |||||||
Penicillamine | TABLET | 250 mg | ORAL | M01CC01 | |||||||
Penicillin 6-3-3 | INJECTION, POWDER, | PARENTERAL | J01RA01 | Benzathine penicillin G 600,000U+Potassium Penicillin G 300,000U+Procaine Penicillin G 300,000U | |||||||
Penicillamine | TABLET, DELAYED RELEASE | 300 mg | ORAL | M01CC01 | 1396/04/27 | ||||||
Penicillin G | Potassium | INJECTION, POWDER | 1,000,000 U | PARENTERAL | J01CE01 | ||||||
Penicillin G | Benzathin | INJECTION,POWDER,EXTENDED RELEASE | 1,200,000 U | PARENTERAL | J01RA01 | ||||||
Penicillin G | Procaine | INJECTION, POWDER | 400,000 U | PARENTERAL | J01RA01 | Potassium Penicillin G 100,000U+Procaine Penicillin G 300,000U | |||||
Penicillin G | Potassium | INJECTION, POWDER | 5,000,000 U | PARENTERAL | J01CE01 | 1384/02/26 | |||||
Penicillin G | Sodium | INJECTION, POWDER | 5,000,000 U | PARENTERAL | J01RA01 | ||||||
Penicillin G | Benzathin | INJECTION,POWDER,EXTENDED RELEASE | 600,000 U | PARENTERAL | J01RA01 | ||||||
Penicillin G | Procaine | INJECTION, POWDER | 800,000 U | PARENTERAL | J01RA01 | Potassium Penicillin G 200,000U+ Procaine Penicillin G 600,000U | |||||
Penicillin V | As Potassium | POWDER, FOR SOLUTION | 125 mg/5ml | ORAL | J01RA01 | 1359/07/13 | |||||
Penicillin V | Benzathine | POWDER, FOR SUSPENSION | 200,000 IU/5ml | ORAL | J01RA01 | 1374/07/30 | |||||
Penicillin V | As Potassium | POWDER, FOR SUSPENSION | 250 mg/5ml | ORAL | J01RA01 | ||||||
Penicillin V | Benzathine | POWDER, FOR SUSPENSION | 400,000 IU/5ml | ORAL | J01RA01 | 1374/07/30 | |||||
Penicillin V | As Potassium | TABLET | 500 mg | ORAL | J01RA01 | ||||||
Pentagastrin | INJECTION | 0.25 mg/ml | PARENTERAL | V04CG04 | |||||||
Pentamidine | Isoethionate | INJECTION, POWDER, LYOPHILIZED | 300 mg | PARENTERAL | P01CX01 | Hospital use only | |||||
Pentazocine | As Lacate | INJECTION | 30 mg/ml | PARENTERAL | N02AD01 | Hospital use only | |||||
Pentazocine | HCl | TABLET | 50 mg | ORAL | N02AD01 | ||||||
Pentoxifylline | TABLET, EXTENDED RELEASE | 400 mg | ORAL | C04AD03 | |||||||
Peritoneal Dialysis I | SOLUTION | PARENTERAL | B05D | Na+ 132 mEq/L + Ca++ 3.5 mEq/L + Mg++ 1.5 mEq/L + Cl- 102 mEq/L + Lactate 35 mEq/L+ Dextrose anhydrous or monohydrate Eq. to 13.62 g/L Dextrose+Water For Inj. Q.S.To 1000ml | |||||||
Peritoneal Dialysis I; Bicarbonate Based | SOLUTION | PARENTERAL | B05D | Glucose anhydrous 75.5 mmol/L Na+ 132 mmol/L + Ca++ 1,25 mmol/L + Mg++ 0.25 mmol/L + Cl- 95 mmol/L + (S)-Lactate 15 mmol/L+ HCo3- 25mmol/L | 1389/08/24 | ||||||
Peritoneal Dialysis II | SOLUTION | PARENTERAL | B05D | Na+ 132 mEq/L + Ca++ 3.5 mEq/L + Mg++ 1.5 mEq/L + Cl- 102 mEq/L + Lactate 35 mEq/L+ Dextrose anhydrous or monohydrate Eq. to 22.70 g/L Dextrose+Water For Inj. Q.S.To 1000ml | |||||||
Peritoneal Dialysis II; Bicarbonate Based | SOLUTION | PARENTERAL | B05D | Glucose anhydrous 126 mmol/L Na+ 132 mmol/L + Ca++ 1,25 mmol/L + Mg++ 0.25 mmol/L + Cl- 95 mmol/L + (S)-Lactate 15 mmol/L HCo3-25mmol/L | 1389/08/24 | ||||||
Peritoneal Dialysis III | SOLUTION | PARENTERAL | B05D | Na+ 132 mEq/L + Ca++ 3.5 mEq/L + Mg++ 1.5 mEq/L + Cl- 102 mEq/L + Lactate 35 mEq/L+Dextrose anhydrous or monohydrate Eq. to 38.60 g/L Dextrose+Water For Inj. Q.S.To 1000ml | |||||||
Peritoneal Dialysis III; Bicarbonate Based | SOLUTION | PARENTERAL | B05D | Glucose anhydrous 214 mmol/L Na+ 132 mmol/L + Ca++ 1,25 mmol/L + Mg++ 0.25 mmol/L + Cl- 95 mmol/L + (S)-Lactate 15 mmol/L + HCo3-25mmol/L | 1389/08/24 | ||||||
Peritoneal Dialysis IV; Icodextrine Based | SOLUTION | PARENTERAL | B05D | Icidextrine 75 g/L+ Na+ 133 mmol/L + Ca++ 1,75 mmol/L + Mg++ 0.25 mmol/L + Cl- 96 mmol/L + Lactate 40 mmol/L | |||||||
Peritoneal DialysisV-I; Bicarbonate Based (Lactate Free) | SOLUTION | PARENTERAL | B05D | Glucose anhydrous 83.25 mmol/L Na+ 134 mmol/L + Ca++ 1,75 mmol/L + Mg++ 0.5 mmol/L + Cl- 104.5 mmol/L + HCo3-34.5mmol/L | 1395/09/01 | ||||||
Peritoneal DialysisV-II; Bicarbonate Based (Lactate Free) | SOLUTION | PARENTERAL | B05D | Glucose anhydrous 126.1 mmol/L Na+ 134 mmol/L + Ca++ 1,75 mmol/L + Mg++ 0.5 mmol/L + Cl- 104.5 mmol/L + HCo3-34.5mmol/L | 1395/09/01 | ||||||
Peritoneal DialysisV-III; Bicarbonate Based (Lactate Free) | SOLUTION | PARENTERAL | B05D | Glucose anhydrous 235.9 mmol/L Na+ 134 mmol/L + Ca++ 1,75 mmol/L + Mg++ 0.5 mmol/L + Cl- 104.5 mmol/L + HCo3-34.5mmol/L | 1395/09/01 | ||||||
Permethrin | CREAM | 1% | TOPICAL | P03AC04 | OTC medicines | 1372/02/12 | |||||
Permethrin | SHAMPOO | 1% | TOPICAL | P03AC04 | OTC medicines | 1374/08/21 | |||||
Permethrin | CREAM | 5% | TOPICAL | P03AC04 | 1381/11/20 | ||||||
Perphenazine | TABLET | 2 mg | ORAL | N05AB03 | |||||||
Perphenazine | TABLET | 4 mg | ORAL | N05AB03 | |||||||
Perphenazine | INJECTION | 5 mg/ml | PARENTERAL | N05AB03 | |||||||
Perphenazine | TABLET | 8 mg | ORAL | N05AB03 | |||||||
Pethidine | HCl | INJECTION | 25 mg/ml | PARENTERAL | N02AB02 | Hospital use only | 1386/03/23 | ||||
Pethidine | HCl | INJECTION | 50 mg/ml | PARENTERAL | N02AB02 | Hospital use only | |||||
Phenazopyridine | HCl | TABLET | 100 mg | ORAL | G04BX06 | 1375/12/12 | |||||
Phenobarbital | TABLET | 100 mg | ORAL | N03AA02 | |||||||
Phenobarbital | Sodium | INJECTION | 100 mg/ml | PARENTERAL | N03AA02 | Hospital use only | |||||
Phenobarbital | TABLET | 15 mg | ORAL | N03AA02 | |||||||
Phenobarbital | As Sodium | INJECTION | 200 mg/ml | PARENTERAL | N03AA02 | Hospital use only | |||||
Phenobarbital | Sodium | INJECTION | 200 mg/ml | PARENTERAL | N03AA02 | Hospital use only | |||||
Phenobarbital | TABLET | 60 mg | ORAL | N03AA02 | |||||||
Phenol | BULK | V03 | Bulk medicines | ||||||||
Phenol Glycerin | SOLUTION/ DROPS | 6.40% | OTIC | D08AE03 | Phenol 6.4 g + Glycerin qs 100 g | OTC medicines | |||||
Phenolsulphonphthalein | INJECTION | 6 mg/ml | PARENTERAL | V04CH03 | |||||||
Phenoxybenzamine | HCl | CAPSULE | 10 mg | ORAL | C04AX02 | 1377/02/09 | |||||
Phentolamine | Mesylate | INJECTION | 10 mg/ml | PARENTERAL | C04AB01 | Hospital use only | |||||
Phenylephrine | HCl | SPRAY | 0.25% | NASAL | R01AA04 | OTC medicines | 1384/03/09 | ||||
Phenylephrine | HCl | SOLUTION/ DROPS | 0.25% | NASAL | R01AA04 | OTC medicines | 1362/08/22 | ||||
Phenylephrine | HCl | SPRAY | 0.5% | NASAL | R01AA04 | OTC medicines | 1384/03/09 | ||||
Phenylephrine | HCl | SOLUTION/ DROPS | 0.5% | NASAL | R01AA04 | OTC medicines | 1362/08/22 | ||||
Phenylephrine | HCl | SOLUTION/ DROPS | 5% | OPHTHALMIC | S01GA55 | ||||||
Phenylephrine | HCl | INJECTION | 10 mg/ml | PARENTERAL | C01CA06 | Hospital use only | |||||
Phenylephrine+Zinc | SOLUTION/ DROPS | OPHTHALMIC | S01GA55 | Phenylephrine HCl 0.12%+ Zinc Sulfate 0.25% | |||||||
Phenytoin | Sodium | CREAM | 1% | TOPICAL | D03 | ||||||
Phenytoin | Sodium | CAPSULE | 100 mg | ORAL | N03AB02 | ||||||
Phenytoin | SUSPENSION | 125 mg/5ml | ORAL | N03AB02 | 1392/03/11 | ||||||
Phenytoin | SUSPENSION | 30 mg/5ml | ORAL | N03AB02 | |||||||
Phenytoin | Sodium | CAPSULE | 50 mg | ORAL | N03AB02 | 1362/10/11 | |||||
Phenytoin | Sodium | INJECTION | 50 mg/ml | PARENTERAL | N03AB02 | Hospital use only | |||||
Phenytoin+Phenobarbital | TABLET | ORAL | N03AB52 | Phenytoin Sodium 100mg+ Phenobarbital 50mg | 1364/09/17 | ||||||
Phosphate (Organic) | INJECTION | PARENTERAL | B05XA14 | (Sodium Glycerophosphate anhydrose 216mg)/ml | |||||||
Phosphate [32P] Sodium | INJECTION, SOLUTION | 5 mCi/ml | PARENTERAL | V10XX01 | Radiopharmaceuticals | 1383/09/22 | |||||
Phosphate, Potassium | INJECTION | PARENTERAL | B05XA06 | (KH2PO4 225mg+ K2HPO4 236mg) / ml | Hospital use only | ||||||
Phosphate, Potassium Monobasic | TABLET | 500 mg | ORAL | A12BA | |||||||
Phosphate, Potassium Monobasic | BULK | V03 | Bulk medicines | 1368/06/19 | |||||||
Phosphate, Sodium | TABLET, EFFERVESCENT | ORAL | A12BA | NaH2PO4 1936 mg+ NaHCO3 350 mg+KHCO3 315 mg | |||||||
Phosphate, Sodium Dibasic | BULK | V03 | Bulk medicines | 1368/06/19 | |||||||
Phosphate, Sodium monobasic | BULK | V03 | Bulk medicines | 1368/06/19 | |||||||
Phosphocysteamine | POWDER | 150 mg | ORAL | A16AA04 | Treatment of cystinosis. | 1375/11/07 | |||||
Phosphocysteamine | CAPSULE | 150 mg | ORAL | A16AA04 | Treatment of cystinosis. | 1375/11/07 | |||||
Phosphorous [32P] Chromic Phosphate Colloid | INJECTION,COLLOIDAL SOLUTION | 5 mCi | INTRACAVITARY | V10AX01 | Radiopharmaceuticals | 1383/09/22 | |||||
Pilocarpine | HCl | SOLUTION/ DROPS | 1% | OPHTHALMIC | S01EB01 | ||||||
Pilocarpine | Nitrate | SOLUTION/ DROPS | 1% | OPHTHALMIC | S01EB01 | ||||||
Pilocarpine | HCl | SOLUTION/ DROPS | 2% | OPHTHALMIC | S01EB01 | ||||||
Pilocarpine | Nitrate | SOLUTION/ DROPS | 2% | OPHTHALMIC | S01EB01 | ||||||
Pilocarpine | Nitrate | SOLUTION/ DROPS | 4% | OPHTHALMIC | S01EB01 | Treatment of xerostomia induced by radiation therapy for head and neck cancer. Treatment of xerostomia and keratoconjunctivitis sicca in Sjogren's syndrome patients. | Orphan medicines | ||||
Pilocarpine | HCl | SOLUTION/ DROPS | 4% | OPHTHALMIC | S01EB01 | ||||||
Pimecrolimus | CREAM | 1% | Topical | D11AH02 | 1388/02/30 | ||||||
Pimozide | TABLET | 4 mg | ORAL | N05AG02 | |||||||
Pimozide | TABLET | 2 mg | ORAL | N05AG02 | 1396/02/02 | ||||||
Pimozide | TABLET | 1 mg | ORAL | N05AG02 | 1395/10/08 | ||||||
Pioglitazone | As HCl | TABLET | 15 mg | ORAL | A10BG03 | 1384/04/12 | |||||
Pioglitazone | As HCl | TABLET | 30 mg | ORAL | A10BG03 | 1384/04/12 | |||||
Pioglitazone | As HCl | TABLET | 45 mg | ORAL | A10BG03 | 1384/04/12 | |||||
Pipecuronium | Bromide | INJECTION, POWDER, LYOPHILIZED | 4 mg | PARENTERAL | M03AC06 | Hospital use only | 1377/06/22 | ||||
Piperacillin | INJECTION, POWDER, | 1 g | PARENTERAL | J01CA12 | Hospital use only | 1364/12/04 | |||||
Piperacillin | INJECTION, POWDER, | 2 g | PARENTERAL | J01CA12 | Hospital use only | 1364/12/04 | |||||
Piperacillin+Tazobactam | INJECTION, POWDER | PARENTERAL | J01CR05 | Piperacillin (as Sodium ) 2g + Tazobactam (as Sodium ) 250mg | Hospital use only | 1381/12/04 | |||||
Piperacillin+Tazobactam | INJECTION, POWDER, | PARENTERAL | J01CR05 | Piperacillin (as Sodium ) 3g + Tazobactam (as Sodium ) 375mg | Hospital use only | 1381/12/04 | |||||
Piperacillin+Tazobactam | INJECTION, POWDER | PARENTERAL | J01CR05 | Piperacillin (as Sodium ) 4g + Tazobactam (as Sodium ) 500mg | Hospital use only | 1381/12/04 | |||||
Piperazine | As Citrate or Phosphate | TABLET | 500 mg | ORAL | P02CB01 | ||||||
Piperazine | As Citrate | SYRUP | 750 mg/5ml | ORAL | P02CB01 | ||||||
Piracetam | LIQUID | 33.33% | ORAL | N06BX03 | 1363/09/11 | ||||||
Piracetam | SOLUTION | 20.00% | ORAL | N06BX03 | 1396/05/28 | ||||||
Piracetam | TABLET | 800 mg | ORAL | N06BX03 | 1363/03/20 | ||||||
Pirfenidone | TABLET | 200 mg | ORAL | L04AX05 | Idiopathic Pulmonary Fibrosis | Orphan medicines | 1395/08/02 | ||||
Pirfenidone | TABLET | 267 mg | ORAL | L04AX05 | Idiopathic Pulmonary Fibrosis | Orphan medicines | 1397/02/11 | ||||
Pirfenidone | TABLET | 534 mg | ORAL | L04AX05 | Idiopathic Pulmonary Fibrosis | Orphan medicines | 1397/03/01 | ||||
Pirfenidone | TABLET | 801 mg | ORAL | L04AX05 | Idiopathic Pulmonary Fibrosis | Orphan medicines | 1397/02/11 | ||||
Piroxicam | GEL | 0.5% | TOPICAL | M02AA07 | OTC medicines | 1371/04/14 | |||||
Piroxicam | CAPSULE | 10 mg | ORAL | M01AC01 | 1366/03/31 | ||||||
Piroxicam | SUPPOSITORY | 20 mg | RECTAL | M01AC01 | 1379/09/27 | ||||||
Piroxicam | INJECTION | 20 mg/ml | PARENTERAL | M01AC01 | Hospital use only | 1375/07/01 | |||||
Plasma | INJECTION | PARENTERAL | B05AX03 | Blood component replacement | Hospital use only | Blood plasma (INN) | 1394/11/13 | ||||
Plasma, Crypoor | INJECTION | PARENTERAL | B05AX03 | Blood component replacement | Hospital use only | Blood plasma (INN) | 1394/11/13 | ||||
Plasma, Cryprecipitate | INJECTION | PARENTERAL | B05AX03 | Blood component replacement | Hospital use only | Blood plasma (INN) | 1394/11/13 | ||||
Plasma, Fresh Frozen | INJECTION | PARENTERAL | B05AX03 | Blood component replacement | Hospital use only | Blood plasma (INN) | 1394/11/13 | ||||
Plastibase | OINTMENT | TOPICAL | D | Bulk medicines | 1390/01/29 | ||||||
Platelet, CMV Negative | INJECTION | PARENTERAL | B05AX02 | Blood component replacement | Hospital use only | Thrombocytes (INN) | 1394/11/13 | ||||
Platelet, Concentrated | INJECTION | PARENTERAL | B05AX02 | Blood component replacement | Hospital use only | Thrombocytes (INN) | 1394/11/13 | ||||
Platelet, Irradiated | INJECTION | PARENTERAL | B05AX02 | Blood component replacement | Hospital use only | Thrombocytes (INN) | 1394/11/13 | ||||
Platelet, Phresis | INJECTION | PARENTERAL | B05AX02 | Blood component replacement | Hospital use only | Thrombocytes (INN) | 1394/11/13 | ||||
Platelet, Phresis and Irradiated | INJECTION | PARENTERAL | B05AX02 | Blood component replacement | Hospital use only | Thrombocytes (INN) | 1394/11/13 | ||||
Platelet, Pooled | INJECTION | PARENTERAL | B05AX02 | Blood component replacement | Hospital use only | Thrombocytes (INN) | 1394/11/13 | ||||
Platelet, Pooled and Leucocyte Reduced | INJECTION | PARENTERAL | B05AX02 | Blood component replacement | Hospital use only | Thrombocytes (INN) | 1394/11/13 | ||||
Platelet, Pooled and Leucocyte Reduced and Irradiated | INJECTION | PARENTERAL | B05AX02 | Blood component replacement | Hospital use only | Thrombocytes (INN) | 1394/11/13 | ||||
Plerixafor | INJECTION, SOLUTION | 20mg/ml | PARENTERAL | A03AX16 | Hospital use only | 1393/01/24 | |||||
Pneumococcal Vaccine | INJECTION | PARENTERAL | J07AL02 | Polysaccharide cojugate adsorbed (10 Valents) | 1361/08/20 | ||||||
Pneumococcal Vaccine | INJECTION | PARENTERAL | J07AL02 | Polysaccharide cojugate adsorbed (13 Valents) | 1361/08/20 | ||||||
Pneumococcal Vaccine | INJECTION | PARENTERAL | J07AL02 | Polysaccharide adsorbed (23 Valents) | 1361/08/20 | ||||||
Poliomyelitis Vaccine | INJECTION | PARENTERAL | J07BF03 | Trivalent Killed | |||||||
Poliovirus Vaccine | SOLUTION | ORAL | J07BF01 | Live attenuated (monovalent, bivalent, trivalent) | |||||||
Poly Ethylene Glycol | POWDER | ORAL | A06AD15 | Macrogol 4000 | |||||||
Poly Ethylene Glycol | POWDER | ORAL | A06AD15 | Macrogol 3350 | 1395/10/07 | ||||||
Poly Ethylene Glycol | BULK | V03 | Bulk medicines | 1384/08/24 | |||||||
Poly Ethylenglycol+Electrolyte 1 | POWDER, FOR SOLUTION | ORAL | A06AD65 | (Macrogol 3350, 13.125 g, Sodium chloride 0.3507 g, Sodium bicarbonate 0.1785 g, Potassium chloride 0.0466 g) / Sachet | Osmotic laxatives | 1381/06/18 | |||||
Poly Ethylenglycol+Electrolyte 2 | POWDER, FOR SOLUTION | ORAL | A06AD65 | (Macrogol 3350, 17.6 mmol, Sodium 125 mmol, Sulfate 40 mmol, Chloride 35 mmol, Bicarbonate 20 mmol, potassium 10 mmol ) / Lit. | Osmotic laxatives | ||||||
Polymyxin B | Sulfate | INJECTION | 500,000 U | PARENTERAL | S01AA18 | Hospital use only | INJECTION/OPHTHALMIC DROPS | ||||
Polymyxin B+Neomycin+Hydrocortison | SOLUTION/ DROPS | OTIC | S02AA11 | (Polymyxin B sulfate 10,000 U + Neomycin Sulfate 5 mg + Hydrocortisone 10 mg)/1 ml | 1361/09/28 | ||||||
Polymyxin B+Neomycin+Hydrocortison | SUSPENSION/ DROPS | OTIC | S02AA11 | (Polymyxin B sulfate 10,000 U + Neomycin Sulfate 5 mg + Hydrocortisone 10 mg)/1 ml | 1379/09/27 | ||||||
Polysaccharide Iron Complex | CAPSULE | 150 mg | ORAL | B03AB | 100% Elemntal Iron | 1396/12/13 | |||||
Polysorbate 80 | BULK | V03 | Bulk medicines | 1368/06/19 | |||||||
Poractant Alfa | INJECTION, SUSPENSION | 80 mg/ ml | INTRATRACHEAL | R07AA | Hospital use only | 1387/12/21 | |||||
Posaconazole | TABLET, DELAYED RELEASE | 100 mg | ORAL | J02AC04 | Mucormyosis | 1395/12/22 | |||||
Posaconazole | SUSPENSION | 40 mg/ml | ORAL | J02AC04 | Mucormyosis | 1396/02/02 | |||||
Potassium acetate | INJECTION, SOLUTION, CONCENTRATE | PARENTERAL | B05XA17 | (2Meq potassium + 2Meq acetate)/ml, 100 ml | Hospital use only | 1389/03/31 | |||||
Potassium Aminobenzoate | POWDER | 3 g | ORAL | D11 | Paba-k; Sachet | ||||||
Potassium Aminobenzoate | TABLET | 500 mg | ORAL | D11 | Paba-k | 1388/09/04 | |||||
Potassium Aminobenzoate | CAPSULE | 500 mg | ORAL | D11 | Paba-k | 1395/11/06 | |||||
Potassium Chloride | TABLET, EXTENDED RELEASE | 500 mg | ORAL | A12BA01 | |||||||
Potassium Chloride | TABLET, EXTENDED RELEASE | 600 mg | ORAL | A12BA01 | 1385/08/17 | ||||||
Potassium Chloride | CAPSULE, EXTENDED RELEASE | 600 mg | ORAL | A12BA01 | 1396/02/02 | ||||||
Potassium Chloride | INJECTION | INTRAVENOUS DRIP | B05XA01 | Potassium Chloride 0.3 % in Dextrose 5 % | 1392/05/29 | ||||||
Potassium Chloride | INJECTION | INTRAVENOUS DRIP | B05XA01 | Potassium Chloride 0.15 % in Dextrose 5 % | 1396/12/13 | ||||||
Potassium Chloride Concentrated | INJECTION, SOLUTION, CONCENTRATE | 1 mEq/ml | INTRAVENOUS DRIP | B05XA01 | Hospital use only | 1385/02/12 | |||||
Potassium Chloride Concentrated | INJECTION, SOLUTION, CONCENTRATE | 2 mEq/ml | INTRAVENOUS DRIP | B05XA01 | Hospital use only | 1361/02/19 | |||||
Potassium Citrate | TABLET, EXTENDED RELEASE | 10 mEq | ORAL | A12BA02 | For the dissolution and control of uric acid and cysteine calculi in the urinary tract. | 1381/05/20 | |||||
Potassium Citrate | POWDER | 10 mEq | ORAL | A12BA02 | For the dissolution and control of uric acid and cysteine calculi in the urinary tract. Sachet | 1384/08/24 | |||||
Potassium Citrate | TABLET, EXTENDED RELEASE | 5 mEq | ORAL | A12BA02 | For the dissolution and control of uric acid and cysteine calculi in the urinary tract. | 1381/05/20 | |||||
Potassium Citrate | TABLET | 5 mEq | ORAL | A12BA02 | For the dissolution and control of uric acid and cysteine calculi in the urinary tract. | In condition of providing clinical trial results | 1395/11/12 | ||||
Potassium Citrate | BULK | V03 | Bulk medicines | 1365/11/19 | |||||||
Potassium Permanganate | BULK | V03 | Bulk medicines | ||||||||
Potassium phosphate | INJECTION, SOLUTION, CONCENTRATE | PARENTERAL | B05XA | (4.4Meq potassium + 3mmol phosphate)/ml, 100 ml | Hospital use only | 1389/03/31 | |||||
Povidone Iodine | SOLUTION | 0.70% | TOPICAL | D08AG02 | OTC medicines; Scrub solution | 1389/03/31 | |||||
Povidone Iodine | SPRAY | 2.50% | TOPICAL | D08AG02 | OTC medicines | 1381/03/12 | |||||
Povidone Iodine | SPONGE | 7.50% | TOPICAL | D09AA09 | OTC medicines | ||||||
Povidone Iodine | SHAMPOO | 7.50% | TOPICAL | D11AC06 | OTC medicines | 1369/10/30 | |||||
Povidone Iodine | SOLUTION | 7.50% | TOPICAL | D08AG02 | OTC medicines ; Surgical Scrub | 1369/10/30 | |||||
Povidone Iodine | GEL | 10% | VAGINAL | G01AX11 | OTC medicines | ||||||
Povidone Iodine | OINTMENT | 10% | TOPICAL | D08AG02 | OTC medicines | 1369/10/30 | |||||
Povidone Iodine | SOLUTION | 10% | TOPICAL | D08AG02 | OTC medicines | 1369/10/30 | |||||
Povidone Iodine | DOUCHE | 10% | VAGINAL | D08AG02 | OTC medicines | 1392/05/29 | |||||
Povidone Iodine | SUPPOSITORY | 200 mg | VAGINAL | G01AX11 | OTC medicines | ||||||
Povidone Iodine | TISSUE | 3 mg/cm2 | TOPICAL | D09AA09 | OTC medicines | ||||||
Povidone Iodine Alcoholic | SOLUTION | 10% | TOPICAL | D09AA09 | Ethanol 300ml/L+ Povidone Iodine 100mg/ml | OTC medicines | 1395/12/22 | ||||
Povidone Iodine | PAINT BOTTLE | 10% | TOPICAL | D08AG02 | OTC medicines | 1395/12/22 | |||||
Pralidoxime | Chloride | INJECTION, POWDER | 1 g | PARENTERAL | V03AB04 | Hospital use only | 1376/06/30 | ||||
Pralidoxime | As Methylsulfate | INJECTION, POWDER | 200 mg | PARENTERAL | V03AB04 | Hospital use only | 1393/10/14 | ||||
Pramipexole | DiHCl | TABLET | 0. 125 mg | ORAL | N04BC05 | Equivalent to 0.088 mg Pramipexole | 1385/09/07 | ||||
Pramipexole | DiHCl | TABLET | 0. 25 mg | ORAL | N04BC05 | Equivalent to 0.18 mg Pramipexole | 1385/09/07 | ||||
Pramipexole | DiHCl | TABLET, EXTENDED RELEASE | 0. 375 mg | ORAL | N04BC05 | Equivalent to 0.26 mg Pramipexole | 1389/06/15 | ||||
Pramipexole | DiHCl | TABLET | 0. 5 mg | ORAL | N04BC05 | Equivalent to 0.35 mg Pramipexole | 1385/09/07 | ||||
Pramipexole | DiHCl | TABLET, EXTENDED RELEASE | 0. 75 mg | ORAL | N04BC05 | Equivalent to 0.52 mg Pramipexole | 1389/06/15 | ||||
Pramipexole | DiHCl | TABLET | 1 mg | ORAL | N04BC05 | Equivalent to 0.7 mg Pramipexole | 1385/09/07 | ||||
Pramipexole | DiHCl | TABLET, EXTENDED RELEASE | 1.5 mg | ORAL | N04BC05 | Equivalent to 1.05 mg Pramipexole | 1389/06/15 | ||||
Pramipexole | DiHCl | TABLET, EXTENDED RELEASE | 3 mg | ORAL | N04BC05 | Equivalent to 2.10 mg Pramipexole | 1389/06/15 | ||||
Prasugrel | As HCl | TABLET | 10 mg | ORAL | B01AC22 | 1390/07/05 | |||||
Prasugrel | As HCl | TABLET | 5 mg | ORAL | B01AC22 | 1390/07/05 | |||||
Praziquantel | TABLET | 600 mg | ORAL | P02BA01 | Treatment of neurocysticercosis. Anti-Taenicide | for Health Dept. of MOH only | 1370/07/07 | ||||
Praziquantel | TABLET | 500 mg | ORAL | P02BA01 | Treatment of neurocysticercosis. Anti-Taenicide | for Health Dept. of MOH only | 1394/11/13 | ||||
Prazosin | As HCl | TABLET | 1 mg | ORAL | C02CA01 | 1359/07/13 | |||||
Prazosin | As HCl | TABLET | 5 mg | ORAL | C02CA01 | 1362/12/21 | |||||
Prednimustine | CAPSULE | 10 mg | ORAL | L01AA08 | 1365/09/16 | ||||||
Prednimustine | TABLET | 10 mg | ORAL | L01AA08 | |||||||
Prednimustine | TABLET | 100 mg | ORAL | L01AA08 | 1365/09/16 | ||||||
Prednimustine | TABLET | 20 mg | ORAL | L01AA08 | 1365/09/16 | ||||||
Prednimustine | CAPSULE | 50 mg | ORAL | L01AA08 | 1365/09/16 | ||||||
Prednimustine | TABLET | 50 mg | ORAL | L01AA08 | |||||||
Prednisolone | Acetate | SUSPENSION/ DROPS | 1% | OPHTHALMIC | S01BA04 | 1361/04/27 | |||||
Prednisolone | TABLET | 20 mg | ORAL | H02AB06 | 1387/05/06 | ||||||
Prednisolone | TABLET | 5 mg | ORAL | H02AB06 | 1387/05/06 | ||||||
Prednisolone | TABLET | 5 mg | BUCCAL | DO7AA03 | 1392/03/11 | ||||||
Prednisolone | TABLET | 50 mg | ORAL | H02AB06 | 1369/02/09 | ||||||
Prednisone | TABLET | 1 mg | ORAL | H02AB07 | 1374/12/20 | ||||||
Prednisone | TABLET | 20 mg | ORAL | H02AB07 | 1387/05/16 | ||||||
Prednisone | TABLET | 5 mg | ORAL | H02AB07 | 1387/05/16 | ||||||
Prednisone | TABLET | 50 mg | ORAL | H02AB0 | |||||||
Pregabalin | CAPSULE | 100 mg | ORAL | N03AX16 | 1388/04/21 | ||||||
Pregabalin | CAPSULE | 150 mg | ORAL | N03AX16 | 1388/04/21 | ||||||
Pregabalin | CAPSULE | 200 mg | ORAL | N03AX16 | 1388/04/21 | ||||||
Pregabalin | CAPSULE | 225 mg | ORAL | N03AX16 | 1388/04/21 | ||||||
Pregabalin | CAPSULE | 300 mg | ORAL | N03AX16 | 1388/04/21 | ||||||
Pregabalin | CAPSULE | 50 mg | ORAL | N03AX16 | 1388/04/21 | ||||||
Pregabalin | CAPSULE | 75 mg | ORAL | N03AX16 | 1388/04/21 | ||||||
Prilocaine+Felypressin | INJECTION | PARENTERAL | N01BB54 | (Prilocaine HCl 30mg+Felypressin (0.03 IU.) 0.54 mcg)/ ml | Cartridge | 1359/07/13 | |||||
Primaquine | As Phosphate | TABLET | 15 mg | ORAL | P01BA03 | For use in combination with clindamycin hydrochloride in the treatment of Pneumocystis carinii pneumonia associated with AIDS. | 1368/07/16 | ||||
Primaquine | As Phosphate | TABLET | 7.5 mg | ORAL | P01BA03 | For use in combination with clindamycin hydrochloride in the treatment of Pneumocystis carinii pneumonia associated with AIDS. | 1368/02/10 | ||||
Primidone | SUSPENSION | 125 mg/5ml | ORAL | N03AA03 | 1373/10/18 | ||||||
Primidone | TABLET | 250 mg | ORAL | N03AA03 | |||||||
Primidone | SUSPENSION | 250 mg/5ml | ORAL | N03AA03 | |||||||
Procainamide | HCl | INJECTION | 100 mg/ml | PARENTERAL | C01BA02 | Hospital use only | 1364/11/06 | ||||
Procainamide | HCl | CAPSULE | 500 mg | ORAL | C01BA02 | 1377/11/18 | |||||
Procarbazine | As HCl | CAPSULE | 50 mg | ORAL | L01XB01 | ||||||
Progesterone | CAPSULE, LIQUID FILLED | 100 mg | VAGINAL or ORAL | G03DA04 | 1389/11/4 | ||||||
Progesterone | SUPPOSITORY | 100 mg | VAGINAL or RECTAL | G03DA04 | 1387/05/16 | ||||||
Progesterone | TABLET | 100 mg | VAGINAL | G03DA04 | |||||||
Progesterone | CAPSULE, LIQUID FILLED | 200 mg | VAGINAL or ORAL | G03DA04 | 1389/11/4 | ||||||
Progesterone | SUPPOSITORY | 200 mg | VAGINAL or RECTAL | G03DA04 | 1381/10/22 | ||||||
Progesterone | INJECTION | 25 mg/ml | PARENTERAL | G03DA04 | |||||||
Progesterone | SUPPOSITORY | 400 mg | VAGINAL or RECTAL | G03DA04 | 1379/11/09 | ||||||
Progesterone | GEL | 8% | VAGINAL | G03DA04 | 1396/03/13 | ||||||
Progesterone | BULK | V03 | Bulk medicines | 1372/02/12 | |||||||
Proguanil | TABLET | 100 mg | ORAL | P01BB01 | For Health Dept. of MOH only | 1388/10/30 | |||||
Proguanil | TABLET | 120 mg | ORAL | P01BB01 | For Health Dept. of MOH only | 1388/10/30 | |||||
Promethazine | HCl | TABLET | 25 mg | ORAL | R06AD02 | ||||||
Promethazine | HCl | INJECTION | 25 mg/ml | PARENTERAL | R06AD02 | 1364/03/12 | |||||
Promethazine | As HCl | SYRUP | 5 mg/5ml | ORAL | R06AD02 | ||||||
Propafenone | HCl | TABLET | 150 mg | ORAL | C01BC03 | 1369/10/16 | |||||
Propafenone | HCl | TABLET | 300 mg | ORAL | C01BC03 | ||||||
Propamidine | Isethionate | SOLUTION/ DROPS | 0.10% | OPHTHALMIC | S01AX15 | 1374/11/29 | |||||
Propantheline | Bromide | TABLET | 15 mg | ORAL | A03AB05 | ||||||
Propofol | INJECTION, SOLUTION | 10 mg/ml | PARENTERAL | N01AX10 | Hospital use only | 1376/01/31 | |||||
Propofol | INJECTION, SOLUTION | 20 mg/ml | PARENTERAL | N01AX10 | Hospital use only | 1385/09/01 | |||||
Propofol | INJECTION, SOLUTION | 5 mg/ml | PARENTERAL | N01AX10 | Hospital use only | 1395/09/01 | |||||
Propranolol | HCl | INJECTION | 1 mg/ml | PARENTERAL | C07AA05 | 1369/10/16 | |||||
Propranolol | HCl | TABLET | 10 mg | ORAL | C07AA05 | ||||||
Propranolol | HCl | TABLET, EXTENDED RELEASE | 160 mg | ORAL | C07AA05 | ||||||
Propranolol | HCl | TABLET | 20 mg | ORAL | C07AA05 | 1385/02/12 | |||||
Propranolol | HCl | TABLET | 40 mg | ORAL | C07AA05 | ||||||
Propranolol | HCl | TABLET | 80 mg | ORAL | C07AA05 | ||||||
Propranolol | HCl | TABLET, EXTENDED RELEASE | 80 mg | ORAL | C07AA05 | ||||||
Propylene Glycol | BULK | V03 | Bulk medicines | ||||||||
Propylthiouracil | TABLET | 50 mg | ORAL | H03BA02 | |||||||
Prostaglandin E1 | INJECTION | 0.5 mg/ml | PARENTERAL | C01EA01 | Ductus Arteriosus | Orphan medicines; Hospital use only | (Alprostadil) | ||||
Prostaglandin E1 | INJECTION, POWDER | 20 mcg | PARENTERAL | G04BE01 | Erection Dysfunction | Orphan medicines; Hospital use only | (Alprostadil) | 1386/04/13 | |||
Prostaglandin E1 | INJECTION, SOLUTION, CONCENTRATE | 20 mcg/ml | PARENTERAL | G04BE01 | Erection Dysfunction | Orphan medicines; Hospital use only | (Alprostadil) | 1385/11/18 | |||
Prostaglandin E2 | GEL | VAGINAL | G02AِِD02 | Hospital use only; With obstetricians prescriptions only | (Dinoprostone) | ||||||
Prostaglandin E2 | INJECTION | 10 mg/ml | PARENTERAL | G02AِِD02 | Hospital use only; With obstetricians prescriptions only | (Dinoprostone) | |||||
Prostaglandin E2 | TABLET | 3 mg | VAGINAL | G02AِِD02 | Hospital use only; With obstetricians prescriptions only | (Dinoprostone) | |||||
Prostaglandin E2 | TABLET, INSERT, EXTENDED RELEASE | 10 mg | VAGINAL | G02AِِD02 | Hospital use only; With obstetricians prescriptions only | (Dinoprostone) | 1397/04/30 | ||||
Prostaglandin F2α | INJECTION | 5mg/ml | PARENTERAL | G02AD01 | Hospital use only | Dinoprost Tromethamine | 1389/10/25 | ||||
Protamine | Sulfate | INJECTION | 1000 UAH/ml | PARENTERAL | V03AB14 | Hospital use only | |||||
Prothionamide | TABLET | 125 mg | ORAL | J04AD01 | |||||||
Prothionamide | TABLET | 250 mg | ORAL | J04AD01 | 1363/10/02 | ||||||
Prothrombin Complex Concentrated | INJECTION, POWDER | 500 IU | PARENTERAL | B02BD | 1386/12/06 | ||||||
Protirelin | INJECTION | 0.2 mg/ml | PARENTERAL | V04CJ02 | |||||||
Pseudoephedrine | HCl | CAPSULE, LIQUID FILLED | 30 mg | ORAL | R01BA02 | 1385/11/18 | |||||
Pseudoephedrine | HCl | SYRUP | 30 mg/5ml | ORAL | R01BA02 | 1369/10/30 | |||||
Purified Talc | INJECTION, POWDER | 5 g | PARENTERAL | 1387/12/18 | |||||||
Pyrantel | As Pamoate | TABLET | 125 mg | ORAL | P02CC01 | 1369/09/18 | |||||
Pyrantel | As Pamoate | SUSPENSION | 250 mg/5ml | ORAL | P02CC01 | 1369/09/18 | |||||
Pyrazinamide | TABLET | 500 mg | ORAL | J04AK01 | |||||||
Pyridostigmine | Bromide | TABLET | 10 mg | ORAL | N07AA02 | 1372/06/21 | |||||
Pyridostigmine | Bromide | TABLET, EXTENDED RELEASE | 180 mg | ORAL | N07AA02 | 1388/02/30 | |||||
Pyridostigmine | Bromide | TABLET | 60 mg | ORAL | N07AA02 | ||||||
Pyrimethamine | TABLET | 25 mg | ORAL | P01BD01 | |||||||
Pyrithione zinc | Shampoo | 2% | TOPICAL | D11AX12 | OTC medicines | ||||||
Pyrvinium | As Pamoate | TABLET | 50 mg | ORAL | P02CX01 | ||||||
Pyrvinium | As Pamoate | SUSPENSION | 50 mg/5ml | ORAL | P02CX01 | ||||||
Quetiapine | as Fumarate | TABLET | 100 mg | ORAL | N05AH04 | Antipsychotic | 1388/03/03 | ||||
Quetiapine | as Fumarate | TABLET | 150 mg | ORAL | N05AH04 | Antipsychotic | 1388/03/03 | ||||
Quetiapine | as Fumarate | TABLET, EXTENDED RELEASE | 200 mg | ORAL | N05AH04 | Antipsychotic | 1390/09/21 | ||||
Quetiapine | as Fumarate | TABLET, EXTENDED RELEASE | 150 mg | ORAL | N05AH04 | Antipsychotic | 1394/07/05 | ||||
Quetiapine | as Fumarate | TABLET | 200 mg | ORAL | N05AH04 | Antipsychotic | 1388/03/03 | ||||
Quetiapine | as Fumarate | TABLET | 25 mg | ORAL | N05AH04 | Antipsychotic | 1388/03/03 | ||||
Quetiapine | as Fumarate | TABLET, EXTENDED RELEASE | 300 mg | ORAL | N05AH04 | Antipsychotic | for local production only | 1391/05/02 | |||
Quetiapine | as Fumarate | TABLET, EXTENDED RELEASE | 50 mg | ORAL | N05AH04 | Antipsychotic | for local production only | 1390/09/21 | |||
Quinacrine | Di HCl | TABLET | 100 mg | ORAL | P01AX05 | ||||||
Quinidine | Sulfate | CAPSULE | 200 mg | ORAL | C01BA01 | ||||||
Quinidine | Sulfate | TABLET | 200 mg | ORAL | C01BA01 | ||||||
Quinidine | Bisulfate | TABLET, EXTENDED RELEASE | 250 mg | ORAL | C01BA01 | 1369/10/16 | |||||
Quinine | HCl | TABLET | 250 mg | ORAL | P01BC01 | For Health Dept. of MOH only | 1367/08/15 | ||||
Quinine | INJECTION | 250 mg/ml | PARENTERAL | P01BC01 | Hospital use only, For Health Dept. of MOH only | ||||||
Quinine | HCl | TABLET | 100 mg | ORAL | P01BC01 | For Health Dept. of MOH only | 1367/08/15 | ||||
Quinine | HCl | TABLET | 200 mg | ORAL | P01BC01 | For Health Dept. of MOH only | 1367/08/15 | ||||
Quinine | Sulfate | TABLET | 300 mg | ORAL | P01BC01 | For Health Dept. of MOH only | 1396/05/28 | ||||
Rabeprazole | Sodium | TABLET, DELAYED RELEASE | 20 mg | ORAL | A02BC04 | 1384/09/20 | |||||
Rabies Immune globulin | INJECTION | PARENTERAL | J06BB05 | Human | |||||||
Rabies Vaccine | INJECTION | PARENTERAL | J07BG | HDC (Freeze-dried Killed Virus) | 1366/01/23 | ||||||
Rabies Vero Vaccine | INJECTION | PARENTERAL | J07BG | 1374/05/15 | |||||||
Raloxifene | HCl | TABLET | 60 mg | ORAL | G03XC01 | Reduction of the risk of breast cancer in postmenopausal women | 1383/07/12 | ||||
Raltegravir | As potassium | TABLET | 400 mg | ORAL | J05AX08 | HIV infection | For Health Dept. of MOH only | 1393/10/14 | |||
Raltegravir | As potassium | TABLET, CHEWABLE | 100 mg | ORAL | J05AX08 | HIV infection | For Health Dept. of MOH only | 1394/11/13 | |||
Ranibizumab | INJECTION, SOLUTION | 10mg/ml | PARENTERAL | S01LA04 | Macular Oedema | Hospital use only | 1395/08/02 | ||||
Ranitidine | As HCl | TABLET, EFFERVESCENT | 150 mg | ORAL | A02BA02 | ||||||
Ranitidine | As HCl | CAPSULE, LIQUID FILLED | 150 mg | ORAL | A02BA02 | 1385/09/15 | |||||
Ranitidine | As HCl | TABLET | 150 mg | ORAL | A02BA02 | ||||||
Ranitidine | As HCl | INJECTION | 25 mg/ml | PARENTERAL | A02BA02 | 1369/02/23 | |||||
Ranitidine | As HCl | CAPSULE, LIQUID FILLED | 300 mg | ORAL | A02BA02 | for local production only | 1389/08/24 | ||||
Ranitidine | As HCl | TABLET, EFFERVESCENT | 300 mg | ORAL | A02BA02 | 1382/04/29 | |||||
Ranitidine | As HCl | TABLET | 300 mg | ORAL | A02BA02 | 1387/07/07 | |||||
Ranitidine | As HCl | INJECTION | 50 mg | INJECTION | A02BA02 | Hospital use only | for local production only | 1390/03/09 | |||
Ranitidine | As HCl | SOLUTION | 75mg/5ml | ORAL | A02BA02 | 1385/09/01 | |||||
Rasburicase | INJECTION, POWDER | 1.5 mg | PARENTERAL | V03AF07 | 1386/12/07 | ||||||
Red Blood Cell | INJECTION | INJECTION | B05AX01 | Blood component replacement | Hospital use only | Erythrocytes (INN) | 1394/11/13 | ||||
Red Blood Cell, CMV Negative | INJECTION | INJECTION | B05AX01 | Blood component replacement | Hospital use only | Erythrocytes (INN) | 1394/11/13 | ||||
Red Blood Cell, Frozen | INJECTION | INJECTION | B05AX01 | Blood component replacement | Hospital use only | Erythrocytes (INN) | 1394/11/13 | ||||
Red Blood Cell, Frozen and Irradiated | INJECTION | INJECTION | B05AX01 | Blood component replacement | Hospital use only | Erythrocytes (INN) | 1394/11/13 | ||||
Red Blood Cell, Irradiated | INJECTION | INJECTION | B05AX01 | Blood component replacement | Hospital use only | Erythrocytes (INN) | 1394/11/13 | ||||
Red Blood Cell, Irradiated and Washed | INJECTION | INJECTION | B05AX01 | Blood component replacement | Hospital use only | Erythrocytes (INN) | 1394/11/13 | ||||
Red Blood Cell, Leukocyte Reduced | INJECTION | INJECTION | B05AX01 | Blood component replacement | Hospital use only | Erythrocytes (INN) | 1394/11/13 | ||||
Red Blood Cell, Leukocyte Reduced and Washed | INJECTION | INJECTION | B05AX01 | Blood component replacement | Hospital use only | Erythrocytes (INN) | 1394/11/13 | ||||
Red Blood Cell, Leukocyte Reduced and Washed | INJECTION | INJECTION | B05AX01 | Blood component replacement | Hospital use only | Erythrocytes (INN) | 1394/11/13 | ||||
Remifentanil | INJECTION, POWDER | 1 mg | PARENTERAL | N01AH06 | Hospital use only | 1381/06/18 | |||||
Remifentanil | INJECTION, POWDER | 2 mg | PARENTERAL | N01AH06 | Hospital use only | 1381/06/18 | |||||
Remifentanil | INJECTION, POWDER | 5 mg | PARENTERAL | N01AH06 | Hospital use only | 1381/06/18 | |||||
Repaglinide | TABLET | 0.5 mg | ORAL | A10BX02 | 1383/08/10 | ||||||
Repaglinide | TABLET | 1 mg | ORAL | A10BX02 | 1383/08/10 | ||||||
Repaglinide | TABLET | 2 mg | ORAL | A10BX02 | 1383/08/10 | ||||||
Reserpine | TABLET | 0.1 mg | ORAL | C02AA02 | |||||||
Resorcinol | BULK | V03 | Bulk medicines | ||||||||
Reteplase | INJECTION, POWDER | 10.4 U | PARENTERAL | B01AD07 | Hospital use only | 1385/03/23 | |||||
Rhenium [186 Re] Etidronate, (186Re-HEDP) | INJECTION, SOLUTION | (35-65) mCi | PARENTERAL | V10BX03 | Radiopharmaceuticals | 1389/10/25 | |||||
Rhenium [186Re] Sulfur Colloid | INJECTION, COLLOIDAL SOLUTION | (5-10) mCi | INTRA-CAVITY | V10AX05 | Radiopharmaceuticals | 1389/10/25 | |||||
Rhenium [188 Re] Etidronate, (188Re-HEDP) | INJECTION, SOLUTION | 1 mCi/kg | PARENTERAL | V10BX03 | Radiopharmaceuticals | 1389/10/25 | |||||
Rhenium[188Re] Sulfur Colloid | INJECTION, COLLOIDAL SOLUTION | (5-10) mCi | INTRA-CAVITY | V10AX05 | Radiopharmaceuticals | 1397/02/18 | |||||
Ribavirin | INJECTION | 100 mg | PARENTERAL | J05AB04 | For Health Dept. of MOH only | 1385/09/07 | |||||
Ribavirin | CAPSULE | 200 mg | ORAL | J05AB04 | For Health Dept. of MOH only | 1379/11/09 | |||||
Ribavirin | TABLET | 200 mg | ORAL | J05AB04 | For Health Dept. of MOH only | ||||||
Rifabutin | CAPSULE | 150 mg | ORAL | J04AB04 | For Health Dept. of MOH only | ||||||
Rifabutin | TABLET | 300 mg | ORAL | J04AB02 | For Health Dept. of MOH only | 1385/09/07 | |||||
Rifampicin | CAPSULE | 150 mg | ORAL | J04AB02 | |||||||
Rifampicin | SOLUTION/ DROPS | 153 mg/ml | ORAL | J04AB02 | |||||||
Rifampicin | SYRUP | 20 mg/ml | ORAL | J04AB02 | 1391/11/02 | ||||||
Rifampicin | CAPSULE | 300 mg | ORAL | J04AB02 | |||||||
Rifampicin | INJECTION, POWDER | 600 mg | PARENTERAL | J04AB02 | For antituberculosis treatment where use of the ORAL form of the drug is not feasible. | Orphan medicines; Hospital use only | |||||
Rifapentine | TABLET | 150 mg | ORAL | J04AB05 | For Health Dept. of MOH only | 1397/07/14 | |||||
Rifaximin | TABLET | 200 mg | ORAL | A07AA11 | 1391/02/07 | ||||||
Rifaximin | TABLET | 550 mg | ORAL | A07AA11 | 1395/12/18 | ||||||
Riluzole | TABLET | 50 mg | ORAL | N07XX02 | 1385/11/24 | ||||||
Ringer Lactate | INJECTION, SOLUTION | 1000 ml | INTRAVENOUS DRIP | B05BB01 | (Na+130mEq + Ca++3mEq + K +4mEq + Cl-109mEq + Lactate 28mEq)/L | ||||||
Ringer Lactate | INJECTION, SOLUTION | 250 ml | INTRAVENOUS DRIP | B05BB01 | (Na+130mEq + Ca++3mEq + K +4mEq + Cl-109mEq + Lactate 28mEq)/L | 1389/02/01 | |||||
Ringer Lactate | INJECTION, SOLUTION | 500 ml | INTRAVENOUS DRIP | B05BB01 | (Na+130mEq + Ca++3mEq + K +4mEq + Cl-109mEq + Lactate 28mEq)/L | ||||||
Ringers | INJECTION, SOLUTION | 1000 ml | INTRAVENOUS DRIP | B05BB01 | (Na+147mEq + Ca++ 4.5mEq + K+4mEq +Cl-156mEq)/L | ||||||
Ringers | INJECTION, SOLUTION | 250 ml | PARENTERAL | B05BB01 | (Na+147mEq + Ca++ 4.5mEq + K+4mEq +Cl-156mEq)/L | 1384/02/12 | |||||
Ringers | INJECTION, SOLUTION | 500 ml | INTRAVENOUS DRIP | B05BB01 | (Na+147mEq + Ca++ 4.5mEq + K+4mEq +Cl-156mEq)/L | ||||||
Risedronate | Sodium | TABLET | 35 mg | ORAL | M05BA07 | 1387/12/21 | |||||
Risedronate | Sodium | TABLET | 5 mg | ORAL | M05BA07 | 1387/12/21 | |||||
Risperidone | TABLET | 1 mg | ORAL | N05AX08 | 1387/01/22 | ||||||
Risperidone | SOLUTION | 1 mg/ml | ORAL | N05AX08 | 1391/02/25 | ||||||
Risperidone | TABLET | 2 mg | ORAL | N05AX08 | 1387/01/22 | ||||||
Risperidone | INJECTION, POWDER, EXTENDED RELEASE | 25 mg | PARENTERAL | N05AX08 | 1390/03/07 | ||||||
Risperidone | TABLET | 3 mg | ORAL | N05AX08 | 1379/05/26 | ||||||
Risperidone | INJECTION, POWDER, EXTENDED RELEASE | 37.5 mg | PARENTERAL | N05AX08 | 1390/03/07 | ||||||
Risperidone | TABLET | 4 mg | ORAL | N05AX08 | 1379/05/26 | ||||||
Risperidone | INJECTION, POWDER, EXTENDED RELEASE | 50 mg | PARENTERAL | N05AX08 | 1390/03/07 | ||||||
Ritodrine | HCl | TABLET | 10 mg | ORAL | G02CA01 | 1363/12/12 | |||||
Ritodrine | HCl | INJECTION | 10 mg/ml | PARENTERAL | G02CA01 | Hospital use only | 1363/12/12 | ||||
Ritonavir | CAPSULE | 100 mg | ORAL | J05AE03 | For Health Dept. of MOH only | 1393/10/14 | |||||
Rituximab | INJECTION | 10 mg/ml | PARENTERAL | L01XC02 | Treatment of immune thrombocytopenic purpura Treatment of non-Hodgkin's B-cell lymphoma. Treatment of chronic lymphocytic leukemia | 1384/02/11 | |||||
Rituximab | INJECTION | 120 mg/ml | PARENTERAL | L01XC02 | Treatment of immune thrombocytopenic purpura Treatment of non-Hodgkin's B-cell lymphoma. Treatment of chronic lymphocytic leukemia | Povided with Hyaluronidase to be Subcutaneous | 1396/06/07 | ||||
Rivaroxaban | TABLET | 2.5 mg | ORAL | B01AF01 | Antithrombotic | Only adjuvant with other anticoagualants | 1397/07/28 | ||||
Rivaroxaban | TABLET | 10 mg | ORAL | B01AF01 | Antithrombotic | 1394/03/31 | |||||
Rivaroxaban | TABLET | 15 mg | ORAL | B01AF01 | Antithrombotic | 1394/03/31 | |||||
Rivaroxaban | TABLET | 20 mg | ORAL | B01AF01 | Antithrombotic | 1394/03/31 | |||||
Rivastigmine | As Hydrogen Tartrate | CAPSULE | 1.5 mg | ORAL | N06DA03 | 1379/12/07 | |||||
Rivastigmine | As Hydrogen Tartrate | CAPSULE | 3 mg | ORAL | N06DA03 | 1379/12/07 | |||||
Rivastigmine | As Hydrogen Tartrate | CAPSULE | 4.5 mg | ORAL | N06DA03 | 1379/12/07 | |||||
Rivastigmine | As Hydrogen Tartrate | CAPSULE | 6 mg | ORAL | N06DA03 | 1383/11/26 | |||||
Rivastigmine | As Hydrogen Tartrate | SOLUTION | 2 mg/ml | ORAL | N06DA03 | 1369/03/21 | |||||
Rizatriptan | As Hydrogen Tartrate | TABLET | 10 mg | ORAL | N02CC04 | 1381/04/23 | |||||
Rizatriptan | As Benzoate | TABLET, ORALLY DISINTEGRATING | 10 mg | ORAL | N02CC04 | 1390/1/29 | |||||
Rizatriptan | As Benzoate | TABLET | 5 mg | ORAL | N02CC04 | 1381/04/23 | |||||
Rocuronium | Bromide | INJECTION, SOLUTION | 10mg/ml | PARENTERAL | M03AC09 | 1393/10/14 | |||||
Romiplostim | INJECTION, POWDER | 250 mcg | PARENTERAL | B02BX04 | Orphan medicines | With hematologists prescriptions only | 1393/02/07 | ||||
Romiplostim | INJECTION, POWDER | 500 mcg | PARENTERAL | B02BX04 | Orphan medicines | With hematologists prescriptions only | 1395/1106 | ||||
Ropinirole | As HCl | TABLET | 0.25 mg | ORAL | N04BC04 | 1379/11/09 | |||||
Ropinirole | As HCl | TABLET | 0.5 mg | ORAL | N04BC04 | 1387/05/06 | |||||
Ropinirole | As HCl | TABLET | 1 mg | ORAL | N04BC04 | 1379/11/09 | |||||
Ropinirole | As HCl | TABLET | 5 mg | ORAL | N04BC04 | 1379/11/09 | |||||
Ropivacaine | HCl | INJECTION, SOLUTION | 2mg/ml | PARENTERAL | N01BB09 | Hospital use only | 1393/05/12 | ||||
Ropivacaine | HCl | INJECTION, SOLUTION | 5mg/ml | PARENTERAL | N01BB09 | Hospital use only | 1393/05/12 | ||||
Ropivacaine | HCl | INJECTION, SOLUTION | 7.5mg/ml | PARENTERAL | N01BB09 | Hospital use only | 1395/07/10 | ||||
Ropivacaine | HCl | INJECTION, SOLUTION | 10mg/ml | PARENTERAL | N01BB09 | Hospital use only | 1395/07/10 | ||||
Rosuvastatin | As Calcium | TABLET | 10 mg | ORAL | C10AA07 | 1392/12/11 | |||||
Rosuvastatin | As Calcium | TABLET | 20 mg | ORAL | C10AA07 | 1392/12/11 | |||||
Rosuvastatin | As Calcium | TABLET | 40 mg | ORAL | C10AA07 | 1392/12/11 | |||||
Rosuvastatin | As Calcium | TABLET | 5 mg | ORAL | C10AA07 | 1392/12/11 | |||||
Rotavirus Vaccine | SOLUTION | ORAL | J07BH02 | Live, Pentavalent | 1395/08/02 | ||||||
Rotavirus Vaccine | POWDER, FOR SUSPENSION | ORAL | J07BH02 | Live, Monovalent | 1396/04/25 | ||||||
Rubella Virus Vaccine | INJECTION, POWDER | PARENTERAL | J07BJ01 | Live | |||||||
Rubidium (81Rb)/Krypton [81mKr] | GENERATOR | 4-12 mCi | RESPIRATORY | V09EX01 | Radiopharmaceuticals | 1383/09/22 | |||||
Salbutamol | As Sulfate | INJECTION | 0.5 mg/ml | PARENTERAL | R03CC02 | Hospital use only | 1367/08/15 | ||||
Salbutamol | INHALER | 100 mcg/dose | RESPIRATORY | R03AC02 | |||||||
Salbutamol | As Sulfate | INHALER | 100 mcg/metered inhalation | RESPIRATORY | R03AC02 | 1388/08/20 | |||||
Salbutamol | As Sulfate | TABLET | 2 mg | ORAL | R03CC02 | ||||||
Salbutamol | As Sulfate | SYRUP | 2 mg/5ml | ORAL | R03CC02 | ||||||
Salbutamol | As Sulfate | INHALER | 2.5 mg/2.5ml | RESPIRATORY | R03AC02 | 1385/03/23 | |||||
Salbutamol | As Sulfate | INHALER | 5 mg/ml | RESPIRATORY | R03AC02 | ||||||
Salbutamol+Beclomethasone | AEROSOL, SPRAY | RESPIRATORY | R03AK04 | Salbutamol 100 mcg+Beclomethasone Dipropionate 50 mcg | 1385/06/14 | ||||||
Salicylic Acid | PLASTER | 12-40% | TOPICAL | D01AE12 | OTC medicines | 1387/09/23 | |||||
Salicylic Acid | BULK | V03 | Bulk medicines | 1376/12/10 | |||||||
Salicylic Acid Compound | SOLUTION | TOPICAL | D01AE12 | Salicylic Acid 16.7g+Lactic Acid 16.7g + Collodion qs to 100g | OTC medicines | 1360/10/27 | |||||
Salmeterol | As Xinafoate | INHALER | 25 mcg/dose | RESPIRATORY | R03AC12 | 1376/06/09 | |||||
Salmeterol | As Xinafoate | INHALER | 50 mcg/dose | RESPIRATORY | R03AC12 | 1376/06/09 | |||||
Salmeterol+Fluticasone | AEROSOL, METERED | RESPIRATORY | R03AK06 | Salmeterol (as Xinafoate) 25mcg +Fluticasone Propionate 250mcg | 1383/09/08 | ||||||
Salmeterol+Fluticasone | AEROSOL, METERED | RESPIRATORY | R03AK06 | Salmeterol (as Xinafoate) 25mcg +Fluticasone Propionate 50mcg | 1383/09/08 | ||||||
Salmeterol+Fluticasone | AEROSOL, METERED | RESPIRATORY | R03AK06 | Salmeterol(as Xinafoate) 25mcg + Fluticasone Propionate 125mcg | 1383/09/08 | ||||||
Salmeterol+Fluticasone | DISC | RESPIRATORY | R03AK06 | Salmeterol(as Xinafoate) 50mcg + Fluticasone Propionate 100mcg /dose | 1389/11/04 | ||||||
Salmeterol+Fluticasone | DISC | RESPIRATORY | R03AK06 | Salmeterol(as Xinafoate) 50mcg + Fluticasone Propionate 250mcg /dose | 1389/11/04 | ||||||
Salmeterol+Fluticasone | DISC | RESPIRATORY | R03AK06 | Salmeterol(as Xinafoate) 50mcg + Fluticasone Propionate 500mcg /dose | 1389/11/04 | ||||||
Salmeterol+Fluticasone | INHALATION, POWDER | RESPIRATORY | R03AK06 | Salmeterol(as Xinafoate) 50mcg + Fluticasone Propionate100 mcg /dose | 1397/09/03 | ||||||
Salmeterol+Fluticasone | INHALATION, POWDER | RESPIRATORY | R03AK06 | Salmeterol(as Xinafoate) 50mcg + Fluticasone Propionate 250 mcg /dose | 1397/09/03 | ||||||
Salmeterol+Fluticasone | INHALATION, POWDER | RESPIRATORY | R03AK06 | Salmeterol(as Xinafoate) 50mcg + Fluticasone Propionate 500 mcg /dose | 1397/09/03 | ||||||
Samarium [153 Sm]-Ethylenediamine tetramethylene phosphonate, (153Sm-EDTMP) | INJECTION, SOLUTION | 1 mCi/kg | PARENTERAL | V10BX02 | Radiopharmaceuticals | 1389/10/25 | |||||
Sapropterin | DiHCl | TABLET | 50 mg | ORAL | A16AX07 | for Phenylketonuria In patients responsive to tetrahydrobiopterin | Orphan medicines | 1387/11/06 | |||
Sapropterin | DiHCl | TABLET | 100 mg | ORAL | A16AX07 | for Phenylketonuria In patients responsive to tetrahydrobiopterin | Orphan medicines | 1395/06/24 | |||
Sapropterin | DiHCl | POWDER | 100 mg | ORAL | A16AX07 | for Phenylketonuria In patients responsive to tetrahydrobiopterin | Orphan medicines | 1395/10/07 | |||
Sapropterin | DiHCl | POWDER | 500 mg | ORAL | A16AX07 | for Phenylketonuria In patients responsive to tetrahydrobiopterin | Orphan medicines | 1395/10/07 | |||
Schick Test | INJECTION | PARENTERAL | V04CX | 1361/08/20 | |||||||
Scopolamine | PATCH, EXTENDED RELEASE | 1 mg/72h | TRANSDERMAL | N05CM05 | |||||||
Secretin | INJECTION, POWDER, LYOPHILIZED | 100 U | PARENTERAL | V04CK01 | Hospital use only | ||||||
Selegiline | HCl | TABLET | 5 mg | ORAL | N04BD01 | As an adjuvant to levodopa and carbidopa treatment of idiopathic Parkinson's disease (paralysis agitans), postencephalitic Parkinsonism, and symptomatic Parkinsonism. | 1370/10/01 | ||||
Selenium | As Sodium Selenite Pentahydrate | INJECTION | 50 mcg/ml | PARENTERAL | A12CE02 | Hospital use only | 1390/03/23 | ||||
Selenium Sulfide | LOTION/ SHAMPOO | %2. 5 | TOPICAL | D01AE13 | 1387/12/21 | ||||||
Serine | CAPSULE | 600 mg | ORAL | Treatment of Serine deficiency | Orphan medicines | 1387/11/06 | |||||
Sertaconazole | Nitrate | CREAM | 2% | TOPICAL | D01AC14 | 1382/03/04 | |||||
Sertaconazole | Nitrate | TABLET | 300 mg | VAGINAL | G01AF | 1387/08/01 | |||||
Sertaconazole | Nitrate | SUPPOSITORY | 300 mg | VAGINAL | G01AF | 1395/11/12 | |||||
Sertaconazole | Nitrate | TABLET | 500 mg | VAGINAL | G01AF | 1382/03/04 | |||||
Sertraline | As HCl | CAPSULE | 100 mg | ORAL | N06AB06 | 1382/04/29 | |||||
Sertraline | As HCl | TABLET | 100 mg | ORAL | N06AB06 | 1379/12/21 | |||||
Sertraline | As HCl | TABLET | 25 mg | ORAL | N06AB06 | ||||||
Sertraline | As HCl | CAPSULE | 50 mg | ORAL | N06AB06 | 1382/04/29 | |||||
Sertraline | As HCl | TABLET | 50 mg | ORAL | N06AB06 | 1379/12/21 | |||||
Sevelamer | HCl | TABLET | 800 mg | ORAL | V03AE02 | 1390/07/04 | |||||
Sevelamer | Carbonate | POWDER , FOR SUSPENSION | 2.4 g | ORAL | V03AE02 | Sachet | 1392/06/12 | ||||
Sevelamer | Carbonate | POWDER , FOR SUSPENSION | 800 mg | ORAL | V03AE02 | Sachet | 1396/04/27 | ||||
Sevelamer | Carbonate | TABLET | 800 mg | ORAL | V03AE02 | 1390/07/04 | |||||
Sevoflurane | INHALER | 250 mg | RESPIRATORY | N01AB08 | 1379/12/21 | ||||||
Sildenafil | Citrate | GEL | 1% | TOPICAL | G04BE03 | 1% W/W | 1392/05/29 | ||||
Sildenafil | As Citrate | TABLET | 100 mg | ORAL | G04BE03 | 1379/06/20 | |||||
Sildenafil | As Citrate | TABLET | 25 mg | ORAL | G04BE03 | 1379/06/20 | |||||
Sildenafil | As Citrate | TABLET | 50 mg | ORAL | G04BE03 | 1379/02/04 | |||||
Sildenafil | As Citrate | TABLET | 20 mg | ORAL | G04BE03 | 1395/08/02 | |||||
Sildenafil | As Citrate | TABLET | 5 mg | ORAL | G04BE03 | 1395/08/02 | |||||
Sildenafil | As Citrate | FILM, DISPERSIBLE | 25 mg | ORAL | G04BE03 | 1396/06/25 | |||||
Sildenafil | As Citrate | FILM, DISPERSIBLE | 50 mg | ORAL | G04BE03 | 1396/06/25 | |||||
Sildenafil | As Citrate | FILM, DISPERSIBLE | 75 mg | ORAL | G04BE03 | 1396/06/25 | |||||
Sildenafil | As Citrate | DISPERSIBLE TABLET | 25 mg | ORAL | G04BE03 | 1397/02/11 | |||||
Sildenafil | As Citrate | DISPERSIBLE TABLET | 50 mg | ORAL | G04BE03 | 1397/02/11 | |||||
Silver Nitrate | BULK | V03 | Bulk medicines | ||||||||
Silver Sulfadiazine | CREAM | 10 mg/g | TOPICAL | D06BA01 | OTC medicines | ||||||
Silver Sulfadiazine+EGF | CREAM | TOPICAL | D06BA51 | Silver Sulfadiazine1% + Epidermal Growth Factor 0.001% | For promotion of cutaneous wound healing in extreme burn treatment protocols. | Orphan medicines | 1386/04/13 | ||||
Simethicone (Dimethicone Activated) | CAPSULE, LIQUID FILLED | 125 mg | ORAL | A07D | OTC medicines | 1385/08/17 | |||||
Simethicone (Dimethicone Activated) | CAPSULE, LIQUID FILLED | 180 mg | ORAL | A07D | OTC medicines | for local production only | 1389/02/01 | ||||
Simethicone (Dimethicone Activated) | TABLET, CHEWABLE | 40 mg | ORAL | A07D | OTC medicines | ||||||
Simethicone (Dimethicone Activated) | TABLET, CHEWABLE | 125 mg | ORAL | A07D | OTC medicines | 1396/04/27 | |||||
Simethicone (Dimethicone Activated) | SOLUTION/ DROPS | 41.2 mg/ml | ORAL | A07D | OTC medicines | ||||||
Simple Eye Oint | OINTMENT | OPHTHALMIC | S01XA | Yellow soft paraffin 80 g + Wool fat 10 g + Liquid paraffin q.s. 100 g | OTC medicines | 1360/09/15 | |||||
Simvastatin | TABLET | 10 mg | ORAL | C10AA01 | 1381/11/20 | ||||||
Simvastatin | TABLET | 20 mg | ORAL | C10AA01 | 1374/08/21 | ||||||
Simvastatin | TABLET | 40 mg | ORAL | C10AA01 | 1388/10/30 | ||||||
Sirolimus | TABLET | 1 mg | ORAL | L04AA10 | 1384/05/16 | ||||||
Sirolimus | TABLET | 2 mg | ORAL | L04AA10 | 1395/09/01 | ||||||
Sirolimus | TABLET | 0.5 mg | ORAL | L04AA10 | 1395/09/01 | ||||||
Sitagliptin | As Phosphate | TABLET | 25 mg | ORAL | A10BH01 | Type 2 Diabetes Mellitus | 1392/12/11 | ||||
Sitagliptin | As Phosphate | TABLET | 50 mg | ORAL | A10BH01 | Type 2 Diabetes Mellitus | 1392/12/11 | ||||
Sitagliptin | As Phosphate | TABLET | 100 mg | ORAL | A10BH01 | Type 2 Diabetes Mellitus | 1394/07/05 | ||||
Sitagliptin+Metformin | TABLET | ORAL | A10BD07 | Sitagliptin (as Phosphate) 50 mg+ Metformin Hydrochloride 500 mg | Type 2 Diabetes Mellitus | 1392/12/11 | |||||
Sitagliptin+Metformin | TABLET | ORAL | A10BD07 | Sitagliptin (as Phosphate) 50 mg+ Metformin Hydrochloride 1000 mg | Type 2 Diabetes Mellitus | 1395/03/09 | |||||
Sitagliptin+Metformin | TABLET. EXTENDED RELEASE | ORAL | A10BD07 | Sitagliptin (as Phosphate) 50 mg+ Metformin Hydrochloride 500 mg | Type 2 Diabetes Mellitus | 1395/12/18 | |||||
Sitagliptin+Metformin | TABLET. EXTENDED RELEASE | ORAL | A10BD07 | Sitagliptin (as Phosphate) 50 mg+ Metformin Hydrochloride 1000 mg | Type 2 Diabetes Mellitus | 1395/12/18 | |||||
Sitagliptin+Metformin | TABLET. EXTENDED RELEASE | ORAL | A10BD07 | Sitagliptin (as Phosphate) 100 mg+ Metformin Hydrochloride 1000 mg | Type 2 Diabetes Mellitus | 1369/02/02 | |||||
Sodium acetate | INJECTION, SOLUTION, CONCENTRATE | PARENTERAL | B05XA08 | (2Meq sodium + 2Meq acetate)/ml, 100 ml | Hospital use only | 1389/03/31 | |||||
Sodium Aminosalicylate | TABLET | 500 mg | ORAL | J04AA02 | Treatment of Crohn's disease. | ||||||
Sodium Benzoate | INJECTION | 2g/10ml | PARENTERAL | Treatment of Hyperammonemia (Grade III and VI hepatic encephalopathy) | Orphan medicines | 1393/11/21 | |||||
Sodium Benzoate | TABLET | 500 mg | ORAL | Rare metabolic conditions for children | Orphan medicines | 1392/07/22 | |||||
Sodium Benzoate+Sodium Phenylacetate | SOLUTION | ORAL | Sodium Benzoate 10%+Sodium Phenylacetate 10% | Treatment of Hyperammonemia | Orphan medicines | 1387/10/15 | |||||
Sodium Benzoate+Sodium Phenylacetate | INJECTION | PARENTERAL | Sodium Benzoate 10%+Sodium Phenylacetate 10% | Treatment of Hyperammonemia (Grade III and VI hepatic encephalopathy) | Orphan medicines | 1387/10/15 | |||||
Sodium Bicarbonate | INJECTION | 7.5% | PARENTERAL | B05XA02 | Hospital use only | 1389/02/01 | |||||
Sodium Bicarbonate | INJECTION | 8.4% | PARENTERAL | B05XA02 | Hospital use only | ||||||
Sodium Bicarbonate | BULK | V03 | Bulk medicines | ||||||||
Sodium Chloride | INJECTION, SOLUTION | 0.45%, 1000ml | INTRAVENOUS DRIP | B05XA03 | Half Saline | Hospital use only | 1385/10/20 | ||||
Sodium Chloride | INJECTION, SOLUTION | 0.45%, 500ml | INTRAVENOUS DRIP | B05XA03 | Half Saline | Hospital use only | |||||
Sodium Chloride | SPRAY | 0.65% | NASAL | R01AX | OTC medicines | 1384/03/09 | |||||
Sodium Chloride | SOLUTION/ DROPS | 0.65% | NASAL | R01AX | OTC medicines | 1364/03/26 | |||||
Sodium Chloride | SPRAY | 0.9% | NASAL | R01AX | OTC medicines | ||||||
Sodium Chloride | INHALATION, SOLUTION | 7.0% | RESPIRATORY | V | Neubulizing product in 4 ml volume | 1397/05/10 | |||||
Sodium Chloride | INJECTION, SOLUTION | 0.9%,1000ml | INTRAVENOUS DRIP | B05XA03 | |||||||
Sodium Chloride | INJECTION, SOLUTION | 0.9%,100ml | INTRAVENOUS DRIP | B05XA03 | |||||||
Sodium Chloride | INJECTION, SOLUTION | 0.9%,10ml | PARENTERAL | B05XA03 | 1385/09/01 | ||||||
Sodium Chloride | INJECTION, SOLUTION | 0.9%, 500ml | INTRAVENOUS DRIP | B05XA03 | |||||||
Sodium Chloride | INJECTION, SOLUTION | 0.9%, 5ml | PARENTERAL | B05XA03 | |||||||
Sodium Chloride | INJECTION, SOLUTION | 0.90% , 250ml | PARENTERAL | B05XA03 | 1384/02/12 | ||||||
Sodium Chloride | SOLUTION | 0.9% | IRRIGATION | B05CB01 | OTC medicines | 1386/11/08 | |||||
Sodium Chloride | SOLUTION | 0.9% | NASAL & OPHTHALMIC | S01XA | |||||||
Sodium Chloride | INJECTION, SOLUTION | 5%, 500ml | INTRAVENOUS DRIP | B05XA03 | Hospital use only | ||||||
Sodium Chloride | INJECTION, SOLUTION | 5%, 50ml | INTRAVENOUS DRIP | B05XA03 | Hospital use only | ||||||
Sodium Chloride | INJECTION, SOLUTION | 20%, 50ml | INTRAVENOUS DRIP | B05CB01 | Hospital use only | 1396/12/13 | |||||
Sodium Chloride | SOLUTION/ DROPS | 5% | OPHTHALMIC | S01XA03 | 1372/04/27 | ||||||
Sodium Chloride | OINTMENT | 5% | OPHTHALMIC | S01XA03 | 1369/10/30 | ||||||
Sodium Chloride | BULK | V03 | Bulk medicines | ||||||||
Sodium Citrate | BULK | V03 | Bulk medicines | ||||||||
Sodium Fluoride [18F] | INJECTION, SOLUTION | 10 mCi | PARENTERAL | V09IX06 | Radiopharmaceuticals | 1389/10/25 | |||||
Sodium Iodide [123I] | CAPSULE | (100-400) micCi | ORAL | V09FX02 | Radiopharmaceuticals | 1389/10/25 | |||||
Sodium Lactate | INJECTION | 1/6 molar | PARENTERAL | B05XA | Hospital use only | 1360/04/17 | |||||
Sodium Nitrite | INJECTION | 30 mg/ml | PARENTERAL | V03AB08 | Treatment of cyanide poisoning | Orphan medicines; Hospital use only | 1361/02/19 | ||||
Sodium Phenylbutyrate | INJECTION | 200 mg/ml | PARENTERAL | A16AX03 | Treatment of hyperamonia as Adjunctive to surgery, radiation therapy, and chemotherapy for primary or recurrent malignant gliome (Hyperammonemia) | Orphan medicines | 1387/10/15 | ||||
Sodium Phenylbutyrate | TABLET | 500 mg | ORAL | A16AX03 | Treatment of hyperamonia as Adjunctive to surgery, radiation therapy, and chemotherapy for primary or recurrent malignant gliome (Hyperammonemia) | Orphan medicines | 1387/10/15 | ||||
Sodium phosphate | INJECTION, SOLUTION, CONCENTRATE | PARENTERAL | B05XA09 | (4Meq sodium + 3mmol phosphate)/ml, 100 ml | Hospital use only | 1389/03/31 | |||||
Sodium phosphate dibasic+Sodium phosphate monobasic | ENEMA | RECTAL | A06AG01 | Sodium phosphate dibasic heptahydrate 7g/118ml+Sodium phosphate monobasic monohydrate 19g/118ml | |||||||
Sodium Picosulfate | SOLUTION/ DROPS | 7.5mg/ml | ORAL | A06AB08 | 1393/03/04 | ||||||
Sodium Picosulfate+Magnesium Oxide+Citric Acid | POWDER, FOR SOLUTION | ORAL | A06A | Sodium Picosulfate 10 mg+Magnesium Oxide 3.5 g+Citric Acid 12 g | 1393/03/04 | ||||||
Sodium Polystyrene | Sulfonate | POWDER, FOR SUSPENSION | 454 g | ORAL | V03AE01 | ||||||
Sodium Polystyrene | Sulfonate | POWDER, FOR SUSPENSION | 15 g | ORAL, RECTAL | V03AE01 | 1395/09/14 | |||||
Sodium Salicylate | TABLET, DELAYED RELEASE | 300 mg | ORAL | N02BA04 | |||||||
Sodium Tetradecyl | Sulfate | INJECTION | 3% | PARENTERAL | C05BB04 | Local sclerosants | Hospital use only | ||||
Sodium Tetradecyl | Sulfate | INJECTION | 0.2% | PARENTERAL | C05BB04 | Local sclerosants | Hospital use only | 1395/03/09 | |||
Sodium Tetradecyl | Sulfate | INJECTION | 0.5% | PARENTERAL | C05BB04 | Local sclerosants | Hospital use only | 1395/07/18 | |||
Sodium Tetradecyl | Sulfate | INJECTION | 1% | PARENTERAL | C05BB04 | Local sclerosants | Hospital use only | 1395/03/09 | |||
Sodium Thiosulfate | INJECTION | 250 mg/ml | PARENTERAL | V03AB06 | Treatment of cyanide poisoning | Orphan medicines; Hospital use only | 1361/02/19 | ||||
Sodium Thiosulfate | BULK | V03 | Sodium Hyposulfite | Bulk medicines | 1376/12/10 | ||||||
Sofosbuvir | TABLET | 400 mg | ORAL | J05AX15 | 1393/11/21 | ||||||
Sofosbuvir+Velpatasvir | TABLET | ORAL | J05AP55 | Sofosbuvir 400 mg +Velpatasvir 100 mg | 1396/05/28 | ||||||
Solifenacin | Succinate | TABLET | 10 mg | ORAL | G04BD080 | 1390/03/07 | |||||
Solifenacin | Succinate | TABLET | 5 mg | ORAL | G04BD080 | 1390/03/07 | |||||
Solifenacin+Tamsulosin | TABLET, EXTENDED RELEASE | ORAL | G04BD080 | Solifenacin Succinte 6 mg +Tamsulosin HCl 0.4 mg | 1397/06/24 | ||||||
Somatostatin | As Acetate Hydrate | INJECTION, POWDER | 0.25 mg | PARENTERAL | H01CB01 | Treatment of bleeding esophageal varices. | Orphan medicines | ||||
Somatostatin | INJECTION, POWDER,FOR SOLUTION | 3 mg | PARENTERAL | H01CB01 | Treatment of bleeding esophageal varices. | Orphan medicines | 1391/07/25 | ||||
Somatropin | INJECTION, POWDER | 4 U | PARENTERAL | H01AC01 | Treatment of short stature in patients with Noonan syndrome Treatment of short stature associated with Turner's syndrome. Adjunct for the induction of ovulation in women with infertility due to hypogonadotropic hypogonadism or bilateral tubal occlusion or unexplained infertility, who are undergoing in vivo or in vitro fertilization procedures. | Hospital use only | |||||
Somatropin | INJECTION, SOLUTION | 4 U/0.5ml | PARENTERAL | H01AC01 | Treatment of short stature in patients with Noonan syndrome Treatment of short stature associated with Turner's syndrome. Adjunct for the induction of ovulation in women with infertility due to hypogonadotropic hypogonadism or bilateral tubal occlusion or unexplained infertility, who are undergoing in vivo or in vitro fertilization procedures. | Hospital use only | 1395/09/13 | ||||
Somatropin | INJECTION, POWDER, LYOPHILIZED | 12 U | PARENTERAL | H01AC01 | Treatment of short stature in patients with Noonan syndrome Treatment of short stature associated with Turner's syndrome. Adjunct for the induction of ovulation in women with infertility due to hypogonadotropic hypogonadism or bilateral tubal occlusion or unexplained infertility, who are undergoing in vivo or in vitro fertilization procedures. | Hospital use only | |||||
Somatropin | INJECTION, POWDER, LYOPHILIZED | 16 U | PARENTERAL | H01AC01 | Treatment of short stature in patients with Noonan syndrome Treatment of short stature associated with Turner's syndrome. Adjunct for the induction of ovulation in women with infertility due to hypogonadotropic hypogonadism or bilateral tubal occlusion or unexplained infertility, who are undergoing in vivo or in vitro fertilization procedures. | Hospital use only | 1395/10/07 | ||||
Somatropin | INJECTION, POWDER, LYOPHILIZED | 15 U | PARENTERAL | H01AC01 | Treatment of short stature in patients with Noonan syndrome Treatment of short stature associated with Turner's syndrome. Adjunct for the induction of ovulation in women with infertility due to hypogonadotropic hypogonadism or bilateral tubal occlusion or unexplained infertility, who are undergoing in vivo or in vitro fertilization procedures. | Hospital use only | 1395/10/14 | ||||
Somatropin | INJECTION | 15 IU/ 1. 5 ml | PARENTERAL | H01AC01 | Treatment of short stature in patients with Noonan syndrome Treatment of short stature associated with Turner's syndrome. Adjunct for the induction of ovulation in women with infertility due to hypogonadotropic hypogonadism or bilateral tubal occlusion or unexplained infertility, who are undergoing in vivo or in vitro fertilization procedures. | Hospital use only | 1388/02/30 | ||||
Somatropin | INJECTION | 15 U/ml | PARENTERAL | H01AC01 | Treatment of short stature in patients with Noonan syndrome Treatment of short stature associated with Turner's syndrome. Adjunct for the induction of ovulation in women with infertility due to hypogonadotropic hypogonadism or bilateral tubal occlusion or unexplained infertility, who are undergoing in vivo or in vitro fertilization procedures. | Hospital use only | 1386/05/24 | ||||
Somatropin | INJECTION,SOLUTION | 22.5 U/1.5 ml | PARENTERAL | H01AC01 | Treatment of short stature in patients with Noonan syndrome Treatment of short stature associated with Turner's syndrome. Adjunct for the induction of ovulation in women with infertility due to hypogonadotropic hypogonadism or bilateral tubal occlusion or unexplained infertility, who are undergoing in vivo or in vitro fertilization procedures. | Hospital use only | 1390/07/04 | ||||
Somatropin | INJECTION,SOLUTION | 30 U/1.5 ml | PARENTERAL | H01AC01 | Treatment of short stature in patients with Noonan syndrome Treatment of short stature associated with Turner's syndrome. Adjunct for the induction of ovulation in women with infertility due to hypogonadotropic hypogonadism or bilateral tubal occlusion or unexplained infertility, who are undergoing in vivo or in vitro fertilization procedures. | Hospital use only | 1392/07/22 | ||||
Somatropin | INJECTION,SOLUTION | 30 U/2.7 ml | PARENTERAL | H01AC01 | Treatment of short stature in patients with Noonan syndrome Treatment of short stature associated with Turner's syndrome. Adjunct for the induction of ovulation in women with infertility due to hypogonadotropic hypogonadism or bilateral tubal occlusion or unexplained infertility, who are undergoing in vivo or in vitro fertilization procedures. | Hospital use only | 1395/09/07 | ||||
Somatropin | INJECTION,SOLUTION | 8 mg/ml | PARENTERAL | H01AC01 | Treatment of short stature in patients with Noonan syndrome Treatment of short stature associated with Turner's syndrome. Adjunct for the induction of ovulation in women with infertility due to hypogonadotropic hypogonadism or bilateral tubal occlusion or unexplained infertility, who are undergoing in vivo or in vitro fertilization procedures. | Hospital use only | 1396/04/27 | ||||
Somatropin | INJECTION,SOLUTION | 6 mg/1.03ml | PARENTERAL | H01AC01 | Treatment of short stature in patients with Noonan syndrome Treatment of short stature associated with Turner's syndrome. Adjunct for the induction of ovulation in women with infertility due to hypogonadotropic hypogonadism or bilateral tubal occlusion or unexplained infertility, who are undergoing in vivo or in vitro fertilization procedures. | Hospital use only | 1396/04/27 | ||||
Sorafenib | Tosilate | TABLET | 200 mg | ORAL | L01XE05 | Orphan medcines; Hospital use only | 1387/06/26 | ||||
Sorbitol | POWDER | 5 g | ORAL | A06AD18 | sachet | 1359/11/15 | |||||
Sotalol | HCl | TABLET | 40 mg | ORAL | C07AA07 | ||||||
Sotalol | HCl | TABLET | 80 mg | ORAL | C07AA07 | 1373/03/01 | |||||
Spectinomycin | As DiHCl | INJECTION, POWDER | 2 g | PARENTERAL | J01XX04 | ||||||
Spinosad | SUSPENSION | 0.9% W/W | TOPICAL | QP53BX03 | 1393/03/25 | ||||||
Spiramycin | TABLET | 500 mg | ORAL | J01FA02 | 1367/08/15 | ||||||
Spironolactone | TABLET | 100 mg | ORAL | C03DA01 | 1378/05/10 | ||||||
Spironolactone | TABLET | 25 mg | ORAL | C03DA01 | |||||||
Starch | BULK | V03 | Bulk medicines | ||||||||
Stavudine | CAPSULE | 40 mg | ORAL | J05AF04 | For Health Dept. of MOH only | ||||||
Stavudine | TABLET | 40 mg | ORAL | J05AF04 | For Health Dept. of MOH only | 1385/09/07 | |||||
Stavudine | POWDER, FOR SOLUTION | 5 mg/5ml | ORAL | J05AF04 | For Health Dept. of MOH only | ||||||
Stearic Acid | BULK | V03 | Bulk medicines | ||||||||
Stibogluconate | Sodium | INJECTION | 100 mg/ml | PARENTERAL | P01CB02 | Eq. To Pentavalent Antimony | 1366/02/06 | ||||
Streptokinase | INJECTION, POWDER | 1,500,000 IU | PARENTERAL | B01AD01 | Hospital use only | 1388/09/04 | |||||
Streptokinase | INJECTION, POWDER, LYOPHILIZED | 250,000 IU | PARENTERAL | B01AD01 | Hospital use only | ||||||
Streptokinase | INJECTION, POWDER | 750,000 IU | PARENTERAL | B01AD01 | Hospital use only | 1367/07/24 | |||||
Streptomycin | As Sulfate | INJECTION, POWDER | 1 g | PARENTERAL | J01GA01 | Hospital use only | |||||
Streptozocin | INJECTION, POWDER | 1 g | PARENTERAL | L01AD04 | |||||||
Strontium [82Sr]/Rubidium [82Rb] | GENERATOR | (20-60) mCi | PARENTERAL | V09GX04 | Radiopharmaceuticals | 1389/10/25 | 1397/02/18 | ||||
Strontium [89Sr] Chloride | INJECTION, SOLUTION | 4 mCi | PARENTERAL | V10BX01 | Radiopharmaceuticals | 1389/10/25 | |||||
Succimer | CAPSULE | 100 mg | ORAL | V03AB | Treatment of lead poisoning in children. | Orphan medicines | 1382/03/04 | ||||
Succimer | CAPSULE | 200 mg | ORAL | V03AB | Treatment of lead poisoning in children. | Orphan medicines | |||||
Succinylcholine | Chloride | INJECTION, POWDER | 1 g | PARENTERAL | M03AB01 | Hospital use only | |||||
Succinylcholine | Chloride | INJECTION, POWDER | 100 mg | PARENTERAL | M03AB01 | Hospital use only | |||||
Succinylcholine | Chloride | INJECTION | 100 mg/ml | PARENTERAL | M03AB01 | Hospital use only | |||||
Succinylcholine | Chloride | INJECTION | 20 mg/ml | PARENTERAL | M03AB01 | Hospital use only | 1381/10/22 | ||||
Succinylcholine | Chloride | INJECTION | 50 mg/ml | PARENTERAL | M03AB01 | Hospital use only | |||||
Succinylcholine | Chloride | INJECTION, POWDER | 500 mg | PARENTERAL | M03AB01 | Hospital use only | |||||
Sucralfate | TABLET | 1 g | ORAL | A02BX02 | OTC medicines | 1369/07/15 | |||||
Sucralfate | POWDER, FOR SUSPENSION | 1 g | ORAL | A02BX02 | Treatment of ORAL complications of chemotherapy in bone marrow transplant patients. Treatment of ORAL ulcerations and dysphagia in patients with epidermolysis bullosa. | 1369/04/03 | |||||
Sucralfate | TABLET | 500 mg | ORAL | A02BX02 | OTC medicines | 1370/10/01 | |||||
Sufentanil | As Citrate | INJECTION | 5 mcg/ml | PARENTERAL | N01AH03 | Hospital use only | 1373/10/18 | ||||
Sufentanil | As Citrate | INJECTION | 50 mcg/ml | PARENTERAL | N01AH03 | Hospital use only | 1389/06/29 | ||||
Sugamedex | As Sodium | INJECTION | 100 mg/ml | PARENTERAL | V03AB35 | Hospital use only | 1396/06/12 | ||||
Sulfacetamide | Sodium | SOLUTION/ DROPS | 10% | OPHTHALMIC | S01AB04 | 1360/09/15 | |||||
Sulfacetamide | Sodium | SOLUTION/ DROPS | 20% | OPHTHALMIC | S01AB04 | ||||||
Sulfadiazine | TABLET | 500 mg | ORAL | J01EC02 | For use in combination with pyrimethamine for the treatment of Toxoplasma gondii encephalitis in patients with and without AIDS. | 1363/02/16 | |||||
Sulfadoxine+Pyrimethamine | TABLET | ORAL | P01BD51 | Sulfadoxine 500 mg+Pyrimethamine 25 mg | 1368/02/10 | ||||||
Sulfasalazine | ENEMA | 30 mg/ml | RECTAL | A07EC01 | 1364/03/12 | ||||||
Sulfasalazine | TABLET | 500 mg | ORAL | A07EC01 | 1382/12/25 | ||||||
Sulfasalazine | TABLET, DELAYED RELEASE | 500 mg | ORAL | A07EC01 | |||||||
Sulfasalazine | SUSPENSION | 250 mg/5ml | ORAL | A07EC01 | 1395/09/01 | ||||||
Sulfur | BULK | V03 | Bulk medicines | Precipitated | |||||||
Sulfur | SOAP | 10% | TOPICAL | D10AB02 | OTC medicines | ||||||
Sumatriptan | As Succinate | INJECTION | 12 mg/ml | PARENTERAL | N02CC01 | ||||||
Sumatriptan | As Succinate | TABLET | 50 mg | ORAL | N02CC01 | ||||||
Sumatriptan | As Succinate | TABLET | 100 mg | ORAL | N02CC01 | 1380/02/09 | |||||
Sumatriptan+Naproxen | TABLET | ORAL | N02CC | sumatriptan (As Succinate) 85 mg+naproxen Sodium 500 mg | |||||||
Sunitinib | As Malate | CAPSULE | 12.5 mg | ORAL | L01XE04 | for local production only | 1391/12/23 | ||||
Sunitinib | As Malate | CAPSULE | 25 mg | ORAL | L01XE04 | for local production only | 1391/12/23 | ||||
Sunitinib | As Malate | CAPSULE | 50 mg | ORAL | L01XE04 | for local production only | 1391/12/23 | ||||
Surfactant | INJECTION , SUSPENSION | 27 mg/ml | INTRATRACHEAL | R07AA02 | bovine lipid extract | 1391/05/02 | |||||
Surfactant TA | LYOPHYLIZED POWDER | 120 mg | INTRATRACHEAL | R07AA | 1387/12/21 | ||||||
Tacrolimus | OINTMENT | 0.03% | TOPICAL | D11AH01 | 1385/09/07 | ||||||
Tacrolimus | OINTMENT | 0.10% | TOPICAL | D11AH01 | 1388/02/30 | ||||||
Tacrolimus | CAPSULE, EXTENDED RELEASE | 0. 5 mg | ORAL | L04AD02 | 1385/04/13 | ||||||
Tacrolimus | CAPSULE | 0.5 mg | ORAL | L04AD02 | Prophylaxis of organ rejection in patients receiving heart transplants. | ||||||
Tacrolimus | CAPSULE | 1 mg | ORAL | L04AD02 | Prophylaxis of organ rejection in patients receiving heart transplants. | 1379/11/09 | |||||
Tacrolimus | CAPSULE, EXTENDED RELEASE | 1 mg | ORAL | L04AD02 | Prophylaxis of organ rejection in patients receiving heart transplants. | 1379/11/09 | |||||
Tacrolimus | CAPSULE, EXTENDED RELEASE | 3 mg | ORAL | L04AD02 | Prophylaxis of organ rejection in patients receiving heart transplants. | 1395/07/17 | |||||
Tacrolimus | CAPSULE | 5 mg | ORAL | L04AD02 | Prophylaxis of organ rejection in patients receiving heart transplants. | 1379/11/09 | |||||
Tacrolimus | CAPSULE, EXTENDED RELEASE | 5 mg | ORAL | L04AD02 | Prophylaxis of organ rejection in patients receiving heart transplants. | 1379/11/09 | |||||
Tacrolimus | INJECTION, SOLUTION, CONCENTRATE | 5 mg/ml | PARENTERAL | L04AD02 | Prophylaxis of organ rejection in patients receiving heart transplants. | ||||||
Tadalafil | TABLET | 2.5 mg | ORAL | G04BE08 | Erectil Dysfunction, Benign Prostatic Hyperplasia | 1397/03/01 | |||||
Tadalafil | TABLET | 5 mg | ORAL | G04BE08 | Erectil Dysfunction, Benign Prostatic Hyperplasia | 1395/05/02 | |||||
Tadalafil | TABLET | 10 mg | ORAL | G04BE08 | Erectil Dysfunction, Benign Prostatic Hyperplasia | 1384/12/09 | |||||
Tadalafil | TABLET | 20 mg | ORAL | G04BE08 | Treatment of pulmonary arterial hypertension | 1384/12/09 | |||||
Tamoxifen | As Citrate | TABLET | 10 mg | ORAL | L02BA01 | ||||||
Tamoxifen | As Citrate | TABLET | 20 mg | ORAL | L02BA01 | 1381/06/31 | |||||
Tamsulosin | HCl | CAPSULE, EXTENDED RELEASE, PELLETS | 0.4 mg | ORAL | G04CA02 | 1382/08/04 | |||||
Tamsulosin | HCl | TABLET, EXTENDED RELEASE | 0.4 mg | ORAL | G04CA02 | 1387/09/23 | |||||
Tartaric Acid | BULK | V03 | Bulk medicines | ||||||||
Technetium [99mTc]-Human Immunoglobulin G | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | (15-25) mCi | PARENTERAL | V09CA04 | Hospital use only | Radiopharmaceuticals | |||||
Technetium [99mTc]-bombesin | INJECTION,POWDER LYOPHILIZED | (20-30) mCi | PARENTERAL | V09 | Radiopharmaceuticals | 1389/10/25 | |||||
Technetium [99mTc]-Pentetate Aerosol, (99mTc-DTPA) | INHALER | (25-30) mCi | RESPIRATORY | V09EA | Radiopharmaceuticals | 1389/10/25 | |||||
Technetium [99mTc] Antimony Sulfur Colloid | INJECTION, COLLOIDAL SOLUTION | (5-50) mCi | SUBCUTANEOUS | V09DB05 | Hospital use only | Radiopharmaceuticals | 1383/09/22 | ||||
Technetium [99mTc]-Ethyl Cysteinate Dimer, (99mTc-ECD) | INJECTION, POWDER, LYOPHILIZED | (10-100) mCi | INTRAVENOUS BOLUS | V09AA02 | Hospital use only | Radiopharmaceuticals | 1383/09/22 | ||||
Technetium [99mTc]-Ciprofluxacin | INJECTION, POWDER, LYOPHILIZED | (20-30) mCi | PARENTERAL | V09H | Hospital use only | Radiopharmaceuticals | 1391/09/01 | ||||
Technetium [99mTc]-Ethylenedicystein, (99mTc-EC) | INJECTION, POWDER, LYOPHILIZED | (10-100) mCi | INTRAVENOUS BOLUS | V09CA | Hospital use only | Radiopharmaceuticals | |||||
Technetium [99mTc]-Etidronate, (99mTc-HEDP) | INJECTION, POWDER, LYOPHILIZED | (up to 150) mCi | INTRAVENOUS BOLUS | V09BA | Hospital use only | Radiopharmaceuticals | |||||
Technetium [99mTc]-Hexamethylpropyleneamineoxime, (99mTc-HMPAO) | INJECTION, POWDER, LYOPHILIZED | (10 30) mCi | INTRAVENOUS BOLUS | V09AA01 | Hospital use only | Radiopharmaceuticals | 1383/09/22 | ||||
Technetium [99mTc]-Glucoheptonate, (99mTc-GH) | INJECTION, POWDER, LYOPHILIZED | (up to 150) mCi | INTRAVENOUS BOLUS | V09CA04 | Hospital use only | Radiopharmaceuticals | 1383/09/22 | ||||
Technetium [99mTc]-Macroaggregated Albumin, (99mTc-MAA) | INJECTION, POWDER, LYOPHILIZED | (5-30) mCi | INTRAVENOUS BOLUS | V09EB01 | Hospital use only | Radiopharmaceuticals | |||||
Technetium [99mTc]-Mebrofenin, (99mTc-Brida) | INJECTION, POWDER, LYOPHILIZED | (up to 100) mCi | INTRAVENOUS BOLUS | V09DA04 | Hospital use only | Radiopharmaceuticals | 1383/09/22 | ||||
Technetium [99mTc]-Medronate, (99mTc-MDP) | INJECTION, POWDER, LYOPHILIZED | (up to 300) mCi | INTRAVENOUS BOLUS | V09BA02 | Hospital use only | Radiopharmaceuticals | |||||
Technetium [99mTc]-Mertiatide, (99mTc-MAG3) | INJECTION, POWDER, LYOPHILIZED | (10-100) mCi | INTRAVENOUS BOLUS | V09CA03 | Hospital use only | Radiopharmaceuticals | 1383/09/22 | ||||
Technetium [99mTc]-Pentetate, (99mTc-DTPA) | INJECTION, POWDER, LYOPHILIZED | (up to 300) mCi | INTRAVENOUS BOLUS | V09CA01 | Hospital use only | Radiopharmaceuticals | 1383/09/22 | ||||
Technetium [99mTc]-Phytate | INJECTION, POWDER, LYOPHILIZED | (up to 100) mCi | INTRAVENOUS BOLUS | V09DB07 | Hospital use only | Radiopharmaceuticals | |||||
Technetium [99mTc]-Pyrophosphate, (99mTc-PYP) | INJECTION | (up to 80) mCi | INTRAVENOUS BOLUS | V09BA03 | Hospital use only | Radiopharmaceuticals | |||||
Technetium [99mTc]-Methoxy Isobutyl Isonitrile, (99mTc-MIBI) | INJECTION, POWDER, LYOPHILIZED | (20-100) mCi | INTRAVENOUS BOLUS | V09GA03 | Hospital use only | Radiopharmaceuticals | |||||
Technetium [99mTc]-Red Blood Cell, (99mTc-RBC) | INJECTION, POWDER, LYOPHILIZED | (10-100) mCi | INTRAVENOUS BOLUS | V09GA06 | Hospital use only | Radiopharmaceuticals | 1383/09/22 | ||||
Technetium [99mTc]-Succimer, (99mTc-DMSA) | INJECTION, POWDER, LYOPHILIZED | (up to 40) mCi | INTRAVENOUS BOLUS | V09CA02 | Hospital use only | Radiopharmaceuticals | |||||
Technetium [99mTc]-Sulfur Colloid, (99mTc-SC) | INJECTION, POWDER, LYOPHILIZED | (10-100) mCi | INTRAVENOUS BOLUS | V09DB05 | Hospital use only | Radiopharmaceuticals | |||||
Technetium [99mTc]-Tin Colloid | INJECTION, POWDER, LYOPHILIZED | (up to 100) mCi | INTRAVENOUS BOLUS | V09DB04 | Hospital use only | Radiopharmaceuticals | |||||
Technetium [99mTc]-Octreotide or Octreotate | INJECTION, POWDER, LYOPHILIZED | (15-25) mCi | INTRAVENOUS BOLUS | V09HA01 | Hospital use only | Radiopharmaceuticals | 1387/05/01 | ||||
Technetium[99mTc]-Pentavalent Succimer, (99mTc-DMSA [V]) | INJECTION, POWDER, LYOPHILIZED | (20-80) mCi | INTRAVENOUS BOLUS | V09IA03 | Hospital use only | Radiopharmaceuticals | |||||
Technetium[99mTc]-Ubiquicidine, (99mTc-UBI) | INJECTION, POWDER, LYOPHILIZED | (29-41) mCi | PARENTERAL | V09H | Hospital use only | Radiopharmaceuticals | 1391/09/01 | ||||
Technetium[99mTc]-TRODAT | INJECTION, POWDER, LYOPHILIZED | 30 mCi | PARENTERAL | V09AA01 | Hospital use only | Radiopharmaceuticals | 1397/02/18 | ||||
Teicoplanin | INJECTION, POWDER, | 200 mg | PARENTERAL | J01XA02 | With infectious diseases specialists prescriptions only | 1382/11/05 | |||||
Teicoplanin | INJECTION, POWDER, | 400 mg | PARENTERAL | J01XA02 | With infectious diseases specialists prescriptions only | ||||||
Temocillin | Sodium | INJECTION, POWDER FOR RECONSTITUTION | 1 gr | PARENTERAL | J01CA17 | Hospital use only | With infectious diseases specialists prescriptions only | 1395/05/09 | |||
Temozolomide | CAPSULE | 100 mg | ORAL | L01AX03 | for local production only | 1389/10/25 | |||||
Temozolomide | INJECTION, POWDER | 100 mg | PARENTERAL | L01AX03 | 1392/04/04 | ||||||
Temozolomide | CAPSULE | 140 mg | ORAL | L01AX03 | 1392/08/20 | ||||||
Temozolomide | CAPSULE | 180 mg | ORAL | L01AX03 | 1395/06/24 | ||||||
Temozolomide | CAPSULE | 20 mg | ORAL | L01AX03 | 1389/10/25 | ||||||
Temozolomide | CAPSULE | 250 mg | ORAL | L01AX03 | 1389/10/25 | ||||||
Temozolomide | CAPSULE | 5 mg | ORAL | L01AX03 | for local production only | 1389/10/25 | |||||
Tenecteplase | INJECTION, POWDER | 50 mg | PARENTERAL | B01AD11 | Fibrinolytic drugs | Hospital use only | 1395/03/09 | ||||
Teniposide | INJECTION | 10 mg/ml | PARENTERAL | L01CB02 | Treatment of refractory childhood acute lymphocytic leukemia. | Orphan medicines | |||||
Tenofovir | Disoproxil fumarate | TABLET | 300 mg | ORAL | J05AF07 | For Health Dept. of MOH only | 1386/04/11 | ||||
Tenofovir | Disoproxil fumarate | TABLET | 200 mg | ORAL | J05AF07 | For Health Dept. of MOH only | 1397/02/11 | ||||
Tenofovir | Alafenamide as Fumarate | TABLET | 25 mg | ORAL | J05AF13 | For Health Dept. of MOH only | 1395/12/22 | ||||
Terazosin | As HCl | TABLET | 2 mg | ORAL | G04CA03 | 1379/11/09 | |||||
Terazosin | As HCl | TABLET | 5 mg | ORAL | G04CA03 | 1379/11/09 | |||||
Terbinafine | HCl | SOLUTION | 1% | TOPICAL | D01AE15 | OTC medicimes | 1372/08/23 | ||||
Terbinafine | HCl | CREAM | 1% | TOPICAL | D01AE15 | OTC medicimes | 1387/05/06 | ||||
Terbinafine | HCl | SPRAY | 1% | TOPICAL | D01AE15 | OTC medicimes | |||||
Terbinafine | HCl | TABLET | 250 mg | ORAL | D01BA02 | 1372/08/23 | |||||
Terbutaline | Sulfate | INJECTION | 0.5 mg/ml | PARENTERAL | R03CC03 | Hospital use only | |||||
Terbutaline | Sulfate | TABLET | 5 mg | ORAL | R03CC03 | ||||||
Terbutaline | Sulfate | NEBULISATION | RESPIRATORY | R03CC03 | 1374/06/26 | ||||||
Teriflunomide | TABLET | 14 mg | ORAL | L04AA31 | For MS pateints only | 1393/02/07 | |||||
Teriparatide | INJECTION | 250 mcg/ml | PARENTERAL | H05AA02 | Diagnostic agent to assist in establishing the diagnosis in patients presenting with clinical and laboratory evidence of hypocalcemia due to either hypoparathyroidism or pseudohypoparathyroidism. Treatment of idiopathic osteoporosis. | 1385/09/07 | |||||
Testosterone | Enantate | INJECTION | 100 mg/ml | PARENTERAL | G03BA03 | 1361/09/14 | |||||
Testosterone | Enantate | INJECTION | 250 mg/ml | PARENTERAL | G03BA03 | 1361/09/14 | |||||
Testosterone | Undecanoate | CAPSULE | 40 mg | ORAL | G03BA03 | Treatment of weight loss in AIDS patients with HIV-associated wasting. | Orphan medicines | ||||
Tetanus Antitoxin uine | INJECTION | PARENTERAL | J06AA02 | ||||||||
Tetanus Immune globulin | INJECTION | 250 IU | PARENTERAL | J06BB02 | |||||||
Tetanus Toxoid Adsorbed | INJECTION | PARENTERAL | J07AM01 | ||||||||
Tetrabenazine | TABLET | 25 mg | ORAL | N05AK01 | Treatment of Huntington's disease. Treatment of moderate/severe tardive dyskinesia. | ||||||
Tetracaine | HCl | SOLUTION/ DROPS | 0.50% | OPHTHALMIC | S01AA09 | 1360/04/17 | |||||
Tetracaine | HCl | INJECTION | 1% | PARENTERAL | N01BA03 | Hospital use only | |||||
Tetracosactide | Acetate | INJECTION, SUSPENSION | 1 mg/ml | PARENTERAL | H01AA02 | Hospital use only | With ZINC PHOSPHATE COMPLEX | ||||
Tetracosactide | As Acetate | INJECTION, SUSPENSION | 1 mg/ml | PARENTERAL | H01AA02 | Hospital use only | With ZINC PHOSPHATE COMPLEX | 1395/07/17 | |||
Tetracosactide | As Acetate | INJECTION | 250 mcg/ml | PARENTERAL | H01AA02 | 1387/05/06 | |||||
Tetracycline | HCl | OINTMENT | 1% | OPHTHALMIC | S01AA06 | ||||||
Tetracycline | HCl | OINTMENT | 3% | TOPICAL | D06AA04 | OTC medicines | 1369/10/30 | ||||
Tetracycline | HCl | CAPSULE | 250 mg | ORAL | J01AA07 | ||||||
Thalidomide | CAPSULE | 100 mg | ORAL | L04AX02 | Treatment of multiple myloma | Orphan medicines | 1387/11/06 | ||||
Thalidomide | TABLET | 100 mg | ORAL | L04AX02 | Treatment of multiple myloma | Orphan medicines | 1387/11/06 | ||||
Thallium [201Tl]-Chloride | INJECTION | 5-10 mCi | INTRAVENOUS BOLUS | V09GX01 | Hospital use only | Radiopharmaceuticals | 1383/09/22 | ||||
Theophylline | TABLET, EXTENDED RELEASE | 100 mg | ORAL | R03DA04 | |||||||
Theophylline | TABLET, EXTENDED RELEASE | 200 mg | ORAL | R03DA04 | 1396/03/21 | ||||||
Theophylline | CAPSULE, EXTENDED RELEASE, PELLETS | 200 mg | ORAL | R03DA04 | |||||||
Theophylline | TABLET | 200 mg | ORAL | R03DA04 | |||||||
Theophylline | CAPSULE, EXTENDED RELEASE, PELLETS | 100 mg | ORAL | R03DA04 | |||||||
Theophylline | CAPSULE, EXTENDED RELEASE, PELLETS | 300 mg | ORAL | R03DA04 | |||||||
Theophylline | CAPSULE, EXTENDED RELEASE, PELLETS | 400 mg | ORAL | R03DA04 | |||||||
Theophylline+Guaifenesin | SOLUTION | ORAL | R03DA54 | (Theophylline anhydrous 50 mg+Guaifenesin 30 mg) / 5 ml | |||||||
Thiabendazole | TABLET, CHEWABLE | 500 mg | ORAL | P02CA02 | |||||||
Thiamine | HCl | INJECTION | 100 mg/ ml | INTRAVENOUS DRIP | A11DA01 | Hospital use only | |||||
Thiethylperazine | As Dimaleate | TABLET | 6.5 mg | ORAL | R06AD03 | ||||||
Thiethylperazine | As Dimaleate | INJECTION | 6.5 mg/ml | INTRAMUSCULAR | R06AD03 | ||||||
Thioguanine | TABLET | 40 mg | ORAL | L01BB03 | |||||||
Thiopental | Sodium | INJECTION, POWDER | 1 g | PARENTERAL | N01AF03 | Hospital use only | |||||
Thiopental | Sodium | INJECTION | 25 mg/ml | PARENTERAL | N01AF03 | Hospital use only | |||||
Thiopental | Sodium | INJECTION | 50 mg/ml | PARENTERAL | N01AF03 | Hospital use only | |||||
Thiopental | Sodium | INJECTION, POWDER | 500 mg | PARENTERAL | N01AF03 | Hospital use only | |||||
Thioridazine | HCl | TABLET | 10 mg | ORAL | N05AC02 | ||||||
Thioridazine | HCl | TABLET | 100 mg | ORAL | N05AC02 | ||||||
Thioridazine | HCl | TABLET | 25 mg | ORAL | N05AC02 | ||||||
Thiotepa | INJECTION, POWDER | 15 mg | PARENTERAL | L01AC01 | Hospital use only | 1396/09/12 | |||||
Thiotepa | INJECTION, POWDER | 100 mg | PARENTERAL | L01AC01 | Hospital use only | 1396/09/12 | |||||
Thiothixene | CAPSULE | 5 mg | ORAL | N05AF04 | 1359/08/26 | ||||||
Thyrotrophin | INJECTION, POWDER, LYOPHILIZED | 10 U | PARENTERAL | V04CJ01 | Treatment of well-differentiated papillary, follicular or combined papillary/follicular carcinomas of the thyroid. As an adjunct in the diagnosis of thyroid cancer. | 1387/05/06 | |||||
Thyrotropin Alfa | INJECTION, POWDER, LYOPHILIZED | 1.1 mg | PARENTERAL | V04CJ01 | Orphan medicines; Hospital use only | 1387/05/06 | |||||
Thyrotropin Alfa | INJECTION, POWDER, LYOPHILIZED | 900 mcg | PARENTERAL | V04CJ01 | Orphan medicines; Hospital use only | ||||||
Ticagrelor | TABLET | 90 mg | ORAL | B01AC24 | Antiplatelet Drug | 1395/08/02 | |||||
Ticagrelor | TABLET | 60 mg | ORAL | B01AC24 | Antiplatelet Drug | 1395/11/06 | |||||
Ticlopidine | HCl | TABLET | 250 mg | ORAL | B01AC05 | 1376/01/31 | |||||
Tigecycline | INJECTION, POWDER FOR RECONSTITUTION | 50 mg | PARENTERAL | J01AA12 | Hospital use only, ICU ward only | With infectious diseases specialists prescriptions only | 1395/05/09 | ||||
Tilactase | TABLET | 3000 FCC U | ORAL | A09AA04 | OTC medicines | Lactolose | 1377/03/10 | ||||
Timolol | As Maleate | SOLUTION | 0.50% | OPHTHALMIC | S01ED01 | 1359/10/24 | |||||
Tinidazole | TABLET | 500 mg | ORAL | P01AB02 | Treatment of intestinal amebiasis and amebic liver abcess caused by E. histolytica in both adults and pediatric patients older than three years of age. It is not indicated for the treatment of asymptomatic cyst passage. | 1382/10/07 | |||||
Tiotropium | As Bromide | SOUTION FOR INHALATION | 2.5 mcg/dose | RESPIRATORY | R03BB04 | 1395/09/28 | |||||
Tiotropium | As Bromide | SOUTION FOR INHALATION | 1.25 mcg/dose | RESPIRATORY | R03BB04 | 1395/09/28 | |||||
Tiotropium | As Bromide | POWDER, INHALATION | 18 mcg/capsule | RESPIRATORY | R03BB04 | 1385/11/24 | |||||
Tirofiban | As HCl | INJECTION, SOLUTION | 0.25mg/ml | PARENTERAL | B01AC17 | 1385/10/05 | |||||
Tirofiban | As HCl | INJECTION, SOLUTION | 5mg/100ml | PARENTERAL | B01AC17 | 1389/06/29 | |||||
Titanium Dioxide | LOTION | TOPICAL | D02AB | Titanium Oxide 3.6% + Zinc Oxide 14% | 1378/02/19 | ||||||
Titanium Dioxide | BULK | V03 | Bulk medi |